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Abstract  
 
Eating behaviour and neural representations of hunger and satiety in patients 
with acquired structural hypothalamic damage: A clinical and functional 
neuroimaging study 
 
Dr Caroline Anne Steele 
 
Hypothalamic obesity (HO) is a relatively rare cause of obesity within the 
population as a whole, but studies of patients with hypothalamic damage show there 
is a significant prevalence of obesity within the patient group. Additionally, the 
obesity is difficult to prevent and manage and increases morbidity and mortality in an 
already at risk patient group. 
 
The work of this thesis had two main objectives. Firstly, to examine the 
prevalence of obesity and associated morbidities in patients with acquired, structural 
hypothalamic damage with a descriptive cohort study (n=110). A separate descriptive 
study quantified obesity and metabolic risk factors in young patients with pituitary 
tumours, with or without hypothalamic damage (n=41), as they were also identified 
as a possible at risk group during clinical observations. The second objective was to 
investigate the underlying pathophysiology of HO using various complementary 
techniques to study patients with hypothalamic damage who remained weight-stable 
(HWS), patients with HO and age- and BMI-matched controls. These cross-sectional 
case-control studies used functional magnetic resonance imaging (fMRI; 9 HO, 7 
HWS, 20 controls), the universal eating monitor (UEM; 6 HO, 6 HWS, 9 obese 
controls [OC], 10 non-obese controls [NOC]), Three-Factor Eating Questionnaire 
(TFEQ; 8 HO, 6 HWS, 9 OC, 11 NOC) and three-day food diaries (6 HO, 7 HWS, 8 
OC, 11 NOC) to assess eating behaviour. 
 
 The first descriptive study included 110 adults with tumours causing 
hypothalamic damage attending a specialist neuroendocrine clinic. There was a 
significant prevalence of weight gain and obesity; 81.8% were overweight/heavier, 
56.4% obese and 13.6% morbidly obese, despite proactive assessment and treatment 
during routine clinic visits. Hypertension (30.9%), dyslipidaemia (54.5%), type 2 
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diabetes mellitus (T2DM) (14.5%) and cardiovascular disease (9.1%) were also 
prevalent. In 41 patients with childhood/adolescent-onset pituitary adenomas there 
was also a relatively high prevalence of obesity (39.0%) and cardiovascular risk 
factors (2 receiving antihypertensive medications, 2 with T2DM and 4 with treated 
dyslipidaemia), despite the majority of tumours being microadenomas (i.e. too small 
to cause hypothalamic damage and indicating the need for long-term follow-up of 
these patients. 
 
 The first study into the pathophysiology of HO involved the use of functional 
MRI in 9 patients with HO, 7 HWS and 20 age- and BMI-matched controls. 
Participants underwent fMRI scans in a fasted state, as well as one hour and three 
hours following a fixed-load breakfast (25% of their calculated basal metabolic rate 
[BMR]). At each scan session participants viewed alternating blocks of photographs 
of high- or low-calorie food, with non-food photographs also viewed to use as a 
baseline comparison, to allow purely visual activation to be subtracted from any 
BOLD signal differences which occurred. Whole-brain statistical analysis revealed 
significantly lower BOLD signal in HWS participants compared to HO (and to 
controls) in the food motivation and reward-related brain regions of the posterior 
insula and lingual gyrus (p=0.001) when viewing high-calorie food photographs 
(compared to non-food photographs). These differences in reward-related brain 
regions may be implicated in the development of HO/the ability to remain weight-
stable despite hypothalamic damage.  
Eating behaviour studies were undertaken on a separate study day where 
participants were asked to eat an unlimited pasta meal until adequately full, while 
seated at the UEM. This allowed monitoring of total intake, eating duration, eating 
rate and intra-meal on-screen ratings of hunger, fullness and meal pleasantness using 
visual analogue scales. Additionally Three Factor Eating Questionnaires (TFEQs) 
and three-day MRC-Human Nutrition Research diaries were completed at home to 
assess more long-term real-world eating habits. None of the eating behaviour studies 
identified significant statistical differences between HO and HWS, but this may have 
been due to lack of statistical power. There was however an unusual pattern of eating 
rate in those with HO on visual ascription. This involved an initial tendency towards 
a higher eating rate, followed by a reduction in rate, with a further increase towards 
the end of the meal. Further investigation of this pattern with larger numbers of 
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participants would be important to determine whether it is a significant finding or 
merely an anomaly due to the small group size.  Interestingly controls ate 
significantly more at the UEM (even when intake was adjusted according to fat-free 
mass or as a proportion of the estimated BMR) and for significantly longer than 
participants with hypothalamic damage, who reported lower hunger at the start of the 
meal, but there was no difference between obese and non-obese participants. In 
keeping with previously published research disinhibition scores measured using the 
TFEQ were higher in participants with simple obesity [1], with no evidence of 
increased disinhibition in HO participants [2], although the small numbers studied 
should be noted.  
 Finally, during both of the study days blood sampling was undertaken to look 
for biochemical/hormonal variances between the groups. Fasting and area under the 
curve (AUC) active ghrelin concentrations were significantly higher in controls than 
in patients, in keeping with some (but not all) previous studies [2-4]. Consistent with 
previously published research leptin concentrations were significantly higher in 
obese compared to non-obese participants 
 
The small size of this study was a significant limitation and limits the 
generalisability of the findings, particularly in the eating behaviour studies. This was 
due in part to the rarity of the condition - the occurrence of acquired, structural 
hypothalamic damage is relatively rare and the number of individuals with 
hypothalamic damage who remain weight stable is small, leading to particular 
difficulty in recruiting patients for the HWS group. Whilst there were some 
interesting findings further larger studies should enable greater clarification and 
would allow correlation between clinical and biochemical findings. Further studies in 
larger cohorts could explore the unusual eating pattern seen in those with HO when 
studied using the UEM and the apparent lack of disinhibition seen in this group.  
 
Although this research provides some preliminary novel evidence to support 
differences in BOLD signal in reward-related regions of the brain as a possible driver 
of HO, the mechanisms through which these differences exert their effects to 
contribute to the development of HO require further elucidation and further study 
with larger numbers of patients is needed.  
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Chapter 1 
 
Introduction 
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Hypothalamic Obesity (HO): causes, definitions and brief historical perspective 
Although “simple” nutritional obesity is increasingly prevalent in the 
population some other types, such as those secondary to underlying medical 
conditions, remain relatively rare; one of these is hypothalamic obesity (HO). HO 
describes obesity occurring secondary to hypothalamic damage. This damage can be 
acquired (due to structural lesions and/or their subsequent treatment, for example 
with surgery or radiotherapy), genetic (for example Prader-Willi syndrome [PWS] or 
congenital leptin deficiency), following intracranial infections, trauma, or vascular 
insult, occur as a side-effect of certain psychotropic medications, or may be 
idiopathic (Table 1.1) [5-8].  
 
 
Definition of Hypothalamic Obesity (HO)  
HO is defined as an acute increase in body weight following a clear 
hypothalamic insult [7], with weight gain faster than any expected age-related 
increase in body mass index (BMI) [9] and despite appropriate replacement of any 
hormone insufficiencies. In the case of adults with acquired, structural hypothalamic 
damage secondary to tumours in the hypothalamus or in the surrounding region 
(causing hypothalamic invasion/distortion) and/or their subsequent treatment, this is 
further refined as BMI ≥ 30 kg/m2 which has increased by ≥2 kg/m2 since tumour 
diagnosis, with weight gain faster than any expected age-related increase and despite 
adequate treatment of any associated pituitary hormone deficiencies [6]. The work in 
this thesis will concentrate mainly on acquired structural hypothalamic damage 
causing HO. 
 
 
Historical perspective 
HO was initially described in patients who had undergone surgical excision 
of tumours in the hypothalamic region, with subsequent significant polyphagia and 
weight gain. The first case reports date back to 1900 and 1901, when Babinski [7, 9, 
10] and Frolich et al. [7, 9-11] respectively described obesity (and sexual 
immaturity) associated with hypothalamic tumours. Numerous case reports and case 
series followed [5, 9]. The naming of solid and cystic tumours of the incompletely  
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Table 1.1. Causes of hypothalamic obesity. Adapted from Hochberg and Hochberg, 
Expanding the definition of hypothalamic obesity, Tables 1-3 [7]  
Anatomic/Acquired Structural Causes 
Tumours Craniopharyngioma, epithelioma, angiosarcoma, 
cholesteatoma, pinealoma, germinoma, endothelioma, 
hamartoma, chordoma, colloid/epidermoid cysts, 
ganglioneuroma, ependymoma, glioma, pituitary 
macroadenoma/prolactinoma (with suprasellar 
extension), meningioma, teratoma, leukaemia, 
Langerhans cell histiocytosis, metastasis. 
Inflammatory Sarcoid, tuberculosis, arachnoiditis, histiocytosis X, 
encephalitis. 
Head trauma  
Neurosurgery  
Cranial radiotherapy  
Cerebral aneurysm  
Genetic Causes 
Single gene 
mutations and 
genetic syndromes 
Leptin, leptin receptor, CART, POMC, Prohormone 
convertase-1, MC4R, BDNF, TrkB, Single-minded 1, Rapid-
onset obesity with hypoventilation, hypothalamic, autonomic 
dysregulation and neural tumour (ROHHAD-NET), Prader–
Willi syndrome, Bardet–Biedl syndrome 
Psychotropic drugs 
Antidepressants Amitriptyline, doxepin, imipramine, clomipramine, 
maprotiline, nortriptyline, trimipramine, paroxetine, 
mirtazapine, desipramine, isocarboxazid 
Mood stabilizers Lithium, valproate, carbamazepine 
Antipsychotic Clozapine, olanzapine, zotepine, quetiapine, chlorpromazine, 
thioridazine, perphenazine, trifluoperazine, risperidone, 
clopenthioxol, sulpiride. 
Idiopathic 
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closed hypophyseal-pharyngeal ducts as craniopharyngiomas by Cushing in 1932 
was an important event, as was the improvement in mortality associated with them in 
the 1950’s [12]. Increased survival has meant that craniopharyngiomas account for a 
substantial proportion of HO secondary to tumours [10]. More recently, with the 
discovery of the impact of certain hormones, genes and medications on the function 
of the hypothalamus (Table 1.1) it has become clear that HO does not affect only 
those with acquired, anatomical damage and that the definition needed to be 
augmented to include these other causes [7, 11].  
 
In the first half of the 20
th
 century the hypothalamus was identified as the 
critical region in HO, rather than the pituitary as had previously been thought [13]. 
Between 1927-1940 animal models in dogs and rats delineated the role of the 
hypothalamus, particularly the ventromedial hypothalamus (VMH), in HO [7, 10, 
14]. These models were later substantiated in humans [14]. In 1969 and 1970 rat 
studies demonstrated that although hyperphagia (defined as “the extreme unsatisfied 
drive to consume food” [15]) was a factor in developing HO, it was not a prerequisite 
[16].   
The “neuroendocrine” era of appetite regulation started with the identification 
of leptin in 1994 [7, 10]. Further studies explored the interaction of multiple new 
(e.g. leptin) and previously identified (e.g. insulin) hormones on weight regulation 
and food intake. Their effects on the hypothalamus and vice-versa have helped 
further knowledge of how HO may develop, although the exact pathophysiology 
remains ambiguous. 
 
 
Anatomy of the hypothalamus and surrounding region 
The hypothalamus forms the ventral part of the diencephalon and lies inferior to the 
thalamus, superior to the pituitary stalk and pituitary gland, posterior to the optic 
chiasm and medial to the temporal lobes and optic tracts (Figure 1.1). It has three 
regions (anterior, tuberal and posterior), each with medial and lateral areas 
containing multiple nuclei (Figure 1.2) with varying functions. 
 
16 
 
Figure 1.1. Midsagittal view of the brain [17] 
 
Figure 1.2. A midsagittal schematic illustrating the nuclei of the hypothalamus [18]  
 
The primary function of the hypothalamus is to control the release of 
hormones from the pituitary gland, however it also facilitates homeostasis by 
controlling many autonomic functions, the sleep-wake cycle and energy regulation 
(balancing energy intake with energy expenditure and body fat stores). Although 
encroachment onto and damage of the hypothalamus by midline lesions (such as 
craniopharyngiomas) are easily seen on MRI scanning (Figure 1.3), the number and 
extent of hypothalamic nuclei affected cannot be precisely determined. 
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Figure 1.3. Coronal and sagittal MRI scans (left), with paired line drawings (right) 
showing: A and B - normal human hypothalamus at the level of the optic chiasm; C 
and D - normal pituitary gland and hypothalamus; E and F - a suprasellar glioma 
with invasion of the mediobasal hypothalamus and 3rd ventricular distortion; G and 
H - suprasellar extension into the medial hypothalamus [5]. 
A      B 
    
C      D 
          
E      F 
               
G      H 
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Prevalence of HO 
The prevalence of weight gain and obesity varies in different series. Studies 
use a variety of methods to report weight (actual weight, body mass index [BMI], 
BMI standard deviation score [SDS], percentage overweight, weight gain) and apply 
varying definitions of obesity (Table 1.2, Appendix 1). Many studies exclusively 
describe patients with craniopharyngioma (CP), often with no clarification regarding 
hypothalamic damage, and information on weight-gain/obesity may only contribute a 
small part to the overall paper (Table 1.3, Appendix 1). The majority of literature 
relates to children with CP. A few papers describe adults with HO, usually including 
both patients with childhood-onset (CO) disease studied as adults, as well as those 
with adult-onset (AO) tumours.  
 
Studies of children and adults with HO secondary to varying pathologies 
A retrospective study from University Hospital Aintree described adults with 
acquired, structural hypothalamic damage [6]. Most were diagnosed with either CP 
(22/52) or pituitary macroadenoma with suprasellar extension (24/52). Forty-two 
patients had serial weight data; 52% had HO after a median follow-up of 5 years. 
This was more than double the rate of obesity at tumour diagnosis (24%). Median 
BMI had increased from 27.8 kg/m
2
 at diagnosis to 30.4 kg/m
2
 over the same time 
period (p<0.0001). Rates of overweight (BMI ≥ 25 kg/m2) had increased from 67% 
to 88% and one patient was morbidly obese (BMI ≥ 40 kg/m2). Another study 
compared 70 adults with CP (24 CO) to 89 with non-functioning pituitary adenoma 
(NFPA) requiring surgery and 29 with hypopituitarism after traumatic brain injury 
(TBI) (Table 1.2) [19]. After a median of 8 years follow-up 66% of patients with CP 
were obese, compared to 47% with NFPA and 31% post-TBI. CP patients had the 
highest median BMI, despite a significantly younger age at diagnosis than the NFPA 
group. The BMI in the post-TBI group was significantly lower than both the CP and 
NFPA groups. Unfortunately, it is not clear at what point after diagnosis BMI was 
recorded, or the length of follow-up in the NFPA or TBI groups. These factors could 
have influenced the findings. Additionally, the presence of hypothalamic damage 
was not specified, making the prevalence of obesity due to hypothalamic damage 
difficult to assess. 
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 A Japanese study described 23 children and adolescents aged 2-22 years with 
suprasellar tumours, primarily CP (10 patients) or germinoma (7 patients), after 2-13 
years of follow-up [20]. At latest follow-up 52% were obese, with no significant 
difference between tumour types.  Another retrospective review studied 46 children 
aged ≤ 16 years at diagnosis of suprasellar tumour with radiological evidence of 
hypothalamic tumour extension [21]. The most common diagnosis was CP (Table 
1.2). The prevalence of obesity increased from 6% at diagnosis to 43% after a 
median follow-up of 3.9 years.  
 
Collectively, across both adult and childhood studies the prevalence of 
obesity at latest follow-up ranged from 43-75%. 
 
Studies of children and adults with craniopharyngioma 
Much of the literature describes weight gain and obesity in patients with CP. 
Some, but not all studies, specify the presence of hypothalamic damage. By 
including some patients without hypothalamic damage the prevalence of HO may be 
underestimated. 
A study of 98 adults and children with surgically-resected CP between 1974-
1991 reported that morbid obesity increased from 10.2% at diagnosis to 35.7% at 
latest follow-up [22]. As height and BMI are not included this study may 
underestimate obesity prevalence, particularly in those diagnosed during childhood 
where growth may have been affected. A retrospective review of UK adults (79 
patients aged 16-83 years) and children (42 patients aged 2.5 to < 16 years) 
diagnosed with CP between 1964-2003 found obesity prevalence increased from 
19.8% 5-years after diagnosis to 38.6% at 10-years and 66.3% after 20-years of 
follow-up in 101 patients with data available [23]. A similar study of 171 French 
patients diagnosed between 1972-2009 included 33 patients diagnosed with CP when 
under 10 years old, 32 patients diagnosed between 10-18 years and 106 with AO CP 
[24]. Suprasellar extension was present in 43.3%, 14.6% had a tumour ≥ 2 cm and 
13% had polydipsia/polyuria/proven central diabetes insipidus (CDI), making 
hypothalamic damage more likely. In those diagnosed under 10 years old 67.9% 
were obese, 14.3% overweight and only 17.9% had a normal BMI. In the cohort 10-
18 years at diagnosis 24% were obese and 30.3% overweight, compared to 42% and 
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36% respectively of those with AO. In keeping with other studies most weight gain 
occurred within the first 12 months of diagnosis. The largest study used data from the 
KIMS (Pfizer International Metabolic Database) growth hormone database of 393 
patients with CP and GH deficiency (GHD, peak GH response to stimulation <3.0 
micrograms/L) who were either GH naïve or untreated for at least six months prior 
[25]. Most had AO CP (> 18 years; 241 patients) compared to 152 with CO (< 18 
years) (Table 1.3, Appendix 1). Given the potential detrimental effects on height of 
GHD in childhood, it was surprising that the prevalence of obesity was greater in AO 
patients (CO 39.1%, AO 51.8%, p = 0.02). It is unknown how many patients had 
hypothalamic involvement as there was no data regarding MRI scanning, although 
almost 60% had panhypopituitarism and over 60% had CDI - both risk factors for 
hypothalamic involvement. Additionally, length of follow-up is unknown and the 
possibility of shorter follow-up in the CO cohort may account for the greater 
prevalence of obesity in AO. Use of the KIMS database as a data source also 
excludes any patients not treated with GH, giving an incomplete picture. In adults in 
the UK, impaired quality of life (QoL) as well as low peak GH on stimulation testing 
is needed to qualify for GH replacement. The cohort studied may therefore be biased 
to include a greater proportion of obese and overweight adults, as these factors can 
lead to decreased QoL. Previous treatment of GHD during childhood for reduced 
height velocity and low peak GH may have influenced the rates of obesity in the CO 
cohort. These significant differences between the cohorts make direct comparison 
difficult.  
 
Across adult and childhood studies of patients with craniopharyngioma the 
prevalence of obesity ranged from 20-68%. 
 
Studies of children with craniopharyngioma 
Studies exclusively including patients with CO CP also describe weight gain 
and obesity (Table 1.3) [26-34]. The largest series is a retrospective review of 185 
children [27]. The authors found severe obesity (BMI > 3 SD) in 44% of patients, 
BMI between +2 and +3 SD in 13% and normal weight (BMI < 2 SD) in 43%. They 
also describe the early-onset weight-gain (within the first three years) noted by 
others. A further study identified risk factors and prognosis associated with severe 
obesity (BMI > 7 SD) [28]. Out of 183 patients in the multicentre HIT-ENDO 
21 
 
database 44.3% had a normal BMI (BMI SD < 2) and 55.7% were obese (BMI SD 
>2), including 30 (16.4%) with severe obesity (BMI ≥ 7 SD). The corresponding 
prevalence of hypothalamic involvement on intraoperative inspection and/or imaging 
illustrates the strong association between hypothalamic damage and obesity (Table 1. 
4). For those with morbid obesity without hypothalamic involvement it is possible 
that damage may have occurred later (for example secondary to radiotherapy) or 
possibly may not have been recognised. 
 
Table 1.4. Prevalence of obesity and hypothalamic involvement 
 Number (%) patients % with hypothalamic 
involvement 
BMI SD < 2 81 (44.3) 33 
BMI SD ≥ 2 <7 72 (39.3) 76 
BMI SD ≥ 7 30 (16.4) 96 
 
Smaller studies collectively show an increase in obesity from 15-30% pre-
operatively to 53-77% after varying lengths of follow-up [26, 29, 33, 34], with a 
weight increase of over 10% in the first three post-operative months in 14/21 patients 
in one study (Table 1.3) [26]. Another study noted an increase in hyperphagia (a 
possible mechanism for HO) from 26% at diagnosis to 70% after a mean follow-up 
of 7 years and morbid obesity (not defined) in 18% of the 66 patients studied [32]. 
BMI was positively correlated with hypothalamic involvement but 32% had no 
hypothalamic involvement on post-operative MRI.  
 
In studies of CO CP the prevalence of post-operative obesity ranged from 24-
77%. Four studies noted the presence/absence of hypothalamic damage, however the 
others gave no indication [28, 32-34]. If patients with CP without hypothalamic 
damage were excluded the prevalence of HO may be even greater than described.  
 
Mechanisms underlying the development of HO  
The hypothalamus regulates weight by integrating afferent inputs such as gut-
derived appetite hormones and initiating efferent stimulation to the periphery to 
control energy expenditure (EE) and physical exertion, thus acting as the homeostatic 
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control centre balancing energy intake (EI), EE and body fat. The proposed 
mechanisms underlying the development of HO include: i) decreased responsiveness 
to afferent signals leading to increased EI (for example impaired gut-brain satiety 
and hyperphagia), ii) increased efferent sympathetic activity leading to decreased EE 
(such as decreased resting metabolic rate and voluntary EE) and iii) increased vagal 
tone (leading to hyperinsulinism). These potential mechanisms will be described 
subsequently. Additionally, in simple obesity the limbic, paralimbic and higher 
cortical brain regions which process non-homeostatic environmental cues and the 
rewarding properties of food influence body weight.  The interactions between the 
hypothalamic homeostatic centre and these other centres in humans remains poorly 
understood and little investigated in those with hypothalamic damage.  
 
Key hypothalamic regions and their hormonal associations 
The key hypothalamic regions associated with control of appetite are:  
 
1. the arcuate nucleus (ARC) (Figure 1.4) which secretes agouti-related peptide 
(AgRP) and neuropeptide Y (NPY) with orexigenic effects and pro-opiomelanocortin 
(POMC) and cocaine- and amphetamine-related transcript (CART) which are 
anorexigenic [7]. Both sets of neurones have receptors for the peripherally-secreted 
hormones leptin (Figure 1.4) and insulin, which stimulate POMC and suppress 
AgRP/NPY [11, 35]. Damage to these neurones may lead to disordered responses to 
leptin and insulin, causing appetite dysregulation and HO. Activation of the 
neurones’ ghrelin receptors stimulates NPY and inhibits POMC, causing orexigenic 
effects. The ARC is connected directly to the paraventricular nucleus (PVN), lateral 
hypothalamus (LH) and other homeostatic brain regions [11]. 
2. the paraventricular nuclei (PVN) which express melanocortin-4 receptors 
(MC4R, Figure 1.4); these are stimulated by -melanocyte-stimulating hormone (-
MSH) cleaved from POMC [11, 35]  and inhibited by AgRP by competitive binding 
with -MSH [35]. Acting through effector neurones which synapse in higher cortical 
brain centres, stimulation of MC4R has anorexigenic effects and inhibition has 
orexigenic effects [11, 35]. MC4R stimulation also results in increased EE [11]. 
Other neuropeptides including the anorexigenic corticotrophin-releasing hormone 
(CRH) and oxytocin are secreted from here [7].  
 
23 
 
  
3. the ventro-medial hypothalamus (VMH) has glucose- and insulin-sensing 
neurones and numerous other neuropeptide receptors (Figure 1.5) [11]. 
4. the lateral hypothalamus (LH) contains hypocretin and melanin concentrating 
hormone (MCH) neurones [11]. 
 
Figure 1.4. Effects of leptin (adapted from Walley et al [35]).  
 
                 Leptin  released from fat cells  
                                                               binds to  
  
 
ARC LEPR    on POMC neurone           LEPR   on AgRP neurone 
           stimulation          inhibition 
   
      produces -MSH                      produces AgRP 
      which  
PVN  stimulates MC4R    inhibits MC4R 
 
               leading to        
      increased BDNF     decreased BDNF 
  
   which           
  
increases NTRK2    decreases NTRK2 
       
which act on higher cortical centres  
 
decreasing food intake    increasing food intake 
 
ARC: arcuate nucleus, LEPR: leptin receptor, POMC: pro-opiomelanocortin, AgRP: 
agouti-related peptide, -MSH: -melanocyte-stimulating hormone, MC4R: 
melanocortin-4 receptor, BDNF: brain-derived neurotrophic factor, NTRK2: 
Neurotrophic tyrosine kinase receptor type 2.  
 
Other important hormones include cholecystokinin (CCK) and glucagon-like 
peptide 1 (GLP-1) (Figure 1.5). There are also mechanical influences on the 
hypothalamus, such as the stretch receptors of the stomach and visual and odour 
stimuli. In addition to the hypothalamus, the amygdala, limbic system, cerebral 
cortex and brainstem all play a role in appetitive neural circuitry [36]. 
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Figure 1.5. Key neural and hormonal interactions regulating appetite and food 
intake. Adapted from text and figures by Roth [37] and Lustig [38]. 
NTS – Solitary tract nucleus, LC – Locus coerulus, MeRa – Median raphe, DMN – 
Dorsomedial nucleus, LH – Lateral hypothalamus, PVN – Paraventricular nuclei, 
VMN – Ventromedial nucleus, ARC – Arcuate nucleus, MC4R – Melanocortin-4 
receptor, INSR – Insulin receptor, LEPR – POMC – Pro-opiomelanocorticotropin, 
CART – Cocaine- and amphetamine-related transcript, AgRP – Agouti-related 
peptide, NPY – Neuropeptide Y, GLP-1 - Glucagon-Like Peptide-1, PP – Pancreatic 
polypeptide, CCK - Cholecystokinin 
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While the hypothalamus is the critical homeostatic centre regulating appetite and 
eating, the limbic, paralimbic and higher-cortical brain regions process non-
homeostatic environmental cues and the rewarding properties of food. 
 
Hormones and hyperphagia 
Hyperphagia has been reported in patients with both non-structural HO [39] 
and those with acquired, structural forms [11, 23, 40, 41]. A study by Daousi et al 
found that compared to 15 age-, BMI- and body fat-matched simple obese (SO) 
controls, 14 participants with HO reported significantly more hunger and desire to 
eat on visual analogue scale (VAS) ratings three hours after eating [2]. This 
suggested that post-prandially those with HO are full for a shorter period than those 
with SO. Interestingly though, their responses to the Three Factor Eating 
Questionnaire (TFEQ) indicated lower long-term hunger than controls. HO has also 
been reported in the absence of increased food consumption however, indicating this 
is not the only causative factor [42, 43]. Several different mechanisms have been 
postulated as the cause of hyperphagia (leptin insensitivity, hyperghrelinaemia, 
hyperinsulinaemia due to vagal disinhibition). 
 
Impaired gut-brain signalling? The role of gut hormones  
 
Ghrelin  
Ghrelin is a gut hormone which consists of 28 amino-acids and is cleaved 
from preproghrelin. It exists in different forms within the human body – active (acyl-
ghrelin) and inactive (desacyl-ghrelin). Post-translational acylation is necessary for 
ghrelin to cross the blood-brain barrier [44] and enable appetitive effects. Assays can 
measure either active acyl-ghrelin or total (acyl- and des-acyl) ghrelin [45]. Ghrelin 
increases when fasted, leading to hunger and meal initiation, and falls post-prandially 
due to inhibition by insulin and PYY which increase once fed [39]. Fasting ghrelin is 
lower in the obese population and increases following weight reduction [36], 
however is increased in patients with PWS compared to normal-weight controls [39, 
46]. In patients with HO the presence of hyperghrelinaemia has been investigated [2-
4, 39, 47]. 
In 16 children with HO secondary to craniopharyngioma or other structural 
lesions fasting total ghrelin concentrations were not different to SO controls (Table 
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1.5, Appendix 1) [47]. Both groups had significantly lower total ghrelin than normal 
weight controls. The same study showed no significant difference in fasting insulin, 
HOMA-IR or leptin between HO and SO but fasting glucose was lower in HO. A 
study of adult patients measured both fasting and post-prandial total ghrelin 
concentrations in patients with HO secondary to craniopharyngioma (BMI > 28 
kg/m
2
 and confirmed hypothalamic damage), non-obese patients with 
craniopharyngioma (CrNW), PWS, SO and non-obese controls (NOC) [39]. The 
authors found that after adjustment for age and gender, fasting ghrelin was lower in 
nine patients with HO than in 15 NOC (p<0.05) and 26 PWS patients (p<0.001, 
Table 1.5) [39]. Ghrelin concentrations were similarly reduced in 16 SO controls. 
Fasting plasma ghrelin was negatively correlated with fasting insulin and percentage 
body fat in HO and CrNW but not in PWS. In a separate fasting and fed arm, 
following a 522-kcal breakfast trough ghrelin concentration was significantly lower 
in HO than NOC with a significantly delayed trough. Postprandial ghrelin AUC was 
lower in HO than NOC but with a similar mean post-prandial fall in both groups. 
Hyperghrelinaemia was evident in PWS patients but not HO patients whose ghrelin 
concentrations were comparable to SO. 
 Two studies found lower ghrelin concentrations in HO compared to SO. 
Fasting total ghrelin was significantly lower in 14 patients with HO compared to 15 
healthy age- and BMI-matched SO controls (p = 0.03, Table 1.5) despite other 
markers such as percentage body fat, fat-free mass and WHR being comparable 
between the groups [2]. In response to a test-meal of 600 kcal both groups 
demonstrated a similar decrease in plasma total ghrelin concentrations, but with a 
significantly lower AUC in HO. Fasting leptin and HOMA-IR were similar in both 
groups. Forty-two adults with childhood onset craniopharyngioma (CP) also had 
significantly lower fasting total plasma ghrelin than 42 age- and gender-matched 
controls (Table 1.5) [3]. Those patients with third ventricular extension (TVE), an 
indication of hypothalamic damage, had significantly lower fasting plasma ghrelin 
than those without (p = 0.008). As the median BMI was significantly higher in 
patients than controls and in those patients with TVE than those without, these 
differences would be expected.  
Finally, lower fasting total ghrelin was demonstrated in 15 obese children 
with craniopharyngioma (CrO) and 15 SO age-, gender- and BMI-matched controls 
than in 12 CrNW and 12 normal weight (NW) controls [4]. However, whereas 
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ghrelin supressed significantly in SO and CrNW and NW there was a non-
statistically significant decrease in the one-hour post-prandial ghrelin in CrO. Their 
baseline and post-prandial ghrelin concentrations were lower than SO. Only 87% of 
CrO and 58% of CrNW had tumours extending into the hypothalamus. Those with 
hypothalamic involvement had a higher BMI SDS and a smaller percentage decrease 
in post-meal ghrelin than those without (p<0.05).  
 
None of the studies demonstrated a role for hyperghrelinaemia in the 
pathophysiology of HO and in fact three [2-4] found lower ghrelin concentrations 
than in healthy age- and BMI-matched controls. 
 
 
Peptide YY (PYY) 
Peptide YY (PYY) is another gut hormone and consists of 36 amino-acids. Its 
release is stimulated by the presence of nutrients in the gut lumen and regulated by 
other peptides such as GLP-1. It also exists in two different forms – PYY(1-36) and 
PYY(3-36). PYY(1-36) shows high affinity to all known Y-receptor subtypes 
through which it acts, however PYY(3-36), formed from cleavage of PYY(1-36) by 
dipeptidyl peptidase IV, shows high affinity only to the Y2 receptors [48]. Both 
forms cross the blood-brain barrier but have differing effects – whilst PYY(1-36) 
stimulates appetite and therefore promotes weight gain, PYY(3-36) is associated with 
meal termination via its actions on the arcuate nucleus to inhibit NPY release [49]. 
PYY(3-36) is reduced in those with SO compared to non-obese [48]. In a 
study of 14 patients with HO, fasting total PYY concentrations were similar to 15 
healthy age- and BMI-matched SO controls (p = 0.06, Table 1.5) [2]. After a 600-
kcal meal those with HO lacked the sustained rise in PYY normally seen following 
food ingestion, although they displayed a similar post-prandial AUC to SO, who also 
did not display a typical post-prandial PYY rise. The increase occurred only 180 
minutes after food ingestion, whereas this would be expected to occur from about 15 
minutes. Another study found similar concentrations of fasting PYY(3-36) in nine 
patients with HO, six CrNW, 16 SO and 15 NOC (Table 1.5) [39]. There was no 
correlation between percentage body fat and fasting PYY(3-36)  in HO or CrNW. 
After a 522-kcal breakfast, post-prandial peak PYY(3-36)  and AUC PYY(3-36)  
concentrations were similar in six HO, nine SO, eight NOC and ten patients with 
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PWS. In contrast, Roth et al’s study  of 12 CrNW, 15 CrO, 12 NW and 15 SO-
controls found that total PYY concentrations increased post-prandially in all groups 
(figures not given), however craniopharyngioma patients (normal weight and obese) 
had a lower percentage increase than BMI-matched controls [4]. BMI SDS correlated 
negatively with postprandial percentage change in PYY but there was no relationship 
with tumour size and no difference in either fasting or postprandial PYY 
concentrations between those with hypothalamic involvement and those without.  
 
There is no conclusive evidence to suggest PYY variations as a 
pathophysiological mechanism for weight gain in those with hypothalamic damage. 
  
 
Other hormones/enzymes influencing appetite 
Leptin  
Leptin is produced by fat cells and is anorexigenic, primarily via the 
hypothalamus [50]. Leptin increases with rising adiposity, however this only appears 
to have a limited effect on food intake and leptin resistance is thought to be an 
evolutionary mechanism to prevent starvation [35]. 
In a study comparing patients with craniopharyngioma (obese and normal 
weight) and BMI-matched controls, leptin was positively correlated with BMI SDS, 
fasting insulin and HOMA-IR and negatively correlated with insulin sensitivity in all 
participants [4]. Holmer et al found higher leptin in 42 adults with CO CP than 42 
controls not matched for BMI (p<0.001) with this difference persisting when 
corrected for fat mass (p<0.001) suggesting possible leptin insensitivity in CP [3]. 
When CP patients with TVE, a marker of hypothalamic involvement, were compared 
to those without TVE there was no significant difference in leptin concentration 
(Table 1.6, Appendix 1) or leptin corrected for fat mass, despite a significantly 
greater BMI in those with TVE (p=0.001). However, in a comparison of 14 children 
with CP (11 with suprasellar extension, 3 with intrasellar tumours) and 53 controls, 
after adjustment for BMI those with suprasellar tumours had higher leptin 
concentrations than controls, with similar concentrations in controls and those with 
intrasellar tumours [40]. The authors theorised that leptin insensitivity in patients 
with suprasellar craniopharyngioma led to increased NPY and decreased CRH 
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(which increase appetite), however assessments of hyperphagia and food 
consumption were not undertaken. Higher leptin in patients with hypothalamic 
involvement was supported in a second study of 23 obese children with 
hypothalamic-pituitary tumours (HPO), 16 non-obese children with hypothalamic-
pituitary tumours (HPNO) and 22 SO controls [51]. The HPO group had higher 
serum leptin:BMI ratio and free leptin index than SO and HPNO (Table 1.6). In the 
17/23 (73.9%) with HPO and tumour involving the thalamus/hypothalamus and the 
4/16 (25%) with HPNO and thalamic/hypothalamic tumour serum leptin was higher 
compared to those without thalamic/hypothalamic involvement.  
One study compared fasting leptin in 28 patients with HO to 18 patients with 
congenital hypopituitarism (CH) and 23 SO-controls [52]. Age and gender were 
similar in all three groups but SO were significantly taller and heavier than HO and 
CH, with a non-significant difference in BMI SDS. Leptin concentrations were 
highest in HO and this difference persisted after adjustment for fat-mass, gender, age 
and pubertal status (Table 1.7, Appendix 1). Even after adjustment for fat-mass leptin 
was 22% higher in HO than in CH and 50% greater than in SO. Other biochemical 
measurements found that fasting glucose was highest in SO, however no participants 
had diabetes mellitus or impaired fasting glycaemia and fasting insulin and insulin 
resistance (HOMA-IR) were not significantly different between groups. Adiponectin 
and resistin were highest in HO - the cause of which and their contribution to HO 
remains unclear and findings in simple obesity are inconsistent.  
Another study compared serum leptin concentrations and leptin binding in 37 
children with hypothalamic-pituitary axis (HPA) tumours and 85 healthy controls 
[53]. Participants were divided into BMI < 2 SDS (17 patients, 57 controls) and BMI 
≥ 2 SDS (17 patients, 28 controls). Within each cohort there was no difference in 
gender, pubertal status or median age, however there was significantly greater  BMI 
SDS in HPA than in controls in both groups. Both serum leptin and leptin adjusted 
for BMI were higher in HPA than controls, however this only reached significance in 
those with BMI SDS < 2. Serum leptin binding activity and BMI-adjusted 
concentrations were lower in HPA than controls so there was no evidence that leptin 
resistance was secondary to increased leptin binding in HO. 
 
 Only one study found no difference in fasting leptin concentrations between 
patients with HO and controls. In 15 children with CP and hypothalamic damage 
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with BMI > 95
th
 percentile for age and gender and 15 age-, gender-, puberty- and 
BMI-matched SO controls leptin concentrations were not different [54].  
 
With the exception of the last study [54], hyperleptinaemia has been 
consistently demonstrated in HO, however it remains unclear whether this is a 
pathophysiological mechanism causing HO, possibly secondary to leptin resistance 
caused by abnormal signalling; leptin insensitivity at the hypothalamus itself [52]; or 
a consequence of HO [29]. 
 
 
Insulin 
The most researched mechanism for HO is hyperinsulinaemia. It has been 
proposed that hypothalamic damage leads to vagal nerve disinhibition. Increased 
vagal stimulation of the pancreas then results in excess insulin secretion leading to 
accumulation of fat and therefore weight gain and obesity [3, 55].  
 
Studies linking hyperinsulinism and HO 
  Bray et al described increased insulin secretion early in the course of HO and 
found impaired glucose tolerance on OGTT in 4/8 [9]. More recently, in 17 children 
with panhypopituitarism following craniopharyngioma resection (not fully pituitary 
hormone replaced), insulin concentrations had already increased significantly one 
month post-operatively (p<0.05) [29]. Leptin had significantly increased 3-6 months 
post-operatively (p<0.01), as had BMI SDS (p<0.01). The authors concluded that as 
insulin increased first, it was the driver for weight gain and that hyperleptinaemia 
was a consequence of the increased body mass. Pre-operative fasting insulin 
concentration was positively correlated with pre-operative BMI, leptin and growth 
factors, and with post-operative weight gain (p<0.01) but not with BMI SDS at 12 
months. Significantly one patient gained weight despite normal insulin 
concentrations. There are several weaknesses in this study. Firstly, although post-
operative BMI SDS was analysed pre-operatively only BMI is noted. Secondly, 
hypothalamic involvement is not clear. Most importantly, the effects of untreated 
GHD and sex-steroid deficiency in some patients may have significantly influenced 
findings.  
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In a case-control study of 15 children with HO following surgically-resected 
craniopharyngioma (CP) and 15 SO age-, gender- and BMI-matched controls, their 
insulin dynamics and the prevalence of metabolic syndrome differed significantly 
[54]. Fasting insulin concentrations were not different between the groups nor was 
calculated whole body insulin sensitivity on OGTT. However OGTT did produce 
significantly greater first and second phase insulin secretion and AUC insulin and 
insulin sensitivity on frequently sampled intravenous glucose tolerance test was 
significantly lower in CP participants (Table 1.8, Appendix 1). The effects of OGTT 
on gut hormones such as GLP-1 may account for the differences found between the 
different methods. While none of the SO had impaired glucose tolerance on OGTT, 
40% of CP did. The incidence of metabolic syndrome was also significantly higher 
in CP (73% vs. 20% in SO, p = 0.03). The main weakness of this study is that (as 
with many of the other studies) it was unable to distinguish cause and effect. As the 
mean time since CP diagnosis was 4.9 years, hyperinsulinaemia may have been a 
consequence of HO rather than causal. Notably, controls had a tendency towards 
being more advanced in puberty - a time of increased insulin resistance – therefore a 
more marked difference may actually have existed. 
 A study of 42 adults with childhood-onset CP (25 with possible hypothalamic 
damage, 17 without) and 42 age- and gender-matched controls found higher fasting 
serum insulin in patients than controls (Table 1.9, Appendix 1), with BMI, 
percentage fat mass and percentage fat-free mass all significantly higher in CP [3]. 
When the patients with and without possible hypothalamic damage were compared, 
those with hypothalamic involvement had significantly greater BMI, fat mass, fat-
free mass and fasting insulin concentration. 
Another case-control study found significantly higher fasting and post-
prandial insulin, and HOMA-IR in 15 obese children with craniopharyngioma (CrO) 
compared to CrNW and age-, gender- and BMI-matched controls [4]. Quantitative 
insulin sensitivity check index (QUICKI) was significantly lower in CrO and BMI 
SDS was positively correlated with fasting and post-prandial insulin and negatively 
correlated with QUICKI. Hypothalamic extension was present in 93% of CrO and 
57% of CrNW. Fasting insulin and HOMA-IR were non-significantly higher in those 
with hypothalamic involvement than those without however this sub-group analysis 
was relatively small (19 and 6 patients respectively) and not separated into obese or 
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normal weight. It is therefore difficult to conclude whether changes in insulin 
dynamics are a cause or a consequence of HO.  
In a study by Goldstone et al, mean fasting and postprandial AUC insulin 
were higher in those with HO than in SO controls and those with PWS (Table 1.8) 
[39]. Both fasting HOMA-IR and post-prandial HOMA-IR were significantly higher 
in HO. 
  
In two studies investigating the effects of the somatostatin analogue 
Octreotide on weight gain in HO [55, 56] Lustig et al found no increase in fasting 
insulin concentration before or following six months treatment with Octreotide 
(Table 1.10, Appendix 1) [56]. However 5/8 patients had impaired glucose tolerance 
on OGTT, with a delayed and higher mean peak insulin compared to non-obese 
controls. The second study of 20 patients also found an increased insulin response to 
OGTT at the start of the study [55]. 
 
Studies finding no association between insulin concentration and HO 
In contrast, other studies have found no evidence for hyperinsulinaemia as the 
cause of HO. Shaikh et al found no significant difference in the prevalence of fasting 
hyperinsulinaemia, insulin resistance or median fasting insulin concentrations in 28 
children with HO, 18 with congenital hypopituitarism and 23 with SO with similar 
BMI SDS [52]. All groups had elevated fasting insulin concentrations. There was a 
positive correlation between insulin concentration and fat mass (p<0.01). As only 
fasting insulin was measured, insulin response to OGTT may have yielded a 
difference [54]. 
In nine patients with CP compared to age-, gender and BMI-matched 
controls, similar fasting glucose and insulin concentrations, insulin sensitivity (Table 
1.8) and rates of fasting hyperinsulinaemia were found [57]. Of note, not all the 
patients were obese and the study used an intravenous glucose tolerance test 
(IVGTT), which is less physiological than an OGTT. Another study compared 23 
obese children with hypothalamic-pituitary tumours (HPO), 16 non-obese children 
with hypothalamic-pituitary tumours (HPNO) and 22 simple obese controls (SO) 
[51]. Fasting glucose, fasting- and 2-hour insulin following OGTT, and HOMA-IR 
were lower in HPO and HPNO than SO controls, however there was a significantly 
greater increase in insulin following glycaemic load in HO (3.5-fold increase) than 
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HPNO (3-fold) and SO (2.5-fold increase). The authors concluded that insulin 
dysregulation, rather than insulin resistance was a feature of HO. Similar findings 
have also been reported in another study [58].  
 
Pinto et al [29] describe weight gain in one patient with acquired 
hypothalamic damage despite a normal fasting insulin concentration and in a study of 
“growth without growth hormone” 2/9 patients had weight gain despite a lower peak 
insulin response to OGTT than found in normal controls [59]. This may imply that 
other mechanisms, either alone or in combination with hyperinsulinism are 
responsible for weight gain in HO. In most of the obese patients studied however, 
hyperinsulinism was found [29, 59] and other studies of “growth without GH” in 
children with craniopharyngioma [60] have found a correlation between 
hyperinsulinism and good height velocity in patients with GHD [60-62]. 
 
There are no studies using clamp techniques to investigate insulin resistance 
in patients with HO and many of the studies described do not assess fat- or muscle-
mass. As BMI is a relatively crude marker, ideally a measure of body composition, 
such as bio-electrical impedance or MRI assessment of fat/muscle proportion and fat 
distribution would be undertaken. 
An alternative hypothesis to hyperinsulinism as a mechanism for HO is 
hyperinsulinaemia secondary to obesity. In conclusion, the role of hyperinsulinaemia 
– whether it is a causative factor or consequence of HO - remains unclear. 
 
 
11β-hydroxysteroid dehydrogenase (HSD) 1 activity 
The enzyme 11β-hydroxysteroid dehydrogenase (HSD) 1 converts inactive 
cortisone to active cortisol. One study investigated whether increased enzyme 
activity in patients requiring replacement glucocorticoids for cortisol deficiency 
secondary to pituitary or hypothalamic damage might result in abnormal 
glucocorticoid metabolism and obesity [42]. This was based on observations that the 
pattern of obesity in HO was similar to that in Cushing syndrome and that weight 
gain did not always seem proportional to reported food intake. The authors compared 
ten patients with HO and ACTH-deficiency needing glucocorticoid replacement with 
six requiring glucocorticoid replacement for other reasons. The BMI SDS of HO 
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patients was wider (-0.02 to +8.36) than controls (-1 to +1) and both groups 
contained participants with below average BMI SDS. Activity of 11β-HSD was not 
measured directly, but estimated using the ratios of various urine steroids and steroid 
metabolites. The authors found increased ratios of active cortisol/inactive cortisone 
(and their respective metabolites) in HO than controls and a significant correlation 
between the conjugated cortisol/cortisone ratio and the visceral fat/total adipose 
tissue ratio on a single slice CT at the umbilicus, but no correlation with BMI or BMI 
SDS. They conclude that these differences identified in patients with HO compared 
to controls indicate altered conversion of pharmacological glucocorticoid 
replacement in HO, potentially promoting obesity. The same ratios measured in 
simple obesity have been inconsistent [42] and further studies in the HO population 
are needed to establish whether this finding is reproducible and consistent. 
 
All Hormones 
 In summary, there is no evidence to support either hyperghrelinaemia or 
abnormalities in PYY concentration as the underlying mechanism leading to HO. 
Hyperleptinaemia and hyperinsulinism have both been demonstrated in studies 
(although not consistently in all studies) and whether their presence are the cause or 
effect of HO remains unclear. 
 
 
Reduced efferent sympathetic activity 
 Reduced sympathetic activity is another mechanism postulated to cause HO, 
possibly through decreased lipolysis resulting in lower resting metabolic rate and 
voluntary energy expenditure (EE) as well as symptoms such as lethargy [38].  
 Sympathoadrenal activity was assessed in eight patients with CP and 
hypothalamic damage by measuring plasma epinephrine and norepinephrine and 
assessing neurogenic and neuroglycopaenic symptoms and heart rate during induced 
hypoglycaemia [63].  Responses were compared to four patients with 
hypopituitarism due to other causes (HP) and six healthy controls. Baseline 
epinephrine did not differ between groups but some CP patients had a poor 
epinephrine response to hypoglycaemia, therefore CP patients were subdivided into 
two groups: poor responders (CPPoor) and good responders (CPGood, similar to that 
of controls).  Plasma norepinephrine was similar in all groups at baseline and in 
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response to hypoglycaemia. Heart rate response to hypoglycaemia was lower in 
CPPoor with fewer adrenergic symptoms (tremor, anxiety, heart pounding), 
reflecting lower epinephrine response. There was no correlation between either 
biochemical markers or symptoms of hypoglycaemia and BMI. An orthostatic test of 
catecholamine and heart rate demonstrated a comparable increase in all groups. The 
authors concluded that the brainstem mediated sympathetic response was intact and 
that the reduction in heart rate response, adrenergic symptoms and epinephrine rise in 
CPPoor indicated damage to hypothalamic neurons needed to mount a counter-
regulatory response to hypoglycaemia. These findings support the hypothesis of 
decreased sympathetic tone in some patients with hypothalamic damage, although 
the absence of a correlation with obesity/increased BMI does not support this as a 
mechanism for HO. 
A second study measured urinary catecholamines and their metabolites 
(homovanillic acid [HVA] and vanillylmandelic acid [VMA]) and assessed physical 
activity, resting heart rate, blood pressure and treatment of hormone deficiencies in 
109 patients with CP [64]. Hypothalamic involvement was present in 69%, but rose 
to 81% in 28 obese patients (BMS SDS 2-4) and 91% in 44 with extreme obesity 
(BMI SDS > 4). Norepinephrine/creatinine ratio was no different in those with and 
without hypothalamic damage. Both HVA and VMA were lower in those with BMI 
SDS > 4 than in those with BMI SDS 2-4 and highest in those with BMI SDS < 2. 
The decrease in catecholamine metabolites in those with obesity/extreme obesity 
suggested decreased sympathetic activity. Physical activity questionnaires 
demonstrated lower self-reported activity in patients with hypothalamic involvement 
than those without and was negatively correlated with BMI SDS. Decreased EE due 
to reduced sympathetic nervous activity secondary to hypothalamic damage is 
supported by these findings. 
 
Energy expenditure (EE) and energy intake (EI) 
Lower levels of physical activity have been described in nine children with 
CP compared to eleven controls in a home setting and 10 patients compared to 15 
controls during hospital admission for a weight-reduction programme (Table 1.11, 
Appendix 1) [43]. Not all CP patients had hypothalamic involvement. On 
accelerometry, movement count was lower in CP than controls (Table 1.11). Seven 
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day self-reported food diaries showed the lowest reported calorie intake in patients 
with intrasellar CP (mean 1916 ± 677 kcal/day), slightly greater in those with 
hypothalamic CP (mean 2075 ± 877 kcal/day) and greatest in controls (mean 2476 ± 
815), however these were completed by only 48% of patients. This significant 
limitation may have led to an underestimate of intake in patients. Under-reporting in 
the completed food diaries, either intentional or unintentional, is also possible. 
Additionally, accelerometry data does not reflect total EE which requires assessment 
of resting energy expenditure and non-exercise activity thermogenesis. 
Another study assessed basal metabolic rate (BMR) and physical exertion in 
18 children with CP and HO, 13 with congenital hypopituitarism (CH) and 16 with 
SO [65]. BMR was measured at rest wearing a ventilated hood and physical exertion 
by seven day accelerometry. Despite no significant difference in BMI SDS between 
groups, mean BMR was significantly higher in SO (Table 1.11) and after adjustment 
for gender, free T3 and lean body mass the differences persisted, with BMR lowest 
in HO. Accelerometry data was inconsistent due to equipment error. Total EI was not 
different between groups and compared to average estimated requirements reported 
EI was low in all groups, indicating possible under-reporting.  
The final study of 42 adults with CO CP and 42 age- and gender-matched 
controls found the CP group were less physically active and had higher weight, BMI, 
fat and muscle mass, waist and WHR than controls, with lower ghrelin and fT3 and 
higher leptin, leptin/kg fat mass and free T4 concentrations [3]. Although BMR was 
significantly higher in CP than controls, the calculated percentage of expected BMR 
was lower (Table 1.11). EI and EI/BMR ratio were significantly lower in CP. TFEQ 
indicated similar disinhibition and hunger but higher restraint in CP, reflecting 
deliberate food restriction despite hunger. In summary, CP patients had greater fat 
accumulation, lower than expected percentage BMR and were more sedentary but 
consumed fewer calories, with little difference in eating behaviour. Subgroup 
analysis of CP patients with third ventricular involvement, a marker of hypothalamic 
damage, found higher BMI, WHR, fat mass and fat-free mass in those with third 
ventricular involvement than those without. There was no difference between the 
groups in BMR, percentage BMR of expected, or EI, although there was a 
significantly lower ratio of EI/BMR in those with third ventricular involvement than 
those without. Ghrelin was significantly lower, and insulin and insulin/kg fat mass 
higher in those with third ventricular involvement than those without. Percentage 
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calorie intake from fat, protein and carbohydrate and TFEQ scores were similar in 
both groups. One of the main disadvantages of this study is the duration of time since 
initial diagnosis and therefore the study may be measuring the effects rather than the 
cause of the HO. 
 
 In addition to reduced sympathetic activity other factors may effect physical 
activity following hypothalamic damage: physical factors such as restricted vision 
secondary to tumour impingement on the optic chiasm, neurological deficits, 
disturbed melatonin production leading to daytime somnolence [66] and finally, 
undertreated hormone deficiencies such as thyroxine, hydrocortisone, GH and 
testosterone. These three studies demonstrated lower physical exertion with a similar 
EI in patients with HO compared to controls. BMR in those with HO was lower than 
controls in one study and greater in another, although with a reduced percentage 
BMR of expected. The small number of studies, with differing methods and different 
findings make it difficult to conclude whether reduced efferent sympathetic activity 
leading to reduced EE (either through physical activity or through resting energy 
expenditure) could contribute to HO. 
 
In summary, the mechanisms underlying the development of HO remain 
poorly understood and in some cases contradictory and are far from conclusive. 
 
 
Clinical features and sequelae of hypothalamic obesity 
 
The pattern of weight gain in HO is well described, with significant and rapid 
post-operative weight increase in the first 6-12 months following treatment [27, 33] 
which then stabilises but does not remit [3, 33]. The sequelae of simple obesity have 
been described in the medical literature for well over half a century, with long-term 
morbidities such as cardiovascular, renal and liver disease and type 2 diabetes 
mellitus [67] which not only impair quality of life, but also increase mortality. More 
recent reports describe sleep-disordered breathing, non-alcoholic fatty liver disease 
and an increase in certain cancers [68]. An increase in the prevalence of some of 
these sequelae and risk factors have also been described in patients with 
hypopituitarism [69, 70], although in most cases not exclusively in patients with 
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hypothalamic involvement. Increased mortality rates in craniopharyngioma are also 
described. 
 
Mortality rates 
An early study (1951-1988) described increased mortality following 
craniopharyngioma (CP) diagnosis, higher in females than males and remaining 
raised after excluding early postoperative deaths (Table 1.12, Appendix 1) [71]. All 
patients had suprasellar tumour extension and 88% had third ventricular involvement 
therefore the proportion with hypothalamic damage is likely to be significant 
although it was not specifically defined. Only 12 patients were treated for GHD and 
as untreated GHD is associated with increased cardiovascular risk factors this may 
have increased morbidity, although a later study found no difference in mortality 
between those with treated and untreated GHD [19]. Subsequent studies also 
reported an increase in mortality (18-30%) [19, 72], with a higher SMR in females 
than males [19, 72-75]. Postulated mechanisms include delayed diagnosis, oestrogen 
supplementation and oral oestrogen supplementation leading to GH resistance [76]. 
A meta-analysis of six studies containing patients with pituitary disease (with or 
without pituitary insufficiency) found an increased SMR in all patients with weighted 
SMR significantly higher in women compared to men (p<0.0001) [74]. 
A large UK study of patients with hypopituitarism of varying causes found 
that even after excluding deaths in the first postoperative month there was increased 
mortality in those who underwent pituitary surgery [73], however Pereira found no 
effect of treatment modality (surgical approach, use of radiotherapy) [72]. Other risk 
factors identified are diagnosis of CP, treatment with radiotherapy, younger age at 
diagnosis of hypopituitarism and untreated gonadotrophin deficiency [73]. For those 
treated with radiotherapy cerebrovascular mortality (SMR 4.4 [2.5-7.7] vs. 1.6 [0.9-
3.0], p=0.001) and other malignancies are significantly increased (SMR not stated, 
p=0.036).  
None of these studies specify the prevalence of obesity or include 
obesity/BMI but a large cross-sectional study did consider both obesity and 
hypothalamic damage [28]. Differences in overall survival were not significantly 
different between those with and without hypothalamic involvement, however 20-
year survival was significantly lower in those with severe obesity compared to 
moderately obese and normal weight patients (p = 0.03).  
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Two studies focussed on cerebrovascular and cardiovascular mortality (Table 
1.12) [77, 78]. The first found increased mortality from cerebrovascular disease 
(higher in females than males), with no relationship to duration of pituitary 
insufficiency but increased risk where pituitary insufficiency was diagnosed when 
under 55 years [77]. Overall cardiovascular mortality was also increased. None of the 
patients were reported to have received GH replacement. The wide study period 
(1952-1992) means there would have been considerable variation in the definition 
and treatment of pituitary hormone deficiencies. The second study found an 
increased estimated relative risk of death compared to that expected based on age, 
gender and period-specific UK mortality rates [78]. Pituitary or hypothalamic disease 
or other brain tumours were the biggest cause of death, but cerebrovascular disease 
was also increased.  
 
All of these studies (Table 1.12) are retrospective and the hormonal 
supplementation of hypopituitarism has changed over time - GHD was previously 
untreated/infrequently treated and higher doses of corticosteroids were used, not 
reflecting current practice. In fact Nielsen et al found a normal SMR in males 
diagnosed from 1985 onwards [74]. Treatment of the underlying disease has also 
changed, with trans-sphenoidal surgery increasingly utilised and evolving 
radiotherapy techniques aiming to spare normal surrounding tissue and reduce 
vascular injury [76]. This may be particularly important since the risk of increased 
mortality in patients treated with standard radiotherapy remains inconclusive [73].                                      
 
Cardiovascular risk factors and disease  
Studies report increased prevalence of cardiovascular risk factors in adults 
with hypothalamic-pituitary disease (Table 1.13, Appendix 1), with at least one risk 
factor in 57% of patients in one study [72]. In addition, these are often inadequately 
treated, with sub-optimal treatment of hypertension and hyperlipidaemia in 44.6% 
and 69% respectively in a study undertaken at University Hospital Aintree [79]. 
Reported prevalence of treated hypertension ranges from 15-37%, dyslipidaemia 
treated with lipid-lowering therapy from 28-47%, diabetes mellitus from 9-18% and 
metabolic syndrome in 47% [19]. Atherosclerotic cardiovascular disease has been 
reported in 11.1% [79]. In studies of patients with pituitary adenomas, the inclusion 
of those with acromegaly or Cushing’s disease, which have additional mechanisms 
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influencing cardiovascular risk factors confer an additional increased risk of 
cardiovascular risk factors and disease.  
In children, Srinivasan found an adverse lipid profile and increased 
abdominal body fat in 9 patients with craniopharyngioma compared to 9 age, gender 
and BMI-matched healthy controls [57]. There was no difference in height, BMI 
SDS, WHR, abdominal or total body fat, insulin sensitivity or lipid profile between 
those with treated and untreated biochemical GHD. A Japanese study found 
hyperlipidaemia in 58% (7/12) of obese children with suprasellar tumours compared 
to just 39% (9/23) of the total group (lean and obese), with increased small dense 
LDL, which was significantly correlated with BMI and percentage fat mass and a 
high Apo B/A1 ratio in 50% (6/12) of obese patients compared to only 1/11 non-
obese patients [80]. These authors also found no difference between treated and 
untreated GHD. In 39 patients followed-up in a comprehensive care clinic for 
children with brain tumour at risk of HO, despite amelioration of weight gain 
compared to that seen during follow-up in standard clinic (31/39 patients previously 
followed-up in a standard endocrine clinic) there was no change in blood pressure or 
biochemical markers of cardiovascular risk such as fasting glucose, triglycerides or 
LDL by the end of the study [81]. 
 
Pereira found increased cardiovascular morbidity in 22% (11/54) of patients 
after a median follow-up of 10 (range 0.5-37) years, at a median age of 49 years, 
with myocardial infarction in 3, transient ischaemic attack in 1 and cerebrovascular 
events in 7 patients [72]. The prevalence was higher in pre-menopausal women 
untreated with oestrogen (40%) compared to only 10% in sex-hormone replete 
patients (p = 0.03). In the general Dutch population of a similar age (20-50 years) the 
prevalence was 4.8%.  
 
Non-Alcoholic Fatty Liver Disease (NAFLD) 
Non-alcoholic fatty liver disease (NAFLD) has been described in case reports 
in children with hypopituitarism [82, 83] as well as several case series. An American 
series found NAFLD in 21/879 (2.3%) of adults and children) with hypopituitarism, 
HO or craniopharyngioma [69]. All had raised liver enzymes and hepatic steatosis on 
imaging. Cirrhosis was found in 6/10 who had a liver biopsy, non-alcoholic 
steatohepatitis (NASH) with fibrosis in two and simple steatosis in two.  Two 
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patients required liver transplantation and 2/6 deaths were liver-related, both in 
patients with cirrhosis. Not all patients had hypothalamic damage, however five had 
hyperphagia, ten had experienced significant weight gain, and nine were receiving 
DDAVP. The study may under-report prevalence as in many cases it was based on a 
one-off measurement of liver enzymes. 
A study of 12 children with craniopharyngioma (CP) and hypothalamic 
damage (9 severely obese, 1 obese) found NASH (not biopsy confirmed) in six, a 
median of 2.4 years after CP surgery [58]. As all CP had untreated GHD, this may 
have increased their prevalence of fatty liver. In 69 adults with untreated GHD 
secondary to hypopituitarism raised liver enzymes improved in 19 patients (including 
11 with NAFLD) after GH replacement [84]. In five who underwent liver biopsy 
before and 6-12 months after GH replacement an improvement in inflammatory and 
fibrotic markers, steatosis and fibrosis were seen. The prevalence of NAFLD 
(diagnosed by ultrasound) was 77% (53/69), compared to 12% in 83 age-, gender- 
and BMI-matched controls (p<0.001).  A further case-control study of 34 men with 
hypopituitarism and 40 age-matched male controls also found increased prevalence 
of NALFD on liver USS in patients (70.6%) than controls (32.5%, p = 0.001) [85]. 
The potential impact of GH deficiency or insufficiency and effects of GH 
replacement on NAFLD is therefore an important consideration. 
 
Daytime somnolence 
Daytime somnolence was explored in 79 patients with craniopharyngioma 
(CP), 19 with hypothalamic pilocytic astrocytoma (HPA) and 30 controls [27]. 
Melatonin concentration was significantly correlated with BMI category (normal 
weight: BMI SDS <2, overweight: BMI SDS 2-4, obese: BMI SDS >4, p = 0.004) 
and patient group (p = 0.03) in the early morning (06.00-08.00) and at night (23.00-
03.00; BMI p = 0.001, patient group p = 0.03), with no difference in daytime 
melatonin concentrations. Severely obese patients with CP and HPA had similar 
melatonin concentrations, as did normal weight patients (BMI SDS <2) and controls. 
Increased daytime sleepiness (a higher Epworth Sleepiness Scale [ESS] score) was 
found in 31 obese CP patients compared to 17 overweight and 31 normal weight CP 
patients (median ESS 10, 7 and 3 respectively, p<0.001). An ESS >10 denotes severe 
daytime sleepiness and was reported in 42% with CP and BMI SDS >4, compared to 
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24% with CP and BMI SDS 2-4 and 11% with CP and BMI SDS <2 (p<0.001). Two 
out of four patients with HPA and BMI SDS >4 had an ESS > 10.  
The ESS of those with CP was negatively correlated with both morning and 
nocturnal melatonin concentrations, suggesting the possibility that disrupted sleep 
may account for daytime somnolence. As the authors suggest, hypothalamic damage 
could be responsible for both increased risk of obesity and disordered melatonin 
secretion, however there was no assessment of sleep disordered breathing, a 
consequence of severe obesity that may have impacted on sleep. Assessment of sleep 
disordered breathing would have added useful information to this study. 
 
Quality of Life and Neuropsychological Outcomes 
There is evidence from the large, multinational KRANIOPHARYNGEOM 
2000 database that both quality of life (QoL) and self-reported functional capacity 
are affected by HO and that increasing obesity inversely correlates with functional 
capacity [28]. Pediatric QoL (PEDQOL) questionnaires completed by 120 patients 
36 months after diagnosis of childhood CP found that the degree of hypothalamic 
involvement correlated negatively with QoL, possibly influenced by their greater 
weight gain (median BMI increased by +3.22 compared to +0.45 in those with no 
hypothalamic involvement). Social function and family aspects were particularly 
affected. BMI SDS correlated negatively with QoL (p<0.001) in 185 patients studied 
and severely obese patients (BMI SDS > 3; 44%, more common in those with 
hypothalamic involvement) had lower QoL than non-obese patients with the 
exception of a few areas [27]. In a cross-sectional study of 183 patients with 
childhood- or adolescent-onset CP, functional capacity was significantly lower 
(p<0.001) in those with BMI SDS 2-7 (median score 46, range 5-100) and BMI SDS 
≥ 7 (median score 33, range 4-64) than those with BMI SDS <2 (median score 50, 
range 1-95) [28].  
Information on adults alone is limited to one small study of 13 patients and 
hypothalamic involvement and BMI were not taken into account [86].  
 
In summary, there is evidence that hypothalamic damage secondary to 
structural lesions reduce quality of life, perhaps secondary to the increase in obesity, 
with stronger evidence in children than in adults. Reduction in the ability to perform 
activities of daily living and psychosocial morbidity may also occur. 
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Pituitary adenomas in children and adolescents 
Whilst this thesis mainly concentrates on hypothalamic obesity (HO) it was 
noted during clinical discussions that some of the sequelae of hypothalamic damage 
(obesity, endocrine deficiencies, increased cardiovascular risk factors) can also be 
seen in children and adolescents with pituitary adenomas (even in the absence of 
hypothalamic damage). As pituitary adenomas can lead to hypothalamic damage 
(and therefore HO) it was of interest that even in those without hypothalamic 
extension these sequelae can be seen. The sequelae of obesity and increased 
cardiovascular risk factors are not well described in the literature relating to pituitary 
adenomas in children and adolescents and due to the overlap of these sequelae with 
HO further investigation of this cohort was felt to be relevant to this research.  
Pituitary adenomas typically occur in the fourth and fifth decades of life [87] 
and are uncommon in childhood and adolescence, accounting for only 3–6% of all 
surgically treated adenomas [88] and constituting less than 3% of childhood 
supratentorial tumours [89]. Many of the childhood adenoma case series are small (≤ 
21 cases [88, 90-92]), although a few larger series, often encompassing patients from 
multiple centres, contain between 26 and 44 patients [93-96]. The two largest series 
(of 136 [97, 98] and 150 [99] patients) describe children and adolescents who were 
entirely surgically managed and these patients represent a very different group.  
Whilst the clinical features at presentation [88, 94, 98, 99], surgical outcomes 
[92, 97, 100] and endocrine outcomes [95, 96] are relatively well-described in these 
papers,  other long-term sequelae described in adult patients with hypopituitarism, 
such as impaired fertility, premature mortality due to increased cardiovascular and 
cerebrovascular events and increased cardiovascular risk factors are generally poorly 
reported. Impaired fertility has been described in adult patients with pituitary 
adenomas [101], patients with hypopituitarism from various causes (including 
various types of adenoma, craniopharyngioma and Rathke’s cleft cyst) [102] and in 
female survivors of childhood cancer who had received ≥ 30 Gy of radiation to the 
hypothalamic/pituitary axis [103]. Premature mortality has been reported in those 
with hypopituitarism, particularly in females, those diagnosed at a young age and 
those who have received radiotherapy [73]. There may however, be confounding 
factors resulting in this increase in mortality, for example it is unknown whether 
those presenting with pituitary tumours at a younger age have a more aggressive 
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pituitary disease and at the other end of the spectrum, it is possible that those 
undergoing radiotherapy may be older/otherwise unfit for surgery, which may of 
course also influence the mortality rate. Adults with hypopituitarism (with or without 
hypothalamic damage) have been found to have an increased prevalence of factors 
such as obesity, dyslipidaemia and hypertension [6, 79], which confer an increased 
cardiovascular risk. The prevalence of these sequelae in children and adolescents 
with pituitary adenomas (with or without hypothalamic damage) is therefore an 
important area for further exploration. 
 
Obesity in children and adults with acquired structural 
hypothalamic damage: endocrine and neuroanatomic risk factors 
 
Endocrine 
Cranial Diabetes Insipidus (DI) 
Cranial diabetes insipidus (DI) is associated with an increased risk of HO in 
many studies, which is unsurprising if hypothalamic-pituitary anatomy is considered. 
Cranial DI is caused by inadequate vasopressin release from the posterior pituitary; 
this area receives neuronal projections directly from the paraventricular nucleus 
(PVN) of the hypothalamus, an area where energy balance is controlled, therefore it 
is not surprising that damage to the neurohypophysis affecting vasopressin release 
may also effect PVN neurones involved in energy homeostasis [6]. In adults with 
tumours causing hypothalamic damage, DI requiring treatment with desmopressin 
significantly increased the risk of new or worsened obesity (odds ratio [OR] 13, p = 
0.007) [6]. In a retrospective case-note review of 148 children less than 14 years old 
when diagnosed with a brain tumour and taking what authors considered to be a 
physiological dose of cortisol replacement (hydrocortisone < 12 mg/m
2
/day) the most 
significant weight gain was seen in patients with DI [104]. However only 5.8% of 
patients were treated with DDAVP and no details of statistical significance are given. 
The presence/absence of hypothalamic damage was not an inclusion/exclusion 
criterion for the study but considered as one of the risk factors for weight gain. In a 
study of 393 adults with GHD secondary to CP, a correlation between DI and 
increasing BMI SDS (r = 0.168, p = 0.001) remained significant only in those with 
CO and not AO (aged 18 years or over) CP, when separated out [25]. Another study 
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which compared 171 patients diagnosed with CP in adulthood, late-childhood 
(between 10-18 years) and early-childhood (< 10 years of age at diagnosis) found the 
highest prevalence of both obesity (19/28, 68%) and  DI (27/28, 96%) in the 
youngest cohort (< 10 years at diagnosis) [24]. In those with adult-onset CO only 
39/94 (42%) were obese and 70/103 (68%) had DI. In those diagnosed between 10-
18 years of age 8/34 (24.2%) were obese and 28/34 (82.3%) had DI. Those 
diagnosed in early childhood had an increased risk of obesity compared to the other 
groups (OR 3.81, 95% confidence interval 1.51-9.62). Not all patients had 
hypothalamic involvement - only 74/171 (43.3%) had extrasellar tumour extension  
and there was no further clarification of hypothalamic involvement, therefore it is 
possible that differences in the prevalence of hypothalamic involvement, rather than 
age at diagnosis, may have accounted for the difference in outcomes [24]. 
In children with CP Ahmet et al found that 38/43 (88%) had DI, 25/43 (58%) 
were obese and 22/25 (88%) of those obese patients had DI [33]. However, as only 
58% (22/38) of those with DI were obese, it may be more appropriate to suggest that 
obese patients are more likely to have DI, but not necessarily the reverse. In a 
separate study of 58 children with CP there was no correlation between the 
prevalence of HO and DI, however nearly all the patients (53/58, 91%) had DI [105]. 
Even in the group reported to have no post-operative hypothalamic damage 
(intrasellar tumour only), 89.4% (17/19) had DI, which may call into question the 
accuracy of the assessment of hypothalamic damage in this study.  
 
Growth Hormone Deficiency (GHD) 
Growth hormone deficiency as a risk factor for HO is not as consistently 
reported and there are several possible reasons for this variance. Firstly, GHD does 
not necessarily reflect hypothalamic involvement in the same way as a diagnosis of 
DI. In children with CP Muller et al found no difference in the prevalence of GHD in 
those with and without hypothalamic damage [106]. Secondly, GHD is difficult to 
compare between studies due to variations in the definition between adults (peak 
growth hormone < 3 micrograms/l) and children (varies between different 
laboratories/hospitals/studies), lower peak GH response to stimulation in those with 
obesity [107], different GH stimulation tests (glucagon-, arginine-, clonidine-, 
GHRH-stimulation and insulin tolerance tests), recent increased sensitivity of GH 
assays and even a change of the units in which GH assays are reported in some 
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countries (mU/L to micrograms/L), necessitating a conversion when comparing older 
studies with more recent ones. Additionally, in the UK for adult patients to meet the 
criteria for GH treatment, in addition to proven biochemical severe GHD, the 
presence of  impaired quality of life (QoL) must be demonstrated using the validated 
self-assessment QoL-AGHDA questionnaire [108]. This multitude of factors makes 
assessing the presence of GHD as a risk factor for HO much more challenging. 
 
The risk of obesity in patients with GHD (treated or untreated) was increased 
in a study of 42 adults with hypothalamic damage secondary to varying tumour types 
(OR 7.6, p=0.04) [6]. In comparison, in 148 children with various brain tumours 
there was no association between increased BMI and GH replacement, although the 
need for replacement of any pituitary hormone including GH was associated with a 
significant increase in BMI compared to that expected for age [104]. Another study 
found no difference in the prevalence of obesity in children with untreated GHD 
secondary to suprasellar tumour (4/11 obese) and those with treated GHD (7/11 
obese, 63.6%), although the numbers involved were small [20]. The prevalence of 
hypothalamic damage may have been similar in both cohorts and treatment with GH 
(or lack of it) may have had little effect and a comparison between those with and 
without GHD may have been more useful. 
A large study compared three-year longitudinal data of pre-pubertal children 
with GHD on the KIGS (Pfizer International Metabolic) database of children 
receiving GH [109]. Patients were divided into three groups - children who 
underwent surgery and/or irradiation for CP, children who underwent surgery and/or 
cranial irradiation for tumours other than CP (other tumours) and those with GHD 
not due to tumour (no tumour, e.g. septo-optic dysplasia). Mean peak GH on 
stimulation was significantly lower in CP (2.1 mcg/L) than the other groups (both >4 
mcg/L) and the incidence of DI was higher (CP 72%, other tumours 61%, no tumour 
28%, p<0.0001), possibly indicating greater likelihood of hypothalamic involvement 
in the CP group. Those with CP had the highest mean BMI SDS and greatest 
incidence of BMI SDS >2 at both the start of GH replacement and after three years, 
despite a decrease in mean BMI SDS over time. The fall in BMI SDS occurred 
despite weight increase, due to an increase in height, consistent with GH treatment. 
In a subgroup comparison of all patients with peak GH < 2 micrograms/L the mean 
BMI SDS of the CP group remained the highest, even when compared to those with 
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hypothalamic-pituitary tumours, suggesting the possibility of different mechanisms 
in obesity secondary to CP.  
Another study of 58 children with CP found BMI SDS four years after 
surgery was unaffected by the need for GH replacement [105] and a smaller study of 
17 children with CP and post-operative panhypopituitarism (including GHD) found 
no correlation between peak GH and BMI, although a positive correlation between 
pre-operative IGF-1 concentration and post-operative BMI was found [29]. Two 
other studies examined IGF-1 and BMI in CP and GHD. One study of adult-onset CP 
and GHD (peak GH following stimulation <3.0 micrograms/L) found a positive 
correlation between IGF-1 SDS whilst untreated with GH and BMI SDS [25]. The 
second study compared five children with treated GHD secondary to CP to ten 
children with CP and untreated GHD with adequate height velocity (HV) [57]. The 
authors found no difference in BMI SDS, WHR or body composition between the 
groups, despite a significantly greater IGF-1 concentration in those treated with GH 
(treated: median 21 nmol/L untreated: median 7.5 nmol/L, p = 0.01). IGF-1 
concentrations are affected by nutrition as well as GH concentrations, making 
interpretation more complex; whether this is a cause or effect of the differences 
found between studies illustrates the complexity of the association between GHD and 
HO.  
In childhood, the phenomenon of growth without growth hormone can result 
in GHD being left untreated [57]. Stahnke et al investigated 10 children with CP who 
had normal post-operative HV despite GHD and 12 with GHD and poor post-
operative growth [62]. In the first group 8/10 rapidly gained weight and were obese 
one year post-resection; mean weight-for-height increased to + 8.38 kg (SD ± 2.23 
kg) above expected at one year. A more modest increase was seen in patients with 
poor post-operative growth, which increased to + 3.78 (± 1.39 SD) kg at one year 
from a lower pre-operative baseline. In another study, 32/73 children with untreated 
GHD and “catch-up” growth also had increased risk of weight gain one year post-
resection (BMI SDS +5.0) compared to those with normal growth (BMI SDS +3.2) 
or inadequate growth (BMI SDS +1.6; p<0.00001) [110]. The underlying 
pathophysiology of growth without growth-hormone remains unknown, however 
increased concentrations of insulin, prolactin or leptin and the extent of hypothalamic 
involvement have all been postulated as possible mechanisms [109]. These factors 
overlap with the possible pathophysiological mechanisms leading to HO.  
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Inclusion of patients without hypothalamic damage in some studies may 
account for differences between them. Additionally, there may be a difference 
between adult- and childhood-onset hypothalamic damage and in treated vs. 
untreated GHD, especially in those with growth without GH. Alongside the 
difficulties described in accurately diagnosing GHD, these factors make the presence 
of GHD as a risk factor for HO more difficult to unravel than that of DI.  
 
 
Other pituitary hormones 
Several studies have examined the relationship between HO and other 
pituitary hormone deficiencies. Daousi et al found an increased risk of new/worsened 
obesity in adults receiving hydrocortisone, thyroxine, or GH [6] and Lustig et al 
found that the presence of any hormonal deficit in children was associated with a 
greater increase in BMI over time [104].  
In children with CP, Pinto et al found no correlation between BMI and 
prolactin, plasma free thyroxine concentration, dose of thyroxine supplementation or 
post-operative peak GH [29] and Park et al found that the number of hormone 
deficiencies had no effect on obesity prevalence [105]. In a comparison of 90 
patients with childhood CP with (n = 48) and without (n = 42) hypothalamic 
involvement, no difference was found in the prevalence of endocrinopathies or dose 
of hormone replacement required, although there was a difference in BMI SDS at 
diagnosis and on annual follow-up between the two groups [106]. In 171 patients 
with CP, those under 10 years of age at tumour diagnosis all had three or more 
anterior pituitary deficits (28/28) and 68% were obese (BMI > 30 kg/m
2
) at latest 
follow-up, compared to the adult-onset cohort in which only 76/104 (74%) had 
three/more anterior pituitary deficits and 39/104 (41%) were obese [24].  
Some studies have reported that prolactinomas may lead to weight gain, even 
without hypothalamic involvement, although the literature is divided on this [111, 
112]. In Lek’s cohort none of the patients with prolactinoma were obese at latest 
follow-up [21]. Daousi et al included a small number of patients with prolactinoma 
in their study but found no association between this diagnosis and increased BMI [6]. 
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As with GHD, the link between HO and deficiencies in other pituitary 
hormones, or the presence of multiple pituitary hormone deficits remains unclear. 
 
Dose of hydrocortisone replacement  
Two studies found no association between the dose of hydrocortisone 
replacement  and BMI  despite the use of supraphysiological doses of steroid up to 
15 mg/m
2
/day [20, 29]. Other studies excluded patients on doses of replacement 
hydrocortisone considered supraphysiological (> 12 mg/m
2
/day) [104] or use a dose 
considered physiologically equivalent (6-10 mg/m
2
/day) [33]. As supraphysiological 
doses of glucocorticoids can result in obesity, it is advisable to keep doses of steroid 
replacement within normal physiological ranges. 
 
Neuroanatomical aspects 
 
Identifying hypothalamic damage is crucial for the definition of HO, however 
whether the extent of the damage can predict the risk of obesity is uncertain. In 
paediatric CP series all but one found an increased risk of HO with greater 
hypothalamic damage on MRI brain scans.  
Post-operative MRI scans of 63 children with CP were graded 0-2 grade 0 – 
no visible damage, 1 – intermediate damage, or 2 – severe hypothalamic damage 
[113]. Those with the most significant hypothalamic damage (i.e. grade 2) had a 
greater increase in median BMI SDS (+5.5) at latest follow-up than those grade 0 
(BMI SDS +1.1) or grade 1 (BMI SDS +2.5). A study of 27 children with CP found 
that whilst pre-operative BMI SDS was comparable between all patients (grade 0-2), 
at one year post-resection those with grade 2 pre-operative hypothalamic 
involvement (12 patients) had a significantly higher BMI SDS (4.0 ± 1.3) than 7 
patients grade 0 on pre-operative assessment (BMI SDS 2.7 ± 1.1) [114]. 
Several studies graded both pre- and post-operative hypothalamic 
involvement on MRI scans. The first described a significant correlation between 
BMI at latest follow-up and the extent of hypothalamic involvement on both pre- and 
post-operative MRI scans [32]. An increase in hyperphagia was also reported (26% 
at diagnosis, 70% at latest follow-up). In a separate study, BMI SDS at diagnosis was 
significantly higher in those where the hypothalamus could no longer be identified 
on pre-operative MRI scan (mean BMI SDS 1.8), compared to those with no 
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involvement (mean BMI SDS 0.34, p<0.02) [115]. A year after surgery, whilst the 
group without hypothalamic involvement had no significant change in BMI SDS, 
patients with some involvement or complete involvement had a significant increase 
in BMI SDS (p <0.002 and p=0.0003, respectively). This increase persisted at latest 
follow-up, at a mean age of 14.9 years (mean age at surgery 7.4 years, range 0.9-14). 
Three further studies used the Saint-Rose classification grade 0 (no 
hypothalamic damage) to 2 (hypothalamus unable to be identified) [32]. A 
retrospective review of 66 patients found significantly higher BMI SDS with 
increasing grade of tumour damage (p=0.007 preoperatively, p=0.001 
postoperatively) [116]. The prevalence of both grade 1 and grade 2 involvement 
decreased from pre-operative (36% and 42% respectively) to postoperative scans 
(30% and 38% respectively), possibly indicating an overestimate in the amount of 
hypothalamic involvement on pre-operative MRI scans, although there may have 
been persisting damage despite subsequent decompression. In the second study, in 58 
children with CP the prevalence of obesity rose from 8/58 (14%) at diagnosis (2 
patients grade 1, 6 grade 2 on pre-operative MRI brain scan) to 22/58 (38%) at latest 
follow-up (2 patients grade 0, 10 grade 1, 10 grade 2 on pre-operative MRI brain 
scan) [105]. BMI SDS after four years of follow-up was significantly associated with 
both BMI SDS at diagnosis and the pre- and post-operative hypothalamic grade. 
After adjusting for pre-operative BMI and pre-operative hypothalamic involvement, 
postoperative hypothalamic grade was the only significant predictor of BMI SDS 
(other factors considered were not stated). A third study used pre-operative MRI 
grading to determine treatment in 22 prospectively studied CP patients [116]. The 
median postoperative BMI SDS was +1.3SD in this group, compared to a median 
post-operative BMI SDS of +2.5 in a retrospective group. The size of the prospective 
group was smaller than the retrospective cohort, however, the proportion of patients 
in each category (preoperative grade 0-2) was similar. Whilst the use of preoperative 
MRI assessment to determine patients’ treatment may have ameliorated 
hypothalamic damage and subsequent weight gain in the prospectively studied 
patients, it is important to note the differences in the length of follow-up 
(prospectively studied patients mean follow-up 1.15 years, retrospectively studied 
patients median follow-up 7 years, range 1-19).  
Muller et al used their own grading system to describe hypothalamic 
involvement in CP: grade 0 remained no hypothalamic damage, grade 1 described 
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anterior hypothalamic damage not involving the mammillary bodies or beyond and 
grade 2 described anterior and posterior hypothalamic damage extending beyond the 
mammillary bodies [117]. In 120 patients from 76 centres grade 2 pre-operative 
hypothalamic involvement was associated with a greater increase in BMI SDS (+ 
3.22 SDS) than grade 0 (BMI SDS + 0.45, p = 0.03) or grade 1 involvement (BMI 
SDS +0.74, p=0.01). The presence of grade 2 hypothalamic damage pre-operatively 
was the only risk factor associated with a change in BMI SDS after 36 months of 
follow-up out of seven considered (p=0.002). A further study using this classification 
did not find an association between the grade of hypothalamic involvement (either 
pre- or post-operatively) and the risk of weight gain or obesity in 33 patients with CP 
[118]. 
 
Two studies considered hypothalamic involvement, without using a grading 
system. In 43 children with CP, the 30 with post-operative hypothalamic damage had 
a +0.74 BMI SDS increase at one year (p=0.014) [33]. In another study, 
hypothalamic involvement (based on MRI and/or operative findings) was found in 
36/45 patients (80%), with the prevalence of obesity (BMI SDS >2) rising from 
15.6% (7/45) at diagnosis to 70.5% (31/44 survivors) at latest follow-up and 
significantly associated with hypothalamic damage (p<0.001) [34]. 
 
In childhood brain tumours of varying types, Lustig et al found tumour 
location to be important, but only compared relatively gross findings, for example 
comparing the risk of obesity in those with hypothalamic versus lateral ventricle 
tumours [104]. In adults with hypothalamic damage secondary to various tumour 
types, tumour width from midline (coronal views), thalamus or temporal lobe 
involvement, distortion of the third ventricle at the infundibulum (coronal views) and 
infringement of the tuber cinereum were assessed [6]. No correlation was found 
between the risk of HO and the degree of hypothalamic damage on neuroimaging (26 
pre-operative and 39 post-operative scans). However another adult study found that 
greater hypothalamic involvement on pre-operative MRI scans positively correlated 
with post-operative weight gain (p = 0.022) in 28 adults with CP after two years of 
follow-up [119]. Although there was a correlation between left-sided hypothalamic 
involvement and post-operative weight gain but not right-sided hypothalamic 
involvement, the study only included a small number of patients and therefore the 
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significance of this finding is unclear. Additionally, there was already a significant 
prevalence of obesity (BMI > 27.3 kg/m
2
 in 61%) pre-operatively in this study, none 
of the patients were treated with GH replacement and the prevalence of GHD is not 
described. These factors may have influenced the findings. 
The usefulness of grading hypothalamic involvement on neuroimaging in 
adults with tumours causing hypothalamic damage to predict the risk of weight gain 
therefore remains equivocal. 
 
 The presence of hydrocephalus or intracranial hypertension requiring a 
ventriculo-peritoneal (VP) shunt as a marker of hypothalamic damage is used in 
some studies, with varying findings. In childhood CP studies three found that 
hydrocephalus was significantly associated with post-operative obesity [24, 27, 33], 
with OR 15.28 in one study of 43 children [33]. Two other studies found no 
relationship between hydrocephalus and post-operative BMI [104, 116]. One adult 
series also found no association between obesity and insertion of a VP shunt 
(although numbers were small) [6]. 
 
Treatment modality 
There are mixed findings regarding the risk of HO and surgical management. 
Avoiding total gross surgical resection of CP in order to minimise hypothalamic 
damage and long-term post-operative morbidity had no effect on the overall 
prevalence of obesity (BMI > 95
th
 percentile for age and gender) reported by Cohen 
et al (53.5% between 1990-2001; 54.8% between 2001-2011) [30]. However, less 
aggressive surgery did result in a decrease in the prevalence of severe obesity (BMI 
> 99
th
 percentile for age and gender) from 34.8% to 17.6%. Potential confounding 
factors include the size of the two cohorts (numbers of patients not provided), 
expertise of the surgeon, age and BMI at diagnosis and use of adjunct therapies. 
Another paper described 51 children with CP, of whom the majority underwent a 
conservative resection with additional radiotherapy [31]. After a median of 7.6 years 
(range 5.0-21.3) 24% were obese and 41% overweight. Dose of radiotherapy is not 
stated and there is no comparison of obesity prevalence when using more aggressive 
surgical management strategies. 
A study of 66 children demonstrated a significant increase in post-operative 
BMI SDS under the care of a less experienced surgeon, with no effect of extent of 
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resection or route of approach [116]. Another study found increased risk of obesity at 
latest follow-up (BMI SDS >2, 28/45 obese) after subtotal resection of CP, second 
operation and with increasing number of surgeries [34]. These overlap with tumour 
recurrence and number of recurrences which were also associated with increased risk 
of obesity. Hypothalamic involvement was considered as a risk factor, and therefore 
not present in all patients in the study. Another study also found a small but 
significant increase in the median number of resections in those with obesity (median 
1.4 operations in those with BMI < 2 SD, median 1.44 operations with BMI 2-7 SD, 
median 1.7 operations with BMI >7SD; p<0.05), although 41% (48/90) had no 
hypothalamic involvement [28]. In 171 children increased obesity was found with 
multiple surgeries (OR 1.4), recurrence (OR 2.3) and tumours needing a pterional 
approach, which indicates a larger initial tumour (OR 6.2). A third study found a 
correlation between the number of surgeries and BMI SDS, but not the type of 
surgery undertaken [25]. Other series considered extent or type of surgery, number of 
surgeries and recurrences in varying study populations and found no effect [6, 23, 
104, 105]. The effect of these factors on the risk of HO therefore remains unclear. 
 
The effect of radiotherapy is also inconclusive. In one study a significantly 
greater increase in BMI occurred in those receiving >51 Gy of hypothalamic 
irradiation (p=0.002) [101]. This remained significant after excluding patients with 
hypothalamic/thalamic tumours. Another study also found an increased risk of 
obesity with radiotherapy (OR 1.79) [20], however other studies failed to find any 
correlation [25, 105, 116]. 
 
Other risk factors 
Many studies unsurprisingly show a correlation between increased BMI/BMI 
SDS before surgery and greater post-operative weight [29, 33, 34, 105, 115, 118], 
although not all studies specify hypothalamic damage. One study found that the risk 
of severe obesity (BMI > 3 SDS) was significantly increased in children with CP 
where BMI SD was > 2 at diagnosis (OR 16.4, p<0.05) [27], however an adult study 
found no correlation between preoperative BMI and postoperative weight gain [119]. 
Higher maternal BMI has also been identified as a risk factor for the development of 
severe obesity following CP (OR: 4.6; p<0.05) [27]. These pre-existing risk factors 
for weight gain/obesity may have some additional effects on the risk of HO. 
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While three studies found a correlation between younger age at diagnosis and 
the risk of weight gain/obesity [24, 33, 104], a comparison of AO and CO CP found 
a greater prevalence of obesity in adult-onset compared to child-onset CP [25] and 
other studies  found no effect of age at diagnosis [21, 105, 106, 116]. 
Two studies found an increased risk of obesity in female patients compared to 
males [21, 25], however other studies have found that the risk of obesity was 
unaffected by gender [105, 106, 116]. 
In summary, the impact of these other risk factors for HO remains 
inconclusive. 
 
Management of hypothalamic obesity: pharmacological and non-
pharmacological treatments                                                    
 
Current options for weight management in simple obesity include diet and 
exercise modification, treatment with the medication orlistat (a lipase inhibitor which 
prevents fat absorption from the gut) and bariatric surgery. Some previous 
medications such as rimonabant (a selective cannabinoid CB1 receptor blocker) and 
sibutramine are no longer available due to health risks (an increased risk of 
psychiatric problems including suicide and cardiovascular events/strokes, 
respectively). Treatment of simple obesity, however, is often ineffective. Some case 
studies and interventional trials describe the utilisation of these treatments for simple 
obesity in patients with hypothalamic obesity. Other medications specific to HO have 
been investigated, including octreotide, dextroamphetamine and melatonin. Incretin 
therapy is a relatively new treatment for type 2 diabetes which alongside 
improvement in glycaemic control, also results in weight reduction and its use in HO 
has been described in several case reports. Bariatric surgery is becoming increasingly 
accepted in the treatment of simple obesity and its use in HO has also been described 
in several case reports and small case series.  
 
There are no studies in humans of the effects of diet or exercise alone on 
weight loss in patients with HO outside the setting of a dedicated multi-disciplinary 
clinic and no reports on the use of orlistat or rimonabant (now withdrawn from the 
market) specifically in the HO population.  
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Medications 
 
Treatment with medications used in simple obesity 
Sibutramine is a sympathomimetic which exerts its effects through the 
arcuate nucleus. It increases anorexigenic hormones, decreases orexigenic hormones, 
increases thermogenesis and prevents the normal weight-loss induced drop in resting 
energy expenditure [120]. In simple obesity (SO) its effects generally last for the first 
six months of treatment, with subsequent weight regain in many cases. A reported 
increase in MI and cerebrovascular accidents in patients treated with sibutramine led 
to its withdrawal by the European Medical Association [120].  
 
Treatment of hyperinsulinaemia  
Octreotide is a somatostatin analogue which inhibits insulin secretion. As 
hyperinsulinaemia is a proposed mechanism for HO some researchers have proposed 
that octreotide could ameliorate weight gain in HO by decreasing insulin release. 
Lustig and colleagues found an amelioration of weight gain with octreotide treatment 
(Table 1.10), with either weight maintenance (3 patients) or weight loss (5 patients), 
in eight patients with HO compared to weight gain in the previous six months [56]. 
After 12 months, two patients had lost 21.7% and 9.8% of their initial body weight. 
No participants developed diabetes mellitus secondary to insulin suppression and 
fasting insulin concentrations remained within normal limits throughout. A second 
study (Table 1.10) found ongoing weight gain in those randomised to placebo 
compared to weight stability in those on octreotide, with weight loss in months 4-6 
[55]. Calorie intake was lower with a greater decrease in serum leptin concentration 
in those on octreotide than placebo, although neither reached statistical significance. 
Neither study considered the effects of octreotide discontinuation, or alternatively its 
long-term suitability and safety for treatment beyond the 6-12 month period studied. 
Another study attempted to ameliorate hyperinsulinism with diazoxide and 
metformin (Table 1.14, Appendix 1) [121]. Diazoxide is used in children with 
hyperinsulinism to supress insulin secretion. Metformin primarily decreases hepatic 
gluconeogenesis but also increases insulin sensitivity. After six months of diazoxide 
and metformin, all seven participants had significant amelioration in weight gain 
compared to the previous six months. Three patients lost weight and four gained less 
than previously, although this may have represented their natural plateau years after 
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hypothalamic damage. The study was a pilot and limited by its small size. It is not 
possible to determine whether diazoxide or metformin alone, or both medications are 
necessary for weight reduction. The effects of stopping treatment were also not 
studied. Given the potential side-effects of diazoxide, such as gallstones and oedema, 
its long-term use may be impractical and therefore the effects of discontinuing it 
should be considered. 
 
Treatment with sympathomimetics for possible impaired sympathoadrenal 
activation 
In addition to sibutramine, other sympathomimetics studied in HO include 
dextroamphetamine, phentermine and combined caffeine and ephedrine.  
 
Dextroamphetamine was studied after weight stabilisation was noted in a 
child started on this for attention problems (Table 1.15, Appendix 1) [41]. Its use has 
been described in adult obesity, with anorectic effects the proposed mechanism 
underlying weight loss. The authors expected to replicate this decreased appetite 
resulting in reduced calorie intake, however diet logs showed no difference in calorie 
intake before and after treatment. There was, however, an increase in physical 
activity. There was no information on subsequent continuation or effects of 
discontinuation. A second study [122] also found either weight stabilisation/loss with 
dextroamphetamine. 
A conference abstract explored the use of phentermine with either dl-
fenfluramine or fluoxetine and behaviour modification (Table 1.16, Appendix 1) 
[123]. The authors report weight loss with no significant side-effects, but no details 
are given of how many patients lost weight, percentage weight loss or cardiovascular 
effects. Greenway et al studied the effects of caffeine and ephedrine, which they 
postulated would lead to weight loss by increasing sympathetic tone and metabolic 
rate (Table 1.17, Appendix 1) [124]. All three women studied lost weight, although 
one regained a significant amount and was referred for bariatric surgery. No details 
of duration of treatment were available for either study and no further studies of 
these medications have been published. 
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Other hormonal interventions 
Supraphysiological doses of triiodothyronine (T3) have been explored after a 
patient was treated for symptoms consistent with hypothyroidism, despite adequate 
serum free T4 and T3 levels (Table 1.18, Appendix 1) [125]. Two children with 
hyperphagia and HO were subsequently treated. In all patients baseline thyroid 
function tests were normal and introduction of T3 resulted in raised serum T3 
concentrations. None exhibited any symptoms of hyperthyroidism except weight 
loss. The first patient had bone mineral density (BMD) monitored due to the known 
sequelae of decreased BMD in patients with hyperthyroidism, however this improved 
after starting T3. All patients reported increased energy levels and decreased appetite. 
No other reports of treatment with T3 are found in the literature.  
Incretin mimetics are a more recent treatment possibility. Secreted from the 
L-cells of the gastrointestinal mucosa, glucagon like peptide-1 (GLP-1) is an incretin 
hormone that increases post-prandially after oral glucose ingestion, acting both 
centrally and peripherally [126]. Although its mechanisms remain only partially 
understood, peripheral actions include potentiation of glucose-dependent insulin 
secretion and suppression of glucagon release, with inhibition of gastric emptying 
and gastrointestinal motility. Centrally, activation of hypothalamic GLP-1 receptors 
inhibits appetite and receptors in the wider central nervous system, such as the 
brainstem, may influence appetite, with delay in gastric emptying leading to a 
secondary effect of increased satiety through central mechanisms [126]. The incretin-
mimetics exenatide and lirgalutide, analogues of GLP-1, have been used in patients 
with type 2 diabetes mellitus (T2DM) and latterly in treatment of SO without 
diabetes [126]. Their use has more recently been reported in patients with HO both 
with [127-129] and without [129] T2DM (Table 1.19, Appendix 1). A small case 
series showed that incretin mimetics were beneficial in HO although mean BMI 
remained within the obese range even at the end of the study period [129]. The 
effects of treatment discontinuation in one patient studied was maintenance of weight 
loss, postulated to be secondary to increased physical activity as reported by the 
patient, however as treatment was restarted after a period of six months, the longer-
term effects of discontinuation on weight maintenance are unknown. Despite 
disruption of one of the potential mechanisms of action (i.e. hypothalamic damage) 
incretin mimetics seem effective in HO, although further investigation is needed. 
Gastro-intestinal side-effects have limited their use in some cases.  
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Bariatric Surgery 
Until lately, only individual case reports (Table 1.20, Appendix 1) [130-134], 
or small series [135, 136]  have described bariatric surgery in HO. More recently a 
larger study of nine patients with HO [137] and a systematic review and meta-
analysis of the literature were published [138]. 
The individual case reports describe reduction in BMI in six patients from 
between 42-67 kg/m
2
 pre-operatively to between 32-53 kg/m
2
 post-bariatric surgery, 
with improvement or resolution of co-morbidities. There were no reported side-
effects in four patients followed-up for 6-30 months, but two developed post-
operative complications of diarrhoea, dumping and acute gallstone pancreatitis 
(follow-up 6 years) and intestinal stenosis requiring laparotomy and unremitting 
bradycardia requiring a pacemaker (follow-up 2 years) [132]. A small series 
described laparoscopic adjustable gastric banding (LAGB) in four children with HO 
secondary to craniopharyngioma (Table 1.21, Appendix 1) [135]. Self-assessed 
quality of life and functional capacity were similar before and after LAGB, but pre-
occupation with food lessened post-insertion and BMI fell. In four adults who 
underwent bariatric surgery (Table 1.21) one patient had ongoing weight gain post-
bypass [136], however as bariatric surgery was undertaken only 1.5 years following 
initial tumour diagnosis when weight gain is known to be greatest it is possible that 
even more weight gain would have occurred without the bypass. Alternatively it is 
possible that bariatric surgery is ineffective in preventing initial weight gain in HO. 
In the largest reported case series only the two patients who underwent gastric bypass 
had good results; no weight loss was seen following LAGB insertion or sleeve 
gastrectomy (Table 1.22, Appendix 1) [137]. This retrospective review of nine 
patients with HO (including one previously described in a case report [131]) 
compared their outcome to that of 154 individuals who had undergone bariatric 
surgery for SO. Complications were the same in both HO patients and controls. 
There are no details of any earlier weight-loss strategies for any of the HO patients 
however weight gain had slowed in the previous year. 
The recently published systematic review and meta-analysis includes the 
published case-reports and case-series (17 patients) and four previously unpublished 
patients (Table 1.23, Appendix 1) [138]. The mean age at CP surgery was 16 years 
and at bariatric surgery was 24 years. After one year, a third of patients (6/18 with 
data available) had lost > 20% of their baseline weight (none after LAGB). Only 
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patients who underwent RYGB or BPD had ongoing weight loss at this time; weight 
increased between 6 and 12 months in the other groups. The prevalence of diabetes 
had decreased from 31.6% at baseline to 8.3%. The overall effects of bariatric 
surgery in this meta-analysis may be disappointing, with a pooled mean weight loss 
of -15.14 kg (-31.68 to 1.39) at 12 months (excluding the patient who underwent 
BPD), however in comparison to the inexorable weight gain often seen in HO, these 
are positive findings. 
 
There are no long-term studies of bariatric surgery in HO, the optimal 
surgical method is unclear and the underlying physiological mechanisms leading to 
weight loss are not yet fully understood. Future trials of bariatric surgery would 
benefit from a multi-centred collaborative effort, with standardised pre-operative 
assessment of clinical and biochemical risk factors and guidelines regarding which 
method of bariatric surgery should be undertaken. 
 
Multi-disciplinary dedicated clinics 
Finally, the setting in which patients at risk of HO are followed-up is 
important.  Children attending a dedicated comprehensive care clinic had lower 
weight-gain than those in “standard care” clinics [81]. In the specialist clinic, 
children could attend monthly (as opposed to six monthly) and meet with a multi-
disciplinary team (including endocrinologist, dietician, psychologists and exercise 
consultant). Oncology, psychiatry and surgical care were accessible if needed and 
patients could contact the MDT by phone or email in-between clinics. Initial 
assessment was extensive, lasting half a day and consisted of diet, exercise and QoL 
assessments. Treatment encompassed psychosocial aspects, diet and fitness advice 
and medication (where indicated). Thirty-nine children attended the specialist clinic, 
including 31 previously cared for in standard follow-up clinic. Most had a diagnosis 
of CP (33/39). The eight newly-diagnosed patients exclusively cared for in the 
comprehensive care clinic had a decrease/stabilisation in their percentage weight-
gain from their first attendance. The percentage weight gain in the 31 children 
previously followed-up in the standard clinic also decreased, although this may have 
reflected the typical slowing of weight-gain in HO after a few years and it is 
impossible to separate out the effects. Other limitations of this study are the lack of 
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clarification of hypothalamic damage and the limited duration of follow-up in some 
patients (mean follow-up 0.97 years, range 3–41 months).  
 
Conclusion 
As with simple obesity, weight-loss treatments in patients with HO have 
limited success and advice regarding a healthy diet and physical activity remains the 
main-stay of treatment. As there is currently very little effectual treatment, further 
research into both prevention and management are imperative.  
 
 
Contribution of this thesis to knowledge and development of studies 
 As can be seen from the literature presented, whilst HO is well described in 
children, particularly in those with craniopharyngioma, it is less well described in the 
adult population and knowledge of the underlying pathophysiology in all cases is 
uncertain. This thesis therefore aims to build on the existing retrospective studies of 
the prevalence of obesity in adults and children with acquired structural 
hypothalamic damage in order to better understand the prevalence and also to 
identify any underlying clinical risk factors for developing HO, to allow clinicians to 
better guide and support those patients at particular risk.  
Clinical experience gained during specialist pituitary clinics reviewing 
patients with pituitary tumours also indicated another group of patients with an 
increased prevalence of obesity and other cardiovascular risk factors compared to the 
general population of a similar age - children and adolescents with pituitary 
adenomas. These tumours are uncommon in this age group and existing literature 
typically describes small case series and concentrates on their presentation and 
endocrine and surgical outcomes. Any evidence of increased obesity and 
cardiovascular risk factors in this young population would be clinically important to 
uncover. In addition, as many of these patients have microadenomas too small to 
encroach on the hypothalamus if this group of patients were confirmed to also have 
an increased prevalence of obesity it may indicate that additional mechanisms 
contribute to weight gain and obesity both in the presence and absence of 
hypothalamic damage. 
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 In addition to the empirical studies planned to address these questions, as 
optimal treatment of HO remains uncertain and HO is often refractory to treatment, 
investigation of its underlying pathophysiology was important. Elucidation of this 
could give further insights into ways to either prevent HO occurring, or possibly aid 
with the development of more efficacious treatments. There are many hypotheses 
regarding the underlying pathophysiology/pathophysiologies of HO (hyperphagia 
due to hyperinsulinaemia, hyperghrelinaemia, leptin resistance or reduced PYY; 
increased 11β-HSD activity; reduced sympathetic activity; reduced physical activity) 
with evidence supporting and refuting all of these to some extent, as can be seen in 
the literature described in this thesis. In simple obesity theoretical models have been 
developed to consider appetite control and the development of obesity [139, 139-
142]. These models explore the interactions of hormonal, neural and behavioural 
aspects of weight regulation, for example the relationships between the classic 
homeostatic regulatory systems (both involving the brain and hormonal/nutrient 
signals), those brain regions responsible for reward, cognition and higher executive 
functions, external/environmental stimuli and energy expenditure. Berthoud 
describes how two interacting regulatory networks – one homeostatic, the other non-
homeostatic – may influence food intake [143, 144]. The former integrates appetitive 
hormones such as leptin and ghrelin and involves brain regions extending from the 
hypothalamus to the caudal medulla. The non-homeostatic network integrates 
metabolic, hedonic, behavioural and autonomic aspects in cortico-limbic regions 
such as the nucleus accumbens (NA; food reward), insula, striatum and hippocampus 
(reward expectancy/learning/memory) and pre-frontal cortex (PFC; executive 
decision making). Berthoud hypothesized that interactions of the non-homeostatic 
network with the homeostatic network through NA/hypothalamic pathways might 
allow the homeostatic network to be “overridden”. The interaction of the neural 
networks controlling appetite and food intake is a mechanism which has not been 
explored in patients with acquired, structural hypothalamic damage. Destruction of 
the hypothalamus in these individuals may mean that these other alternative areas 
assume increased importance and just as in Berthoud’s model the cortico-limbic 
areas may become dominant over the homeostatic regulators of food intake and 
appetite. In addition to identifying any changes in the neural networks of patients 
with hypothalamic damage, their effects on eating behaviour were also important to 
explore. Investigative techniques to explore both neural networks and eating 
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behaviour in patients with acquired, structural hypothalamic damage (both those 
becoming HO and those remaining weight-stable despite hypothalamic damage) 
were therefore researched to allow development of studies which considered both of 
these aspects and add novel information to the existing literature. The use of 
functional MRI (fMRI) scanning to investigate neural networks, the universal eating 
monitor (UEM) to examine the microstructure of eating behaviour and both Three 
Factor Eating Questionnaires (TFEQ) and three-day food diaries to examine the 
macrostructure of eating behaviour have been employed in studies of simple obesity 
as well as in studies of participants with an underlying medical disorder, however the 
first two have not yet been utilized to study adults with acquired, structural 
hypothalamic damage. Their use in obesity research is discussed in the subsequent 
pages and their application to the study of HO explained. In addition, measurement 
of appetitive hormones such as insulin, ghrelin and leptin during the study days was 
planned to augment existing knowledge.  
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Investigative Techniques 
 
Use of fMRI in obesity research 
In recent years, functional neuroimaging (positron emission tomography 
[PET] and functional magnetic resonance imaging [fMRI]) has identified brain areas 
differentially activated by appetite and food consumption in different clinical and 
experimental conditions. PET works by injecting a radioisotope tracer into the 
peripheral circulation, combined with either glucose (
18 
F-FDG) or water (
15
O). 
Radioisotope decay in various brain regions (as a marker of metabolic rate or blood 
flow, respectively) can then be detected. PET has reasonable spatial resolution and 
specific radioisotopes for various neurotransmitter receptors or transporters can be 
used. The disadvantages/limitations are exposure to ionising radiation administered 
via an invasive procedure (injection/cannulation) [145] and spatial resolution (5mm, 
compared to fMRI which can be as little as 1 mm). Functional MRI (fMRI) is a non-
invasive modality that can detect transient haemodynamic changes in the brain in 
response to a variety of stimuli by utilising the different magnetic properties of oxy- 
and deoxy-haemoglobin. These changes in blood-flow are representative of 
underlying neuronal activation and compare two states (e.g. looking at food- vs. non-
food pictures). The advantages over PET are its non-invasive nature, no radiation 
exposure and a higher spatial and temporal resolution [146] which is important in 
monitoring a dynamic process such as feeding. One disadvantage is the difficulty in 
imaging certain areas, for example the brainstem due to motion/other artefacts 
caused by respiratory and cardiac cycles [145] or the orbito-frontal cortex (OFC) as 
air in the nasal cavity/sinuses can lead to signal loss, causing areas of drop-out [147]. 
Neither technology measures neuronal activity directly and therefore cannot identify 
the specific neuron activated, only a region where increased blood flow is likely to 
indicate increased neuronal activity. Small areas or brain structures are therefore 
difficult to identify as it would require large changes in blood flow to detect a signal 
difference large enough to survive contrast and further statistical analysis [146, 148]. 
Both are costly and are somewhat restrictive in the size/weight of obese participants 
that can be studied, however have been successfully used to explore the homeostatic 
and non-homeostatic brain regions involved in regulating appetite and eating. 
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Whereas PET studies examine resting brain activity or metabolism, fMRI studies 
compare responses to tasks, such as viewing different types of food pictures. 
Cerebral regions of interest in appetite and eating identified from neuroimaging 
studies 
Multiple brain areas related to appetite and eating have been identified in fMRI and 
PET studies, reflecting the many different aspects of feeding-related cerebral 
processes and also the differences in the study protocols and paradigms. Tataranni 
undertook the seminal PET study of hunger and satiety in humans (using 
15
O-
labelled water), with many subsequent studies identifying both common and novel 
brain regions (Table 1.24, Appendix 1) [149]. Many early studies contrasted fasting 
and fed states, with later studies using food images under different conditions, e.g. 
after eucaloric- vs. over-feeding or in lean vs. obese participants. Variations in study 
design make direct comparison between studies difficult and may account for some 
of the apparent discrepancies in findings. Carnell et al categorise these design 
differences into three areas - imaging methodology, study paradigms (including the 
physiological state of the participant) and participants involved [150]: 
 
1. Imaging modality: PET scanning (which uses different radioisotopes, most 
commonly 
18 
F-FDG, but also 
15
O) offers a more direct assessment of neuronal 
activation than fMRI but has inferior spatial resolution which must be considered 
when comparing studies using these two different modalities. Physical issues such as 
the size of the hypothalamus, where there can be difficulty in distinguishing between 
functionally distinct areas, and signal drop-out in areas such as the OFC (close to 
sinus air cavities) may make it difficult to detect variations in some areas without 
using specific techniques to modify image acquirement or analysis which specifies 
these areas as a priori regions of interest (ROIs). In order to include some small 
ROIs which may be of interest the field of view may need to be narrowed to allow 
for adequate image quality or thinner “slices” acquired. 
 
2. Study paradigms: Whilst some studies use resting-state scanning, others involve 
task-related paradigms. There is not only a difference between the cues used (real 
food, liquid meal, food images, imagined food), but in the ways that they are 
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presented (taste of a food/liquid meal, feeding to satiety, images of high- vs. low-
calorie foods, high- vs. low-fat foods, palatable/unpalatable/disgusting foods, with 
comparison to neutral object images, food-related images or images matched for 
emotional valence). Some study methodologies include only fasting or fed states, 
while others compare fasting with fed states. One problem in studies comparing 
fasted and fed states is the potential confounding of scan order (satiation must always 
follow fasting if a significant period of fasting is required) [151] or alternatively the 
need to undertake scans on separate days, which also may introduce bias. Variations 
in the length of fasting will also have an impact on physiology – where some fasting 
periods were as short as 1.5 hours, others were significantly longer with the potential 
that prolonged fasting may have led to increased salience of the stimuli across all 
groups, therefore potentially negating differences between participants in different 
study groups.  
 
3. Participants: Physical size and technical limitations may restrict studies to 
participants with a BMI <40 kg/m
2
. Another inadequately studied group are those 
with BMI 25-30 kg/m
2
 who are neither lean (BMI <25 kg/m
2
) or obese (BMI >30 
kg/m
2
). Varying definitions of obese and non-obese/lean have been used in different 
studies. Individual factors such as age, gender, handedness, phase of the menstrual 
cycle of female participants and pubertal stage of adolescents studied may also 
account for variations between (or within) studies. A few papers describe repeated 
fMRI studies of within-participant changes in weight over time, which also has 
advantages and disadvantages. 
 
Additionally, data analysis methods vary between studies, for example 
whole-brain analysis vs. a priori ROIs, different software packages (SPM, brain 
voyager) are used and varying statistical thresholds are employed when reporting 
significance.  
 
 
In spite of these difficulties with variations in study design, review papers do 
identify with some consistency several brain areas in which food cues are associated 
with activation differences [145, 150, 152-157]. These are not only homeostatic areas 
which regulate appetite, but also reward-related regions like the insula, orbitofrontal 
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cortex (OFC) and dorsal striatum. Differences in cerebral activation with food/food 
cues are often more significant when fasted compared to fed, with more 
palatable/pleasant food and with greater hunger [145]. 
 
Many studies demonstrate increased activation in reward-related regions in 
obese compared to lean participants, as summarised in several review papers  [145, 
150, 152-156] (Table 1.25), however individual studies vary, possibly due to the 
reasons described above.  
 
Table 1.25. Brain regions frequently associated with increased activation in obese 
compared to lean participants/predictive of weight gain and their described function. 
Brain regions  Function Reference 
Anterior cingulate 
cortex (ACC) 
Conflict monitoring/cognitive inhibition 
/reward-based learning/decision making 
[150, 152-
155] 
Amygdala Emotion/aversion [150, 152-
155, 158] 
Anterior insula/insula Taste/interoception/emotion/ gustatory 
processing 
[150, 152-
156] 
Caudate/putamen 
(dorsal striatum) 
Reward/motivation [150, 152-
156] 
Hippocampus Memory [150, 153] 
Medial/lateral 
orbitofrontal cortex 
(OFC) 
Reward/emotional decision-making [150, 152-
156, 158] 
Nucleus accumbens 
(NA)/ventral striatum 
Reward/anticipation/motivation/expectancy [150, 152-
155, 158] 
Parietal cortex Spatial attention [150] 
Pre-frontal cortex 
(PFC)/medial PFC/ 
dlPFC/vmPFC 
Motivation/executive function/ processing 
of cues into behaviour/ self-
control/expectation 
[150, 153] 
Ventral pallidum Reward/incentive motivation [152, 153] 
Ventral tegmental area 
(VTA) 
Dopaminergic projections to limbic areas [153] 
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Although many studies identify hyperactivation in reward-related regions in 
obese compared to lean participants, there remains a seemingly opposing hypothesis 
of hypoactivation of reward-related systems underlying the development of obesity 
[152, 154, 158-160]. Differences in study paradigms (as described above) may 
account for these divergences, for example several review papers describe an 
increased striatal response with palatable food cues (i.e. where there is the prospect 
of ingestion), but a decreased response to actual ingestion [153-155, 158]. 
Hypoactivation in areas responsible for homeostasis, cognitive control and 
attention have also been identified in obese compared to lean participants [156], for 
example reduced inhibitory control from the PFC [157, 158]. 
 
The most recent review paper describes the introduction of techniques such as 
functional connectivity and brain network analysis, which have led to further 
developments [160]. It also conveys the evolution of functional neuroimaging in 
investigating obesity, describing the latest studies where consideration of the 
interaction between hormonal, behavioural and neuroimaging data has allowed 
studies to explore the underlying mechanisms of obesity based on hypotheses formed 
using disease models. Longitudinal studies investigating the neural control of 
ingestive behaviour preceding weight gain/obesity are important as cerebral 
responses to food/food cues identified in participants who are already overweight 
may be due to neural adaptations to the adiposity which has developed and represent 
a consequence of obesity, rather than a cause [145, 160]. 
 
 
Food presentation during fMRI studies 
Early neuroimaging studies using PET scanning demonstrated differences in 
brain activation in various regions before and after a liquid meal [149, 161, 164, 166, 
168, 169]. A few studies have used imagined [167] or actual food [170], but most 
recent studies have used photographs of food and non-food items . The non-food 
items are used to distinguish brain activation due to any visual stimuli from 
activation due to food stimuli.  
Some studies have investigated whether differences exist in cerebral 
activation between different types of food; high- vs. low-calorie [175-177, 179], 
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high- vs. low-incentive [167], high- vs. low- hedonic [178] and high- vs. low-fat 
foods [180]. These categories are similar, but not identical, making comparison 
between studies difficult.  
On review, these studies used non-standardised images, for example the size 
and quantity of food in the photographs was different, or they contained distracting 
backgrounds such as a checked table cloth. This potentially influenced their 
outcomes and was important to consider when designing the fMRI study described in 
this thesis and when analysing and comparing these studies. 
 
 
Hormone, nutrient and appetite correlates in functional neuroimaging studies 
Several studies have measured nutrients and hormones, such as glucose, free 
fatty acids, insulin, leptin, GLP-1, gastrin and pancreatic polypeptide alongside 
functional neuroimaging [169]. Plasma insulin in particular has often been correlated 
with differences in brain activation [168]. Peptide YY 3–36 (PYY3-36), insulin, 
leptin and ghrelin are known to be involved in cerebral regulation of appetite [182], 
with receptors present in areas such as the amygdala and hippocampus (ghrelin 
receptors) [183]. The hypothalamus in particular has numerous hormone receptors 
including ghrelin, leptin, NPY, AgRP, insulin and glucose in hunger and satiation-
signalling nuclei [184].   
Both observational studies of ghrelin concentrations and BOLD signal [185] 
and the effects of infused ghrelin on brain activation have been studied using fMRI 
[186-188]. The observational study of 26 normal weight (mean BMI 21.1±2.0 
kg/m2) young adults (mean age 24.4±3.4 years, 13 male) found a correlation 
between endogenous fasting unacylated ghrelin concentrations and fMRI BOLD 
signal when viewing food (as opposed to control) pictures in the bilateral caudate, 
pallidum and midbrain (reward-related regions), middle and superior 
occipital/temporal/fusiform gyri (visual processing regions), rolandic operculum, 
amygdala, thalamus and anterior cingulate gyrus (taste regions) and right 
hypothalamus [185]. The authors found no significant correlations between BOLD 
signal and a decrease in endogenous ghrelin concentrations seen following an oral 
glucose load. The first study involving infused ghrelin compared BOLD signal whilst 
viewing food images before and after ghrelin infusion in 12 normal weight males 
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(mean age 24.1±1.1 years, mean BI 22.2±0.5 kg/m2) with that of 8 normal weight 
male controls (mean age 23.2±1.3 years, mean BI 22.3±0.7 kg/m2) who received a 
saline infusion [186]. Imaging commenced three hours after a standardised breakfast, 
when endogenous ghrelin would be at its lowest, with the relevant infusion given 
between two scanning sessions. Those who received ghrelin had significantly greater 
BOLD signal in response to food compared to scenery photographs in reward-related 
regions - bilateral amygdala and anterior/mid-dorsal insula, left OFC and caudate, 
right substantia nigra/VTA and hippocampus, as well as visual areas (pulvinar and 
fusiform gyrus). The increase in BOLD signal in the bilateral amygdala, left OFC 
and left pulvinar following ghrelin administration correlated with self-reported VAS 
ratings of hunger. The control group were included to exclude order effects. 
Examination of the interaction effect between the groups found significantly greater 
increases in BOLD signal in the bilateral anterior insula and fusiform gyrus, left 
OFC, mid-insula and pulvinar, and right substantia nigra/VTA in those who received 
ghrelin. A physiological/ pharmacological fMRI study of 20 non-obese adults (mean 
BMI 25.1, range 21-28 kg/m
2
) showed that a post-prandial ghrelin bolus caused a 
decrease in the BOLD signal in the medulla, midbrain and pons, cerebellum, superior 
hypothalamus, insula, para-hippocampal (amygdala/hippocampus) and post-central 
gyri and thalamus compared to a saline infusion during a 30 minute 
physiological/pharmacological fMRI scan, likely signifying a blunted response to 
feeding following ghrelin administration [187]. When ghrelin was given alongside an 
intra-gastric infusion of C12 fatty acid, the CCK-induced hypothalamic, brainstem, 
insula and amygdala/ hippocampal activations were reduced. A pre-prandial ghrelin 
infusion led to a small increase in BOLD signal in similar areas (also motor cortex 
and inferior hypothalamus) during a 54 minute physiological/pharmacological fMRI. 
Another study compared 22 normal weight adults (17 male) under different 
physiological conditions, whilst undergoing an fMRI picture-evaluation task – a) 
following an overnight fast and subsequent saline infusion (fasted-saline) where 
ghrelin would be endogenously increased; b) following a standardised breakfast meal 
with subsequent saline infusion (fed-saline) where ghrelin would be suppressed; and 
c) following a standardised breakfast meal followed by a ghrelin infusion (fed-
ghrelin) where ghrelin would be exogenously increased [188]. Whole-brain analysis 
found no significant differences between these three states for the contrasts any food, 
high-energy or low-energy food photographs compared to objects however 
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examination of a priori ROIs showed significant differences in the OFC and 
hippocampus. In the OFC, BOLD signal was significantly greater with higher ghrelin 
concentrations (fasted-saline and fed-ghrelin) than with lower concentrations (fed-
saline) when viewing both high-energy foods and all foods (high- and low-energy) 
compared to objects. In the hippocampus there was significantly greater BOLD 
signal with higher ghrelin concentrations (fasted-saline and fed-ghrelin compared to 
fed-saline) when viewing all foods compared to objects. Additionally, when viewing 
high-energy or low-energy foods compared to objects there was a significant 
difference in BOLD signal between fasted-saline and fed-saline for both picture 
types, and fed-ghrelin and fed-saline for low-energy foods. There was no significant 
difference in any of the other ROIs studied (NA, caudate, anterior insula or 
amygdala) with any of the photograph contrasts (high-energy, low-energy or all 
foods compared to objects) in any of the conditions (fasted-saline, fed-saline, fed-
ghrelin). There was no correlation between BOLD signal and food appeal rating or 
ghrelin concentrations in any of the conditions in either the OFC or hippocampus. 
Similar results were found when female participants were excluded and data from 
only males examined. 
The differing effects of glucose and fructose on the brain have been 
investigated. Glucose ingestion significantly decreased cerebral blood flow to the 
hypothalamus (an a priori region of interest) compared to fructose when given to 20 
participants (10 female, 10 male; mean BMI±SD 22.5 ± 2.5 kg/m
2
) following an 
overnight fast in a blinded, randomised cross-over manner [148]. Participants 
underwent an MRI scan, followed by ingestion of a drink containing either glucose 
or fructose, with a repeat scan after 60 minutes. Participants then received the 
alternate sugar in a second episode between one week and two months later. Whole 
brain analysis showed that whilst glucose decreased hypothalamic, thalamic, insula, 
anterior cingulate and striatal activation, fructose lessened activation in the thalamus, 
hippocampus, posterior cingulate, fusiform and visual cortex. Functional 
connectivity analysis, using the hypothalamus as the starting point (seed region) 
showed increased connectivity between the hypothalamus and the thalamus, caudate 
and putamen with glucose, but only with the thalamus following fructose ingestion. 
In further analysis, changes in the striatum (caudate and putamen) correlated with 
changes in plasma insulin in response to glucose ingestion. These areas are involved 
with motivation and reward [148]. 
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Feelings of hunger and satiety experienced by individuals during 
neuroimaging studies have been evaluated using Visual Analogue scale (VAS) 
ratings [189]. These quantify participants’ subjective feelings of appetite by asking 
them to mark their hunger, fullness and desire to eat on a straight 10 cm line, which 
is then measured. VAS ratings have been used to confirm hunger and fullness when 
comparing fasted and fed states [147, 161, 164, 166, 167, 178, 179, 183, 190]. Long-
term eating behaviour and attitudes are also important and the Three Factor Eating 
Questionnaire (TFEQ) [191] has been used to quantify long-term hunger, whether 
participants actively restrict their diet or if they have disinhibited eating [164, 167, 
171, 190, 192]. These are particularly important where disordered eating (such as 
Prader-Willi Syndrome or bulimia) may exist. 
 
 
Use of functional neuroimaging in participants with an underlying medical 
disorder  
 
Of particular interest and relevance are functional neuroimaging studies 
undertaken in participants with disordered eating such as leptin deficiency, Prader-
Willi Syndrome (PWS) and melanocortin 4-receptor (MC4R) mutations.  
 Individuals with congenital leptin deficiency are significantly hyperphagic. 
This resolves with leptin supplementation. An fMRI study of three leptin-deficient 
adults examined participants in a fed state after 57 months of leptin supplementation, 
subsequently stopped for 33 days, then re-introduced before final data was gathered 
[193]. Self-reported hunger was higher without leptin treatment (statistically 
significant difference in 2 participants and approaching significance in the third), as 
was BMI (mean increased from 27.7 to 29.6 kg/m
2
, p = 0.009). Viewing high-calorie 
compared to low-calorie foods in the leptin deficient state led to greater activation of 
the bilateral insula, right limbic lobe/parietal postcentral gyrus/occipital precuneus 
and left parahippocampus/parietal supramarginal and temporal fusiform gyri. Leptin 
supplementation resulted in greater activation of the left superior-, bilateral medial- 
and right middle-frontal gyri of the PFC, left cingulate gyrus/occipital cortex, right 
frontal lobe/pons and bilateral cerebellum. Increased insula activation during leptin 
deficiency was particularly noted, correlating with increased reported hunger and the 
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known insatiable appetite of those with leptin deficiency. The effects of leptin 
supplementation in greater activation of the PFC may reflect the satiation-induced 
inhibitory processes described in other studies. Another study of two adolescents 
with leptin deficiency compared VAS ratings of hunger, satiety and food-photograph 
“liking” and differential brain activation using fMRI before and after seven days of 
leptin treatment [194]. The short duration of treatment meant that no changes in BMI 
had occurred, but a significant effect on food intake was documented. Leptin 
treatment resulted in decreased fasting hunger, increased post-meal satiety and 
decreased liking of food photographs, compared to pre-treatment. Comparison of 
fMRI-measured brain activation showed that before treatment, food photographs (vs. 
non-food images) resulted in increased activation of the NA, caudate, putamen and 
globus pallidus. This was not evident in the leptin-replaced state. Food-photograph 
liking ratings were also decreased in the leptin-replaced fed state, compared to when 
untreated. Activation of the NA and caudate were positively correlated with liking 
ratings in both the fasting and fed states pre-treatment, but post-treatment only in the 
fasted state. This reflects changes in neuronal activation in the leptin-treated state in 
an area responsible for food reward, suggesting that leptin is important for this aspect 
of eating behaviour. Both studies are limited by the extremely small number of 
participants, which reflects the extreme rarity of the condition. The first study 
reported uncorrected whole brain analysis, with the second corrected for multiple 
comparisons, although it is not stated whether ROI or whole brain analysis was 
undertaken. 
 
In Prader-Willi Syndrome (PWS), extreme hyperphagia leads to morbid 
obesity. A study of 13 adults with PWS compared PET findings (with 
15
O tracer) 
whilst viewing food photographs in fasted and fed (400 kcal or 1200 kcal breakfast) 
states [189]. The authors found that when fasted there was greater activation in the 
hypothalamus, amygdala, basal ganglia and ACC (similar to their findings in non-
obese individuals [167]), as well as the lateral OFC and inferior temporal cortex. In 
contrast to individuals without PWS [149, 167-169], there was no increased activity 
in areas associated with satiety (PFC, OFC and temporal cortices) when comparing 
fed to fasted states. VAS ratings before scanning showed significantly higher hunger 
and desire to eat and lower fullness on the fasted study day than when fed a 1200 
kcal breakfast. However, ratings taken immediately after scanning on both of these 
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days were not significantly different, indicating that not all participants remained 
satiated following breakfast, which may have influenced the findings. Post-hoc 
analysis found increased activation in the medial OFC of the 6 participants who 
remained significantly full, compared to the 6 other participants. The authors also 
found that the medial OFC was greater activated following a 1200 kcal breakfast, 
compared to the lateral OFC which showed increased activation after a 400 kcal 
breakfast. They hypothesized that the medial OFC evaluates reward, whereas the 
lateral OFC has a separate function associated with punishment leading to behaviour 
change. The study is limited by a lack of direct comparison between participants with 
and without PWS.  
This has been undertaken in other studies. One study compared 9 adolescents 
with PWS to 9 age-matched, normal-weight controls, undertaking fMRI whilst 
viewing images of food or animals [195]. In the PWS group, following a 500 kcal 
meal there was greater activation in the right amygdala/OFC/fusiform gyrus, left 
parahippocampus and bilateral medial PFC/insula when viewing food photographs 
compared to controls (Table 1.26a, Appendix 1). A second study (also fMRI) 
compared 14 young overweight/obese participants with PWS to 14 age-matched SO 
controls and 15 lean controls [171]. There was significantly greater reported hunger, 
disinhibition and dietary restraint in SO than in lean controls and in PWS than in 
both other groups using a modified TFEQ. ROI analysis demonstrated significantly 
greater activation (uncorrected for multiple comparisons) in the NA and amygdala in 
PWS compared to SO when viewing food stimuli before a meal (Table 1.26b, 
Appendix 1). Post-prandially the PWS group had greater hypothalamic and 
hippocampal activation compared to SO, with persistence of increased amygdala 
activation. Greater post-prandial dorso-lateral PFC activation in SO compared to 
PWS participants remained significant when corrected for multiple comparisons. 
This study supported many of the findings of the earlier paper by Hinton [189].  
The authors concluded that in PWS there was hypoactivation of the left 
dlPFC, however the same area also had greater activation in SO compared to LCo, 
therefore hyperactivation in SO rather than hypoactivation in PWS may be present. 
One possibility is that individuals with SO need greater dlPFC activation post-
prandially to inhibit areas responsible for the initiation of feeding, as found by 
Gautier [168], whereas in PWS the hyperphagia is due to increased activation of the 
hypothalamus, amygdala and hippocampus (all greater activated post-meal compared 
74 
 
to both SO and LCo). As PWS is associated with hyperghrelinaemia and ghrelin 
receptors are prolific in these areas [171], the increased activation present here seems 
logical. This is consistent with a different underlying pathophysiological mechanism 
for obesity in PWS compared to SO. 
 
 Melanocortin 4-receptors (MC4R) are found in significant numbers in the 
hypothalamus, brainstem, striatum and other brain regions [196]. As part of the leptin 
pathway stimulation of these receptors by -MSH has anorexigenic effects and 
inhibition by AgRP has orexigenic effects [11, 35]. They are also affected by ghrelin 
and PYY. There is evidence from rat models that they are important in food reward. 
An fMRI study compared BOLD signal in eight patients with MC4R mutations to 18 
controls (10 overweight/obese, 8 lean) one hour after a standardised lunch meal, 
calculated as a proportion of estimated daily energy requirements [196]. As the 
authors were interested in the effects of food reward, they primarily conducted an 
ROI analysis of the caudate/putamen and ventral striatum. This revealed lower 
BOLD signal in the left dorsal striatum of SO controls than in those with MC4R 
mutations and lean controls when viewing appetising compared to non-appetising 
foods. The same contrasts also showed lower activation in the left ventral striatum in 
SO controls than in those with MC4R mutations and increased activity in the inferior 
parietal cortex in MC4R participants than SO and lean controls during exploratory 
analysis (at a statistical threshold of p<0.001 uncorrected). When contrasting BOLD 
responses to appetising food photographs against non-food photographs, again there 
was decreased activation in the left dorsal striatum of SO controls compared to those 
with MC4R mutations and lean controls. There was no difference detected in the 
amygdala or OFC between the groups at p<0.001 uncorrected. Pleasantness and 
disgust were measured using VAS ratings and did not differ between the groups. The 
authors speculate that the reduced responsiveness of the reward-related striatum in a 
satiated state seen in SO controls may lead to over-eating to compensate, resulting in 
obesity. As the decrease is not seen in those with MC4R mutations, the authors argue 
that this implies that the decreased striatal response is not secondary to 
overconsumption, but that the alterations in neural response occur with the weight 
gain and need a working melanocortin pathway to arise. The reason for the 
somatosensory changes in MC4R participants is unclear and it is interesting to note 
the lack of differences except for this between them and lean controls. 
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Conclusions 
The use of functional neuroimaging in participants with congenital leptin 
deficiency, PWS and MC4R mutations and the differences found between these 
groups and lean or SO controls demonstrates its utility in studying participants with 
disordered eating. Functional neuroimaging therefore lends itself to the study of 
adults with HO, a group in whom it has not yet been used. This thesis therefore 
describes the novel use of functional neuroimaging in adults with acquired, structural 
hypothalamic damage and explores the differences between those who develop HO 
and those who remain weight-stable (HWS). 
 
 
Study of human eating behaviour: Assessment of the 
microstructure and macrostructure of feeding behaviour 
 
Eating behaviour is an important consideration when investigating the 
pathophysiology of HO as hyperphagia has been described in both humans [11, 23, 
32, 40, 41] and animal models, although is not considered essential for the 
development of HO [16, 42, 43]. Eating behaviour can be considered in terms of its 
macrostructure and microstructure. The macrostructure of eating behaviour describes 
patterns of food consumption throughout an entire day as well as longer-term 
behaviours, whereas the microstructure of eating behaviour relates to the pattern of 
food consumption during individual eating episodes [197]. Studying the micro- as 
well as the macro-structure of eating behaviour allows additional information, such 
as eating rate and changes in eating rate to be gathered [198], alongside intra-meal 
subjective assessments of appetite feelings. Since both single meal and longer-term 
intake may lead to excessive weight-gain, it is important to consider both in patients 
with hypothalamic damage and subsequent obesity.  
Eating behaviour has different components, including physiological, 
behavioural and cognitive factors. Assessment of all these various factors is 
important however is not an easy undertaking [199] and can never be error-free 
[200], with advantages and disadvantages to all methods. Whether to assess eating 
behaviour in the laboratory or the “real-world” is another consideration. The 
reliability and accuracy of laboratory-based assessments must be balanced with its 
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potential to influence findings, whereas assessment of eating in participants’ 
everyday environment, where normal influences and patterns have been established, 
may be less accurate [201].  
 
Study of within-meal microstructure of human eating behaviour 
The study of the microstructure of eating behaviour involves assessing food 
intake within (and/or immediately before or after) a meal and recording of  subjective 
appetite measures such as hunger and satiety using visual analogue scale (VAS) 
ratings [202, 203].  
Microstructure studies have demonstrated differences between groups with 
different characteristics, under different experimental conditions and influenced by 
disease. The first direct measurement of within-meal food intake involved liquid-
food consumed through a straw from a hidden reservoir [204]. The system accurately 
recorded intake in 14 individuals studied, with good correlation between subjective 
measures of hunger and the rate/amount of liquid ingested.  A similar system 
compared obese, normal-weight and under-weight subjects (described in detail 
below) [205]. Assessment of semi-solid food consumption was first undertaken in 
1980 [206]. The authors compared liquid and semi-solid meals of the same caloric 
value consumed on different study days. Computer-connected scales recorded intake 
every 3 seconds until no significant change occurred for 15 minutes. There was no 
difference in the total amount consumed between conditions, however rate of 
consumption, initial eating rate and deceleration in eating rate were greater with 
liquid. Both meals were equally well-liked. The authors concluded that their 
equipment could be used with either semi-solid or liquid food. 
Kissileff et al named their equipment the Universal Eating Monitor (UEM) 
[206]; other similar equipment with differing names (Endogram, Sussex Meal Pattern 
Monitor and VIKTOR) has been described by others since [197, 207-209]. For 
consistency, all papers described in this thesis will be referred to as UEM studies. 
The UEM works by measuring food intake via sensitive scales connected to a 
computer, hidden under a thin plastic mat under the bowl/plate of food (Figure 1.6). 
To allow continual monitoring, the food must be liquid or semi-solid, for example 
yoghurt [203, 206, 210-212], Swedish hash [213-216], chocolate pudding [217, 218] 
or pasta [197, 207]. Foods such as sandwiches (picked up to eat) or meat and 
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vegetables (requiring cutting and eating in chunks) are not suitable for several 
reasons. Firstly, cutting of food may affect the accuracy of the scales, due to pressure 
exerted. Secondly, solid foods which are picked up whole may not be entirely 
consumed and need to be returned to the plate, which may not always occur, leading 
to inaccuracies. Even if the entire portion picked up is eaten, this may take a varying 
amount of time, leading to less accuracy than using food consumed in a single 
mouthful. UEMs continually record intake, enabling generation of cumulative intake 
curves in addition to accurate measurement of total consumption and meal duration. 
Contemporary systems allow subjective assessment of appetite ratings of hunger, 
satiety and food pleasantness with VAS measures by regularly interrupting 
participants (time- or quantity-based) to complete on-screen ratings. The advantages 
over paper-based VAS ratings are that the participant can be accurately interrupted 
without need for an experimenter and each rating is individual as it cannot be 
compared to previous ratings [219].  
 
Figure 1.6. Photograph of participant consuming food at the UEM. 
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Validity 
An important consideration is whether laboratory eating is reflective of real 
world intake. Kissileff and Thornton found a significant correlation between UEM 
consumption and real world intake when comparing food diaries and laboratory 
intake. Mean lunch intake eaten in the laboratory was 888kcal (±387 SD) in males, 
compared to 850kcal (±547 SD) eaten in a non-laboratory setting and 492kcal (±143) 
compared to 381kcal (±112 SD) in females, respectively. The variability in intake 
outside of the laboratory however (reported in food diaries) was greater, reflecting 
the multitude of influences on eating in everyday life such as nutritional variability 
and social interactions [220].  
 
Reliability 
Also important are consistency and reliability. Several papers describe good 
consistency within individual participants [204, 218, 220, 221], with greater inter-
participant variability than intra-participant [205, 222]. One study found that after 
two days of familiarisation with the equipment, little variation in individual intake 
occurred over subsequent visits (3-7 days) [205], while another  found it took 
between 3-5 visits before participants demonstrated a consistent intake (within 5-
35% of their mean ingestion) [204].  Familiarisation is important as other studies 
have found lower intake on the first occasion compared to subsequent episodes 
(376.82 g vs. 419.21 g, p<0.04) [212], with no significant difference in subsequent 
sessions [220]. Hubel found that whilst the test-retest correlation for intake amount 
was good, the mean intake at each episode was significantly different (i.e. all 
individuals ate more on the second occasion, giving a consistent increase) [212]. 
These findings suggest that unfamiliarity with the laboratory environment and UEM 
equipment at the first episode may falsely lower intake, with a more authentic 
consumption on subsequent episodes. This is important when drawing conclusions 
from studies based on two eating episodes and also in study design.  
Not all factors are so consistent. Hubel found that while intake amount and 
duration, initial eating rate, number of bites and bite size were significantly 
reproducible on re-testing, change in eating rate was not well correlated [212]. The 
authors speculated that changes in eating rate may be influenced by external stimuli, 
rather than inherent. Given this, studies showing changes in eating rate under 
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different experimental conditions need to be interpreted with caution. Other factors 
speculated to influence reliability are intrinsic differences between participants, 
although in 61 participants studied, differences such as gender, BMI, disinhibition 
and cognitive restraint did not affect the reliability of food intake across two episodes 
[212]. These may, however, be causes for variations between different groups, as 
discussed below. 
 
UEMs have therefore been shown to be both reliable and reproducible in 
investigating the microstructure of eating behaviour and can determine differences in 
the rate of food consumption across a meal, although comparisons between eating 
rate on different occasions must be interpreted with caution.  
 
Analysis 
Finally, the method of data analysis must be considered. Various methods of 
analysing UEM data have been used, which makes comparison across studies 
difficult and may lead to differences in data interpretation [207]. Kissileff’s first 
paper used graphs, termed cumulative intake curves, to measure food intake [206]. 
Subsequently, 11 different methods of data analysis were compared to find the best 
model to fit the data of 16 participants [220]. The quadratic equation accounted for 
96.3-99.9% of variance in cumulative intake and provided the simplest model. 
Cumulative intake curves were useful for visual comparison of eating patterns, but 
could be up to 30% different from the mean actual intake over several meals. 
Quadratic equations were more accurate and allowed more precise inter- and intra-
participant comparison. The parts of the quadratic equation fit two distinct parts of 
the curve - initial intake rate (linear coefficient) and rate of deceleration at the end of 
the meal (quadratic coefficient). These correspond with the stimulatory/excitatory 
aspect of eating (hunger) and negative feedback/inhibition of eating (satiety) 
respectively [220]. A negative quadratic coefficient indicates a decrease in eating 
rate (seen with a decelerated eating curve), a positive coefficient describes an 
accelerated eating rate and where the quadratic coefficient is zero, the eating rate has 
stayed constant (a linear or non-decelerated curve).  
Other investigators have compared the amount eaten in different segments of 
the meal (temporal quarter analysis). Temporal quarter analysis of data from 92 
80 
 
participants found that in 39 participants who had decelerated intake curves 
deceleration was secondary to decreasing bite size rather than eating rate, which 
remained constant [223]. Decrease in consumption began in the third quarter but only 
became significantly different from the initial rate during the 4
th
. Fixed time analysis 
undertaken for 55/92 did not identify a particular time when eating rate changed. 
There was no difference in the total meal size, meal length, or percentage change in 
the cumulative intake slope (i.e. rate of deceleration) between the 86 normal-weight 
and 50 overweight females studied. 
Yeomans concluded that both the quadratic equation method and meal 
quartiles approach should be used due to a lack of evidence regarding the best 
method [219]. Dovey et al analysed a single data set using three different 
methodologies; visual ascription, area under the curve and coefficient approaches 
[207]. They found that whilst the first two methods did not demonstrate any 
difference between data obtained in a control condition (relaxation before the eating 
episode) and an experimental condition (a stressor consisting of submerging a hand 
in cold water before the eating episode), the coefficient approach revealed 
differences in VAS ratings of fullness. They describe a modified coefficient 
approach where data may be quadratic (eating rate changes at one point over the 
course of food ingestion) or cubic (eating rate changes at more than one point). 
Whilst the authors acknowledge the possibility of a Type I or II statistical error 
leading to the difference found when using this method, they argue that the highly 
significant nature of the difference on MANOVA analysis (F(2,20)=5.621; p = 0.012) 
makes this unlikely. This paper demonstrated that although the total cumulative 
intake was similar between two experimental conditions, the pattern of subjective 
rating of fullness differed.  
 
 
Intrinsic and extrinsic factors influencing eating behaviour 
Initial eating rate is felt to reflect hunger however can also be influenced by 
factors such as food palatability or duration of fasting [220]. Eating rate at the end of 
a meal, reflecting satiety, may be influenced by factors such as the energy density of 
food consumed or the effects of gut hormones. While meal intake could be proposed 
to be a balance of hunger and satiety, termination of eating may not necessarily 
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reflect merely a physiological equilibrium of the two. In a comparison of predicted 
and actual mean intake, one study found that actual meals terminated before that 
predicted [220]. The authors proposed several possible reasons for this: i) use of a 
single homogenous food resulted in sensory specific satiety; ii) participants’ previous 
experiences may result in meal termination (knowledge that continuing to eat will 
result in discomfort); iii) cognitive factors (awareness of calorie intake and effects on 
weight). Additionally, as there is a significant correlation between initial eating rate 
(hunger) and rate of deceleration at meal end, the deceleration may reflect a decline 
in hunger rather than increasing satiety. It is therefore important to consider both 
intrinsic and extrinsic factors influencing eating behaviour. 
 
Intrinsic factors 
 
1. Bodyweight 
One study reported increased intake in obese/overweight participants [217], 
whilst most report no difference [205, 222, 224]. Laessle et al found a significantly 
greater mean intake in overweight compared to normal-weight participants (both 
genders), with larger spoonful size and faster initial eating rate [217]. The duration of 
eating and deceleration in intake was not significantly different. Another study found 
no difference between lean and obese participants in total intake or intake duration, 
but that obese participants ate faster (p<0.05) [224]. Binge-eating was seen in 22 
obese individuals compared to only 4 lean participants.  
Initially it was proposed that overweight/obese individuals fail to slow their 
eating rate towards the end of a meal, with two distinct patterns of consumption 
described –  
1: 80% of intake in the first half of the meal, with a decelerating eating rate at 
the end; 
2: linear intake with ≤ 50% consumed during the first half, giving a non-
decelerating eating pattern [205]. 
Non-overweight individuals were more likely to eat in the first pattern, while those 
overweight were more likely to have a non-decelerated pattern. The authors 
postulated that normal-weight individuals feel satiated and decrease their eating rate 
at the end of a meal, but in overweight individuals a loss of normal satiety signals 
leads to lack of deceleration. Mean total intake was similar across the groups, but 
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there was greater variation in the overweight group, with a tendency to hyperphagia 
during stressful stimuli. Another study of 20 obese and 20 normal-weight 
participants found that those with normal-weight had a greater decrease in eating rate 
and significantly higher proportion of decelerated curves than obese [216]. This may 
suggest that although there was no significant difference in the amount eaten, obese 
individuals have blunted satiety awareness. Whilst these findings have been 
replicated in some studies [225, 226], other studies have found that overweight 
individuals have a decelerated eating pattern [197, 214, 217, 223, 224] with 
accelerating eating patterns found in a third of obese participants [227, 228].  
 
One difficulty when comparing studies is the lack of consistency (definitions 
of obese vs. overweight, length of fasting, type of test-meal and study design) which 
should be taken into account in future research to allow more robust conclusions and 
comparisons. 
 
2. Bodyweight and restraint 
Several studies have found no relationship between BMI and change in 
terminal eating rate but have found eating rate and cognitive restraint closely linked 
[202, 222, 223]. These authors argue that restraint, rather than physiological factors, 
influences eating behaviour. The first study found greater cognitive restraint of 
eating, disinhibition and hunger in overweight compared to normal weight women 
(p<0.001 to p<0.05) [222]. Cognitive restraint and disinhibition were negatively 
correlated with decelerated eating in normal-weight women, but slightly positively 
correlated in overweight women. In those with greater disinhibition, normal-weight 
women were consistently non-decelerated eaters whilst overweight women were 
decelerated eaters. Differences in BMI alone were unrelated to the pattern of intake 
however restraint and disinhibition were significant factors. In a second study, there 
was no significant difference in intake between the groups normal-weight restrained 
(NWR), normal-weight unrestrained (NWU) and overweight (OW) (Table 1.27), 
however intake was negatively correlated with cognitive restraint on TFEQ [202]. 
Herman-Polivy (HP) restraint was positively correlated with TFEQ cognitive 
restraint and BMI. Change in eating rate was negatively correlated with TFEQ and 
HP restraint, age and BMI, however as BMI and HP restraint were positively 
correlated it was not possible to disentangle these factors further.  
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Table 1.27. Comparison of mean intake in normal-weight restrained (NWR), 
normal-weight unrestrained (NWU) and overweight (OW) women. 
 NWR NWU OW 
Number 9 women  9 women  6 women 
BMI (kg/m
2
) < 25 < 25 > 25  
Mean BMI (kg/m
2
) 21.3 ± 1.9 21.1 ± 1.0 27.3 ± 1.4 
Cognitive restraint: 
TFEQ 
Herman-Polivy [HP] 
restraint 
 
> 9  
> 15 
 
≤ 9  
≤ 15 
 
> 9  
> 15 
Mean Intake ± SD 365 ± 118 g 481 ± 144 g 424 ± 161 g 
 
Both studies found that restrained eaters had a non-decelerated intake, with 
those of normal weight terminating eating before they were full. The second study 
found that the more restrained the eating behaviour (i.e. higher cognitive restraint on 
TFEQ), the more linear (non-decelerated) the intake. Those with unrestrained eating 
had decelerated intake curves where physiological factors (such as satiety) are likely 
to have played a role in terminating food intake. There was a positive correlation 
between age, non-decelerated intake and restraint. Significantly, eating rate was 
positively correlated with palatability. 
These studies indicate that in some individuals, restraint may be more 
important in terminating eating than physiological factors, making it important to 
consider when analysing eating behaviour. 
 
3. Gender 
Only one study has found no significant difference in total intake between genders 
[229], with most studies finding that males ingest more than females [217, 224, 226]. 
Males have also been shown to eat faster initially, whether normal-weight [220, 224] 
or overweight [217]. Food diaries support a greater real-world intake in males [220]. 
Given these findings, it is possible that studies comparing groups unbalanced in 
gender may erroneously identify differences which in fact only reflect gender 
differences between the groups.  
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4. Age 
Only one study has reported the effects of age and found this was positively 
correlated with a decelerated eating pattern [222]. This needs further investigation 
and should be considered when analysing data with significant differences in age 
between groups. 
 
5. Perception of consumption 
One study found no significant difference in intake when eating from closed 
and open containers and speculated that perceived intake, rather than actual intake 
(amount or calorie), influenced ingestion [220]. Another study however found poor 
correlation between actual and perceived amount ingested, suggesting that other 
factors play a role, for example hunger correlated with the amount ingested in the 
subsequent 5 minutes [204]. A study of 16 lean men with unrestrained eating found 
no difference in total intake due to soup labelling, however the actual fat content did 
effect ensuing intake, with less food consumed following a high-fat soup preload 
[209]. Whilst intake amount was not affected by labelling, this did alter the soup’s 
perceived characteristics, while the actual fat content had no effect. There was no 
effect of soup labelling on hunger and fullness. The authors concluded that although 
food labels affected expectation, the effect did not persist. In contrast the actual fat-
energy content led to a difference in intake. Labelling of foods and expectation in 
eating behaviour studies may therefore be less important than feared. 
 
6. Vision 
It would be expected that vision would have a significant impact on eating 
behaviour and as vision may be affected by midline brain tumours in patients with 
hypothalamic damage, it is an important factor to consider. Individuals with long-
standing blindness and no visual memories of food have been found to eat more 
slowly than controls (both blindfolded and un-blindfolded, Table 1.28), with no 
difference in other outcomes [215]. As the controls ate less and for a shorter period 
when blindfolded, the authors concluded that vision influenced their eating 
behaviour, although unfamiliarity with the situation (blind-folded) and the UEM 
equipment and the small number of participants may have influenced the findings. 
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Table 1.28. Comparison of eating behaviour in blind participants, blindfolded and 
un-blindfolded controls. 
 Blind 
participants 
Controls p-value 
Number 6 female, 3 male 6 female, 3 male - 
Mean age (range) 
years 
49 (41-59) 55 (40-58) NS 
Mean BMI 
(range) kg/m
2
 
23.4 (21.2-34.6) 25.0 (22.1-34.2) NS 
  With 
blindfold  
Without 
blindfold 
 
Median eating 
rate (range) 
g/minute  
30 (21-53) 39 (21-59) 39 (28-77) <0.05 between 
blind participants 
and controls 
unblindfolded 
Median intake 
(range) g 
281 (195-717) 248  
(117-317)  
316  
(190-440) 
<0.05 within 
control groups 
Median intake 
time (range) 
minutes 
8.9  
(6.8-27.8) 
6.5  
(4.8-10.4)  
 
7.0  
(4.6 to 
10.3) 
<0.05 within 
control groups 
Median rate of 
deceleration 
(range) g/minute
2
 
-1.5  
(-4.1 to 1.7) 
0.5  
(-4.2 to 3.0) 
1.2 (-3.5 
to 1.5) 
<0.05 within 
control groups 
NS = non-significant 
 
 
Extrinsic factors 
Extrinsic influences such as food palatability, duration of fasting, presence of 
another individual, or consumption of different preloads may affect food 
consumption and have been considered in UEM studies. 
 
1. Food palatability 
 Several studies have manipulated the palatability of test-meals, influencing 
initial eating rate, total intake and duration of eating. Two different approaches have 
been used: making a pleasant food unpleasant by adding cumin [230] and making a 
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bland meal more palatable by adding seasoning [231, 232]. Palatability was 
hypothesised to influence initial eating rate (hunger), but not rate of deceleration 
(satiety) [230]. Adding cumin reduced total intake, eating duration, post-prandial 
satiety and palatability, with a slower initial eating rate and higher post-prandial 
hunger. The amount consumed was positively correlated with post-prandial 
palatability. In studies with soup preloads, the palatability of test-meals affected the 
total amount consumed, rate of initial intake and post-prandial satiety [231, 232]. 
Total daily intake was also higher on days where a more palatable meal was served. 
 
2. Interruptions 
As many studies interrupt participants to complete appetite ratings, it is 
important to consider whether this may affect outcomes. One study found increased 
intake when participants were interrupted, compared to continuous eating [233]. 
Duration of eating was also longer, although this may have reflected time taken to 
complete the ratings. Despite greater mean intake when meals were interrupted 
hunger remained higher and fullness lower than for meals eaten continuously, 
however as fullness was inexplicably lower before interrupted meals post-prandial 
differences may have been coincidental. A second paradigm found that the reason for 
interruption (to complete appetite-related VAS ratings or anagrams) had no effect in 
9 normal-weight males. Duration of interruption (5-60 seconds) also had no 
significant effect on total intake or eating duration in 16 non-obese males, however 
hunger was significantly greater post-prandially with interruptions of 30 or 60 
seconds and fullness greatest with 5 second interrupts. These results are important 
when designing and analysing UEM studies.  
 
3. Eating Rate 
An adapted UEM showing eating rate in real-time has been used to study the 
effects of manipulating eating rate on total intake and satiety (Table 1.29) in normal-
weight women [234]. 
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Table 1.29. Difference in total intake compared to control condition by eating type. 
 Amount of total intake 
compared to control condition 
Satiety compared to control 
condition 
Condition Decelerated 
eaters 
Non-decelerated 
eaters 
Decelerated 
eaters 
Non-decelerated 
eaters 
40% Shorter 
than original 
meal* 
Less More Lower  NS 
Increased rate* Less More Lower NS 
Decreased rate NS Less NS Higher 
Interrupted* NS More NS Higher 
NS = non-significant. For all cases, where a difference was found p<0.001. 
* = significant difference between decelerated and linear eaters. 
 
Satiety was greater in decelerated compared to non- decelerated eaters in the control 
condition. Decelerated eaters consumed less during a shorter meal and when eating 
more quickly, despite reporting lower satiety at the end of the meal. There was no 
difference in hunger between the groups. This study demonstrated a difference in 
total intake and satiety by using an adapted UEM to influence eating rate. Eating for 
a shorter period, or more slowly or quickly than normal may therefore influence 
study outcomes and participants must feel unrushed in their meal consumption 
during UEM studies. 
 
4. Preloads 
Preloading is a standard appetite-research methodological technique. It 
enables the effects of a manipulation in food given before a meal on subsequent 
appetite and food intake to be assessed. One of the earliest UEM studies considered 
preload effects [204]. Ingestion of a preload at any time-point decreased subsequent 
ingestion, but the timing which affected each participant most was variable. Even 
water preloads affected subsequent intake, although not for as long, or as much, as 
milk or Metrecal preloads. A study examining the effects of different carbohydrate 
preloads at breakfast found that whilst a bread-based breakfast resulted in higher 
post-breakfast insulin and glucose concentrations than a pasta-based breakfast, there 
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was no difference in the total amount eaten, eating rate, or change in eating rate of 
the lunch meal, or differences in VAS ratings of hunger and satiety [235]. Preload 
volume is also important, with lower mean hunger, increased fullness and 
significantly lower intake following a higher-volume, higher-energy soup preload 
[236]. 
In another study, authors hypothesized that non-decelerated eaters ate too 
quickly to feel satiated and used a preload followed by an 8 minute break to assess 
whether a break allowed satiation to develop [223]. All 10 non-decelerated eaters 
remained non-decelerated, therefore individuals who do not vary their eating 
behaviour in different situations may be at increased risk of weight gain.  
 
Although not all studies involve a preload, the effects of earlier food intake 
(e.g. a breakfast meal) may affect subsequent food intake at the UEM and therefore 
should be controlled, or at least accounted for, when designing the study and 
interpreting the data. 
 
5. Energy content of food 
 In contrast to food volume, a calorie increase of 25-30% had no effect on the 
shape/type of eating curve in one study [223]. The hypothesis that energy enrichment 
would lead to earlier satiation and therefore an increase in the prevalence of 
decelerated eating patterns was not demonstrated. The major determinant of satiation 
is volume, which is not surprising as fullness is important towards the end and 
immediately post-meal. It also explains the increase in obesity seen over recent 
decades with the increase in availability of energy-dense foods. 
6. External influences 
A study comparing the eating behaviour of overweight to normal-weight 
children found that in the presence of the child’s mother, although the quantity eaten 
was no different between the groups, there was a significantly faster eating rate, 
larger bite size and acceleration of eating rate at the end of the meal in overweight 
compared to normal-weight children [226]. It may be important, therefore, in studies 
of childhood obesity for mothers to be present during eating to more accurately 
reflect the usual situation at home. The authors postulate that the mother’s presence 
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may reflect learnt behaviour, where she has perhaps previously encouraged a child to 
“eat up”, despite no prompting during the test-meal. 
A study into stress while eating found no difference in cumulative intake 
between occasions when eating was preceded by a social stress test and that without, 
which is important as it is quite commonly perceived that some participants may feel 
stressed in study situations [217]. 
 
7. Influence of the experimental setting 
Studies have used a variety of methods to try and minimise variability and/or 
distractions for participants, for example using recorded instructions [210, 230], 
playing background music [204], or eating in a windowless room [222, 223]. 
Another consideration is whether overweight/obese participants might artificially 
restrict their intake if they are aware that eating is being monitored and is the focus 
of the experiment [217]. A recent study examined whether awareness that food 
intake was being monitored led to differences in consumption at the UEM in 20 
female university students who were told that their intake was being monitored, 
compared to 19 who were unaware [237]. The authors found that there was no 
significant effect on total intake, eating duration, time between mouthfuls or eating 
rate whilst consuming a pasta meal. When eating chunks of cookies following the 
pasta consumption those who were aware that intake was being monitored ate 
significantly more slowly (10.2 g/min) than those unaware (13.4g/min, t37 = 2.39, 
p<0.05) but there remained no difference in total intake, eating duration or time 
between mouthfuls. VAS ratings of fullness were significantly lower during the pasta 
meal in those aware that their eating was monitored (55 vs 63mm, t37=2.12, p<0.05) 
and hunger was significantly higher when consuming the cookies (18 vs 9mm, t37=-
2.48, p<0.05). Given that 72 participants were initially recruited to the study, but data 
had to be discarded from 25 participants who were unaware of the use of the UEM 
due to leaning on the scales, compared to only five who were aware of its use, this 
may offer obvious benefits to informing participants of the purpose/techniques 
involved in UEM studies. This may not be generalisable to the study of all 
populations however as the study was restricted to females, with a mean (SEM) age 
of 20.0(0.4) years in the unaware group and 19.4(0.2) years in the aware group 
(t=1.39, p=0.17) and more importantly for obesity studies mean BMI was 21.9(0.5) 
and 21.8(0.5) kg/m
2
 (t=0.06, p=0.95), respectively. 
90 
 
As UEM studies use a single food-type, sensory-specific satiety may occur, 
with a lower intake than in the normal free-living eating environment where multiple 
foods are freely available [233] and this must also be considered. 
 
 
 
 
Participants with Additional Pathology 
UEM studies have been undertaken in participants with atypical eating, such 
as Prader-Willi Syndrome (PWS), bulimia nervosa and binge-eating disorder (BED). 
 
A study comparing 9 children with PWS, 20 normal-weight controls (NWC) 
and 20 obese controls (OC) found no significant differences in total consumption, but 
PWS participants ate for longer with a slower initial rate than NWC and OC (Table 
1.30, page 91) [216]. PWS participants ate more slowly throughout the entire meal 
than OC, with less deceleration in eating rate than NWC, signifying a constant eating 
rate over a longer time. Limitations of the study included a set amount of food served 
(550g), differences in pubertal stage and a wide range of age and BMI SDS in the 
PWS group. The lack of an initial rapid eating rate indicated no evidence of 
increased hunger in the PWS group, with a longer eating time and constant rate of 
ingestion reflecting loss of satiety commonly described in PWS. 
 
 
Women with bulimia may represent another group with aberrant satiety. 
Compared to 11 controls, 11 bulimic women consumed more of a test-meal (1597 g 
vs. 1004 g, p = 0.02), with no difference in food questionnaire responses before or 
after the yoghurt meal [203]. Bulimic women consumed more to reach maximal 
fullness and intake was higher at 50% and 75% of total intake, implying delayed 
satiety rather than eating past satiety. Other studies have found that ingestion rate 
accelerates during eating [227, 228].  
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Table 1.30. Comparison of food intake in participants with PWS, NWC and OC. 
 PWS NWC OC p-value for 
comparison 
between all 
3 groups 
Number 7 male, 
2 female 
11 male, 
9 female 
8 male, 
12 female 
- 
Mean age (range) 
years 
9.9  
(5-17.5) 
11.8  
(5.9-18) 
12.3  
(6.4-17.8) 
- 
Mean BMI SDS 
(range) 
3 
(-0.1 to 6.4) 
0.4  
(-1.2 to 1.8) 
6.3 
(4.3 to 9.2) 
- 
Median intake (g) 267 270 314 NS 
Median duration 
(range) minutes* 
21.4  
(5.8 - 43.9) 
 
9.9  
(4.0-28.7)
a,c
 
7.7  
(3.8-19.0)
b,c
 
0.04  
Initial rate (range)  
g/minute* 
19  
(3-46) 
 
40  
(12-93)
c,d 
 
47  
(17-79)
c,d 
 
<0.01 
Median eating rate 
(range) g/minute 
16  
(4-38) 
28  
(8-68)
c,e
 
42  
(15-65)
 c,e
 
<0.01 
Deceleration in eating 
rate (range) g/minute
2
 
0 
(–4.6 to 3.6) 
–2.4 
(–14.3 to 
0.7)
d,f
  
–0.9 
(–9.3 to 
3.7)
e,f
 
<0.01 
% of decelerated 
curves 
4/9, 44% 18/20, 90% 14/20, 70% 0.03 (Fisher 
exact) 
a: p=0.05 compared to PWS, b: p<0.02 compared to PWS, c: non-significant 
difference between NWC and OC, d: p<0.01 compared to PWS, e: non-significant 
difference compared to PWS, f: p=0.05 between NWC and OC. 
Significant differences between groups identified on Kruskal-Wallis analysis of 
variance and where significant Mann-Whitney U tests established where the 
difference lay. 
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 In women with BED both initial eating rate and change in eating rate were 
affected by stress, whilst there was no significant difference in total intake, reported 
hunger (pre-meal) or satiety (post-meal) under stressful conditions (Table 1.31) 
[218]. Participants with BED had an increased initial ingestion rate under stressful- 
compared to the neutral-condition and a smaller decrease in rate at the end of the 
meal. Controls ate more slowly with greater deceleration at the end of the meal under 
the stressful condition. The increased rate in BED was due to larger spoonful size, 
rather than an increased frequency. Women with BED ate a similar volume of food 
more quickly when stressed and did not identify a feeling of increased hunger. 
 
Table 1.31. Comparison of food intake in participants with and without BED. 
 Participants with BED Controls 
Mean BMI, kg/m
2
 37  36 
 Stress 
condition 
Neutral 
condition 
Stress 
condition 
Neutral 
condition 
Mean initial eating 
rate, g/sec 
0.53 0.33 0.47 0.53 g 
Mean change in eating 
rate, g/sec
2
 x 1000 
0.04  2.1 0.74 0.17 
 
 
Conclusions 
In summary, the UEM has been used in multiple settings, is reliable and 
sensitive to changes in eating behaviour in different populations and contributes 
unique data to the study of the microstructure of eating behaviour. Using the UEM in 
participants adequately familiarised with the equipment can demonstrate differences 
in hunger/satiety between different groups. Variances in eating patterns due to 
intrinsic and extrinsic factors must, however, also be taken into account. There are 
currently no studies using the UEM in the HO population. If differences in eating 
rate are found to be associated with the development of HO, these findings may shed 
some light on the underlying pathophysiological mechanism(s) contributing to the 
development of HO.  
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Study of the macrostructure of human eating behaviour 
Assessment of the macrostructure of eating behaviour is often undertaken in 
the “real-world” environment. A recent systematic review of 31 studies undertaken 
between 1985-2010 found that the most common method of reporting intake was 
using a food diary (13/31) [238]. One advantage of food diaries is that they do not 
rely on memory [239]. Three-day food diaries have been shown to have fewer 
absolute errors and less missed or erroneously included foods than 5-day diaries or 
24 hour recalls [240, 241]. However they still include errors, with 25% of foods 
observed eaten not reported and 10% of foods reported eaten not actually consumed 
in an observational study of girls aged 9 and 10 years [240]. In addition to 
underreporting another disadvantage of food diaries is the work-load on both 
participants (perhaps leading to underreporting) and on those assessing them [239]. 
Eating away from the home, which is common, can make it more difficult to 
accurately report food intake and a certain level of both literacy and numeracy skills 
are required. Undertaking food diaries may itself lead to a change in eating [239], or 
participants may choose to underreport certain food groups, for example fatty foods 
in those who are overweight/obese.  
 
While food diaries reveal eating behaviour over a period of days, reflecting 
fluctuating physiological states (hunger versus fullness) along with short-term 
behaviour, certain more persistent eating traits can influence eating [242]. These 
more stable traits tend to influence food choices over a long period of time and 
become eating habits, influencing cognitive choices and can supersede hunger and 
satiety cues. Traits such as eating restraint, self-control and internal and external 
factors affecting hunger can be measured. The Three Factor Eating Questionnaire 
(TFEQ) [191] is the most commonly-used questionnaire [201]. The 51-item 
questionnaire can be used for adults of both genders and consists of true/false 
questions and ones answered on a scale of 1-4 or 1-6, with dichotomous scoring even 
for the scale questions [243]. Three overarching traits or “factors” are considered: 
dietary restraint, disinhibition and hunger. Dietary restraint describes the amount of 
behavioural control someone has over their eating behaviour. This has been 
inconsistently associated with BMI and energy intake (both higher and lower intake 
has been described in restrained eaters). Disinhibition describes the likelihood of 
94 
 
eating under certain environmental conditions, for example when upset or in the 
presence of palatable food. High disinhibition scores have most consistently been 
associated with increased BMI and energy intake. Hunger questions show how 
sensitive participants are to feelings of hunger and their tendency to eat, but has been 
less strongly correlated with outcomes than the other factors in studies so far [201].  
Scores for normal-weight and obese populations have been compared. The 
TFEQ has been used to study large cohorts, particularly in relation to obesity/weight-
loss trials and has high internal and test-retest reliability in both laboratory and non-
laboratory settings [191, 201]. In a study of 233 adults comparing TFEQ to 
laboratory measures (reinforcing value of food and explicit liking/implicit wanting) 
BMI was most strongly correlated with disinhibition, with hunger also significantly 
correlated and none of the other measures showing significant correlation. Energy 
intake was negatively correlated with restrained eating; disinhibition, hunger, liking 
and wanting were all positively correlated [201]. 
 
Studying the macrostructure, as well as the microstructure, of eating 
behaviour in patients who are HWS and those with HO may help to elucidate the 
underlying mechanisms and behaviours leading to the difference in outcomes in 
patients with hypothalamic damage. 
 
 
 
Aims of Thesis 
The primary aims of this research were: 
1. To assess the prevalence of obesity and other cardiovascular risk factors in 
patients with hypothalamic damage. 
2. To assess the prevalence of obesity and other cardiovascular risk factors in 
children and adolescents with pituitary adenomas. 
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3. To investigate the underlying pathophysiology of HO using the complementary 
approaches described above to determine whether disturbances in neural pathways 
affect food intake and eating behaviour, leading to weight-gain.  
 
Hypotheses 
1. Individuals with acquired hypothalamic damage would have a high prevalence of 
obesity and other cardiovascular risk factors, despite appropriate awareness and aims 
at prevention of these sequelae amongst the treating physicians. Also that patients 
with growth hormone deficiency and cranial diabetes insipidus would be particularly 
at risk of HO. 
2. Children and adolescents with pituitary adenomas (both with and without 
hypothalamic damage) would have an increased prevalence of metabolic 
disturbances such as obesity, dyslipidaemia and hypertension (conferring an 
increased cardiovascular risk) and impaired fertility, as described in adult patients 
with pituitary adenomas and hypopituitarism. 
3. That the fMRI study would demonstrate that compared to those participants with 
hypothalamic damage remaining weight stable (HWS), those with HO (and obese 
controls) would have increased activation in non-homeostatic brain regions which 
process food reward, such as the insula, orbito-frontal cortex (OFC) and striatum 
when viewing food photographs. 
4. Patients with HO would consume more food (demonstrated in both the UEM 
experiment and in the 3-day food diaries) than those HWS and non-obese controls 
and have increased levels of disinhibition and hunger, and lower restraint than the 
other groups.  
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Chapter 2 
 
Methods  
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Methods 
Ethical Approval, Recruitment and Consent 
For the two retrospective reviews (Chapters 3 and 4), the permission of the 
Audit Departments and Caldicott Guardians at University Hospital Aintree (UHA), 
Walton Centre for Neurology and Neurosurgery (WCNN) NHS Foundation Trust 
and Alder Hey Children’s Hospital (all Liverpool, UK) were obtained and data 
retrieved from medical casenotes. 
 
 For the fMRI and eating behaviour case-control studies (Chapters 5 and 
6) the study protocol was reviewed and given favourable ethical opinion for 
conduct in the NHS by Sefton Research Ethics Committee (REC Ref: 
09/H1001/4, submission date 07/01/2009) and the University of Liverpool. 
Approval was also granted by the Research and Development Department at 
UHA.  
 
Study patients (Chapters 5 and 6) were recruited from either the weekly joint 
pituitary clinic at WCNN, run jointly by a consultant neurosurgeon and consultant 
endocrinologist, or from the weekly endocrine follow-up clinic at UHA run by a 
consultant endocrinologist with a special interest in pituitary disorders, where 
patients with a more long-standing diagnosis not requiring further neurosurgical 
intervention were seen. All had acquired, structural, hypothalamic damage caused by 
a tumour within the hypothalamus or directly adjacent to it causing compression or 
invasion. Hypothalamic damage was assessed and scored by a Neuroradiologist 
[245]. Patients were defined as hypothalamic obese (HO) or as having hypothalamic 
damage but remaining weight-stable (HWS). HO was defined as BMI ≥ 30 kg/m2 at 
latest clinic follow-up with an increase ≥2 kg/m2 since tumour diagnosis, based on a 
previous study by Daousi et al [6]. HWS patients’ BMI was < 30 kg/m2 and had 
remained stable since tumour diagnosis. All patients were adequately replaced for all 
pituitary hormone deficiencies caused by their tumour/surgery as clinically indicated 
(hydrocortisone, growth hormone, thyroxine, sex steroids, desmopressin).  
As part of their standard clinical care all patients diagnosed with 
hypothalamic damage secondary to a structural lesion underwent serial endocrine 
assessment following diagnosis and treatment. The glucagon stimulation test 
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(GlucaGen; NovoNordisk Pharmaceuticals, Crawley, UK) was used to assess growth 
hormone (GH) and adrenocorticotropic hormone (ACTH) reserve [246], alongside 
basal measurement of thyroid-stimulating hormone (TSH), free thyroxine (fT4), 
prolactin, oestradiol or testosterone (depending on gender) and insulin-like growth 
factor 1 (IGF-1). Patients found to have inadequate ACTH (and therefore cortisol) 
response to the glucagon stimulation test underwent standard dose short-synacthen 
testing (250µg) and if cortisol deficiency was verified then treatment with 
hydrocortisone was commenced. Biochemical severe growth hormone deficiency 
was defined as a peak GH ≤ 3 μg/L, with treatment of severe adult GHD indicated in 
those who fulfilled the NICE criteria of impaired quality of life, as assessed by the 
‘Quality of life assessment of growth hormone deficiency in adults’ (QoL-AGHDA) 
questionnaire [247]. Treatment for thyroxine, oestrogen or testosterone deficiency 
was started as clinically indicated. 
 
Healthy controls were recruited by advertisement within the University of 
Liverpool and from participants in previous obesity studies at UHA or the University 
of Liverpool. Healthy controls were matched to patients for age and BMI, with 
obesity defined as BMI ≥ 30 kg/m2.  
 
All interested participants were given a participant information sheet (non-
patient information sheet in Appendix 5) and had the opportunity to ask questions 
before giving written informed consent. Those seeking consent were either 
previously and/or currently involved with other research studies and understood the 
ethical principles underpinning informed consent following appropriate training. The 
validity of informed consent was ensured by providing adequate information and 
potential participants were assessed to confirm that they had the capacity to decide 
for themselves whether or not to take part.  
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Inclusion and exclusion criteria for participants 
Inclusion criteria: 
1. Patients: evidence of hypothalamic damage (secondary to tumours such as 
craniopharyngioma, midline tumour with hypothalamic involvement, or 
pituitary macroadenoma with supra-sellar extension/optic chiasmal 
compression with visual field defects where hypothalamic damage was 
visible on MRI). 
2. Controls: BMI- and age-matched controls with none of the exclusion criteria. 
 
Exclusion criteria: 
For all participants 
- Presence of metal implants or objects in the body which cannot be removed 
(e.g. cardiac pacemaker, mini−defibrillator or neurostimulator, artificial heart 
valve; metal-containing surgical clips; history of injury which may have left 
metal particles in the body) which would pose a safety risk to the participant. 
- Claustrophobia in the MRI scanner 
For controls 
- A history of eating disorder such as bulimia nervosa, anorexia nervosa or 
binge−eating disorder (according to DSM IV criteria). 
- History of psychiatric disorder (schizophrenia, major depression, bipolar 
affective disorder). 
- Diabetes mellitus (type 1 or 2). 
- Current history of excess alcohol consumption or substance abuse/addiction. 
- Current (or previous 3 months) use of centrally acting medication (such as 
psychotropic or antidepressant medication, sibutramine, rimonabant) which 
are known to influence feeding behaviour. 
- History of traumatic brain injury (which may affect the hypothalamus and/or 
pituitary and therefore affect the validity of any findings). 
- Genetic forms of hypothalamic obesity (Prader−Willi syndrome, 
Biedl−Bardet syndrome). 
For control subjects, exclusion criteria were chosen as they would have a direct 
influence on eating behaviour and patterns. 
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Study visits (see Appendix 4 for timelines) 
 
Study day 1 (screening visit): During the first visit informed consent was undertaken, 
anthropometry was collected (height and weight to calculate BMI using the standard 
formula, and estimation of percentage body fat by whole-body bioelectrical 
impedance analysis [Tanita Systems, Tanita Corp, Tokyo, Japan]) and participants 
were given the TFEQ and 3-day food diaries for completion (Appendix 2). All 
participants (patients and controls) were medically screened prior to MRI scanning, 
with adequacy of vision assessed in the patient group. Participants also ate a meal 
seated at the UEM. The fixed load breakfast meal (estimated to provide 25% of 
participants calculated daily BMR and eaten on both study days 2 and 3) was 
presented, to enable familiarisation with the UEM and also to ensure that participants 
were able to consume the entire portion provided.  
 
Study day 2 (fMRI study day): Participants able to undertake this part of the study 
attended for fMRI scanning and blood sampling, as well as undertaking VAS ratings 
of appetite throughout the day (further details in Chapter 5 and Appendix 2). 
 
Study day 3 (UEM study day): Participants attended for blood sampling, a fixed 
breakfast load and an ad-libitum lunch-meal (both eaten at the UEM) (further details 
in Chapter 6 and Appendix 4). TFEQs and 3-day food diaries (Appendix 2) were 
collected at this visit and those not returning these were given a stamped-addressed 
envelope in which to return them. 
 
On all three study days participants ate a fixed load breakfast-meal of 
porridge and orange juice, consuming 25% of their calculated basal metabolic rate 
(BMR) using the Harris-Benedict formula. For men: 66.5 + (13.75 x weight) + 
(500.3 x height) - (6.775 x age) and for women: 655.1 + (9.563 x weight) + (185 x 
height) - (4.676 x age). The exact quantities served varied according to the calculated 
BMR, but in general portions of 45g porridge made with 340mL of semi-skimmed 
milk and 200mL quantities of orange juice were served in equivalent proportions. 
Details of the nutritional content of the breakfast meal are shown in Table 2.1.  
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Table 2.1 Nutritional content of the breakfast-meal 
 Orange Juice 
Per 100mL 
Porridge 
Per 100g 
Semi-skimmed milk 
Per 100g 
Energy (kcal) 47kcal 356 49 
Protein (g) 0.5g 11.0 3.6 
Carbohydrate  (g) 10.5g 60.0 4.8 
of which sugars  10.5g 1.1 - 
Fat (g) 0.1g 8.0 1.8 
of which saturates  Nil 1.5 - 
Fibre (g) - 9.0 - 
of which soluble - 4.0 - 
of which insoluble - 5.0 - 
 
 
Most participants took part in all aspects of the study (fMRI and eating behaviour 
studies), however some participants were not able to take part in the fMRI study (due 
to claustrophobia or an inability to tolerate looking at the photographs whilst in the 
MRI scanner) or failed to return the TFEQ and 3-day food diary, therefore the groups 
were not identical. Further details of the methods for each study day, the participants 
involved and the analysis of the data are given in each relevant chapter (Chapters 5 
and 6). 
 
Plasma hormone analysis 
All samples (taken on either the fMRI or the UEM study day) were assayed in 
duplicate and in one assay to eliminate inter-assay variation. Plasma insulin was 
taken into a serum separating tube (SST) and measured using a Siemens Immulite 
2000 Immunoassay system. Blood for glucose determination was collected into a 
tube containing sodium fluoride and potassium oxalate and measured using YSI 2300 
STAT Plus
™
 Glucose & Lactate Analyzer (YSI Life Sciences). Blood taken for 
measurement of active GLP-1, PYY(3-36) and active ghrelin was collected into 
chilled EDTA tubes containing 50 µl of aprotinin to prevent degradation by 
proteolytic enzymes, centrifuged at -4°C and stored at -80°C until assayed. Active 
GLP-1 and active ghrelin were determined using commercial enzyme-linked 
immunoassay (ELISA) kits (Millipore, Billerica, USA). The standard curve range for 
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GLP-1 ELISA was 0.8-100 pmol/L, inter and intra-assay precisions were 8% and 7% 
respectively. Active ghrelin was measured using the assay kit Millipore #EZGRA-
88K. Although AEBSF [4-(2-aminoethyl) benzenesulphonyl fluoride hydrochloride] 
was not available aprotinin was used, which is also a good serine protease inhibitor. 
The standard curve range for active ghrelin ELISA was 10-2000 pg/mL, inter- and 
intra-assay precisions were 10-16% and 7-10% respectively. PYY(3-36) was 
measured using an enzyme immunoassay kit from Phoenix Pharmaceuticals Inc. 
(range 0.06-100 ng/mL). Leptin was assayed following collection in a chilled blood 
tube containing EDTA using a human leptin “Dual Range” ELISA (EZHL-80SK, 
Millipore, Billerica, USA). Inter- and intra-assay precisions were 2.6-6.2% and 2.6-
4.6% respectively and the standard curve range was 0.5-100 ng/mL. 
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Chapter 3  
Prevalence of Hypothalamic Obesity, Risk Factors and 
Metabolic Outcomes in Adults With Acquired Structural 
Hypothalamic Damage 
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Abstract 
Objective: Children with acquired, structural hypothalamic damage have a high 
prevalence of obesity. Similar data are emerging in adults, although these patients are 
less well-studied. The aims of this study were: i) to review the prevalence of obesity 
in adult patients with acquired hypothalamic damage, ii) to determine the hormonal 
and neuroanatomical variables associated with weight gain and obesity and iii) to 
reflect on early instigation of weight-loss measures undertaken in clinics following 
an earlier published review of adult patients with hypothalamic obesity.  
 
Study design: Retrospective case-note review of 110 adults with tumours causing 
hypothalamic damage attending a specialist neuroendocrine clinic. Serial BMI was 
calculated (at diagnosis and latest clinic follow-up in n=77), endocrine data 
(including hormone replacement), neurosurgical procedures, additional therapies 
(such as radiotherapy) and weight loss measures were recorded and all available 
brain imaging reviewed. The prevalence of hypothalamic obesity (HO) was 
determined, defined by a body mass index (BMI) ≥30 kg/m2 at latest follow-up, 
which had increased by at least 2 kg/m
2
 since tumour diagnosis. 
 
Results: After a median follow-up of 9.5 years (range 1-49), data from 100 patients 
showed that 91% were overweight/heavier (BMI ≥ 25 kg/m2), 63% were obese (BMI 
≥ 30 kg/m2) and 16% morbidly obese (BMI ≥ 40 kg/m2). Multivariate analysis 
revealed that requirement for desmopressin (odds ratio [OR] = 3.5, p = 0.026), 
growth hormone [GH] (OR = 2.7, p = 0.031) and thyroxine replacement (OR = 3.0, p 
= 0.03) were associated with HO. No correlation was found between neuroimaging 
features and weight gain. Despite proactive treatments offered in clinic in recent 
years (counselling, dietetic and physical activity advice, and anti-obesity 
medications), patients have continued to gain weight. 
 
Conclusions: Obesity is significantly more prevalent in adult patients with acquired, 
structural hypothalamic damage than in the general population. The risk of HO is 
increased in those requiring desmopressin, thyroxine and GH therapy, but 
neuroimaging findings did not predict the risk of HO. Despite an increased 
awareness of the risk of HO by clinicians in neuroendocrine clinics it remained 
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difficult to prevent and treat those with HO. Improved understanding of the 
pathophysiological mechanisms underlying HO and multicentre collaborative trials 
to examine the efficacy of novel obesity interventions would be advantageous. 
Summary of Justification and Aims 
The prevalence of obesity in patients with acquired, structural hypothalamic 
damage is high, however reports on prevalence and the risk factors associated with 
developing obesity vary between studies and within different groups, for example 
children with craniopharyngioma or adults with hypothalamic damage due to varying 
causes (see Chapter 1, Introduction). Most of the published studies concentrate on 
the endocrine sequelae of hypothalamic pituitary disease in childhood (including 
obesity), particularly in children with craniopharyngioma (as discussed in Chapter 1) 
and data from studies in adults are sparse [6]. Obesity is associated with adverse 
health outcomes such as cardiovascular disease (CVD), type 2 diabetes mellitus 
(T2DM) and non-alcoholic fatty liver disease (NAFLD) which lead to increased 
morbidity and mortality. Cardiovascular risk factors are highly prevalent and often 
inadequately treated in adult patients with hypothalamic–pituitary disease [71, 77, 
79]. Aggressive treatment of these factors is essential to reduce mortality and 
morbidity from CVD in these patients [73], particularly as effective treatments for 
HO have not yet been developed or evaluated.  
 
Aims: 
(i) to assess the prevalence of HO in a large cohort of adult patients with 
acquired, structural hypothalamic damage attending follow-up in a single 
adult neuroendocrine service and to ascertain whether the prevalence of HO 
had changed since an earlier review of the service was undertaken in 2002 
[6]. Following the service review in 2002 (published in 2005), a more 
proactive approach to the management of patients at risk of HO and its 
complications was adopted in the clinic with the aim to limit the severity of 
weight gain by early provision of dietary and behavioural advice, 
counselling, encouraging regular physical activity, use of anti-obesity 
medications (where appropriate) and referral to multidisciplinary weight 
management services if necessary.  
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(ii) to assess the endocrine and neuroanatomical risk factors for HO, as 
investigated in other studies containing mainly paediatric populations  [6, 
20, 24, 25, 32-34, 57, 104-106, 109, 114-119].  
(iii) to examine the prevalence of treated cardiovascular risk factors, such as 
hypertension and dyslipidaemia, which are likely to be more prevalent in 
this patient group [79] than in the general population.  
 
Hypothesis: 
Individuals with acquired hypothalamic damage would have a high 
prevalence of obesity and other cardiovascular risk factors, despite good awareness 
and aims at prevention of these sequelae amongst the treating physicians. Those with 
growth hormone deficiency and cranial diabetes insipidus would be particularly at 
risk of HO. 
 
Participants and Methods 
Participants 
Permission was obtained from the relevant audit departments for retrieval of 
data from the medical case notes and electronic records of adult patients attending 
the regional joint neurosurgical and neuroendocrine clinic at the Walton Centre for 
Neurology and Neurosurgery (WCNN) and the neuroendocrine follow-up clinic at 
University Hospital Aintree (UHA), both in Liverpool, UK. One hundred and ten 
patients who had tumours involving the hypothalamic region were identified. All 
patients had undergone treatment for either hypothalamic tumours, or adjacent 
tumours directly compressing or invading the hypothalamus until early 2011 and had 
a clinical diagnosis of hypothalamic destruction, with Grade 2 hypothalamic damage 
(as per Saint-Rose et al. grading [32, 115]) on objective MRI review by a 
Neuroradiologist. Tumour type, neurosurgical procedure(s) undertaken (including 
whether the approach was transphenoidal or via craniotomy), the need for ventricular 
drainage and the administration of conventional fractionated external beam 
radiotherapy for either residual tumour or recurrence was recorded. 
 Tumour types included: pituitary macroadenomas (53 patients, 48.2%); 
craniopharyngiomas (38 patients, 34.5%) and primary hypothalamic lesions 
including hypothalamic hamartoma, glioma and histiocytosis X (19 patients, 17.3%) 
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as documented in Table 3.1. All patients with pituitary adenomas had suprasellar 
extension with optic chiasm compression and visual field defects, with hypothalamic 
damage confirmed by a Neuroradiologist. 
 
Table 3.1 Diagnoses and prevalence of tumour types for all 110 patients with 
hypothalamic damage. 
Diagnosis Frequency Percentage 
Craniopharyngioma 38 34.5 
Hypothalamic lesion (e.g./ Histiocytosis X) 9 8.2 
Other tumour with hypothalamic extension 4 3.6 
Pituitary adenoma with suprasellar extension 40 36.4 
Prolactinoma with suprasellar extension 13 11.8 
Primary brain tumour in close proximity to 
hypothalamus, where hypothalamus included in 
irradiation field (e.g./ optic nerve glioma) 
6 5.5 
Total 110 100.0 
 
Anthropometry 
Where data were available height and weight at diagnosis and latest follow-
up clinic visit were used to calculate BMI (kg/m
2
). The presence of hypothalamic 
obesity (HO) at latest clinic follow-up was determined. This was defined as a BMI 
≥30 kg/m2, with an increase of at least 2 kg/m2 since tumour diagnosis, based on 
previous work from Daousi et al [6]. Patients whose BMI remained <30 kg/m
2
 or in 
whom this had not increased >2 kg/m
2
 were defined as having hypothalamic damage 
remaining weight-stable (HWS). Serial anthropometric data (from the time of 
diagnosis to the most recent follow-up) were available for n=77 patients. 
 
Endocrine assessment 
All patients underwent routine hypothalamic-pituitary-target organ axis 
testing following diagnosis of their tumour and subsequent serial testing following 
treatment. Adrenocorticotropic hormone (ACTH) and growth hormone (GH) reserve 
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were assessed using the glucagon stimulation test (GlucaGen; Novo Nordisk 
Pharmaceuticals, Crawley, UK). Patients with an inadequate ACTH response to 
glucagon (as measured by low cortisol concentrations) underwent a standard dose 
(250 microgram) short synacthen test to confirm cortisol deficiency. Measurement of 
basal concentrations of thyroid-stimulating hormone (TSH), free thyroxine (FT4), 
free triiodothyronine (FT3, where indicated), prolactin, oestradiol or testosterone, 
cortisol and insulin-like growth factor-1 (IGF-1) were also undertaken on a routine 
basis during clinic visits. 
 
Neuroimaging 
A single Neuroradiologist blind to the clinical data reviewed and scored all available 
computed tomography (CT) and magnetic resonance imaging (MRI) scans (pre- and 
post-operative where possible) for each patient. The anatomical features noted on the 
scans were used to produce a score of hypothalamic damage for each patient (as per 
Daousi et al [6]) and the factors assessed included:  
1. the primary site of the tumour 
2. its maximum extent (in mm) from the midline to the right and left (on coronal 
views) 
3. presence of suprasellar extension in cases of pituitary tumour 
4. pituitary tumour encroachment on the optic chiasm 
5. invasion/compression of hypothalamic tissue by extra-hypothalamic tumours 
6. distortion of the third ventricle at the level of the infundibulum (on coronal views) 
7. abnormality of the floor of the third ventricle  (partial or complete deficiency of 
the floor) 
8. breach of the tuber cinereum by the tumour 
9. tumour infiltration of other brain areas (including thalamus and temporal lobes).  
 
Statistical analysis 
Statistical analyses were performed using SPSS, versions 18.0 and 24.0 
(SPSS Inc., Chicago, Illinois). Data are expressed as mean (standard deviation [SD]) 
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or median (IQR). Longitudinal changes in BMI were compared using the Wilcoxon 
signed-rank test in the 77 patients with serial weight data available. McNemar tests 
were performed to examine for any differences in the prevalence of patients in each 
BMI category at diagnosis compared to latest follow-up. Either the chi-squared test 
or Fisher exact test were used to examine categorical data (as appropriate) and 
continuous data were examined with the t test (if normally distributed) or the Mann-
Whitney U test (if non-normally distributed).  
Features associated with weight gain were identified by multiple logistic 
regression analysis. For patients with HO, variables that differed significantly in 
univariate analysis were entered into the original model, along with current age and 
age at diagnosis of the tumour, and subjected to forward stepwise logistic regression 
analysis. Examination of a possible correlation between tumour size and subsequent 
weight gain was undertaken using the Spearman rank correlation coefficient for non-
normally distributed data. Statistical significance was defined as p<0.05 (two-tailed).  
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Results 
 
Prevalence of obesity in the entire cohort  
At the time of study, 110 patients were attending the neuroendocrine clinics, 
with a median age of 55.5 years; 16 were diagnosed with a tumour during childhood. 
At the time of latest follow-up (data collected in 2010-11) BMI was available for 
100/110 patients. Mean (SD) BMI was 33.7 (7.9, range 19-60) kg/m
2
; 91 patients 
(91%) had a BMI ≥25 kg/m2, making them overweight or heavier; 63 (63%) were 
obese (BMI ≥30 kg/m2); 37 (37%) had a BMI ≥35 kg/m2 and 16 (16%) patients were 
morbidly obese (BMI ≥40 kg/m2). Figure 3.1 shows the prevalence of BMI by 
category. Within the general population of a similar age (aged 55-64), according to 
the Health Survey for England 2012 [256] the mean BMI was 28.3 kg/m2 and 73% 
were overweight or heavier (BMI ≥25 kg/m2), with the prevalence of obesity (BMI 
≥30 kg/m2) more than half (30.7%) of that seen in the patient cohort studied.  
 
Figure 3.1. Prevalence of BMI category at latest follow-up in 100/110 patients with 
hypothalamic damage with full data available. 
 
 
Treatment of obesity 
Seventeen of the 110 patients had been treated with the weight loss 
medication orlistat and four had received multiple weight loss medications (orlistat, 
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sibutramine and rimonabant - the latter two before their withdrawal from the market 
due to drug safety concerns). Six patients were attending a hospital-based multi-
professional weight management clinic where they had regular clinical review with a 
dietician and physician with a special interest in weight management. None of the 
patients had a clinically significant weight-loss following these interventions and 
many continued to gain weight. None of the patients in the study cohort had 
undergone bariatric surgery. 
 
Endocrine replacement at follow-up 
At latest clinic follow-up 103 (94%) of the 110 patients needed replacement 
therapy for one/more pituitary hormone deficiencies. These included 30 receiving 
desmopressin for cranial diabetes insipidus (DI), 63 with treated growth hormone 
deficiency (GHD), 53 on thyroxine replacement, 57 requiring hydrocortisone  and 43 
patients taking sex steroid replacement. These figures do not reflect entirely the 
prevalence of pituitary hormone deficiencies within the cohort. For example patients 
with severe biochemical GHD (defined as peak GH < 3 micrograms/L in response to 
provocative testing) require adequate replacement of all other pituitary hormone 
deficiencies and impaired quality of life as assessed by the QoL-AGHDA 
questionnaire before qualifying for a trial of GH replacement therapy. Additionally 
older patients with sex steroid deficiency may not have been treated as they were 
above the age commonly associated with menopause. Fourteen patients with severe 
GHD had declined treatment and five patients had suffered only transient post-
operative DI. 
 
Longitudinal changes in weight and BMI (n=77) 
Height and weight measurement at both diagnosis and latest clinic assessment 
were available for 77 of the 110 patients (Figure 3.2). Their mean (±SD) age at latest 
follow-up was 44 ± 16.5 years; 43 (55.8%) were male (Table 3.3). Median BMI 
increased significantly (p<0.0001) from diagnosis (28.1 kg/m
2
, IQR 24.3-32.4) to 
latest follow up (32 kg/m
2
, IQR 27.7-38.4) a median of nine years later. The 
prevalence of obesity and severe obesity (BMI ≥35 kg/m2) increased during the 
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follow-up period (Table 3.2), with a statistically significant difference in severe 
obesity (p<0.001). As demonstrated consistently in studies in children the increase in 
weight was fastest in the year following diagnosis and treatment of their tumour 
(mean BMI increased to 30.4 kg/m
2
 in this time, p<0.0001) with a subsequent 
deceleration in weight gain but no plateau. 
Table 3.2. Prevalence of overweight/obesity/morbid obesity at diagnosis and latest 
follow-up in 77 patients with paired weight and height data. 
 
Category (BMI [kg/m
2
]) Prevalence 
(%) at 
diagnosis 
Prevalence (%) at 
latest follow-up 
(2010/11) 
p-
value 
Overweight (25-29.99) 29 (37.7) 22 (28.6) 0.23 
Obese (30-34.99) 15 (19.5) 21 (27.3) 0.31 
BMI ≥ 35 12 (15.6) 26 (33.8) <0.001 
p-value calculated using McNemar test. 
 
Figure 3.2. Prevalence of BMI category at diagnosis and latest follow-up in 77 
patients with hypothalamic damage with serial weight data available. 
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Endocrine replacement associated with obesity and weight gain since diagnosis 
Patients with HO at latest follow-up were more likely to be receiving growth 
hormone replacement therapy (p = 0.007), thyroxine (p = 0.008), or desmopressin (p 
= 0.02) (Table 3.3). In a multivariate model, the development of HO during follow-
up was associated with the use of desmopressin (odds ratio [OR] = 3.5; 95% 
confidence interval [CI]: 1.2 to 10.8; p = 0.026), growth hormone (OR = 2.7; 95% 
CI: 1.1 to 6.9; p = 0.031) and thyroxine (odds ratio [OR] = 3.0; 95% CI: 1.1 to 8.0; p 
= 0.03). 
 
Table 3.3 Characteristics of patients with serial data (n=77), according to obesity 
status 
   HO  
(n = 42) 
HWS 
(n = 35) 
 
Characteristic Number (%) or Mean ±SD p value 
Current age (years) 55.7 ± 13.1 54.2 ± 17.7 0.9 
Age at diagnosis (years) 43.4 ± 15.7 44.5 ± 17.7 0.4 
Male sex 22 (52.4) 21 (60) 0.4 
Years of follow-up 10.8 ± 6.8 8.5 ± 5.9 0.6 
Baseline BMI (kg/m
2
) 30.9 ± 6.8 26.2 ± 4.8 0.001 
Current BMI (kg/m
2
) 38.6 ± 7.2 27.4 ± 3.6 <0.001 
Hydrocortisone replacement 34 (81) 23 (66) 0.2 
Hydrocortisone dose (mg) 22.3 ± 5.3 25.7 ± 6.2 0.04 
GH replacement 29 (69) 14 (40) 0.007 
Thyroxine replacement 35 (83) 18 (51) 0.008 
Sex steroids 27 (64) 16 (46) 0.9 
Desmopressin 15 (36) 6 (17) 0.02 
HO - hypothalamic obese; HWS - hypothalamic damage remaining weight-stable; 
BMI - body mass index; GH - growth hormone. p-value calculated using the t test.  
 
114 
 
Neuroanatomic features associated with obesity and weight gain since diagnosis 
Preoperative neuroimaging scans were available for 45 patients and 
postoperative scans for 67. None of the neuroradiological features considered were 
associated with weight gain or an increased risk of HO. On preoperative coronal 
views, no correlation was found between the width of the tumour from the midline 
and the change in BMI from diagnosis to latest follow-up (Spearman r = −0.3, p = 
0.09). On postoperative coronal views, there was no correlation between the width of 
any remaining tumour from the midline and the development of HO (Spearman r = 
−0.2, p = 0.14). Radiological involvement of the thalamus or temporal lobe, 
distortion of the third ventricle at the level of the infundibulum (on coronal images), 
abnormalities of the third ventricular floor and breach of the tuber cinereum by 
tumour were not associated with weight gain (Table 3.4), neither was grade 1 
(hypothalamus compressed/displaced) or grade 2 (hypothalamus unable to be 
identified) hypothalamic damage, assessed according to the Sainte-Rose grading 
system [32, 115]. 
There was no association between the risk of HO and either tumour type or 
treatment modality, including the need for transfrontal surgery (indicating a more 
extensive tumour and greater likelihood of perioperative hypothalamic damage), 
insertion of a ventriculo-peritoneal shunt and radiotherapy (where a greater 
theoretical risk of hypothalamic damage exists, in combination with the likelihood of 
a larger tumour which could not be fully resected at operation). Three of the patients 
were treated with radiotherapy alone. 
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Table 3.4 Neuroanatomic characteristics of patients with serial data (n=77), 
according to obesity status 
 HO (n = 42) HWS (n = 35)  
Characteristic Number (%) or Mean ±SD p value 
Diagnosis: Craniopharyngioma 
                  Hypothalamic tumour 
                  Pituitary adenoma 
                  Prolactinoma 
                  Hypothalamic      
                  Radiotherapy 
                  Other 
20 (39.2) 
4 (7.8) 
15 (29.4) 
7 (13.7) 
3 (5.9) 
2 (3.9) 
12 (27.9) 
2 (4.7) 
19 (44.2) 
7 (16.3) 
2 (4.7) 
1 (2.3) 
0.70 
Mean maximum extent of tumour 
from midline in mm (right) 
14.09 
(SD6.63) 
15.73 
(SD7.39) 
0.51 
Mean maximum extent of tumour 
from midline in mm (left) 
12.7 
(SD6.33) 
15.6 (SD10.3) 0.11 
Suprasellar extension (for pituitary 
tumours) 
28 (90.3) 26 (86.7) 0.65 
Pituitary tumour encroachment on 
optic chiasm 
21 (84) 22 (78.6) 0.61 
Invasion/compression of 
hypothalamic tissue (extra-
hypothalamic tumours) 
18 (60) 20 (69.0) 0.47 
Distortion of third ventricle (at 
infundibulum) 
19 (59.4) 21 (67.7) 0.49 
Abnormality of third ventricle  
floor/breach of tuber cinereum 
15 (41.7) 17 (53.1) 0.35 
Invasion of thalamus on MRI 3 (7.9) 1 (3.0) 0.38 
Temporal lobe invasion on MRI 6 (16.2) 9 (27.3) 0.26 
TSS 18 (43) 22 (63) 0.2 
Transfrontal surgery 21 (50) 10 (29) 0.07 
Radiotherapy 26 (62) 18 (51) 0.4 
VP shunt 7 (17) 4 (11) 0.5 
HO - hypothalamic obese; HWS - hypothalamic damage remaining weight-stable; 
MRI - magnetic resonance imaging; TSS - Trans-sphenoidal surgery; VP - 
Ventriculo-peritoneal. p-value calculated using the t test. 
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Cardiovascular risk factors in the entire cohort (n=110) 
For 99 patients with data available, mean cholesterol was 5.3mmol/L (range 
2.6–9.2 mmol/L), mean triglycerides 2.7 mmol/L (range 0.8-12.4), mean HDL 1.4 
(range 0.7-4.0) and mean LDL 2.7 (range 1.1-4.8). Thirty-four of the 110 patients 
(30.9%) were treated for hypertension and 60 (54.5%) for dyslipidaemia; 16 patients 
(14.5%) had T2DM, 10 (9.1%) had known CVD and 2 (1.8%) cerebrovascular 
disease. Nineteen patients were known to smoke (17.3%), but smoking data was 
missing for 29 patients. According to the Health Survey for England 2012 [256], in 
the general population of a similar age (55-64 years) 22.3% had treated hypertension, 
10.4% had doctor-diagnosed diabetes, 6.3% reported CVD, 3.2% reported having 
suffered a stroke and 18% were smokers. 
 
Patients diagnosed with hypothalamic tumours between 2002 and 2011 (new 
cohort, n=35) 
 As noted above, following a review of patients attending the neuroendocrine 
clinics at WCNN and UHA, and subsequent publication of this study on the 
prevalence of HO and associated cardiovascular risk factors [6], a more proactive 
approach to the prevention of HO and its complications was adopted during clinic 
follow-up visits from 2002 onwards. Thirty-five of the 110 patients studied were 
diagnosed after 2002; assessment of these newly diagnosed patients was undertaken 
to see whether the increase in awareness had resulted in better weight outcomes. The 
mean (±SD) age at diagnosis was 50.9 (± 15.6 years) and mean age at latest follow-
up was 54.8 years; 23 (66%) were male. Ten patients were diagnosed with 
craniopharyngioma, 1 with hypothalamic tumour and 24 with pituitary 
macroadenoma and suprasellar extension (including 7 with prolactinoma), all of 
whom had optic chiasmal compression and visual field defects. One patient referred 
due to significant weight gain during childhood was obese at presentation; further 
investigation then revealed the diagnosis of craniopharyngioma.  
 
 
117 
 
Prevalence of obesity in cohort diagnosed after 2002 
Height and weight measurements at both diagnosis and latest clinic visit were 
available for 27/35 patients (Figure 3.3). The prevalence of severe obesity increased 
during the follow-up period (Table 3.5; 22.2% at diagnosis, 37% at latest follow-up, 
p=0.13). Although this was not statistically significant (p=0.13), this may be due to 
the small number of patients available to study. Median BMI increased significantly 
(p<0.001) from 29.9 kg/m
2
 (IQR 26.5-33.4) at diagnosis to 31.7 kg/m
2
 (IQR 27.8-
38.8) at latest follow-up, a median of 3 years later. Therefore despite the increase in 
awareness of obesity and strategies to curtail weight gain, patients diagnosed since 
2002 (with adequately but not over-replaced pituitary hormone deficiencies) had 
gained weight. 
 
 
 
Table 3.5 Prevalence of overweight/obesity/morbid obesity at diagnosis and latest 
follow-up in 27/35 patients diagnosed between 2002-2011 with paired weight and 
height data. 
 
Category (BMI [kg/m
2
]) Prevalence (%) 
at diagnosis 
Prevalence (%) at latest 
follow-up (2010/11) 
p-value 
Overweight (25-29.99) 11(40.7) 9 (33.3) 0.73 
Obese (30-34.99) 7 (25.9) 6 (22.2) 1.0 
BMI ≥ 35 6 (22.2) 10 (37) 0.13 
p-value calculated using McNemar test. 
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Figure 3.3. Prevalence of BMI category at diagnosis and latest follow-up in patients 
diagnosed and treated for a hypothalamic tumour during the period 2002-2011 (n = 
27).  
 
 
 
Treatment of obesity 
Five of the 35 patients had received anti-obesity medications (4 orlistat, one 
orlistat then sibutramine) and one attended the hospital-based weight management 
clinic. None of the patients had a clinically significant weight-loss following these 
interventions and many continued to gain weight. 
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Discussion 
 
This series is the largest study to date to investigate the pattern of weight gain 
and BMI trends in adult patients with acquired structural hypothalamic damage. 
Despite efforts during clinic follow-up to prevent/treat HO, patients continued to 
gain weight and the median BMI of the cohort increased. In the entire cohort 
followed-up for a median of nine years (77 patients with serial weight data) median 
BMI increased significantly from 28.1 kg/m
2
 at diagnosis to 32 kg/m
2
 at latest 
follow-up (p<0.0001), with McNemar’s test showing a significant difference in the 
prevalence of severe obesity (15.6% at diagnosis to 33.8% at latest follow-up, 
p<0.001). Patients diagnosed since 2002, when there was increased awareness of 
obesity within the clinics, also had a significant increase in median BMI (29.9 kg/m
2
 
at diagnosis to 31.7 kg/m
2
 at latest follow-up, p<0.0001), although there was no 
statistically significant difference in the prevalence of obesity or severe obesity 
within this group. This, however, may be due to the small number of patients 
involved and also the high prevalence of both obesity and severe obesity at 
presentation, meaning more patients were already in these BMI categories at 
diagnosis. It would have been interesting to directly compare weight change in the 
two cohorts (pre- and post-2002) however the median follow-up was 9 years and 3 
years, respectively. It was not possible to compare the data from the two cohorts at 
the three year time-point as there was not enough data available, however if the data 
had been available, presuming the linear model assumptions were not violated, a 
linear model for BMI at 3 years could have been constructed (adjusted for BMI at 
diagnosis and whether the patient was diagnosed pre- or post-2002). 
As discussed previously, obesity is associated with multiple co-morbidities, 
including CVD, T2DM, hypertension, NAFLD, sleep apnoea and certain cancers. 
Cardiovascular risk factors were found to be highly prevalent in this cohort, as in 
other studies of patients with hypothalamic–pituitary disease [79] and 
craniopharyngioma [57, 71].  Those who sustain hypothalamic damage at a relatively 
young age are particularly vulnerable to this increase in cardiovascular risk factors 
[257], which occurs despite adequate pituitary hormone replacement. The high 
prevalence of obesity, which is an independent risk factor for CVD [258], in a 
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population with already increased cardiovascular risk factors is therefore even more 
concerning. 
  
Analysis of the data showed that the risk of developing HO was greater in 
those treated with GH, levothyroxine and desmopressin, which likely reflects a 
greater degree of hypothalamic damage, leading to multiple pituitary hormone 
deficiencies. The paraventricular nucleus (PVN) is responsible for vasopressin 
release (absence of which leads to cranial DI) and has a role in the neuroendocrine 
control of energy balance. It is likely therefore that damage to the PVN leading to DI 
would also result in some effect on the energy balance circuitry. In agreement with 
earlier findings from a smaller cohort of the same patients [6], there was no 
correlation between the risk of postoperative obesity and either pre- or post-operative 
MRI findings. This is in contrast to studies of children with craniopharyngioma, 
where all but one study [117] found an increased risk of HO in those with more 
extensive hypothalamic damage on either preoperative, or pre- and post-operative 
MRI scans [32, 115]. One study of adult patients with craniopharyngioma [119] 
found that greater hypothalamic involvement on preoperative MRI scan was 
positively correlated with greater postoperative weight gain (p = 0.022). This study 
included 28 adults with craniopharyngioma only, had a limited follow-up of two 
years and none of the patients were treated with GH replacement (the prevalence of 
symptomatic severe GHD warranting replacement is not stated), therefore this study 
is not directly comparable to the findings from the patient cohort described in this 
thesis and these factors may account for the differences in findings.  
 
Some of the patients described in this cohort were prescribed orlistat (with 
variable results) however no clinical trial of orlistat has been undertaken in this 
patient population. At the time of study no patients were receiving GLP-1 agonists, 
although since then this treatment was introduced in one patient with concurrent 
T2DM whose weight fell from 148 kg to 135 kg three years after starting the 
medication, with a subsequent increase and stabilisation of weight to 140 kg four 
years after initiation [127]. The treatment of HO is even more challenging than that 
of simple obesity. HO is often refractory to conventional therapeutic interventions, 
possibly due to its underlying structural neurobiological nature, with limited 
evidence of success with a variety of pharmacological interventions [259]. Since 
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2007 a few case reports [130, 131], small series [135] and a meta-analysis [138] of 
bariatric surgery in patients with HO secondary to structural hypothalamic lesions 
have been published. Although the meta-analysis demonstrated a reasonable net 
weight-loss (6.1-20.2%) at 12 months, there is lack of long-term follow-up data and 
as surgery is often only undertaken in those with extreme morbid obesity (mean BMI 
49.6 kg/m
2
 in the meta-analysis), many of the patients remained in the obese 
category, even after successful bariatric surgery. One of the additional difficulties in 
studying weight-loss therapies and interventions in patients with HO is the possibility 
of multiple pathophysiological mechanisms underlying and contributing to the 
development of the syndrome. 
  
Based on clinical experience and data from the series described here and the 
earlier published series [6] the standard practice in the neuroendocrine clinics at 
WCNN and UHA is to undertake weight measurement of patients at every clinic visit 
and to ensure that any pituitary hormone deficits are adequately (but not excessively) 
replaced. In those with no evidence of direct invasion of the hypothalamic nuclei by 
tumour at presentation, further surgical management aims to minimise the risk of 
hypothalamic damage wherever possible.  In those who have already demonstrated 
weight gain and in those who are newly diagnosed, the problem of weight gain and 
obesity secondary to hypothalamic damage is discussed with the patient and dietary 
and exercise advice are offered as first-line measures. For those newly diagnosed the 
risk of weight-gain, particularly within the first year after diagnosis and treatment of 
a tumour causing hypothalamic damage, is emphasized. As lifestyle modification 
alone is unlikely to be preventive/curative of excessive weight-gain in those prone to 
HO referral to the regional multi-disciplinary weight management service at UHA is 
also considered, although patients are warned that their weight gain may be difficult 
to treat, even if an appropriately healthy diet and active lifestyle are followed. Whilst 
weight gain and obesity may be more refractory in this patient group, the limited 
current treatment options mean that it is even more important to ensure that diet and 
exercise are adequately addressed by the patient. Stabilisation of weight, rather than 
weight loss, may need to be the objective for many patients, particularly those who 
have experienced years of incessant weight gain.  
Despite little evidence for improved outcomes in the prevalence of HO in 
patients with acquired, structural hypothalamic damage, the findings from this study 
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could be used to help to shape best-practice guidelines. Adoption of a multi-
disciplinary approach would help to ensure that neurosurgical, endocrine and dietetic 
issues are considered. Routine monitoring of cardiovascular risk factors (blood 
pressure, lipids, smoking status, family history), with a low threshold for treatment of 
these may help to prevent the increased morbidity and mortality seen in this patient 
group [72], although long-term studies would be necessary to substantiate this 
approach. The complications of obesity (such as T2DM, NAFLD and sleep apnoea) 
should also be considered, screened for and adequately treated when identified. 
 
There are many theories regarding the underlying pathophysiological 
mechanisms involved in weight gain and obesity in those with acquired structural 
hypothalamic damage. These include hyperphagia and increased energy intake, 
hyperinsulinism secondary to autonomic nervous system dysregulation, leptin 
resistance, reduced energy expenditure due to lower levels of physical activity and/or 
reduced basal metabolic rate, melatonin dysregulation leading to increased daytime 
somnolence and enhanced 11-β hydroxysteroid dehydrogenase-1 activity leading to 
increased concentrations of cortisol [11, 260-262]. As the hypothalamus is 
responsible for both integrating and initiating multiple pathways influencing body 
weight, it is likely that any, or in fact several of these mechanisms could contribute to 
the development of HO and that this may vary between individual patients [5, 7, 11]. 
To further investigate these underlying mechanisms, modalities such as functional 
neuroimaging (positron emission tomography [PET] and functional MRI [fMRI]) 
may provide useful insights, as seen in studies of simple obesity. Functional 
neuroimaging (PET and more recently fMRI) is non-invasive and has helped to 
identify neuroanatomical correlates of hunger, satiety and feeding in simple obesity 
[168, 169]. Functional neuroimaging studies have demonstrated how the brain is 
affected under different experimental conditions - fed versus fasted state [147, 149, 
169, 175], with presentation of food [263] or food images and with high-calorie, low-
calorie and neutral picture stimuli [175, 180]. A difference in brain activation 
between obese and lean individuals [168, 169, 175] has also been shown. These 
studies have demonstrated that regulation of hunger and satiety is complex, involving 
both homeostatic and non-homeostatic (e.g. cognition, emotion and reward) factors 
which are processed and integrated in different brain regions, including the 
hypothalamus, thalamus, orbito-frontal cortex, limbic and paralimbic areas. Studies 
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which identify potential brain regions of difference in those with HO (either with or 
without hormonal correlates) may suggest potential future therapeutic targets. 
Functional neuroimaging studies of patients with HO before and after treatment with 
incretin-mimetics or bariatric surgery, as have been conducted in patients with type 2 
diabetes and simple obesity, may help to elucidate why therapies have been 
successful in some individuals but not others. Due to the relative rarity of HO, 
further research would ideally be undertaken in the form of multi-centre, possibly 
multi-national, collaborative trials involving specialist centres. Both medical and 
bariatric surgical studies, as well as trials of intensive lifestyle intervention compared 
to routine care, ideally conducted in a randomised manner, would be beneficial to 
facilitate improved management of patients with hypothalamic obesity. A UK 
database and epidemiological study of all patients with suprasellar tumours would be 
a useful resource, taking a lead from the HIT-ENDO and KRANIOPHARYNGEOM 
2000 studies involving all children and adolescents in Germany, Austria and 
Switzerland diagnosed with craniopharyngioma since 1996 [28, 117].  
In clinical practice, complete versus partial resection of hypothalamic 
tumours to facilitate preservation of the hypothalamus without compromising on 
long-term disease control or restoration of visual field defects, and timing of post-
operative radiotherapy are some of the management dilemmas encountered by 
clinicians and neurosurgeons. An individualised approach within a multi-disciplinary 
setting is required to help determine the optimal management of patients, both at 
initial presentation and upon tumour recurrence, in order to minimise hypothalamic 
damage and aim to reduce the significant long-term morbidity and mortality 
associated with this. 
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Chapter 4 
Pituitary Tumours In Children And Adolescents: 
Presentation And Long-Term Endocrine And Metabolic 
Outcomes 
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Abstract 
 
Objective: To describe the long-term sequelae of pituitary adenomas diagnosed in 
children and adolescents, focussing on metabolic and endocrine outcomes. 
 
Study design: A retrospective review of patients diagnosed with a pituitary adenoma 
aged 21 years or younger attending a continuous neuroendocrine service in 
Liverpool, UK. 
 
Results: There were 41 patients (33 female) with mean age at diagnosis 17.3 years 
(range 11 - 21) and mean follow-up of 9.6 years. Adenomas were sub-classified by 
hormone type into prolactinoma (29 patients, 15 macroprolactinomas), non-
functioning adenoma (NFPA; six), ACTH-secreting (Cushing's disease - CD; five) 
and growth-hormone secreting (acromegaly; one patient). Ten patients were 
receiving pituitary hormone replacement: hydrocortisone (9 patients), thyroxine (5 
patients), sex steroids (7 patients) and growth hormone (5 patients). Another 7 
patients had asymptomatic severe biochemical GH deficiency.  
Thirteen patients had gained a significant amount of weight after diagnosis of 
their pituitary tumour (defined as an increase in body mass index [BMI] >2 kg/m
2
 
since tumour diagnosis); 16/41 were obese (BMI >30 kg/m
2
) at latest follow-up. Five 
patients had been prescribed orlistat and one was attending a multi-disciplinary 
weight management service. Other cardiovascular risk factors present included two 
patients receiving antihypertensive medications, two with type 2 diabetes mellitus 
and four with treated dyslipidaemia. Three female patients were treated for 
infertility; 2/3 had successful pregnancies, the third patient was undergoing 
treatment. An underlying genetic cause was found in only two of the patients; both 
had multiple endocrine neoplasia (MEN) type 1 syndrome and a prolactinoma. 
 
Conclusions: This is one of the largest case series reviewing patients aged 21 years 
or younger at diagnosis of a pituitary adenoma and followed up by a single service. 
Just over two-thirds of the patients had a prolactinoma. The sequelae of increased 
cardiovascular risk factors (obesity and dyslipidaemia) found in this patient cohort 
and infertility warrant long-term follow-up to allow active identification and 
treatment if necessary. 
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Summary of Justification and Aims 
Pituitary adenomas typically occur in the fourth and fifth decades of life [87] 
and are uncommon in childhood and adolescence. These patients account for only 3–
6% of all surgically-treated adenomas [88] and constitute less than 3% of childhood 
supratentorial tumours [89]. Pituitary adenomas are one differential diagnosis of 
sellar lesions, along with craniopharyngiomas (which account for nearly 50% of 
childhood suprasellar masses [264]) and other even less common diagnoses [7]. 
Pituitary adenomas can cause hypothalamic damage through suprasellar extension, 
however are most often microadenomas (<10 mm diameter) and therefore confined 
entirely to the sella, with no impingement on the hypothalamus.  They are 
biologically different from craniopharyngiomas, but adult series have shown that 
they can still cause significant morbidity [73], including obesity - some of this occurs 
through hypothalamic damage, but as morbidity can also occur in those without 
hypothalamic damage, other mechanisms must also be involved.  
Whilst clinical features at presentation [88, 94, 99], surgical outcomes [92, 
97, 100], remission rates and endocrine outcomes [95, 96] are well described other 
long-term sequelae described in adult patients with hypopituitarism, such as impaired 
fertility, increased cardiovascular risk factors and premature mortality due to 
increased cardiovascular and cerebrovascular events [73] have not generally been 
reported in younger patients. Impaired fertility has been described in adult patients 
with pituitary adenomas [101], patients with hypopituitarism from various causes 
(including various types of adenoma, craniopharyngioma and Rathke’s cleft cyst) 
[102] and in female survivors of childhood cancer who had received ≥ 30 Gy 
radiation to the hypothalamic/pituitary axis [103]. Premature mortality has been 
reported in those with hypopituitarism, particularly in females, those diagnosed at a 
young age and those who received radiotherapy [73]. There may however be 
confounding factors resulting in this increase in mortality, for example it is unknown 
whether those presenting with pituitary tumours at a younger age have more 
aggressive pituitary disease and at the other end of the spectrum, it is possible that 
those undergoing radiotherapy may be older/otherwise unfit for surgery, which may 
of course also influence mortality rate. Adults with hypopituitarism have been found 
to have an increased prevalence of metabolic disturbances such as obesity, 
dyslipidaemia and hypertension [6, 79], which confer an increased cardiovascular 
risk. It was therefore important to include a study of children and adolescents with 
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pituitary adenomas (both with and without hypothalamic damage) in this series of 
studies, to explore whether there is an increased prevalence of obesity and other 
metabolic risk factors in this cohort of patients, as is seen in adult studies [73]. 
 
The definition of adolescence in previous series has been variable, with the 
upper-age limit ranging between 17 and 20 years. Given this lack of consensus in the 
definition of adolescence and that symptoms of pituitary adenoma have been 
reported as early as 2-5 years before presentation [95, 97, 265, 266] patients 
diagnosed with pituitary adenoma up to the age of 21 years were included in this 
case-series. 
 
 
Aims: 
The main aim of this study was to identify the prevalence of obesity and other 
less well-described long-term sequelae of pituitary tumours (such as 
metabolic/cardiovascular risk factors for premature mortality) in children and 
adolescents with pituitary adenomas with and without hypothalamic damage, as has 
been described in adult patients with hypopituitarism. Secondary aims were to assess 
the presenting features, tumour type and treatment, endocrine sequelae (including 
impaired fertility) and underlying genetic diagnoses in this patient group. 
 
 
Hypothesis: 
Children and adolescents with pituitary adenomas (both with and without 
hypothalamic damage) would have an increased prevalence of metabolic 
disturbances such as obesity, dyslipidaemia and hypertension (conferring an 
increased cardiovascular risk) and impaired fertility, as described in adult patients 
with pituitary adenomas and hypopituitarism. 
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Participants and Methods 
 
Participants 
Permission was obtained from the Audit Departments at The Walton Centre 
for Neurology and Neurosurgery [WCNN], University Hospital Aintree [UHA] and 
Alder Hey Children’s Hospital [AHCH] for retrieval of data from medical case-notes 
and electronic records of patients aged ≤ 21 years at diagnosis of pituitary adenoma. 
Sefton Research Ethics committee gave permission for some additional data to be 
gathered by contacting patients no longer attending follow-up to ask them to 
complete a questionnaire regarding weight and fertility status. All patients had 
attended either the local tertiary paediatric endocrine clinic (AHCH), with 
subsequent referral to the adult neuroendocrine clinic at UHA, or the joint 
neurosurgical/neuroendocrine clinic at the WCNN and UHA between 1984 and 
2009.  
 
Methods 
Where available, data was obtained regarding clinical history, physical 
examination, auxology and baseline pituitary hormone results at presentation; 
treatment (medical, surgical, or both); ongoing endocrine problems, such as 
obesity/weight gain, growth hormone deficiency (GHD), panhypopituitarism and 
infertility; current medical problems and medications history. Height and weight at 
diagnosis and latest follow-up were used to calculate BMI (kg/m
2
).  
 
Endocrine assessment 
Patients underwent routine hypothalamic-pituitary axis testing at tumour 
diagnosis and as further indicated during treatment and follow-up. The glucagon 
stimulation test (GlucaGen; Novo Nordisk Pharmaceuticals, Crawley, United 
Kingdom) tested for growth hormone deficiency (GHD) in the adult setting; severe 
adult-onset GHD was diagnosed in those ≥ 17 years with a peak GH < 3 μg/L who 
had completed growth. Patients in the paediatric setting aged ≤ 16 years who had not 
completed growth and puberty underwent either glucagon stimulation test, insulin 
tolerance test or arginine test (two separate tests were undertaken in some cases, as 
per standard practice in children with short-stature of unknown cause). Severe 
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childhood-onset GHD was defined as peak GH < 5 μg/L. Hormones not requiring 
stimulation testing were routinely measured during clinic visits; thyroid-stimulating 
hormone (TSH), free thyroxine (FT4), prolactin, sex steroids (oestradiol or 
testosterone), cortisol and insulin-like growth factor-1 (IGF-1). 
 
Statistical analysis 
Statistical analyses were performed using SPSS, version 15.0 (SPSS Inc., 
Chicago, Illinois). Longitudinal changes in BMI were compared using the Wilcoxon 
signed-rank test. Comparisons between groups were made with the Student’s t test or 
the Mann-Whitney U test for normally and non-normally distributed data, 
respectively. Statistical significance was defined as p<0.05 (two-tailed).  
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Results 
 
Of the 41 patients (33 female) diagnosed with pituitary adenoma, the mean 
age at diagnosis was 17.3 years (median 17, range 11 - 21) and mean current age 
26.9 years (median 26, range 15 - 46). Mean follow-up was 9.6 years (range 0.1 – 
26). All patients were symptomatic, with none presenting as a co-incidental finding 
of neuroimaging (Table 4.1).  
 
Table 4.1 Presenting symptoms and signs of children and adolescents with a 
pituitary adenoma: overall and by tumour type. 
 Total PRLma ACTH-
secreting 
GH-
secreting 
NFPA/ 
apoplexy 
Number of patients 41 29 5 1 6 
Gender (F/M) 33/8 28/1 1/4 0/1 4/2 
Symptoms & signs      
Primary amenorrhoea 7 6 1 0 0 
Secondary amenorrhoea 17 16 0 0 1 
Oligomenorrhoea 4 3 0 0 1 
Galactorrhoea 14 13 0 0 1 
Weight gain 14 7 5 0 2 
Short stature 4 1 1 0 2 
Tall stature 1 0 0 1 0 
Headache 11 5 2 0 4 
Visual defects 6 3 0 1 2 
Apoplexy 3 1 0 1 1 
PRLma – prolactinoma; ACTH – adrenocorticotrophic hormone; GH – growth 
hormone; NFPA- non-functioning pituitary adenoma. 
 
Prolactinoma was diagnosed in 29/41 patients (70.7%), 15 were 
macroprolactinomas (>10mm) and 14 microprolactinomas (≤ 10mm); five patients 
had Cushing’s disease (CD), one a growth-hormone (GH) secreting adenoma and six 
were non-functioning pituitary adenomas (NFPAs). Seven of the 29 patients with 
prolactinoma reported weight-gain at presentation. The five with CD all presented 
with significant weight gain and reported recent slow growth, however only one had 
short stature. The six patients with NFPAs (three microadenomas, three 
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macroadenomas) presented with various symptoms, including obesity. The male 
patient with acromegaly presented with pituitary apoplexy (visual field deficits and 
seizures) aged 20. Tall stature was noted, but baseline GH levels were not available. 
Following craniotomy and conventional fractionated radiotherapy GH and insulin-
like growth factor-1 (IGF-1) were within normal limits (0.7 μg/L and 16 ng/mL 
respectively). 
Two patients had multiple endocrine neoplasia (MEN) type 1 syndrome. Both 
had a prolactinoma and a family history of MEN-1. The first patient had 
hyperparathyroidism requiring surgery and was diagnosed clinically; she developed a 
jejunal leiomyoma, a gastrinoma and a pancreatic lesion whilst under follow-up. The 
second patient was diagnosed on genetic testing and has developed a pancreatic body 
tumour and mild hyperparathyroidism. There was no family history of pituitary 
disorders in any of the remaining patients in the cohort. 
 
 
Current endocrine and metabolic status  
 
1. Hormone replacement 
Of the 41 patients, ten currently receive pituitary hormone replacement 
(Table 4.2); five have anterior panhypopituitarism (GH, gonadotrophin, thyroxine 
and cortisol deficiency) but only one patient has central diabetes insipidus (a patient 
with CD). With the exception of oestrogen in one patient, none of the 14 patients 
with microprolactinoma have required any hormone replacement. 
Thirteen patients were diagnosed with severe GHD during follow-up, four 
during childhood. At latest follow-up two of these were receiving GH replacement 
(GHR) for growth, one had adequate growth (50th centile for height) and declined 
GHR; the fourth had now reached adulthood but remained on GHR as they fulfilled 
the UK National Institute for Health and Clinical Excellence (NICE) criteria for 
continuing GHR into adulthood [247], including impaired quality of life assessed by 
the Quality of Life - Assessment of GHD in Adults (QoL-AGHDA). Of the nine 
patients diagnosed with severe GHD in adulthood, two were receiving GHR.  
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Table 4.2 Treatment and current pituitary hormone replacement of the entire cohort 
with pituitary adenomas 
 Total 
(n=41) 
Prolactinoma 
(n=29) 
ACTH-
secreting 
(n=5) 
GH-
secreting 
(n=1) 
NFPA 
(n=6) 
Tumour 
Treatment 
Dopamine agonists 
Surgery – TSS 
Surgery – 
craniotomy 
Radiotherapy 
 
 
30 
9 
4 
 
4 
 
 
29 
2 
1 
 
1 
 
 
0 
5 
0 
 
1 
 
 
0 
0 
1 
 
1 
 
 
1 
2 
2 
 
1 
Current hormone 
replacement 
Hydrocortisone 
Thyroxine 
Sex-steroid 
replacement 
Growth hormone 
Desmopressin 
 
 
9 
5 
7 
 
5 
1 
 
 
4 
1 
3 
 
2 
0 
 
 
2 
1 
1 
 
2 
1 
 
 
1 
1 
1 
 
0 
0 
 
 
2 
2 
2 
 
1 
0 
TSS: transphenoidal surgery. 
 
Of the 29 patients with prolactinoma 28 were female and the fertility status of 
six is known. Three had spontaneous pregnancies (two had two children each and 
one a single child) and three required treatment for infertility - two had successful 
pregnancies (one following treatment with clomiphene, another where treatment was 
unknown) and one was awaiting fertility treatment. In five female patients with non-
prolactin secreting adenomas there were no documented pregnancies, however it is 
not known how many were attempting pregnancy. In the general UK population 
fertility problems have been reported to affect 1:7 heterosexual couples [267], with 
47,422 women undergoing in-vitro fertilisation (IVF) or intra-cytoplasmic sperm 
injection (ICSI) and 2,265 women receiving donor insemination in 2012 [267]. At 
the time of the last national census (27 March 2011), there were 32.2 million women 
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in the UK [268]. As the numbers in this patient cohort are small and the proportion 
desiring pregnancy unknown, direct comparison would be misleading. 
 
2. Auxology and obesity 
Excluding patients with CD whose mean BMI, as expected, decreased from 
diagnosis to latest follow-up and two patients diagnosed less than 2 years previously 
(with inadequate follow-up data) the mean BMI/BMI-SDS of the cohort increased 
over the follow-up period (Table 4.3). Thirteen had a significant increase in weight 
(BMI increased > 2kg/m
2
). At time of study 16 patients (39%) were obese (BMI ≥ 30 
kg/m
2
): 11 with BMI between 30-35 kg/m
2
, two between 35-40 kg/m
2 
and three had 
morbid obesity with BMI ≥ 40 kg/m2. Data from the Health Survey for England 2012 
[256] showed that within the general female population of a similar age (age 25-34 
years) at that time 21% were obese (BMI ≥30 kg/m2), nearly half that seen in the 
patient cohort.  
 
Five patients were receiving treatment with the weight-loss medication 
orlistat and one was referred to the tertiary multi-disciplinary weight-management 
service at UHA. None of the patients had a clinically significant weight-loss 
following intervention and all had a higher BMI when last measured than at 
diagnosis (increase of between 3.6-9 kg/m
2
 since diagnosis). 
 
In the patients with CD (4 with serial measurements) mean BMI fell from 
27.6 kg/m
2
 at diagnosis to 24.5 kg/m
2
 at latest follow-up (p=0.18). In the 29 patients 
with prolactinoma (21 with serial weight measurements) mean BMI increased from 
27.9 kg/m
2
 at diagnosis to 30.9 kg/m
2
 at latest follow-up (p = 0.04). The five patients 
with the highest BMI (33.8-41.3 kg/m
2
) at diagnosis all had prolactinomas; three lost 
weight following diagnosis and treatment of prolactinoma, however two gained 
significant weight (BMI increased from 35 to 41.2 kg/m
2
 and 33.8 to 39.5 kg/m
2
) 
despite normalisation of prolactin to well within the normal range (130 mU/l and 11 
mU/l). 
 
3. Other cardiovascular risk factors 
At latest clinic follow-up two patients were receiving antihypertensive medications 
and two had type 2 diabetes mellitus. Twenty-six patients had non- 
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Table 4.3 Distribution of BMI in the entire cohort 
 At diagnosis At latest follow-up t(26) p value 
BMI (kg/m
2
) of the entire 
cohort (excluding those 
with CD and 2 patients 
diagnosed < 2 years ago) 
Mean 26.9 
Median 25 
Range 17.2-41.3 
Mean 30.2 
Median 30.7 
Range 17.4-46.7 
2.75 0.01 
BMI SDS of the entire 
cohort (excluding those 
with CD and 2 patients 
diagnosed < 2 years ago) 
Mean 1.3 
Median 1.2 
Range -1.6 – 3.7 
Mean 1.9 
Median 2.2 
Range -1.5 – 4.6 
2.57 0.02 
 At diagnosis At latest follow-up t(3) p value 
BMI (kg/m
2
) of patients 
with Cushing’s disease 
Mean 27.6 
Median 26.6 
Range 24.4-32.6 
Mean 24.5 
Median 24.4 
Range 18.7-30.4 
1.67 0.18 
 At diagnosis At latest follow-up t(20) p value 
BMI (kg/m
2
) of patients 
with prolactinoma 
Mean 27.9 
Median 25.7 
Range 17.2-41.3 
Mean 30.9 
Median 31 
Range 17.4-46.7 
2.17 0.04 
p-values show where a significant difference exists between BMI at diagnosis and at 
latest follow-up. Calculated using paired samples t-test. 
 
 
fasting serum lipids measured. Mean total cholesterol (TC) was 5.6 (range 3.2-9.5) 
mmol/l, mean HDL 1.3 mmol/l and mean LDL 3.2 mmol/l. Mean TC was higher 
than that found in the general population of a similar age, based on data from the 
2003 Health Survey for England data [269], where mean TC was 4.5 mmol/l (males) 
and 4.6 mmol/l (females) in the 16-24 year old age group. In the general population, 
65.9% of men and 66.4% of women had raised cholesterol (classified as a total 
cholesterol > 5 mmol/l), compared to 73.1% in this cohort of patients. Four of the 
patients in the cohort were treated for dyslipidaemia; TC reduced from mean 9.2 
(median 7.7) mmol/l pre-treatment to mean 5.7 (median 5.5) mmol/l on lipid-
lowering treatment. Mean TC in patients with severe GHD receiving GHR was 5.9 
mmol/l, in those with untreated GHD was 5.7 mmol/l and in those GH-sufficient was 
5.5 (range 4-8) mmol/l.  
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Discussion 
 
Pituitary adenomas diagnosed in childhood and adolescence were frequently 
hormonally active (85%) in keeping with that reported in the literature (80-97% [90, 
92, 95-97]). Presenting symptoms were typically in keeping with the hormonal sub-
type, rather than visual field deficits which are seen commonly in older adults.  
Weight gain before diagnosis occurred in all patients diagnosed with CD, but 
also in 7/29 (24%) patients with prolactinoma and 2/6 (33%) patients with NFPA. In 
contrast to the expected findings, the five patients in the series with the highest BMI 
at diagnosis (range 33.8-41.3 kg/m
2
) had a prolactinoma and not CD; three have lost 
weight following treatment, however two gained further significant amounts of 
weight despite a decrease in prolactin to well within the normal range. In adult 
patients with prolactinoma there is conflicting evidence with regards the impact of 
normalisation of prolactin concentrations on weight loss [111, 112]. Weight gain and 
obesity are not only distressing sequelae of pituitary adenomas and/or their 
treatment, but can lead to significant morbidity and mortality. Given the increased 
prevalence of obesity found in this patient cohort (39%) compared to the general 
female population of a similar age (21%), despite the predominance of 
microadenomas and therefore lack of hypothalamic damage within this cohort, this 
provides some evidence that hypothalamic damage is not the only factor contributing 
to an increased prevalence of obesity in children and adolescents with pituitary 
tumours. This is important to bear in mind when considering the underlying 
pathophysiological mechanisms responsible for hypothalamic obesity as it suggests 
that there may be other contributing factors causative of weight gain, in addition to 
the hypothalamic damage, at least in young patients with pituitary adenomas. 
Dyslipidaemia in overweight and obese adolescents has been associated with 
a higher carotid intima-media thickness in adulthood [270]. Carotid intima-media 
thickness is a surrogate marker of atherosclerosis, which can begin in childhood and 
progress with age [271] and may result in cardiovascular damage. Adachi et al found 
39% of children and adolescents with suprasellar tumours had hyperlipidaemia 
(lipids >5.7 mmol/L), rising to 58% in those with BMI > 90th percentile [80]. The 
authors also found a higher incidence of Apo B/A1 elevation and higher sdLDL-C in 
obese patients with suprasellar tumours compared to obese controls, despite a lower 
mean BMI in patients and comparable levels of TC, triglycerides and LDL-/HDL-
136 
 
cholesterol. These factors are associated with increased risk of vascular events [80]. 
NICE currently recommends that UK clinicians consider investigating lipid 
concentrations in children with BMI ≥ 98th centile for age. In children and 
adolescents with pituitary adenoma however, the evidence suggests it is advisable to 
assess lipid profiles even in patients below this BMI cut-off. Both obesity and 
hyperlipidaemia are important, modifiable risk factors for cardiovascular disease and 
therefore in this at-risk patient group early identification and targeted dietary and 
weight loss interventions are extremely important. 
 
As seen in other series [95, 96] prolactinoma was the commonest type of 
pituitary adenoma (71%) found in the patients attending the clinics at WCNN, UHA 
and AHCH and all but one patient were female. In contrast with many of these series 
[93, 95] all but two (4.9%) were treated with dopamine agonists (DA) as first-line 
therapy. DA therapy has been proven effective in treating prolactinomas and reduces 
the risk of hypopituitarism. Colao et al described 26 patients with prolactinomas; 15 
had macroprolactinomas (5 with VF defects) and 11 microprolactinomas [93]. Nine 
underwent surgery prior to assessment by the authors for “symptoms of tumour 
expansion”, despite VF defects being present in only two patients and presence of a 
microprolactinoma in seven without threat to the optic apparatus. Notably, in all 26 
patients prolactin normalised within 6-12 months of DA initiation (both those who 
had undergone surgery and those treated with DA alone) and significant reduction in 
tumour size was seen in 10/26. The authors of the paper note the effectiveness of 
DAs and raise the possibility that surgery could have been avoided in the nine 
operated cases. This is significant as out of seven patients with pituitary insufficiency 
in their series, five developed this post-operatively. In other series all patients 
underwent surgical management. Kunwar and Wilson describe 78 patients with 
prolactinoma, all managed with TSS undertaken as first-line treatment due to a “good 
outcome” (although this is not defined) [99]. They reason that long-term surgical 
cure is reported in 82% of patients [97] compared to a need for lifelong DA 
treatment, however make no mention of subsequent hormone sufficiency/deficiency 
outcomes or relapse/cure rates in their patients. In a series of 18 patients with 
prolactinoma undergoing TSS (13 with suprasellar extension) only 7/18 (39%) 
normalised prolactin postoperatively and 6/18 had a reduction in prolactin [100]. The 
authors attribute a low rate of “cure” (normal prolactin concentrations) to higher 
137 
 
concentrations of prolactin at diagnosis. In the cohort of patients seen in our service, 
DA therapy has been successfully discontinued in 9 patients (7 with 
microprolactinoma, 2 with macroprolactinoma) with no evidence of recurrence after 
a median duration of follow-up of 4 years (range 1–10 years). Based on this 
experience, the clinical effectiveness of DAs, the frequency of recurrence of 
hyperprolactinaemia following surgery [93, 95, 100, 272] and the scarceness of VF 
defects at presentation, children and adolescents with both macro- and 
microprolactinomas could most effectively and safely be treated with DAs as first-
line therapy, as is recommended in adults [272]. Given the increased risk of 
premature mortality associated with hypopituitarism [73] medical management of 
prolactinomas with DAs may decrease the risk which these young people are 
exposed to. 
 
The prevalence of Cushing’s disease was 12% (5/41) in the patients attending 
the joint service. All patients presented with the characteristic stigmata of significant 
weight gain and the single female patient in the group also had primary amenorrhoea. 
Weight gain and obesity are increasingly common in childhood and adolescence and 
identification of the relatively few patients with CD as the cause can be challenging, 
with reliance on other symptoms such as growth or pubertal arrest and headache. 
TSS for these adenomas can be technically challenging, with failure to achieve cure 
even in the most experienced hands. Cure rates vary widely (45-97%) between 
paediatric series [100, 273-278] and recurrence after initial cure is possible, therefore 
life-long follow-up is mandatory. 
 
Pituitary adenomas are familial in about 5% of cases [279] and are known to 
be associated with multiple endocrine neoplasia (MEN) type 1 syndrome (present in 
two patients in our series), Carney complex and mutations in the aryl-hydrocarbon 
receptor interacting protein (AIP) gene. AIP mutations have been described in some 
cases of familial isolated pituitary adenoma (FIPA) and, significantly to this series, 
have been associated with earlier-onset, larger, more invasive/aggressive tumours 
[280-286], typically secreting GH, prolactin or both GH and prolactin [287]. AIP is a 
tumour suppressor gene, with more than 60 mutations reported and approximately 
20% of FIPA families have a heterozygous germline AIP mutation [287]. Given 
these underlying genetic syndromes, routine questioning regarding family history of 
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pituitary adenomas is important in this age group and consideration should be given 
to biochemical screening in families where multiple members have pituitary 
adenomas. 
 
 
 
Conclusions 
 
This is one of the largest reviews of patients aged 21 years or younger at 
diagnosis of a pituitary adenoma seen in a joint neuroendocrine setting and followed 
up by a single, continuous service. In this age group hormonally active tumours are 
more common than non-functioning adenomas, particularly prolactinomas in 
females. DA treatment is both safe and efficacious and should be first-line treatment 
for prolactinoma. Surgery is required as first-line treatment only in CD or 
acromegaly, or in those with adenoma and threat of visual impairment. An 
underlying genetic cause should be considered by careful attention to tumour type, 
age of onset and by taking a careful family history. 
The sequelae of pituitary tumours are important and include increased 
cardiovascular risk factors (obesity and dyslipidaemia) and infertility. Active 
identification and treatment of these sequelae is essential. In particular relevance to 
this thesis, the increased prevalence of obesity despite the lack of hypothalamic 
damage in many of the patients studied points towards the possibility of additional 
contributing factors causative of weight gain in patients with pituitary pathology, 
regardless of whether hypothalamic damage exists. These patients could be further 
studied to elucidate the possibility of alternative/additional mechanisms causing 
weight gain following pituitary and/or hypothalamic damage.  
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Chapter 5 
 
Cerebral activations during viewing of food stimuli in adult 
patients with acquired structural hypothalamic damage: a 
functional neuroimaging study  
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Abstract 
Objective: Acquired hypothalamic damage secondary to tumours commonly leads to 
obesity, known as hypothalamic obesity (HO). Brain regions controlling homeostatic 
and non-homeostatic processes of eating and appetite are well described, but their 
interaction following hypothalamic damage is unknown. It was hypothesized that in 
patients with hypothalamic damage who became obese (HO), aberrant processing of 
food stimuli leads to abnormal appetite and excessive food consumption and possibly 
hyperphagia, which has been described in some patients with HO. This study aimed 
to compare those with HO to patients with hypothalamic damage who remained 
weight-stable (HWS) and age- and BMI-matched controls without hypothalamic 
damage to ascertain any differences in activation of cerebral regions associated with 
food-motivation and reward.  
 
Study design: Cross-sectional study of 9 patients with HO, 10 age and BMI-matched 
obese controls (OC), 7 patients who remained weight-stable (HWS) and 10 non-
obese controls (NOC). Functional magnetic resonance imaging (fMRI) was 
performed when fasted, 1 hour and 3 hours after a fixed-load breakfast (25% of 
participants calculated basal metabolic rate [BMR]). During each scan session 
participants viewed alternating blocks of photographs of high- or low-calorie food, 
with non-food photographs also viewed to use as a baseline comparison, to allow 
purely visual activation to be subtracted from any BOLD signal differences which 
occurred. Appetite-associated hormones (glucose, insulin, active GLP-1, PYY(3-36) 
and active ghrelin) were measured throughout the experiment, as were self-reported 
visual analogue scale (VAS) appetite ratings of hunger, fullness and desire to eat. 
 
Results: Whole-brain statistical analysis (corrected for multiple comparisons using a 
false discovery rate (FDR) of p≤0.05 and cluster size k ≥ 3,000 voxels) found mean 
BOLD signal was significantly lower in HWS compared to the other 3 groups in the 
posterior insula and lingual gyrus (p = 0.001) when viewing high-calorie food 
photographs compared to non-food photographs. These brain regions are associated 
with food motivation and reward. There were no significant differences between the 
four groups in fasting or area under the curve (AUC) hormone concentrations, with 
the exception of ghrelin (both fasting and AUC) which was significantly higher in 
controls compared to patients. VAS ratings of hunger and desire to eat were 
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significantly higher in obese compared to non-obese participants throughout the 
study day, but there were no differences in fullness. 
 
Conclusions: A difference exists in food motivation-related BOLD signal in patients 
with hypothalamic damage who remain weight-stable (HWS) compared to those who 
develop HO and controls. The differences in these neural pathways associated with 
food motivation and reward-related behaviour may be implicated in the 
pathophysiology of HO. 
 
Summary of Justification and Aims 
 
Introduction 
 
Weight gain and obesity are common sequelae of acquired, structural 
hypothalamic damage, which can occur secondary to pathology such as 
hypothalamic tumours or craniopharyngiomas [6, 245]. Hypothalamic obesity (HO) 
is an acute increase in body weight following such damage, with weight gain faster 
than any expected age-related increase and occurring despite adequate treatment of 
any associated pituitary hormone deficiencies. Substantial weight gain often occurs, 
but predicting which patients will be affected and adequately treating them remains 
difficult [6, 245] and the underlying pathophysiology remains unclear. Exploration of 
the various factors controlling appetite and eating may help to elucidate answers to 
these problems and provide areas of investigation for future treatment methods. In 
addition to helping elucidate the pathophysiology underlying HO, areas of interest 
for further “simple obesity” research may be identified. 
While the hypothalamus is the critical homeostatic centre, the nucleus 
accumbens (NA) and brainstem (particularly the ventral tegmental area [VTA] of the 
midbrain) are also important. Non-homeostatic factors, such as emotion, cognition 
and reward are regulated by limbic, paralimbic and higher cortical regions; these 
areas process environmental and hedonic cues and food reward. Interactions between 
homeostatic and non-homeostatic systems remain poorly understood. Studying 
patients with damage to the major homeostatic regulator (i.e. the hypothalamus) 
allows exploration of reward-related non-homeostatic areas influencing appetite and 
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feeding. Over the last 10 -15 years, human appetite and eating regulation has been 
studied using functional neuroimaging (functional magnetic resonance imaging 
[fMRI] and positron emission tomography [PET]) to explore both the homeostatic 
and non-homeostatic cerebral regions involved. Early neuroimaging studies using 
PET demonstrated differences in brain activation in several regions before and after a 
liquid meal [149, 168, 175]. A few studies have used imagined food [167] or actual 
food [170], but most recent studies have used photographs of food and non-food 
items [162, 175-178] to distinguish brain activation due to visual effects from 
activation due to food stimuli.  
Aims: The main objective of the study was to identify differences in brain responses
 
to visual food-stimuli using fMRI in participants with HO, compared to those with 
hypothalamic damage who remained weight-stable (HWS) and BMI-matched 
controls.  
 
Hypothesis: Participants with HO would have greater activation of the reward-
related brain regions than those HWS, where the homeostatic pathways may have 
remained more influential. If this hypothesis was supported by the findings then an 
increase in reward-related eating in those with HO would be reflected in an increase 
in food intake, as explored in other aspects of the study (food diaries, TFEQ and 
UEM study day, Chapter 6). 
 
 
 
Participants and Methods 
Participants 
The recruitment of patients for the study is fully described in chapter 2. 
Thirty-six participants aged 18-75 were recruited (Table 5.1a); nine with HO, seven 
HWS and 20 BMI-matched, otherwise healthy controls (10 obese [OC], 10 non-
obese [NOC]) of similar gender and age). 
Patients were recruited from pituitary/neuroendocrine clinics at University 
Hospital Aintree (UHA) or the Walton Centre for Neurology and Neurosurgery 
(WCNN). All had undergone treatment of a tumour of the hypothalamus or a 
surrounding structure with direct hypothalamic compression/invasion (Table 5.2). 
All had grade 2 hypothalamic damage (Saint-Rose et al. grading [32, 115]), assessed 
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by a Neuroradiologist. HO was defined as body mass index (BMI) ≥ 30 kg/m2 at 
latest follow-up, increased ≥ 2 kg/m2 since tumour diagnosis. HWS participants had 
a BMI < 30 kg/m
2
, within 2 kg/m
2
 of that at tumour diagnosis. All patients were on 
adequate replacement of pituitary hormone deficits - 8 required hydrocortisone, 9 
levothyroxine, 3 desmopressin for permanent cranial diabetes insipidus (DI), all pre-
menopausal women and 3 men with secondary hypogonadism received sex steroids 
and 9/11 participants with GHD received growth hormone (two did not qualify for 
treatment as they were asymptomatic on QOL-AGHDA questionnaire).  
Healthy controls were recruited by advertisement within the University of 
Liverpool and from previous obesity studies. Obesity was defined using the standard 
definition of BMI ≥ 30 kg/m2. All participants were medically screened, with visual 
adequacy assessed in the patient group. 
The study was approved by the local ethics committee (Northwest Research 
Ethics Committee, 09/H1001/4). Signed, informed consent was obtained from each 
participant prior to study participation.  
 
Study design and methods 
Participants were instructed to fast from 22:00 the previous night and to 
refrain from alcohol, strenuous physical activity, cigarettes and caffeine-containing 
drinks for at least 72 hours (see Appendix 4 for timeline).  Participants attended the 
MARIARC (Magnetic Resonance And Image Analysis Research Centre), University 
of Liverpool, around 08:30. Blood samples were collected and participants asked to 
rate their feelings of hunger, fullness and the strength of their desire to eat using 
Visual Analogue Scale (VAS) ratings (Appendix 2), before undergoing two MRI 
scans  (Figure 5.1). The first was an anatomical scan and the second an fMRI scan 
during which photographs were viewed using a mirror and screen inside the scanner 
(paradigm described in Figure 5.3). Participants were asked to try and remember 
each photograph for a recognition test at the end of each fMRI scan, when they were 
asked to look through a photo album containing photographs identical to those 
shown during the scanner session, presented in the same order, and rate on VAS 
scales how much they liked the food and how much they wanted to eat that food at 
that moment (Figure 5.2). This data was not analysed as it was purely to ensure that 
participants were concentrating on the food photographs shown during the fMRI 
scanning session.  
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Participants then consumed a breakfast meal of porridge and orange juice 
totalling 25% of their estimated basal metabolic rate (BMR), calculated using the 
Harris-Benedict formula (see Chapter 2, Methods for details). Details of the 
nutritional content of the breakfast meal are shown in Table 2.1 (Chapter 2).  
A second and third fMRI scan were undertaken one and three hours after the 
breakfast meal whilst undertaking the same paradigm as during the first fMRI scan 
(Figure 5.3). Between scans participants rested in a quiet room whilst on-going blood 
samples and VAS ratings of appetite were completed. Blood samples were taken 
prior to breakfast and at 15, 30, 60, 120 and 180 minutes after the breakfast meal for 
measurement of glucose, insulin, active ghrelin, PYY(3-36) and active GLP-1. VAS 
ratings of hunger, fullness, and desire to eat were completed by the participants in the 
fasting state and at the end of each scanning session.  
The protocol for collection, storage and measurement of these biochemical 
parameters is fully described in chapter 2 (Methods).  
 
Figure 5.1. Timeline for participants. 
Previous 
Day 
Study Day 
22.00 08.30 09.00 09.30 10.30 12.30 
Start fasting Fasted 
blood 
sample 
Anatomical 
MRI and 
baseline 
fMRI 
VAS ratings prior to 
breakfast (porridge and 
orange juice equivalent 
to 25% of BMR) 
2
nd
 
fMRI 
(1hPB) 
3
rd
 fMRI 
(3hPB) 
 
Figure 5.2. Example of the food photograph rating undertaken by participants after 
each fMRI scanning session. 
Photo 1  
How MUCH DO YOU LIKE THIS FOOD at this moment? 
Not at all        A large amount 
 
How MUCH DO YOU WANT TO EAT THIS FOOD at this moment? 
Not at all        A large amount 
145 
 
MRI and fMRI acquisition 
MR images were obtained on a 3.0 Tesla Siemens Trio (Siemens Medical, 
Erlangen, Germany) scanner with [248] eight-channel head coil. Foam padding 
minimised head movement during each scan and alignment with the first scanning 
session was attempted as much as possible on subsequent scanning sessions. Whole-
brain T1-weighted anatomical sagittal brain images were acquired using Modified 
Driven Equilibrium Fourier Transform (MDEFT) to minimise susceptibility effects 
[248] (TR7.92 ms, TE 2.48 ms, flip angle 16˚, FOV 256×240, 180 1mm slices, voxel 
1×1×1 mm
3
). Structural images provide anatomical representations against which 
functional scans (usually of low spatial resolution with poor tissue contrast) can be 
compared. fMRI sequences used echoplanar EPI (TR 3000 ms, TE 30 ms, flip angle 
90˚, FOV 192×192 mm2, 56 oblique 2 mm slices with slice gap 0.8 mm, voxel 
3×3×3 mm
3
). 
 
Functional neuroimaging (fMRI): Activation paradigm  
An activation paradigm was generated using ‘Presentation’ software 
(https://nbs.neuro-bs.com) which combined an initial on-screen written instruction, 
food and non-food photographs and a fixation cross (to be viewed during rest periods 
in between blocks of photographs). The software programme was used with each 
fMRI scan to ensure accurate timing and consistency of images and rest periods and 
was viewed via a mirror mounted in the scanner which reflected a projected 
computer screen. The presentation began with the written instruction “Please 
concentrate on the pictures and imagine what they taste like!”, followed by a fixation 
cross shown for six seconds. The photographs (32 per category; high-calorie, low-
calorie, non-food) were presented in blocks, with no repeat of any photograph within 
each scanning session (although the same photographs were used in subsequent 
sessions, but in differing orders). Each block contained photographs from a single 
category (high-calorie, low-calorie, non-food), with each photograph presented for 
four seconds and four photographs presented in one block (Figure 5.3). Each block 
was 16 seconds with a rest period (6 seconds) showing a fixation cross in-between. 
Each condition (high calorie, low calorie, non-food) appeared once in each cycle in a 
random order, with a total of eight cycles.  
 
146 
 
Figure 5.3. Schematic representation of the block experimental design. Each shaded 
rectangle represents a 16 second period during which 4 pictures of the same category 
were presented (4 seconds each). 
 
 
 
 
 
 
 
 
 
 
 
 
A pilot study using this fMRI paradigm was undertaken in five healthy, lean 
or overweight individuals to ensure that it elicited a BOLD response in the regions 
that you might expect when viewing high and low calorie food images, as previously 
reported in studies using similar experimental paradigms. Data from these subjects 
were not included in the final analysis.  
 
Food photographs 
The photographs shown were a series of standardised pictures, composed 
specifically for use in this study to ensure that differences between photographs were 
not contributing to differences in cerebral activation. Food and non-food photographs 
were generated using a Nikon D80 camera with additional flash, taken on a non-
distracting, white infinity curve background using freshly prepared food products and 
cropped so that the food or object filled almost the entire screen to ensure 
standardised images. The best photograph of each item was then selected and 
categorised as: high-calorie food (e.g. sausage rolls, doughnuts), low-calorie food 
(e.g. steamed salmon with fresh vegetables, mixed fruit salad) or non-food objects 
(e.g. calculator, candles) (Appendix 3). Of 92 food photographs taken, 64 were 
shown (32 in each category) based on responses to an online questionnaire of 
University of Liverpool staff and students who responded to an internal University 
advertisement (University of Liverpool Ethics approval PSYC07080300). 
Participants judged whether each food photograph was high or low calorie and rated 
its pleasantness (hedonic value). Photographs with the greatest agreement on calorie 
Non-
food 
images 
1
st
 cycle 8
th
 cycle 2
nd
 cycle 
High 
calories 
images 
Low 
calories 
images 
 
Rest 
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content (high or low) and rated most pleasant were included. This allowed 
comparison between food-energy categories, with less influence of food 
pleasantness, although did not allow for individual food preferences as the same 
images were used for each participant. Low- and high-calorie food and object 
photographs were well matched for visual interest (variety, colour, size) in order to 
minimise other variability which might then account for differences found.  
 
Image processing and analysis  
Pre-processing and statistical analyses of fMRI data was undertaken using SPM8 
(http://www.fil.ion.ucl.ac.uk/spm; Statistical Parametric Mapping software package, 
Wellcome Department of Cognitive Neurology, London, UK) as follows:  
 
1. The first two images of each experimental run were collected with the 
participant at rest and discarded for noise. 
2. A reference slice (number 25 of 1-50) was chosen for slice-timing correction 
and all slices shifted to that time-point using an interpolation method; changes in 
the BOLD (blood-oxygen -level-dependent) fMRI response then started at the 
same time for each voxel in each slice of the volume.  
3. Realignment to the same reference image was undertaken to correct for head 
movement. Spatial transformation was performed using a least squares (rigid 
body) approach.  
4. A mean functional image volume was created for each participant using the 
realigned images and coregistered with the EPI template supplied by SPM8 in 
Montreal Neurological Institute (MNI) space. The resulting pixel size in standard 
stereotaxic coordinates was 2 mm
2
, with an interplane distance of 2 mm. 
5.  The normalized images were subsequently smoothed with an isotropic 6 mm
3
 
FWHM Gaussian kernel to compensate for normal variations in brain size and 
individual gyral pattern, filter out any high-frequency noise potentially introduced 
in the previous processing steps and to improve signal to noise ratio [288, 289]. 
 
Biochemical assays  
These are fully described in Chapter 2.  
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Visual Analogue Scale (VAS) ratings 
Unipolar VAS ratings to assess hunger and satiety consist of a question 
accompanied by a 100mm unmarked scale, with descriptors of extreme state (e.g. not 
hungry at all-extremely hungry) anchoring each end (Appendix 2). Unipolar scales 
such as these (as opposed to bipolar scales, where anchors are hungry to sated) are 
more accurate and less likely to skew the data [250]. VAS ratings have been found to 
be a reliable measure in appetite research [251]. 
Participants were asked to mark on a 100mm paper VAS scale a single, 
vertical line which best corresponded with their subjective feelings of appetite 
(hunger, fullness and their strength of desire to eat). The scales were anchored by 
“Not at all” and “Extremely” at either end. This allowed participants’ subjective 
sensations to be quantified numerically by later measurement of the point along the 
scale and analysed. VAS ratings were made at various time points throughout the 
study day (as described above and in the timeline in Appendix 4). 
 
Statistical analysis 
Two-way ANOVA was used to compare age, body composition and VAS 
ratings of appetite between obese (HO/OC) vs. non-obese (HWS/NOC) participants, 
patients (HO/HWS) vs. controls (NOC/OC) and the interaction between these factors. 
Levene’s test was used to check the ANOVA assumption of equality of variances. 
For BMI and VAS ratings of hunger at three hours data required transformation to 
equalise the variances. A ladder of power [290] was performed in order to choose the 
best transformation for the data; the inverse function was used for BMI and the 
square for hunger at three hours. Further Levene’s tests on the transformed data sets 
were non-significant (p>0.05), indicating that the problem of unequal variance was 
resolved. The two-way ANOVA undertaken on these transformed data and 
transformed means (SD) are reported. 
Fisher’s exact test was used to examine the categorical data of the patient 
groups (due to the small sample size) and continuous data (duration of diagnosis in 
the two patient groups) was examined using the Mann-Whitney U test, as it was non-
normally distributed.  
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For the fMRI data statistical analysis tested for significant regional BOLD 
signal differences. Functional images were smoothed and normalised then included 
in the first level design matrix. For each participant the contrast for determining 
BOLD signal differences was the contrast between all foods (high- and low-calorie) 
and objects (and not a contrast with baseline). This contrast was selected to eliminate 
activation related purely to visual stimulation. Second level analysis using a one 
sample t-test of the single contrast images (one per participant) determined mean 
BOLD signal secondary to viewing all foods amongst all participants. Results were 
corrected for multiple comparisons using a false discovery rate (FDR) of p≤0.05. As 
it was an exploratory study it was decided to conduct whole brain analysis and not to 
use a priori regions of interest (ROIs) initially. The ROIs identified were delineated 
using MarsBaR (MARSeille Boîte À Région d’Intérêt, a toolbox in SPM used for 
ROI analysis; http://marsbar.sourceforge.net/ [249]) and those with a cluster size 
k3000 voxels subsequently analysed. A cut off of k3,000 voxels was chosen as 
this allowed for a reasonable but not excessive number of ROIs with significant 
BOLD signal, but did exclude smaller potential ROIs such as the amygdala or NA. In 
total six significant BOLD signal clusters were found (Table 5.3). Using MarsBaR, 
contrast values for both high- and low-calorie foods for each of the three fMRI 
scanning sessions were defined using each participant’s first level design matrix, 
generating a total of six contrast values for each participant. 
Further statistical analysis was performed using SPSS v.17, v. 22 and v. 24 
(http://www.spss.com/uk/). Six linear mixed-effects models were computed - one for 
each of the six  clusters identified. Linear mixed-effects models were chosen because 
they allow for the inclusion of both fixed factors (e.g. gender, patient/control group) 
and random factors (which account for the within-subject correlation in the data, e.g. 
correlation which occurs due to the inclusion of high- and low-calorie foods 
belonging to the same participant). Potential interactions between patient/control 
group, non-obese/obese group and high/low calorie foods were also considered in 
each of the models. Each interaction was incorporated in the model by adding the 
product of the corresponding two variables as an additional explanatory variable. 
These additional variables did not significantly improve the fit of the models 
(p>0.05) and were therefore excluded. Contrast values for high- and low-calorie 
foods for each of the three sessions within each ROI were entered as the outcome 
variable in the first repeated-measures ANOVA. The grouping factors non-
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obese/obese (HWS and NOC/HO and OC), control/patient (OC and NOC/HO and 
HWS) and the interaction between these two, along with the variables high-/low-
calorie foods and fMRI session (fasting, 1hPB and 3hPB) were entered as the 
predictor variables. Identical analysis was performed for each of the six ROIs. As the 
assumption of sphericity is unlikely to be met in a repeated-measures ANOVA and 
violations of sphericity are detrimental to the accuracy of ANOVA, the Greenhouse-
Geisser results for within-subject effects were interpreted, as this correction adjusts 
the degrees of freedom and decreases the likelihood of a Type I error. 
 
Mean insulin, glucose, active ghrelin, active GLP-1 and PYY(3-36) across 
the timepoints were calculated, to reflect the amalgamated timepoints used in the 
fMRI analysis. Additional linear mixed-effects models were calculated using mean 
hormone concentrations as the outcome variable, with non-obese/obese, 
patient/control and session (at all three fMRI timepoints i.e. fasting, 1hPB and 
3hPB) used as predictor variables.  
Further analysis of the hormonal variables glucose, insulin, PYY(3-36), 
active GLP-1 and active ghrelin was undertaken using Microsoft Excel 2013 to 
calculate mean fasting concentrations and area under the curve (AUC) by trapezoidal 
integration. Any values below the limit of quantification were set to zero. 
Differences between the groups in fasting and AUC hormone concentrations were 
assessed using two-way ANOVA. Levene’s test was used to check the ANOVA 
assumption of equality of variances.  For AUC insulin and fasting glucose, ghrelin 
and PYY, transformations were needed to equalise the variances. For each of these 
variables a ladder of power was undertaken to identify the best transformation for the 
data [290]. The inverse of the square root was used for AUC insulin, the inverse 
function for fasting glucose, the square root for fasting active ghrelin and the natural 
logarithm for fasting PYY(3-36). A further Levene’s test on the transformed data 
was non-significant (p>0.05), indicating that the problem of unequal variance was 
resolved. The two-way ANOVA undertaken on the transformed data is reported and 
transformed means (SD) reported, where appropriate. 
 
For all analyses p≤0.05 (two-tailed) were taken to be significant.  
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Results 
 
Participant characteristics 
Nine patients with HO, seven who remained weight-stable following 
hypothalamic insult (HWS) and 20 age-matched obese (OC) and non-obese controls 
(NOC) were studied. There was no significant difference in age between obese 
(HO/OC) vs. non-obese (HWS/NOC), controls (NOC/OC) vs. patients (HO/HWS), or 
the interaction between these factors on two-way ANOVA (results of interaction in 
Table 5.1a). There was significantly lower transformed BMI (inverse BMI) in obese 
(HO/OC) than non-obese (HWS/NOC) (mean transformed BMI in obese 0.027, mean 
transformed BMI in non-obese 0.038, F[1,32]= 68.0, p<0.001), however there was no 
significant difference between controls (NOC/OC) vs. patients (HO/HWS) (F[1,32]= 
0.25, p=0.62), or the interaction between these factors (Table 5.1a). There was 
significantly higher percentage body fat in obese (HO/OC) than non-obese 
(HWS/NOC) participants (mean percentage body fat in obese 44.4, mean percentage 
body fat in non-obese 31.3, F[1,30]= 21.5, p<0.001), however there was no significant 
difference between controls (NOC/OC) vs. patients (HO/HWS) (F[1,30]= 0.06, 
p=0.81), or the interaction between these factors (Table 5.1a). 
 
None of the participants had glucose intolerance or diabetes. Hormone deficiencies 
and duration of diagnosis are noted for participants with hypothalamic damage 
(Table 5.1b). 
 
Eleven patients (HO or HWS) had severe GHD (growth hormone deficiency) with 
nine receiving replacement therapy; two were asymptomatic on QOL-AGHDA 
questionnaire and did not qualify for treatment under UK guidelines. There was a 
significant difference in the prevalence of hypothyroidism (p=0.02). There was no 
significant difference in time since diagnosis of the hypothalamic lesion (p=0.48). 
The gender, current age and BMI, disease duration and diagnosis of participants with 
hypothalamic damage are noted (Table 5.2). The duration of diagnosis of 
hypothalamic damage ranged from 2 to 38 years. 
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Table 5.1a. Characteristics of the four participant groups. Mean (SD) reported for 
age, BMI and percentage body fat 
 HO HWS OC NOC F value p-value 
Participants 9 7 10 10 - - 
Gender: F 
               M 
4 
5 
4 
3 
8 
2 
6 
4 
- - 
Age, years  45.2 
(14.6) 
57.9 
(17.1) 
45.5 
(11.7) 
47.6 
(20.2) 
F[1,32] 
0.94 
 
0.34 
Median BMI 
[IQR](kg/m
2
) 
38.4 
[8.6] 
27.8 
[4.0] 
38.8 
[10.2] 
26.6 
[5.0] 
0.29
a 
0.59
a 
Percentage 
body fat 
43.9 
(6.1) 
31.1 
(7.9) 
44.9 
(5.7) 
31.5 
(11.1) 
F[1,30] 
0.18 
 
0.90 
Body fat category:      
Healthy 
Overfat 
Obese 
0 
0 
8 
3 
2 
2 
0 
1 
8 
4 
4 
2 
- - 
F = female; M = male.  F-ratio and p-values for the interaction between obese 
(HO/OC) vs. non-obese (HWS/NOC) and patients (HO/HWS) vs. controls (NOC/OC) 
on two-way ANOVA. 
a
BMI data required transformation (using the inverse function) 
to equalise the variances. Statistical comparison was performed using these values. 
 
Table 5.1b. Characteristics of the two patient groups.  
 HO 
Mean (SD) 
HWS 
Mean (SD) 
p-value 
Number of participants 9 7 - 
Duration diagnosis 12.1 (13.6) 13.1 (8.0) U=21.5, z=-0.75, p=0.48 
Cortisol deficiency 5 3 0.59 
GHD 6 5 0.22 
Hypothyroidism 7 2 0.02 
Hypogonadism 2M, 2F 1M, 2F 0.79 
Permanent DI  2 1 0.56 
F = female; M = male. Statistical comparisons using two-sided Fisher’s exact test, 
except for duration of diagnosis (Mann-Whitney test). 
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Table 5.2. Tumour types of patients with hypothalamic damage.  
ID Gender Current 
age (yrs) 
Current BMI 
(kg/m
2
) 
Duration 
(yrs) 
Group Diagnosis 
HO1 F 70 28.1 12 HWS PA 
HO2 F 40 43 29 HO HG 
HO3 M 68 30 5 HWS PA 
HO4 F 52 38.4 4 HO CP 
HO5 F 18 34.7 9 HO CP 
HO6 F 66 28.96 14 HWS PA 
HO7 M 22 23.7 12 HWS CP 
HO8 F 52 26 26 HWS PA 
HO12 M 34 32.4 2 HO PA 
HO13 M 40 32.9 6 HO Prolactinoma 
HO14 M 67 27.7 3 HWS Prolactinoma 
HO15 M 60 48.2 5 HO CP 
HO16 M 56 32.3 38 HO CP 
HO18 M 64 39.4  HO PA 
HO20 F 58 24 20 HWS PA 
HO21 F 42 34.5 4 HO Midline cyst 
F = female, M = male. HWS = hypothalamic weight-stable, HO = hypothalamic 
obese. PA = pituitary adenoma, HG = hypothalamic glioma, CP = 
craniopharyngioma. 
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fMRI data 
 
Effects of photograph category: food vs. object 
Across all participants and all fMRI sessions, there were 6 ROIs with 
significantly greater BOLD signal for food images than objects (Table 5.3; activation 
maps Figure 5.3). These were: left-sided posterior insula and middle frontal gyrus; 
right-sided lingual gyrus, middle temporal (precentral) gyrus, anterior cingulate and 
posterior cingulate gyrus.   
 
 
Table 5.3. ROIs identified where BOLD signal was significantly greater for all food 
images compared to objects, across all participants (results corrected for multiple 
comparisons using an FDR of p≤0.05 in areas with k>3,000 voxels)  
Region Nearest 
BA 
Talairach 
coordinates  
Cluster 
volume (mm
3
) 
T-score 
Lingual gyrus (R) 18 6, -88, -4 52640 11.37 
Posterior insula (L) 13 -38, -4, 4 12448 8.0 
Anterior cingulate gyrus (R) 32 2, 18, 42 45752 7.10 
Precentral gyrus (R) 21 66, -16, 34 4640 6.18 
Posterior cingulate gyrus (R) 32 4, -28, 32 17336 5.71 
Middle frontal gyrus (L) 46 -42, 38, 22 6736 4.7 
Abbreviations: L = left hemisphere, R = right hemisphere. BA = Brodmann Area. 
Talairach coordinates (x, y, z) are given for the most significant voxel in the cluster, 
however ROIs cover larger areas.  
 
 
The mean BOLD signal values of these 6 regions for high- and low-calorie 
foods in each of the four participant groups are given (Table 5.4) and activation maps 
shown (Figure 5.4). 
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Table 5.4. Mean % BOLD signal (SD) and [minimum, maximum] BOLD signal 
within each ROI for high-calorie and low-calorie foods compared to objects. 
Area Calorie 
type 
HWS HO NOC OC 
Lingual 
gyrus (R) 
High 1.31 (0.42) 
[0.61,2.26] 
1.64 (0.49) 
[-0.93,2.5] 
1.7 (0.58) 
[0.81,2.96] 
1.61 (0.25) 
[1.12,2.08] 
Low 1.34 (0.42) 
[0.61,2.22] 
1.78 (0.57) 
[0.86,2.74] 
1.78 (0.53) 
[1.14,3.07] 
1.61 (0.40 
[0.46,2.51] 
Posterior 
Insula (L) 
High -0.04 (0.27) 
[-0.66,0.58] 
0.28 (0.53) 
[-0.34,2.05] 
0.19 (0.2) 
[-0.24,0.77] 
0.18 (0.28) 
[-0.54,0.92] 
Low -0.03 (0.25) 
[-0.59,0.39] 
0.22 (0.58) 
[-0.16,2.45] 
0.21 (0.17) 
[-0.23,0.44] 
0.22 (0.35 
[-0.33,1.58] 
Anterior 
Cingulate 
gyrus (R) 
High 0.08 (0.19) 
[-0.33,0.38] 
0.19 (0.25) 
[-0.34,0.66] 
0.02 (0.24) 
[-0.49,0.49] 
0.14 (0.26) 
[-0.6,0.82] 
Low 0.12 (0.19) 
[-0.29,0.52] 
0.14 (0.19) 
[-0.42,0.46] 
0.11 (0.22) 
[-0.42,0.49] 
0.12 (0.23 
[-0.26,0.98] 
Precentral 
gyrus (R) 
High 0.09 (0.47) 
[-0.7,0.85] 
0.18 (0.51) 
[-0.76,1.21] 
0.07 (0.29) 
[-0.47,0.8] 
0.1 (0.4) 
[-0.67,1.17] 
Low 0.21 (0.28) 
[-0.16,0.8] 
0.05 (0.56) 
[-1.1,1.17] 
0.12 (0.28) 
[-0.74,0.63] 
0.08 (0.27 
[-0.44,0.79] 
Posterior 
Cingulate 
gyrus (R) 
High -0.05 (0.33) 
[-0.6,1.05] 
0.11 (0.54) 
[-1.02,1.62] 
-0.12 (0.19) 
[-0.5,0.21] 
0.07 (0.41) 
[-0.46,1.4] 
Low 0.01 (0.27) 
[-0.53,0.5] 
0.1 (0.42) 
[-0.55,1.44] 
-0.08 (0.20) 
[-0.54,0.24] 
0.09 (0.38 
[-0.52,1.43] 
Middle 
Frontal 
gyrus (L) 
High 0.12 (0.22) 
[-0.32,0.52] 
0.22 (0.45) 
[-0.68,1.36] 
-0.002 (0.3) 
[-0.59,0.84] 
0.13 (0.41) 
[-0.69,1.42] 
Low 0.15 (0.29) 
[-0.43,0.66] 
0.21 (0.4) 
[-0.3,1.45] 
0.15 (0.31) 
[-0.47,0.97] 
0.16 (0.42 
[-0.44,1.76] 
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Figure 5.4. Brain maps showing BOLD signal across the 6 ROIs for the contrast all 
foods (high- and low-calorie) vs. objects (results corrected for multiple comparisons 
using an FDR of p≤0.05 in areas with k>3,000 voxels) 
 
 
 
ROIs are shown in sagittal, coronal and axial planes on a single-subject template 
from SPM8. Talairach coordinates (x, y, z) for the most significant voxel in the 
cluster are given. Colour corresponds to T-scores. L = left hemisphere, R = right 
hemisphere. 
 
Effects of photograph category: high- vs. low-calorie 
There was no significant effect of high- vs. low-calorie food photographs in 
any of the 6 linear mixed effects models (p>0.05). Interactions between group (non-
obese/obese, patient/control) and food-type (high/low-calorie) were entered into each 
model by adding the product of the corresponding two variables as an additional 
explanatory variable. As none significantly improved the fit (p>0.05) they were 
excluded.  
 
As there was no significant difference between high- and low-calorie foods 
and as fMRI analysis cannot exceed three levels, only the data produced by viewing 
high-calorie foods was used for further analysis. 
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Between-group comparison: obese vs. non-obese 
In five of the six areas obese participants (HO/OC) exhibited increased 
BOLD signal when viewing high-calorie foods compared to non-obese participants 
(HWS/NOC). Box plots show BOLD signal in each of the six ROIs in each 
participant group (Figure 5.5). 
There was significantly lower posterior insula (p=0.001; coefficient -0.2, SE 
0.06, 95% CI: -0.33, -0.08) and lingual gyrus (p=0.001; coefficient -0.34, SE 0.1, 
95% CI: -0.53, -0.15) BOLD signal in non-obese (HWS/NOC) compared to obese 
(HO/OC) participants on the linear mixed-effects model. The BOLD signal cluster in 
the insula showed spatial maximum in the posterior insula, but spread to middle 
insular cortex.  
 
Between group comparison: patient/control, obese/non-obese 
There was a statistically significant interaction between non-obese 
(HWS/NOC) vs. obese (HO/OC) and controls (NOC/OC) vs. patients (HO/HWS) in 
the posterior insula (p=0.028; coefficient 0.19, SE 0.08, 95% CI: 0.02, 0.35) and the 
lingual gyrus (p<0.001; coefficient 0.47, SE 0.13, 95% CI: 0.22, 0.73).  
Viewing high-calorie food photographs resulted in a significant difference in 
insula BOLD signal (F[1,103]=5.554, p=0.02) between the groups (Figure 5.5). 
Significantly lower BOLD signal was seen in HWS (mean=-0.042) compared to HO 
(mean=0.237), NOC (mean=0.186) and OC (mean=0.175). 
Within the lingual gyrus of the occipital lobe (F[1,103]=5.176, p=0.025) there 
was significantly lower BOLD signal in HWS (mean=1.309) than in HO 
(mean=1.633), NOC (mean=1.698) and OC (mean=1.609) (Figure 5.5). 
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Figure 5.5. Box plots showing median % BOLD signal across all three sessions 
[(thick central line), interquartile range (upper and lower box edges) and minimum/ 
maximum (lowest/uppermost horizontal lines, with outliers depicted as stars/circles)] 
whilst viewing high-calorie foods (compared to objects) in the 6 ROIs, shown by 
participant group. A. Posterior Insula, B. Middle Frontal Gyrus, C. Anterior 
Cingulate, D. Posterior Cingulate, E. Middle Temporal Gyrus, F. Lingual Gyrus 
 
A.  
 
 
B.  
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HO15 
CO21 
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C. 
 
 
 
 
D.  
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E.  
 
 
F.  
 
 
 
 
Light-grey bars = non-obese, dark-grey bars = obese. Outliers are labelled with their 
participant code. 
HO5 
HO13 
HO16 
CO11 
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Between session comparison: fasted, 1hPB and 3hPB 
Post-hoc pair-wise comparisons were performed for the variable “session” (at 
three timepoints: fasted, 1hPB and 3hPB) in each linear mixed-effects model. The 
variable “session” was significant for posterior insula (F[2,151]=3.024, p=0.05), lingual 
gyrus (F[2, 138]=4.542, p=0.012) and posterior cingulate gyrus (F[2,148]=3.556, p=0.03). 
Pairwise comparisons showed that the difference in posterior insula BOLD signal 
was between fasted and 3hPB (p=0.04; mean difference 0.12, SE=0.06, 95%CI: 
0.004 to 0.23) and 1hPB and 3hPB states (p=0.05; mean difference 0.09, SE=0.05, 
95%CI: -0.001 to 0.18), with greater posterior insula BOLD signal when fasted and 
at 1hPB compared to 3hPB. Lingual gyrus BOLD signal was greater fasted than 
3hPB (p=0.003; mean difference 0.24, SE=0.8, 95%CI: 0.08 to 0.40), with lower 
posterior cingulate gyrus BOLD signal when fasted than 1hPB (p=0.012; mean 
difference -0.15, SE=0.06, 95%CI: -0.27 to-0.034). 
 
There were no significant differences between the groups (patients/controls, 
non-obese/obese) when BOLD signal across sessions was compared (data not 
shown). 
  
 
Hormonal analysis 
 The results of the mean (SD) area under the curve concentrations for glucose, 
active GLP-1, active ghrelin and PYY(3-36) and median insulin in each participant 
group are given (Table 5.5). Mean fasting concentrations for insulin and active GLP-
1 and median glucose, active ghrelin and PYY(3-36) in each participant group are 
also given (Table 5.6, Figure 5.6).  
 
There were no significant differences in AUC hormone concentrations between 
obese (HO/OC) vs. non-obese (HWS/NOC) or patients (HO/HWS) vs. controls 
(NOC/OC), or the interaction between these factors on two-way ANOVA (results of 
interaction in Table 5.5), except for ghrelin AUC where there was significantly 
higher AUC ghrelin in controls (NOC/OC; mean 18,389, SD 18.055) than in 
patients(HO/HWS; mean 7,609, SD 5998) (F[1,30]= 4.56, p=0.04), but no significant 
difference between obese (HO/OC) vs. non-obese (HWS/NOC) (F[1,30]= 2.52, p=0.12) 
or the interaction between these factors (Table 5.5). 
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Table 5.5. Mean (SD) AUC hormone concentrations in each participant group 
 HO HWS OC NOC F ratio p-value 
Median[IQR] insulin 
(mIU*180mins/mL) 
5978 
[1458] 
5764 
[6693] 
5629 
[8453] 
7563 
[3827] 
F(1, 27) 
0.10
a
  
0.75
a 
Glucose 
(mmol*180mins/L) 
1412 
(617)  
1438 
(152)  
1353 
(255)  
1257 
(225)  
F(1, 29) 
0.21 
0.65 
Active GLP-1 
(pmol*180mins/L) 
563 
(494) 
795 
(696) 
689 
(515) 
695 
(509) 
F(1, 31) 
0.37 
0.55 
Active ghrelin 
(pg*180mins/mL) 
6957 
(6839) 
8786 
(4548) 
11484 
(15489) 
25295 
(18502) 
F(1, 30) 
1.48 
0.23 
PYY(3-36) 
(ng*180mins/mL) 
122.7 
(22.0) 
137.5 
(25.1) 
122.6 
(31.3) 
123.9 
(28.5) 
F(1, 26) 
0.42 
0.52 
F-ratio and p-values for the interaction between obese (HO/OC) vs. non-obese 
(HWS/NOC) and patients (HO/HWS) vs. controls (NOC/OC) on two-way ANOVA. 
a
AUC insulin data required transformation (using the inverse of the square root) to 
equalise the variances. Statistical comparison was performed using these transformed 
values. 
 
 
 There were no significant differences in fasting hormone concentrations 
between obese (HO/OC) vs. non-obese (HWS/NOC) or patients (HO/HWS) vs. 
controls (NOC/OC), or the interaction between these factors on two-way ANOVA 
(results of interaction in Table 5.6), except for transformed fasting ghrelin where 
there was significantly higher fasting ghrelin in controls (NOC/OC; mean 81.4, SD 
111.2) than in patients(HO/HWS; mean 9.9, SD 14.7) (F[1,31]= 9.48, p=0.004), but no 
significant difference between obese (HO/OC) vs. non-obese (HWS/NOC) (F[1,31]= 
0.57, p=0.46) or the interaction between these factors (Table 5.6). 
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Table 5.6. Mean (SD) or median [IQR] fasting hormone concentrations in each 
participant group 
 HO HWS OC NOC F(1,32) p-
value 
Insulin (mIU/mL) 15.7 
(20.1) 
6.9 (3.3)
 
10.6 
(4.4)
 
12.5 
(4.2)
 
1.15 0.29 
Median glucose 
(mmol/L) 
6.9 [2.7] 7.2 
[10.0] 
6.1 [2.0] 7.7 [3.1] 1.34
a 
0.26
a 
GLP-1 (pmol/L) 1.7 (2.2) 1.9 (0.8) 3.2 (3.5) 3.3 (3.2) 0.003 0.96 
Median active ghrelin 
(pg/mL) 
8.13 
[14.6] 
0.50 
[18.5] 
16.3 
[61.0] 
82.1 
[153.9] 
F(1,31) 
1.36
b 
 
0.25
b 
Median PYY (3-36) 
(ng/mL) 
0.65 
[0.17] 
1.03 
[0.72] 
0.72 
[0.55] 
0.67 
[0.43] 
1.14
c 
0.29
c 
F-ratio and p-values for the interaction between obese (HO/OC) vs. non-obese 
(HWS/NOC) and patients (HO/HWS) vs. controls (NOC/OC) on two-way ANOVA. 
a
Fasting glucose, 
b
active ghrelin and 
c
PYY(3-36) required transformation to equalise 
the variances using the inverse function, the square root and the natural logarithm, 
respectively. Statistical comparisons (two-way ANOVA) were then performed using 
this transformed data. 
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Figure 5.6. Boxplots showing median (thick central line), IQR (upper and lower box 
edges) and minimum/maximum (lowest/uppermost horizontal lines, with extreme 
outliers depicted as stars/circles), for A. Glucose, B Transformed insulin, C. Active 
GLP-1, D. Active ghrelin and E. PYY(3-36) AUC concentrations  in each of the four 
subject groups 
A. 
 
 
B. 
 
 
HO4 
HO4 
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E. 
 
 
Between-group comparison of hormones: obese vs. non-obese 
The effect obese (HO/OC) vs. non-obese (HWS/NOC) was statistically 
significant in the linear mixed-effects models where PYY(3-36) was the outcome 
variable (F(1,27)=8.99, p=0.006); obese participants (HO/OC) had lower PYY(3-36) 
than non-obese (HWS/NOC) (coefficient -0.24, SE 0.1, 95% CI: -0.4 to -0.1). There 
was no group effect significantly associated with levels of active GLP-1, active 
ghrelin or insulin (p>0.05).  
Between-group comparison of hormones: patient/control 
 The linear mixed-effects models showed a significant effect for control vs. 
patient group where glucose (F[1,27]=5.25, p<0.03) and active ghrelin (F[1,34]=5.65, 
p<0.03) were the outcome variables. Patients (HO/HWS) had higher glucose than 
controls (OC/NOC) (coefficient -1.06, SE 0.5, 95% CI: -2.0 to -0.1). There was no 
group effect significantly associated with concentrations of PYY(3-36), active GLP-
1 or insulin (p>0.05). 
 
VAS appetite ratings 
 The results of the mean (SD) VAS scores for each question regarding appetite 
at all three timepoints are given, according to participant group (Table 5.7). For 
HO13 
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hunger at three hours the median [IQR] of the data is given, but the statistical 
comparison was undertaken on transformed data (square of the original data). 
There were no significant differences in any of the VAS ratings between the 
groups in the comparisons between obese (HO/OC) and non-obese (HWS/NOC) 
participants, participants with hypothalamic damage (HO/HWS) and controls 
(OC/NOC) or the interaction between obese (HO/OC) vs. non-obese (HWS/NOC) 
and patients (HO/HWS) vs. controls (NOC/OC) using two-way ANOVA. 
 
Table 5.7. Mean (SD) VAS scores across the four groups (score out of 100) 
 HO HWS OC NOC F(1,32) p-value 
Hunger 
(fasted) 
56.0 
(24.0) 
70.0 
(16.0) 
57.2 
(30.5) 
67.5 
(23.9) 
0.18 0.9 
Hunger  
(1hPB) 
29.1 
(15.8) 
30.2 
(20.6) 
28.6 
(21.6) 
38.7 
(21.8) 
0.42 0.52 
Median [IQR] 
hunger (3hPB) 
60.0 
[49.5] 
71.0 
[17.0] 
70.0 
[47.8] 
67.5 
[24.3] 
0.001
a 
0.98
a 
Fullness 
(fasted) 
23.4 
(28.4) 
19.2 
(14.9) 
11.3 
(13.2) 
21.3 
(13.3) 
1.84 0.18 
Fullness 
(1hPB) 
55.3 
(21.4) 
57.3 
(23.1) 
58.5 
(26.1) 
58.8 
(25.8) 
0.01 0.92 
Fullness 
(3hPB) 
36.6 
(28.6) 
26.2 
(28.0) 
31.8 
(22.6) 
28.0 
(18.2) 
0.26 0.61 
Desire to eat 
(fasted) 
57.4 
(20.9) 
71.3 
(19.3) 
60.1 
(31.8) 
70.0 
(19.4) 
0.12 0.92 
Desire to eat 
(1hPB) 
31.8 
(13.7) 
39.3 
(20.2) 
28.8 
(21.6) 
48.3 
(23.3) 
0.73 0.40 
Desire to eat 
(3hPB) 
46.9 
(26.3) 
40.5 
(32.1) 
53.2 
(21.7) 
67.4 
(16.0) 
1.14 0.29 
hPB = hours post-breakfast. F-ratio and p-values for the interaction between obese 
(HO/OC) vs. non-obese (HWS/NOC) and patients (HO/HWS) vs. controls (NOC/OC) 
on two-way ANOVA. 
a
For the VAS ratings of hunger at three hours data required 
transformation (square of the data) to equalise the variances. Statistical comparison 
(two-way ANOVA) was then performed using these transformed values. 
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Discussion 
Of the six regions with significantly greater BOLD signal when viewing food 
(vs. object) photographs, two (insula and anterior cingulate cortex [ACC]) were first 
identified in Tataranni’s seminal PET study of human hunger and satiety [149], as 
well as in multiple further studies since [147, 161, 164, 166, 167, 170, 178, 180, 181, 
190, 291-293]. The middle temporal gyrus (BA 21) [181, 294] and lingual gyrus of 
the occipital lobe (BA 18) [181] have also been identified as important in obesity-
related neuroimaging studies. The multiple regions identified reflect the numerous 
aspects of eating-related cerebral processes and each region has discrete roles 
relating to appetite and eating; some determine the incentive/reward value of food 
(e.g. OFC [164, 167]), some are linked to meal termination (PFC [149, 161]) and 
satiation [149] and some with liking [161]. These regions have been shown to be 
differentially activated in obese and lean individuals [168, 169]. 
In the fMRI study presented in this thesis, in patients with hypothalamic 
damage remaining weight-stable (HWS) viewing high-calorie food photographs 
resulted in significantly lower BOLD signal in cerebral regions which process 
interoceptive inputs and promote food ingestion (i.e. posterior insula) [161, 164, 295, 
296] or are responsive to food-related reward (i.e. lingual gyrus) [168, 177] 
compared to all other groups (HO, OC, NOC). This reduced activation may result in 
lower hunger and desire to eat, leading to reduced food intake compared to patients 
who gain significant weight (HO), despite significant damage to the homeostatic, 
energy-regulating hypothalamus in both groups. These findings may suggest the 
possibility of greater preservation of functional and anatomical connectivity between 
areas processing food-related reward/stimulating ingestion and extra-hypothalamic 
homeostatic areas (such as the midbrain VTA and NA) in HWS compared to HO, 
allowing continued coordinated response between homeostatic and reward-related 
networks regulating appetite/eating and energy balance. 
 
Lingual gyrus (BA18) 
There was significantly greater BOLD signal of the lingual gyrus (BA18) in 
response to high-calorie food photographs in all groups compared to HWS and 
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significantly greater BOLD signal when fasted than fed in all four groups. The 
lingual gyrus, part of the occipital lobe located immediately behind the 
parahippocampal gyrus, processes food reward [168, 177]. PET imaging has 
demonstrated that obese males (BMI ≥35 kg/m2) have a greater decrease in lingual 
gyrus activation than lean males (BMI ≤25 kg/m2) following satiation [168]. An 
fMRI study also found increased activation in the left lingual gyrus (and insula) in 
obese compared to lean individuals when viewing high-calorie foods, consistent with 
the two main areas of difference found in our study [177]. 
An fMRI study found that mood affected food-related lingual activity in lean 
females (BMI 22.1 +/- 2.4 kg/m
2
) [297]. When viewing high-calorie food pictures, 
right lingual gyrus activation was correlated with positive affect (mood), on the 
Positive and Negative Affect Schedule. The lingual gyrus therefore seems to be 
activated in response to rewarding stimuli, with mood possibly influencing the 
salience of food cues. The authors note the link between visual cortex activation and 
other types of reward (such as financial reward in gamblers) described in other 
studies [244]. No assessment of mood was included in our study. 
 
Insula cortex 
The role of the human insula is not as well described as other brain regions, 
mainly due to its anatomical inaccessibility and more limited functional data 
compared to other brain regions [296], however it has been found to be involved in 
processing multiple different stimuli and regulating attention and emotion [163]. It 
can be divided into anterior and posterior sections based on macroscopic appearance 
(divided by the central sulcus), or three sections based on cytoarchitecture (anterior 
agranular cortex, intermediate dysgranular cortex and posterior granular cortex). 
Functional connectivity analysis has differentiated between anterior and posterior 
insular networks, which connect to the ACC and posterior cingulate cortex, 
respectively [163]. The posterior insula receives afferents from the amygdala, dorsal 
thalamus and sensory cortices, whereas the ventral/anterior insula mostly receives 
afferents from the limbic system, such as the posterior OFC and cingulate gyrus 
[296]. The mid-dorsal insula also receives input from the thalamus [298] 
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The posterior and middle insula, where significantly lower BOLD signal was 
observed in HWS compared to HO participants, has been identified as an important 
region in appetite and feeding, although much of the published functional 
neuroimaging literature lacks differentiation between the regions of the insula. 
Where differentiation between the different areas has been made there has been 
debate as to the location of the primary gustatory cortex; whereas the anterior insula 
has typically been described as the location for this in non-human primates [296, 
299] Small argues that there is considerable evidence that the posterior insula may be 
the location in humans, with the possibility of multiple insula regions being involved 
[299]. An early review of 
15
O-PET studies described activation peaks scattered 
throughout the insula, including several in the posterior insula, in regions previously 
identified as related to gustation in animal studies [295]. Subsequent studies have 
also found evidence of posterior insula involvement in appetite, although the 
methods involved in each were significantly different. In nine participants 
15
O-water 
PET scanning showed significant decreases in bilateral posterior insula activation 
(and other brain regions) as chocolate was eaten to excess by chocolate lovers, with 
decreases in activation correlated with decreasing chocolate ratings [161]. In a study 
of cocaine users, food cues resulted in greater activation in the posterior insula than 
neutral cues (whilst cocaine cues resulted in lower activation compared to neutral 
cues) [300]. An electro-cortical stimulation study of five females with intractable 
epilepsy also indicated that the posterior insula is related to taste, as stimulation of 
both central and posterior insular electrodes resulted in gustatory (and other sensory) 
phenomena [296]. Differences between studies may be influenced by their differing 
study paradigms, as shown in a study of adolescents (mean age 15.2±0.8 years, mean 
BMI 22.8±4.4 kg/m
2
) who underwent fMRI following a four hour fast. The authors 
found that whilst a taste of Coke resulted in greater activation in the midbrain 
extending into the insula than a tasteless solution, pictures of Coke products caused 
increased activation in the left putamen extending into the posterior insula (compared 
to non-food adverts) and viewing Coke adverts (which included the logo but not 
necessarily the Coke product) led to greater bilateral lingual gyrus activation 
(amongst other areas) compared to non-food adverts [301]. 
Differences in activation have also been shown to alter with BMI. A PET 
study using 
15
O-water found that 21 obese participants had greater increases in mid-
dorsal insula activation compared to 20 lean participants after a 2ml taste of a liquid 
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meal given following a 36 hour fast, with percentage body fat, disinhibition 
(measured on TFEQ) and plasma glucose concentration positively correlated with 
middle-dorsal insula activation on multivariate regression [164]. An fMRI study of 
gastric distension using a balloon inserted into the stomach and filled with water 
found that increased BMI was positively linearly associated with increased left 
posterior insula activation and was significantly higher in five obese compared to 11 
lean participants [302].  
One study did report conflicting findings, with greater activation of the 
posterior insula in five lean (mean BMI 22.0±2.9 kg/m
2
) compared to five obese 
women (mean BMI 41.6±5.0 kg/m
2
) on fMRI scanning whilst smelling food 
compared to non-food odours [303]. This study however was small, with the scans of 
3/5 obese women not fully completed (two were not able to tolerate the complete 
protocol and one had excessive head movement) and the statistical threshold for 
comparison between the groups was p<0.001 uncorrected with an extent threshold of 
k=5. 
 
The BOLD signal cluster identified in the posterior insula in the study 
reported in this thesis showed a spatial maximum in the posterior insula, but also 
spread to the middle insular cortex. Based on results from an fMRI study of nine 
healthy participants given solutions that were either pleasant or unpleasant and varied 
in intensity, Small et al proposed that the middle insula relates to taste intensity, with 
the dorsal insula representing affect [304]. The viscosity of food has also been linked 
to the mid-insula, where oral somatosensory stimuli are processed [305]. 
A meta-analysis of 13 functional neuroimaging experiments involving 
activation to tastants compared to a tasteless baseline found bilateral activation of 
both the anterior dorsal and dorsal mid- insula [298]. Another study of 23 obese 
individuals, 11 previously obese participants who had lost weight and 21 lean 
participants found increased activation in the middle insula of obese and previously 
obese participants, with no change in the lean participants on 
15
O-water labelled PET 
scanning undertaken after 2ml of liquid food was given following a 36 hour fast 
[166]. The authors hypothesize that this persistence of “abnormal responses” in the 
insula and hippocampus (linked to memory processing, spatial learning and 
enteroception) in post-obese individuals and may indicate the pathophysiology of 
obesity/weight gain. However, since the individuals were not studied prior to 
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becoming obese, it is possible that the insula changes could be secondary to the 
weight gain. The authors postulate that increased middle insula activation in obese 
and post-obese individuals reflects an increased desire for the coming meal (as is 
described with other cravings, for example drug use), with either a greater craving of 
the anticipated satiating meal to follow, or greater anticipation of the reward of that 
meal in obese individuals [166]. 
 
Although the study described in this thesis is unique in that the patient groups 
have lost the influence of the main homeostatic control centre (the hypothalamus), 
the finding of significantly greater posterior and middle insula BOLD signal in obese 
(HO) compared to non-obese (HWS) adults with hypothalamic damage is in keeping 
with these previous findings described. These studies support the finding of lower 
insula activation in HWS vs. HO and may indicate a mechanism protecting against 
HO.  
One hypothesis is that in HWS patients the insula connections with other 
feeding-related brain areas (particularly extra-hypothalamic homeostatic 
neurocircuitry like the VTA or NA) may be better preserved despite hypothalamic 
damage, explaining the pattern of reduced insula activation with high-calorie food 
stimuli, although there is no evidence from the work undertaken to corroborate this 
theory.  
The only other study similar to that described in this thesis is a small study of 
4 children with craniopharyngioma (CP) and hypothalamic damage (2 obese, 2 
weight-stable; all at least one year post-surgery/radiotherapy) and 4 controls [306]. 
The 13-17 year olds were asked to fast overnight and then underwent an fMRI scan 
three hours after consumption of a standardised breakfast (totalling 10% of their 
estimated total daily calorie requirement), following which they consumed a 
milkshake totalling 20% of their estimated daily calorie requirement with a second 
fMRI scan 30 minutes afterwards. During the fMRI paradigm the participants viewed 
a total of three blocks of “fattening” (high-calorie), three blocks of “non-fattening” 
(low-calorie) and seven blocks of non-food photographs, with 10 photographs per 
block and each photograph shown for 2.4 seconds. The photographs were viewed in 
a mirror whilst lying in the 3T fMRI scanner. Food and non-food photograph blocks 
alternated and participants were told they would be tested on the photographs later. 
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In five a priori ROIs (bilateral insula, bilateral NA and medial OFC), those with CP 
had a tendency towards lower activation compared to controls before a test meal, but 
had a trend towards higher activation following the meal, compared to a reduction in 
activation seen in controls. While this trend was seen in all five ROIs, only the 
medial OFC showed a statistically significant difference in BOLD signal between CP 
patients and controls, with no differences between the patients of different weight 
groups (weight-stable or obese), possibly due to the small size of the study. 
 
Hormonal/biochemical findings 
There was significantly lower AUC active ghrelin and transformed fasting 
active ghrelin in patients (HO/HWS) compared to controls, but no difference 
between obese (HO/OC) and non-obese (HWS/NOC) participants. Previous studies 
have found mixed results [2, 3, 39, 47], although three of the studies found evidence 
of lower fasting total ghrelin in participants with HO/craniopharyngioma compared 
to those with SO/BMI-matched controls [2-4]. Whilst there was no difference 
between obese and non-obese groups (which would be expected as ghrelin is known 
to be lower in obesity [36]) it is important to note that whilst the mean BMI was 
lower in the non-obese (26.1 kg/m
2
 and 27kg/m
2
) than in the obese groups (38.0 
kg/m
2
 and 37.7 kg/m
2
) studied many of those in the non-obese groups fell into the 
“overfat” and “obese” percentage body fat ranges on Tanita assessment (1 overfat 
and 8 obese in the NOC group and 2 each in the HWS group), reflective of these 
groups not being “lean” participants. 
PYY, which may influence postprandial satiety, has been shown to be similar 
when fasting in HO and obese controls, without an immediate or sustained post-
prandial rise [2]. PYY concentrations have been lower in obese than lean individuals 
in previous studies [307, 308], however no difference was found here. Differences in 
experimental design and macronutrient and energy content of the breakfast meal 
(based on each individual’s calculated BMR) may account for this disparity.  
 Leptin reduces the perception of food reward and increases the response to 
satiety signals [194, 309]. Leptin supplementation in leptin-deficient and 10% 
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weight-reduced obese participants reduces insula activation [150]. Although leptin 
concentrations were not analysed on the fMRI study day, fasting leptin 
concentrations have been found to be similar between HO and OC in a previous 
study [2] and on the UEM study day (Chapter6) while there was significantly higher 
leptin concentrations in obese compared to non-obese participants, there was no 
difference between patients and controls, or in the interaction between these 
parameters.  
 
Strengths and limitations of the study 
This study has its limitations: 
- The small size of this study was a significant limitation. This was due in part to the 
rarity of this condition and particularly the difficulty in finding HWS participants. 
Whilst there were some interesting findings, further larger studies may give greater 
clarification and would allow correlation with other clinical and biochemical 
findings. 
- Although the original intention had been to consider fMRI findings alongside 
biochemical/hormonal differences, statistical advice was that in order for regression 
analysis to be robust a minimum of 10 participants per group was required for each 
co-variate in the model [310, 311] and therefore the groups were not appropriately 
powered for this statistical analysis. 
- It was not possible to personalise the food photographs to an individual’s food 
preferences (likes/dislikes), therefore the foods shown may have had a different 
valence for each participant. The foods shown however, were chosen as they were 
the highest rated in each category (high- or low-calorie foods) for valence and had 
the greatest agreement on calorie category.  
 
- Amongst participants there was likely to have been differing knowledge of the 
calorie-content of some of the foods. The photographs were shown in blocks of four, 
grouped according to calorie-content to try and prevent this causing a significant 
difference. 
- It was not possible to control for handedness, gender, or timing of menstruation 
(females) due to the complex nature of the study group. Previous studies have 
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identified gender differences in various states: insula response to satiation [147, 292], 
increased anterior insula activation after eating chocolate to satiety in males but not 
females [147]; caffeine, sodium chloride, citric acid and sucrose causing greater 
change in insula activation in males than in females from hungry to satiated states 
[292]. As hypothalamic damage/HO is relatively rare it was not possible to study 
only a single gender; the mixed gender groups may therefore contribute to a lack of 
stronger pre- and post-prandial differences in our study. 
 
- Weight-stable patients (HWS) were not lean (BMI < 25 kg/m
2
), therefore the BMI-
matched control group were also non-obese but not lean; many were overweight (and 
were classed as overweight or obese on the Tanita percentage body fat assessment) 
and this may account for the greater insula BOLD signal found in NOC.  
 
- As with all fMRI studies, artefacts can cause lack of homogeneity in image quality 
in some cerebral regions [170]. The lack of a statistically significant difference 
between groups in hypothalamic BOLD signal does not exclude differences due to 
the spatial and contrast resolution required to detect changes in the hypothalamus 
[150].  
 
- A stringent statistical threshold was used for analysis which may have reduced the 
quantity of ROIs, however this adds weight to the positive findings. 
 
- Ideally the patient group would have been homogenous, with one underlying 
histological diagnosis causing hypothalamic damage. As noted, it is a relatively rare 
condition and therefore it was accepted at the outset that studying a more 
heterogeneous group would be necessary. 
 
The strengths of this study are: 
- A standardised, reasonably physiological overnight fasting period. 
- All photographs (food and non-food) were taken on a standardised photographic 
background, producing images of similar size and visual interest (shape, colour) 
without distracting features as used in some other studies (e.g. chequered table cloth) 
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in order to minimise other factors which may have accounted for differences found in 
other studies, or additional areas of activation. 
- Food photographs had comparable hedonic values, as rated by a normal population 
(unreported) with good visual variability in both low-calorie and high-calorie 
photographs and without repetition of photographs within a single scan session. 
- The use of strict statistical thresholds. 
- Use of fMRI gives better spatial and temporal resolution than PET [170, 291] and 
does not entail the toxicity of radionuclide injection. 
 
Possible future analyses on existing data 
Further analyses could be performed using the data generated from this fMRI 
study, including analysis of between-group differences in BOLD signal when 
viewing low-calorie/any food pictures compared with non-food pictures. Subcortical 
a priori ROIs such as the amygdala and nucleus accumbens (NA) could also be 
studied. These ROIs were too small to survive the threshold of k3,000 voxels used 
as a cut-off for analysis, but have been identified in numerous studies as differing 
between lean and obese participants [150, 152-155, 158]. In addition, a small fMRI 
study demonstrated lower activation of the NA pre-prandially and a trend towards 
higher activation post-prandially in five participants with craniopharyngioma 
compared to controls [306].  
 
Conclusions 
 This is the first evidence of food motivation-related differential BOLD signal 
in adults with hypothalamic damage who remained weight-stable compared to those 
who developed HO. The hypothesis of greater activation in reward-related cerebral 
regions in those with HO compared to those with HWS was supported in two areas - 
lingual gyrus and posterior insula. It is clear that these regions, both influenced by 
food-reward, are an integral part of the brain network which processes food stimuli 
and are differentially activated in those remaining weight-stable. Comparatively 
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lower posterior insula and lingual gyrus activation in HWS may protect these 
individuals from the weight-gain seen in those who become HO. What leads to the 
differences in insula and lingual gyrus activation unfortunately cannot be elucidated 
from this study. Unravelling the underlying neurochemical/neuroendocrine 
mechanisms involved may provide vital clues in understanding the pathophysiology 
of weight-gain in both patients with HO and obesity in the general population. 
Further research into the underlying pathophysiology of weight-gain in this 
interesting group of patients should be encouraged, potentially in a large multi-centre 
trial.  
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Chapter 6 
 
Microstructure and macrostructure of eating behaviour in 
adult patients with acquired, structural hypothalamic 
damage: a laboratory study of eating rate, total intake and 
within meal appetite ratings and a real-world assessment of 
eating behaviour and food intake  
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Abstract 
 
Objective: Part 1: To examine the microstructure of eating behaviour in adults with 
hypothalamic obesity (HO) secondary to acquired, structural hypothalamic damage, 
compared to adults with hypothalamic damage remaining weight-stable (HWS) and 
age and BMI-matched obese and lean controls without hypothalamic damage (OC 
and NOC, respectively) using the Universal Eating Monitor (UEM) to explore any 
differences in eating behaviour within a single meal. Part 2: To assess the influence 
of day-to-day and longer-term eating behaviours in HO compared to HWS, OC and 
NOC. 
 
 
Study design: Part 1: Cross-sectional study of 6 patients with HO, 6 HWS, 9 OC and 
10 NOC. Participants consumed an unlimited pasta lunch at the UEM. Total intake, 
eating duration and visual analogue scale (VAS) ratings of self-reported hunger, 
fullness and food pleasantness were recorded. Eating rate and changes in eating rate 
were calculated. Appetite-associated hormones (glucose, insulin and leptin) were 
measured before lunch and glucose and insulin were measured post-prandially. Part 
2: Three Factor Eating Questionnaires (TFEQs) and three-day MRC-Human 
Nutrition Research diaries were given to all participants at their screening visit and 
returned subsequently. Participants were asked to self-complete a full record of their 
food and drink consumption over three standard days, including at least one weekend 
day. 
 
Results: Part 1: There was significantly higher total intake (F[1,27]=7.74, p=0.01), 
calorie intake per kg of FFM (F[1,26]=23.3, p<0.001) and amount of calories 
consumed as a percentage of estimated BMR (F[1,27]=18.2, p<0.001) by controls 
(OC/NOC) than those with hypothalamic damage (HO/HWS), but no significant 
difference between obese (HO/OC) and non-obese (HWS/NOC) participants or 
interaction between these factors. Eating duration was also significantly longer in 
controls than in participants with hypothalamic damage (F[1,27]=6.43, p=0.02). There 
were no significant differences in overall eating rate between the groups on two-way 
ANOVA or on repeated-measures ANOVA however visual ascription showed a 
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tendency towards an initial higher eating rate in HO, followed by a reduction and 
later acceleration in rate.  
There was significantly lower hunger at the start of the meal in participants with 
hypothalamic damage compared to controls (F[1,27]=4.55, p=0.04), but no significant 
differences in fullness (F[1,27]=3.43, p=0.08) or pleasantness (F[1,27]=1.87, p=0.18) at 
baseline. There was no significant difference in baseline hunger, fullness or 
pleasantness after a taste of the pasta meal between obese and non-obese participants 
or in the interaction between obese vs. non-obese and patients vs. controls in any of 
the outcomes. Repeated-measures ANOVA showed no evidence of significant 
interaction between participant group and time or group effect on hunger, fullness or 
pleasantness of the pasta meal, however the outcome means changed over the 
quartiles of the meal for all three parameters, as would be expected. Pre-lunch leptin 
concentrations were significantly higher in obese compared to non-obese participants 
(F[1,27]=7.78, p=0.01), but there was no significant difference between participants 
with hypothalamic damage and controls or in the interaction between obese vs. non-
obese and patients vs. controls. There was no significant difference in pre-lunch 
glucose or pre-lunch insulin in any of the between-group comparisons undertaken.  
There was no significant difference in AUC glucose between obese and non-obese 
participants or between participants with hypothalamic damage and controls, 
however there was a significant difference in the interaction between obese vs. non-
obese participants and patients vs. controls in AUC glucose (F[1,26]=8.14, p=0.008).  
There was significantly higher AUC insulin in obese compared to non-obese 
participants (F[1,26]=11.87, p=0.002), but no significant difference between 
participants with hypothalamic damage and controls or in the interaction between 
obese vs. non-obese and patients vs. controls. Part 2: Thirty-four participants 
returned the TFEQ (8 HO, 6 HWS, 9 OC, 11 NOC). Kruskal-Wallis testing showed a 
significant difference between the groups in age and BMI. Box-plots indicated that 
participants remaining HWS had a higher median age than the other participant 
groups (HO, OC and NOC) and that obese (HO/OC) participants had a greater mean 
BMI than non-obese (HWS/NOC). Disinhibition also differed significantly between 
the groups on Kruskal-Wallis testing and boxplots demonstrated the median to be 
highest in OC. There were no significant differences between the groups in hunger or 
restraint. There was no correlation between BMI and restraint, disinhibition or 
hunger across all of the participants on Spearman’s rho. 
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Thirty-two participants had a three-day food diary analysed (6 HO, 7 HWS, 8 OC, 11 
NOC). There were no significant differences between the groups in age, BMR or fat-
free mass (FFM) but Kruskal-Wallis testing showed a significant difference in BMI 
and percentage body fat between the groups. Boxplots indicated that obese 
participants had a greater median BMI and percentage body fat than non-obese. 
There were no differences between the groups in the number of reported eating 
episodes, total calories reportedly eaten (including when adjusted for FFM and as a 
percentage of BMR) or the amount of fat, protein, carbohydrate or sugar consumed. 
 
Conclusions: The UEM failed to show any significant difference in the 
microstructure of eating behaviour in HO compared to HWS,  although the patient 
groups consumed significantly less food at the UEM than controls. Visual ascription 
showed a tendency towards an unusual eating pattern in HO which warrants further 
investigation, but the small numbers studied must be noted and may account for this 
finding. The lack of increased hunger and total food intake in HO suggests that 
within-meal hyperphagia is not a key pathophysiological component of weight-gain 
in HO, however numbers studied were small. The trend towards lower hunger in 
patients at the start of the meal may account for their lower intake compared to 
controls, but does not help to explain the difference in BMI between those with 
hypothalamic damage who remain weight-stable and those who become obese (HO). 
In relation to longer-term eating behaviour there was no significant increase 
in disinhibition reported by those with HO compared to those remaining HWS. 
Increased median disinhibition seen in OC is in keeping with other literature where 
this has been associated with over-eating and increased body mass index (BMI). The 
lack of greater disinhibition in HO compared to HWS may simply reflect the small 
size of the groups studied or perhaps reflects a regulatory disturbance in appetite 
accounting for the weight-gain/obesity in HO rather than an external drive to over-
eat. Greater disinhibition leading to increased food intake was not reflected in the 
returned food diaries (or at the UEM), however under-reporting in food diaries is a 
well described phenomenon and the numbers studied were again small. The lack of 
difference in reported food intake in food diaries may reflect the inconsistencies 
inherent in this method. 
 
 
182 
 
Summary of Justification and Aims 
Identification of abnormal eating behaviour in patients with hypothalamic 
obesity (HO) may help elucidate underlying pathophysiological mechanisms, 
particularly as some studies report hyperphagia [11, 23, 32, 40, 41] Eating behaviour 
can be considered in terms of microstructure (single-meal intake and immediate 
preceding/following-effects) and macrostructure (longer-term eating patterns). Either 
or both of these could be altered in HO. 
 
By studying the microstructure of eating behaviour, aspects such as eating 
rate and changes in eating rate can be evaluated, in addition to intra-meal subjective 
appetitive feelings [202, 203]. Previous studies have demonstrated differences in 
eating patterns between groups with different characteristics (lean, obese), under 
different conditions (pre-loads, interruptions in eating) and with underlying 
pathology (Prader-Willi syndrome, bulimia). One method used to assess the 
microstructure of eating is the Universal Eating Monitor (UEM). This uses a hidden 
scale connected to a computer which frequently records food intake (every few 
seconds), allowing not only the total eating duration and amount consumed to be 
recorded, but also measures overall eating rate, initial eating rate and any changes in 
eating rate and allows cumulative intake curves to be calculated. The UEM has been 
developed over the past 35 years and can assess intake of a semi-solid food, such as 
chocolate pudding or pasta. The computer can also interrupt and prompt participants 
to complete on-screen ratings of hunger, satiety and food pleasantness using VAS 
scales, without involving the researcher [219]. Intake at the UEM has been shown to 
correlate well with real-world intake [220], and intake amount, meal duration and 
initial eating rate are consistent and reliable within each individual participant after a 
period of familiarisation with the equipment, whilst demonstrating variability 
between individuals [204, 205, 218, 220-222]. UEMs are therefore a reliable and 
reproducible research tool for studying the microstructure of eating behaviour. 
Additionally they have previously been used in participants with atypical eating 
behaviour due to underlying medical diagnoses such as Prader-Willi Syndrome 
(PWS) [216], bulimia nervosa [207, 227, 228] and binge-eating disorder [218]. 
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To assess the macrostructure of eating behaviour food diaries are the most 
commonly used tool to assess daily intake in a real-world environment [238]. These 
have the advantage of not relying on memory (as needed in food recall assessments) 
[239] and three-day diaries have been shown to contain fewer errors (including 
missed or erroneously added foods) than 5-day diaries or 24 hour recalls [240, 241], 
although errors still occur [239, 240].  
 
More persistent traits such as eating restraint, self-control and 
internal/external factors affecting hunger can be measured using the Three Factor 
Eating Questionnaire (TFEQ) [191]. These long-standing behaviours influence food 
choices over the longer-term and can influence cognitive choices and can surpass 
physiological hunger and satiety cues. Dietary restraint describes the amount of 
behavioural control someone has over their eating behaviour; disinhibition describes 
the probability of eating under certain conditions, for example when served palatable 
food; hunger demonstrates the sensitivity of individuals to feelings of hunger and 
their inclination to eat. High disinhibition scores in particular have been consistently 
associated with increased BMI and energy intake [201].The TFEQ has been used in 
large cohorts, particularly in obesity studies, and has high internal and test-retest 
reliability in both laboratory and non-laboratory settings [191, 201].  
 
Aims: The aims of this study were to assess the eating behaviour of patients with 
hypothalamic damage and to evaluate whether they differed between those who were 
HO and those remaining HWS; additionally to compare eating behaviour between 
participants with hypothalamic damage to obese and non-obese controls. The 
objective was to assess both the microstructure and macrostructure of eating 
behaviour to assess what contribution each might play to the development of HO or 
the ability to remain HWS. 
 
Hypothesis: Participants with HO would consume greater amounts (demonstrated in 
both the UEM experiment and in the three-day food diaries) than all other groups, 
especially those remaining HWS and have increased levels of disinhibition and 
hunger, and lower restraint than the other groups on TFEQ. 
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Participants and Methods 
Participants 
As described in detail in Chapter 2, patients were recruited through clinics at the 
Walton Centre for Neurology and Neurosurgery or University Hospital Aintree and 
controls through general advertisement within the University of Liverpool and from 
previous obesity studies. 
 
Part 1: Assessment of the microstructure of eating behaviour with 
the Universal Eating Monitor (UEM) 
 
Study design and methods 
 The microstructure of eating behaviour was assessed using the Universal Eating 
Monitor (UEM). This equipment consists of a hidden digital balance (Sartorius 
Model BP 8100, Sartorius Ltd., Epsom, UK; 0.1g accuracy) positioned underneath a 
thin, circular, plastic placemat 37cm in diameter, which conceals the upper surface of 
the scales from view. The balance underneath protrudes slightly above the surface of 
the table allowing accurate measurement of the bowl placed on top  and measures 
weight change during consumption of a test-meal. Total amount eaten and eating rate 
are monitored without participants’  awareness. The balance is connected to an Apple 
Macintosh computer (model 4G) with custom-programmed UEM software which 
records the weight output from the scales, producing raw data of cumulative intake 
and also interrupts the participant in real-time after a pre-set amount of food has been 
consumed [207]. The UEM software used was the Sussex Ingestion Pattern Monitor 
(SIPM), under license from its owner (University of Sussex). At each interruption 
(every 100g in this study) the participant completes on-screen VAS ratings of 
hunger, fullness and pleasantness of food to provide measurement of within-meal 
satiety ratings.  
 
All UEM data were collected at the Clinical Sciences Centre, UHA. The first 
session was undertaken during the screening visit to allow familiarisation of 
participants with the UEM equipment and to ascertain that they would be able to 
consume the fixed-load porridge and orange juice breakfast-meal during subsequent 
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fMRI and UEM study days. A further breakfast meal of porridge was consumed at 
the UEM at the third visit to remind participants how to use the equipment, as it is 
important participants do not move the bowl or rest their spoon on it in-between 
mouthfuls to ensure accurate weight-measurement by the hidden scales. The data 
from these breakfast-meal sessions were collected but not used in the final analysis. 
 
On the UEM study day participants attended the investigational unit in the 
Clinical Sciences Centre at around 09:00, having fasted from 22:00 the previous 
evening (Appendix 4). They were asked to refrain from smoking, alcohol and 
strenuous exercise in the 24 hours preceding the study day. They consumed an 
identical fixed-load breakfast to that eaten on the screening visit and fMRI study day 
(porridge and orange juice accounting for 25% of their calculated basal metabolic 
rate [BMR] see Chapter 2 for details). After three hours participants had blood 
samples taken (pre-lunch) and were then presented with a standardised lunch meal of 
pasta in a tomato-sauce (each 100g providing: energy 117kcal; fat 1.0g; protein 3.8g; 
carbohydrate 22.7g) which they were instructed to eat until they felt full. The UEM 
software interrupted them to complete on-screen VAS ratings of hunger, fullness and 
pleasantness after a taste of food and then every 100 grams of food that was 
consumed. At these interruptions the bowl was refilled with pasta if needed to allow 
participants to continue an otherwise uninterrupted consumption of the test-meal. 
After completing the test-meal further blood samples were continued hourly for a 
further three hours.  
 
Measurements during UEM study day  
Anthropometry: this is fully described in Chapter 2. The measured percentage body fat 
and bodyweight were used to calculate fat-free mass (FFM). 
 
UEM: See Appendix 4 for flow-diagram of the study day. As noted, food intake at 
the UEM was measured from first bite to last and eating duration was also recorded. 
 
VAS ratings: Three appetite-related questions were asked during the meal eaten at 
the UEM using a 0-500mm on-screen VAS scale. Participants were asked to use the 
mouse attached to the computer where they ate and drag a cursor to a place on the VAS 
scale which best corresponded with how hungry and full they felt and how pleasant the 
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food tasted. The scale was anchored by “Not at all” and “Extremely” at either end. 
This allowed participants’ subjective sensations to be quantified numerically by 
computer calculation and analysed. The VAS ratings were measured on a 0-500 scale 
as this is the only scale available on the software. Assessments were made during both 
the breakfast and lunch meal eaten at the UEM, however only the data from the lunch 
meal was analysed. The ratings were only completed during the breakfast meal to allow 
participants to re-familiarise themselves with the UEM and the on-screen VAS ratings 
and there was never any intention to analyse this data. 
 
Blood sampling and biochemical assays: Blood samples were taken for glucose, 
insulin and leptin measurement before the lunch meal. Further bloods were taken for 
glucose and insulin following the meal (see Appendix 4) and area under the curve 
was calculated. Details of the blood bottles used and biochemical assays undertaken 
are fully described in Chapter 2.  
 
Statistical analysis 
The raw data collected at the UEM during consumption of the pasta-meal was 
converted into an analysable format using Microsoft Excel. This allowed calculation 
of the total amount consumed during this free-eating session, generation of 
cumulative intake curves, calculation of eating rate (by dividing total amount eaten 
[grams] by time taken [seconds]) and assessment of VAS ratings of hunger, fullness 
and pleasantness of the food. Intake (in grams and kilocalories) and within-meal 
VAS parameters (reported at each interrupt) were reported or extrapolated to provide 
data at five incremental stages of the test meal (0%, 25%, 50%, 75% and 100% 
intake) for all participants. Extrapolation was undertaken using a simple interpolation 
rule. 
 
Data were analysed using SPSS for Windows, versions 21, 22 and 24.  
 Kolmogorov-Smirnov (K-S) testing revealed one outlier in terms of food consumed, 
who ate much more than all other participants (total intake 1169.2 g over 1142 
seconds). Removing this person allowed for a more normal distribution of the sample 
population.  After calculation of the quadratic equation the difference between 
groups for the intercept (appetite at the start of meal), coefficient (orosensory reward) 
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and quadratic (satiation throughout the meal) for hunger, fullness and pleasantness 
was assessed. The development of satiation describes the interaction of the change in 
appetite rating throughout the meal in relation to the calories consumed during it 
(pre-prandial hunger rating – post-prandial hunger rating/test-meal calories 
consumed).  
Data are presented as mean (± SD) unless stated. They were further analysed 
using two-way independent ANOVA, except where two-way repeated-measures 
ANOVAs were undertaken to test for the effect of time and participant group, and 
the interaction between these for the VAS ratings hunger, fullness and pleasantness 
of the food. Time was the within-subject effect and participant group the between-
subject effect. As the assumption of sphericity is unlikely to be met in a repeated-
measures ANOVA and violations of sphericity are detrimental to the accuracy of 
ANOVA the Greenhouse-Geisser results for within-subject effects are reported, as 
this adjusts the degrees of freedom and decreases the likelihood of a Type I error. 
 
Statistical significance was taken at p<0.05 in all cases. 
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Results 
 
Thirty-eight participants undertook the UEM part of the study, however for 
one control participant and 5 participants with hypothalamic damage (3 with HO and 
2 HWS) UEM data could not be analysed due to technical difficulties. At the analysis 
stage it became apparent that the UEM had not properly recalibrated during one 
episode of refilling during the meal and therefore the amount of food consumed was 
uninterpretable. Statistical analysis found an outlier in total intake (in the HO group) 
and data from this person was excluded from further analysis. The data presented 
therefore is for 31 participants. 
 
 
Anthropometry 
Between-group comparisons: obese vs. non-obese, patient vs. control and 
interaction between these factors 
There was no significant difference in age between obese (HO/OC) vs. non-
obese (HWS/NOC) or patients (HO/HWS) vs. controls (NOC/OC), or the interaction 
between these factors on two-way ANOVA (results of interaction in Table 6.1).  
 
There was significantly higher BMI in obese (HO/OC, mean [SD] BMI 
37.0[5.4] kg/m
2
) compared to non-obese (HWS/NOC, mean [SD] BMI 26.5[2.9] 
kg/m
2
) participants (F[1,27]= 40.9, p<0.001), as would be expected, however there was 
no significant difference between patients (HO/HWS) vs. controls (NOC/OC) 
(F[1,27]= 0.02, p=0.88), or the interaction between these factors (Table 6.1).  
There was also significantly higher body fat percentage in obese (HO/OC, 
mean [SD] 44.3[5.3]) vs. non-obese (HWS/NOC, mean [SD] 31.0[9.8]) participants 
(F[1,26]= 16.3, p<0.001), with no significant difference between patients (HO/HWS) 
vs. controls (NOC/OC) (F[1,26]= 0.12, p=0.73), or the interaction between these 
factors (Table 6.1). There was no significant difference in fat-free mass (FFM) 
between obese (HO/OC) vs. non-obese (HWS/NOC), patients (HO/HWS) vs. controls 
(NOC/OC), or the interaction between these factors on two-way ANOVA (results of 
interaction in Table 6.1). 
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Table 6.1. Mean (SD) demographics and anthropometry of UEM study participants 
 HO HWS OC NOC F[1,27] p-value 
Number of 
participants 
6 6 9 10 - - 
Gender: F 
               M 
2 
4 
2 
4 
7 
2 
6 
4 
- - 
Mean (SD) age, 
years 
45.7 
(17.7) 
54.4 
(20.1) 
57.0 
(19.1) 
47.6 
(20.6) 
0.64 0.43 
FFM (kg) 57.6 
(7.3) 
57.6 
(7.3) 
55.2 
(11.4) 
52.2 
(10.1) 
0.20 0.89 
% body fat 42.3 
(5.0) 
31.1 
(8.4) 
45.4 
(5.5) 
30.7 
(11.0) 
0.40 0.54 
Body fat 
category 
Healthy 
Overfat 
Obese 
 
 
0 
0 
5 
 
 
2 
0 
4 
 
 
0 
1 
8 
 
 
6 
2 
2 
  
F=female, M=male. F-ratio and p-values for the interaction between obese (HO/OC) 
vs. non-obese (HWS/NOC) and patients (HO/HWS) vs. controls (NOC/OC) on two-
way ANOVA. 
 
 
Intake at the UEM 
 
Amount consumed 
Between-group comparisons: obese vs. non-obese, patient vs. control and 
interaction between these factors 
 There was no significant difference between obese (HO/OC) and non-obese 
(HWS/NOC) participants in total intake at the UEM (F[1,27]=3.26, p=0.08), total 
intake per kg of fat-free mass (FFM) (F[1,27]=1.67, p=0.21) or amount of calories 
consumed as a percentage of estimated BMR (F[1,27]=0.79, p=0.38). 
There was significantly higher total intake (F[1,27]=7.74, p=0.01), calorie 
intake per kg of FFM (F[1,26]=23.3, p<0.001) and amount of calories consumed as a 
percentage of estimated BMR (F[1,27]=18.2, p<0.001) by controls (OC/NOC, mean 
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[SD] total intake 537.6[184.8]g, calories/kg FFM 11.7[3.3], calories as percentage of 
estimated BMR 37.4[10.1]) than those with hypothalamic damage (HO/HWS, mean 
[SD] total intake 345.3[207.7]g, calories/kg FFM 6.1[2.6], calories as percentage of 
estimated BMR 20.0[8.2]), however there was no statistically significant interaction 
between obese (HO/OC) vs. non-obese (HWS/NOC) and patients (HO/HWS) vs. 
controls (NOC/OC) in any of these parameters (Table 6.2). Figure 6.1 shows the 
mean total amount consumed over time by each participant group. 
 
Figure 6.1. Mean cumulative intake curves from the lunch meal measured by the 
UEM for all participants, by participant group. 
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Table 6.2. Mean (SD) total intake at the UEM (in grams and kcal), calculated BMR 
and calories consumed adjusted for BMR and FFM 
 HO HWS OC NOC F[1,27] p-value  
Intake (g) 430 
(263) 
260.5 
(91.4) 
581 
(176.8) 
498.4 
(192.4) 
0.38 0.54 
Calories consumed 
(kcal) 
503 
(308) 
305 
(107) 
680 
(206) 
583 
(225) 
0.38 0.54 
BMR (kcal/day) 1982 
(295) 
1688 
(270) 
1819 
(471) 
1566 
(266) 
0.16 0.69 
Calories consumed (as 
% calculated BMR) 
24.1 
(11.9) 
19.0 
(6.7) 
38.2 
(10.3) 
36.6 
(10.3) 
0.23 0.64 
% body fat 42.3 
(5.0) 
31.1 
(8.4) 
45.4 
(5.5) 
30.7 
(11.0) 
0.30 0.59 
Body fat category 
Healthy 
Overfat 
Obese 
 
0 
0 
5 
 
2 
0 
4 
 
0 
1 
8 
 
6 
2 
2 
  
FFM (kg) 57.6 
(7.3) 
57.6 
(7.3) 
55.2 
(11.4) 
52.2 
(10.1) 
0.17 0.69 
Calories consumed/kg 
FFM 
6.9 
(3.3) 
5.4 
(1.9) 
12.5 
(3.3) 
11.0 
(3.2) 
0.001 0.97 
Eating duration (secs) 383 
(131) 
406 
(119) 
574 
(216) 
546 
(187) 
0.15 0.70 
Overall eating rate 
(g/sec) 
62.4 
(23.5) 
42.0 
(19.8) 
65.2 
(28.2) 
59.9 
(21.4) 
0.74 0.40 
BMR = basal metabolic rate, FFM = fat-free mass. F-ratio and p-values for the 
interaction between obese (HO/OC) vs. non-obese (HWS/NOC) and patients 
(HO/HWS) vs. controls (NOC/OC) on two-way ANOVA. 
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Eating Duration 
 
Between-group comparisons: obese vs. non-obese, patient vs. control and 
interaction between these factors 
 There was no significant difference in mean eating duration between obese 
(HO/OC) and non-obese (HWS/NOC) participants (F[1,27]=0.02, p=0.97). Participants 
with hypothalamic damage (HO/HWS) ate for a significantly shorter mean duration 
(394.7[119.6SD] seconds) than controls (OC/NOC, mean [SD] 559.2[196] seconds) 
(F[1,27]=6.43, p=0.02), however there was no statistically significant interaction 
between obese (HO/OC) vs. non-obese (HWS/NOC) and patients (HO/HWS) vs. 
controls (NOC/OC) in eating duration (Table 6.2, Figure 6.1 – mean eating duration 
shown as large symbol with black outline).  
 
 The graph in Figure 6.1 shows the mean intake every 60 seconds in all 
participants. At the later time points some of the participants had finished eating 
therefore the mean amount consumed drops despite ongoing food consumption in 
those who continue to eat, reflecting in these participants a longer duration of eating 
but not necessarily a greater amount consumed. Whilst all participants were eating at 
the earliest timepoints, many had finished eating before the latest timepoints. 
 
 
Measures of eating rate 
Between-group comparisons: obese vs. non-obese, patient vs. control and 
interaction between these factors 
There were no significant differences in overall eating rate between obese 
(HO/OC) and non-obese (HWS/NOC) participants (F[1,27]=2.16, p=0.15) or 
participants with hypothalamic damage (HO/HWS) and controls (OC/NOC) 
(F[1,27]=1.40, p=0.25) and no significant interaction between obese (HO/OC) vs. non-
obese (HWS/NOC) and patients (HO/HWS) vs. controls (NOC/OC) in overall eating 
rate (Table 6.2). 
 
Repeated-measures ANOVA for cumulative changes in eating rate were not 
significantly different between groups (F[4.3,39]=1.13, p=0.36) or over time 
(F[1.4,39]=1.43, p=0.24), most likely due to the small numbers of participants. On 
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visual ascription however, those with HO tended to have a higher initial eating rate 
than the other groups, which then reduced, but was followed by an increase towards 
the end of the meal (Figure 6.2); due to low numbers this did not reach statistical 
significance.  
 
Figure 6.2 Changes in eating rate across the meal
 
 
 
Within-meal measures of appetite 
Between-group comparisons: obese vs. non-obese, patient vs. control and 
interaction between these factors 
There was no significant difference in baseline hunger (F[1,27]=0.30, p=0.60, 
Figure 6.2), baseline fullness (F[1,27]=2.87, p=0.10, Figure 6.3) or baseline 
pleasantness after a taste of the pasta meal (F[1,27]=0.32, p=0.57, Figure 6.4) between 
obese (HO/OC) and non-obese (HWS/NOC) participants. 
 
There was significantly lower reported hunger at the start of the meal in 
participants with hypothalamic damage (HO/HWS, mean [SD] 284.7[98.0]) than 
controls (OC/NOC, mean [SD] 362.4[93.8]) (F[1,27]=4.55, p=0.04), but no significant 
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differences in fullness (F[1,27]=3.43, p=0.08) or pleasantness (F[1,27]=1.87, p=0.18) at 
baseline. 
There was no significant difference in the interaction between obese 
(HO/OC) vs. non-obese (HWS/NOC) and patients (HO/HWS) vs. controls (NOC/OC) 
in any of the outcomes considered using two-way ANOVA (Table 6.3).  
 
Table 6.3. Mean (SD) intercept of the on-screen VAS ratings (scored out of 500) at 
the start of the meal.  
 HO HWS OC NOC F[1,27] p-value 
Hunger 283 
(77) 
286 
(123)
 
 
341  
(97)
 
 
381   
(91)
 
 
0.28 0.60 
Fullness  127  
(82) 
259
  
(124) 
132  
(59) 
121  
(113) 
3.97 0.06 
Pleasantness 280 
(132) 
319 
(157)
 
 
356
 
 
(121) 
370 
(104) 
0.06 0.80 
F-ratio and p-values for the interaction between obese (HO/OC) vs. non-obese 
(HWS/NOC) and patients (HO/HWS) vs. controls (NOC/OC) on two-way ANOVA. 
 
 
Hunger: Repeated-measures ANOVA showed no evidence of significant interaction 
between participant group and time (F[4.96,44.60]=1.12,  p=0.36) or group effect on 
hunger (F[3,27]=2.11, p=0.12). However, the outcome mean changed over the 
quartiles of the meal (F[1.7,44.6]=45.6, p<0.001). 
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Figure 6.2 Changes in mean hunger rating across the meal (by participant group) 
 
 
 
Fullness: Repeated-measures ANOVA showed no evidence of significant interaction 
between participant group and time (F[6.18,55.66]=1.08,  p=0.39) or group effect on 
fullness (F[3,27]=1.91, p=0.15). However, the outcome mean changed over the 
quartiles of the meal (F[2.06,55.66]=49.94, p<0.001). 
There was no significant difference between the groups in the experience of 
orosensory reward, as reflected by the change in fullness (F[3,30]=1.98, p=0.14) and 
no difference in the development of satiation throughout the meal (F[3,30]=1.41, 
p=0.26) (Figure 6.3). 
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Figure 6.3 Changes in mean fullness rating across the meal (by participant group) 
 
 
Pleasantness: Repeated-measures ANOVA showed no evidence of significant 
interaction between participant group and time (F[6.61,57.26]=1.40,  p=0.23) or group 
effect on pleasantness (F[3,27]=2.08, p=0.12). However, the outcome mean changed 
over the quartiles of the meal (F[2.2, 57.26]=6.73, p=0.002). 
There were no significant differences between the groups in the orosensory reward of 
the meal (F[3,30]=2.42, p=0.09) or the development of satiation (F[3,30]=1.36, p=0.28). 
There were no significant differences in changes in pleasantness affecting hunger or 
fullness within the meal between the groups (Figure 6.4). 
 
197 
 
Figure 6.4 Changes in mean pleasantness rating across the meal (by participant 
group) 
 
 
Hormonal analysis 
 
Between-group comparisons of pre-lunch hormones: obese vs. non-obese, 
patient vs. control and interaction between these factors 
There was no significant difference in pre-lunch glucose (F[1,26]=0.20, 
p=0.66) or insulin (F[1,26]=0.003, p=0.96) between obese (HO/OC) and non-obese 
(HWS/NOC) participants, however pre-lunch leptin was significantly higher in obese 
(HO/OC, mean [SD] 21.1[16.1] ng/mL) compared to non-obese (HWS/NOC, mean 
[SD] 7.6[7.0] ng/mL) participants (F[1,27]=7.78, p=0.01). 
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There was no significant difference in pre-lunch glucose (F[1,26]=0.10, 
p=0.76), pre-lunch insulin (F[1,26]=1.87, p=0.19) or pre-lunch leptin (F[1,26]=2.93, 
p=0.10) between participants with hypothalamic damage (HO/HWS) and controls 
(OC/NOC). 
There was no significant difference in the interaction between obese 
(HO/OC) vs. non-obese (HWS/NOC) and patients (HO/HWS) vs. controls (NOC/OC) 
in any of these parameters (Table 6.4).  
 
Table 6.4. Mean (SD) of the pre-lunch blood samples taken on the UEM study day. 
 HO  HWS  OC  NOC  F[1, 26] p-value 
Mean (SD) leptin  
(ng/mL) 
13.2 
(9.4) 
6.4
  
(5.4) 
26.4
 
  
(17.9) 
8.4 
(8.1) 
1.59 0.22 
Mean (SD) 
glucose (mmol/L) 
5.3
 
 
(0.72) 
5.7
 
 
(0.73) 
5.6
 
 
(0.40) 
5.4
 
 
(0.78) 
1.60 0.22 
Mean (SD) insulin 
(mIU/mL) 
24.9
 
 
(11.8) 
28.3
 
 
(18.7) 
17.5
 
 
(17.8) 
15.0
 
 
(26.9) 
0.15 0.70 
F-ratio and p-values for the interaction between obese (HO/OC) vs. non-obese 
(HWS/NOC) and patients (HO/HWS) vs. controls (NOC/OC) on two-way ANOVA. 
 
Between-group comparisons of AUC hormones: obese vs. non-obese, patient vs. 
control and interaction between these factors 
There was no significant difference in AUC glucose between obese (HO/OC) 
and non-obese (HWS/NOC) participants (F[1,26]=0.06, p=0.81) or between 
participants with hypothalamic damage (HO/HWS) and controls (OC/NOC) 
(F[1,26]=1.46, p=0.24), however there was a significant difference in the interaction 
between obese (HO/OC) and non-obese (HWS/NOC) and patients (HO/HWS) vs. 
controls (NOC/OC) in AUC glucose (Table 6.5, Figure 6.5). As can be seen by the 
line graph and Table 6.5 AUC glucose was greater in HWS and OC and lower in HO 
and NOC. 
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Figure 6.5. Line graph showing the interaction of the mean AUC glucose by 
participant group 
 
 
 
There was significantly higher AUC insulin in obese (HO/OC, mean [SD] 
17,173[7,335] mIU*180mins /mL) compared to non-obese (HWS/NOC, mean [SD] 
8,908[4,338] mIU*180mins /mL) participants (F[1,26]=11.87, p=0.002), but no 
significant difference between participants with hypothalamic damage (HO/HWS) 
and controls (OC/NOC) (F[1,26]=0.40, p=0.53) or in the interaction between obese 
(HO/OC) vs. non-obese (HWS/NOC) and patients (HO/HWS) vs. controls (NOC/OC) 
(Table 6.5). 
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Table 6.5. Mean (SD) AUC of glucose and insulin concentration on the UEM study 
day. 
 HO  HWS  OC  NOC  F[3,29] p-value 
Mean (SD) glucose 
concentration 
(mmol*180mins/L) 
1111
 
(158) 
1362
 
(269) 
1440
 
(252) 
1229
 
(169) 
8.14 0.008 
Mean (SD) insulin 
concentration 
(mIU*180mins /mL) 
15029
 
(8463) 
9318
 
(6002) 
18603
 
(6607) 
8634
 
(3194) 
0.88 0.36 
F-ratio and p-values for the interaction between obese (HO/OC) vs. non-obese 
(HWS/NOC) and patients (HO/HWS) vs. controls (NOC/OC) on two-way ANOVA. 
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Part 2: Macrostructure of feeding behaviour: Assessment of self-
reported eating behaviour with the Three Factor Eating 
Questionnaire (TFEQ) and the MRC-Human Nutrition Research 
Diary 
 
Study design and methods 
Three Factor Eating Questionnaire (TFEQ) 
The Three Factor Eating Questionnaire (TFEQ) is a self-assessment 
questionnaire which assesses restraint (21 questions), disinhibition (16 questions) 
and hunger (14 questions) to determine the long-term behavioural and cognitive 
aspects of eating (Appendix 2) [191]. There are 51 questions: 36 true/false (scored 0 
or 1 as per the answer key), 14 Likert-scaled questions (scale 1-4, with ratings of 1 or 
2 scored as 0 and ratings of 3 or 4 scored as 1) and one 0-10 scaled-question 
regarding eating restraint (scored 0 or 1 at analysis). The questions relate to the three 
categories described and scores are totalled for each category. Restraint questions 
reflect conscious control of food intake for bodyweight control; disinhibition 
questions reflect loss of control of eating, influenced by emotion and external 
triggers; hunger questions measure food cravings/chronic subjective hunger [252, 
253]. Higher scores indicate greater restraint, disinhibition and hunger predisposition 
[254]. 
 
TFEQs were given to participants at their screening visit and they were asked 
to return these on either of their subsequent visits/by post. Participant responses were 
analysed using a Microsoft Excel spreadsheet which automatically scored the 
answers and subdivided them into the relevant categories of cognitive restraint of 
eating, disinhibition or hunger.  
 
 
MRC-Three-Day Food Diaries 
 The MRC-Human Nutrition Research Diary (or three-day food diary, 
Appendix 2) is a self-completed record of individuals’ food and drink consumption 
completed over three standard days in the “real-world” environment, with 
participants asked to include at least one weekend day. Participants were advised not 
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to undertake this on a day which did not reflect their routine diet, e.g. on a special 
occasion. Anything consumed (food or drink, including water) was to be noted. The 
food diaries were given to participants at their screening visit and they were asked to 
return these on either of their subsequent visits or by post. Participant responses were 
analysed using WinDiets, a specialist dietary software. The elements calculated were 
total calorie, fat, protein, carbohydrate (CHO) and sugar consumption per day for 
three days. This data was then averaged over the three days to give an average daily 
intake. The total calorie consumption was then compared to calculated basal 
metabolic rate (BMR) as a percentage and the total calorie consumption per kg of 
FFM was also calculated. 
 
Statistical analysis 
Further analysis of both the TFEQ data and the three-day food diaries was 
undertaken using SPSS for Windows, versions 22 and 24. A non-parametric 
approach was chosen for the analysis of this data as many of the variables considered 
did not have a normal distribution. Also the small number of observations and 
different sample sizes across the groups made it problematic to attempt suitable 
transformation of the data to allow parametric tests to be undertaken (i.e. two-way 
ANOVA, as undertaken for data in the rest of the thesis). Kruskal-Wallis tests were 
therefore used to explore the data. The adjusted statistic test and the relative p-value 
are reported in the presence of ties. For the TFEQ data correlation between BMI and 
the various TFEQ scores were examined using Spearman’s rho. 
 
For all data median (IQR) are reported and p<0.05 considered significant.  
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Results 
 
TFEQ 
TFEQ demographics 
Thirty-four participants returned the TFEQ. The mean rank differed 
significantly across the groups for age and BMI on Kruskal-Wallis testing (Table 
6.6). An explorative boxplot by group suggested that the median age was highest in 
the HWS group (Figure 6.6) and median BMI was higher in obese (HO/OC) than 
non-obese (HWS/NOC) participants (Figure 6.7). 
 
Table 6.6. Median (IQR) demographics and anthropometry of TFEQ participants 
 HO HWS OC NOC H(3) p-value 
Number of 
participants 
8 6 9 11 - - 
Gender: F 
              M 
4 
4 
7 
2 
3 
3 
6 
5 
- - 
Age, years 47.0 
(19) 
67.5 
(15) 
48.0 
(17) 
49.0 
(40) 
8.5 0.04 
BMI, kg/m
2
 36.6 
(8.8) 
27.9 
(4.6) 
36.9 
(12.1) 
27.2 
(4.7) 
24.8 <0.001 
F = female, M = male. Comparison between groups using the Kruskal-Wallis test. 
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Figure 6.6. Box-plots showing differences in median age between the groups [(thick 
central line), interquartile range (upper and lower box edges) and minimum/ 
maximum (lowest/uppermost horizontal lines, with outliers depicted as circles)] 
 
 
Light-grey bars = non-obese, dark-grey bars = obese. Outliers are labelled with their 
participant code. 
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Figure 6.7. Box-plots showing differences in median BMI between the groups [(thick 
central line), interquartile range (upper and lower box edges) and 
minimum/maximum (lowest/uppermost horizontal lines)] 
 
Light-grey bars = non-obese, dark-grey bars = obese 
 
 
 
TFEQ scores 
There was no significant difference in restraint or hunger between the groups 
on Kruskal-Wallis testing however for disinhibition the mean rank differed 
significantly across the groups (Table 6.8). An explorative boxplot by group 
suggested that disinhibition was affected by patient characteristics, with a higher 
median score in OC than the other groups (Figure 6.8).  
 
There was no correlation between BMI and restraint, disinhibition or hunger across 
all participants (not separated by participant group). 
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Table 6.7. Median (IQR) TFEQ scores across the four groups  
     Kruskal-
Wallis 
Spearman’s 
rho 
 HO HWS OC NOC H(3) 
[p-value] 
rs 
[p-value] 
Restraint 
(max 21) 
13.0 
(14) 
13.0 
(1) 
9.0 
(8) 
9.0 
(11) 
1.85 
[0.61] 
.03 
[0.86] 
Disinhibition 
(max 16) 
4.0 
(6) 
2.5 
(6) 
10.0 
(7) 
4.0 
(5) 
8.96 
[0.03] 
.33 
[0.06] 
Hunger 
(max 14) 
2.5 
(7) 
3.0 
(4) 
5.0 
(6) 
4.0 
(4) 
1.41 
[0.70] 
.09 
[0.58] 
Comparison between groups using the Kruskal-Wallis test. Spearman’s rho 
examined correlation between BMI and TFEQ scores (across all participant groups). 
Figure 6.8. Box-plots showing differences in disinhibition between the groups 
[median (thick central line), interquartile range (upper and lower box edges) and 
minimum/maximum (lowest/uppermost horizontal lines)] 
 
Light-grey bars = non-obese, dark-grey bars = obese 
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MRC-Three Day Food Diaries 
Thirty-three participants returned a 3-day food diary, however one HWS 
patient was excluded as reported total calories (TC) varied by up to 200% across the 
three days and on average was substantially lower than the estimated basal metabolic 
rate (only 42.1%) and the accuracy of the data was therefore uncertain. The data for 
32 participants is therefore reported (Table 6.8). 
 
 
Food Diary demographics/anthropometry 
There was no significant difference in age between the groups on Kruskal-
Wallis testing, however for BMI the mean rank differed significantly across the 
groups (Table 6.8). An explorative boxplot by group suggested that the BMI was 
affected by patient characteristics and HO and OC showed higher medians and a 
more widely spread distribution compared with the other two groups (Figure 6.9).  
 
There was no significant difference in basal metabolic rate or fat-free mass 
between the groups on Kruskal-Wallis testing however for percentage body fat the 
mean rank differed significantly across the groups (Table 6.8). An explorative 
boxplot by group suggested that the percentage body fat was affected by patient 
characteristics and HO and OC showed higher medians than the other two groups 
(Figure 6.10).  
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Table 6.8. Characteristics of participants who returned food diaries, reported as 
median (IQR) 
 HO HWS OC NOC H(3) p-value 
Number of 
participants 
6 7 8 11 - - 
Gender: F 
              M 
3 
3 
4 
3 
7 
1 
6 
5 
- 
- 
- 
- 
Age, years 47.0 
(23) 
66.0 
(18) 
48.5 
(23) 
49.0 
(40) 
4.81 0.19 
BMI, kg/m
2
 34.6 
(8.1) 
27.7 
(4.9) 
34.2 
(8.8) 
27.2 
(4.7) 
22.8 <0.001 
BMR 
(kcal/day) 
1843 
(381) 
1699 
(556) 
1596 
(441) 
1449 
(387) 
3.38 0.34 
% body fat 45.5 
(11.5) 
32.5 
(8.5) 
44.0 
(8.8) 
31.0 
(21.5) 
13.46 0.004 
FFM (kg) 51.7 
(7.9) 
50.5 
(19.2) 
50.6 
(10.0) 
48.0 
(16.0) 
0.83 0.84 
F = female, M = male. BMI = body mass index, BMR = basal metabolic rate, FFM = 
fat-free mass. For percentage body fat and fat-free mass data only available for 5 HO 
participants as one was wearing a compression stocking and therefore Tanita could 
not assess these parameters. Comparison between groups using Kruskal-Wallis test. 
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Figure 6.9. Box-plots showing differences in median BMI between the groups [(thick 
central line), interquartile range (upper and lower box edges) and 
minimum/maximum (lowest/uppermost horizontal lines] 
 
 
Light-grey bars = non-obese, dark-grey bars = obese. Outliers are labelled with their 
participant code. 
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Figure 6.10. Box-plots showing differences in percentage body fat between the 
groups [median (thick central line), interquartile range (upper and lower box edges) 
and minimum/maximum (lowest/uppermost horizontal lines] 
 
 
Light-grey bars = non-obese, dark-grey bars = obese. Outliers are labelled with their 
participant code. 
 
 
Reported consumption 
There was no significant difference in the number of eating episodes, total 
calories consumed, total calories/kg fat-free mass or total calories as a percentage of 
BMR between the groups on Kruskal-Wallis testing (Table 6.9).  
 
 
Calculated macronutrient consumption based on food diary responses 
There was no significant difference between the groups in the amount of fat, 
protein, carbohydrate or sugar consumed in weight (g), or as a percentage of total 
calories consumed on Kruskal-Wallis testing (Table 6.10).  
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Table 6.9 Median (IQR) consumption over three days, as reported in the MRC three-
day diary 
 HO HWS OC NOC H(3) p-value  
Eating Episodes 3.8 
(0.5) 
4.0 
(1.8) 
4.2 
(1.9) 
4.7 
(0.7) 
5.6 0.13 
Total Calories 
[TC] (kcal/day) 
3263 
(1329) 
3304 
(2567) 
3562 
(1307) 
3258 
(639) 
0.76 0.86 
TC/kg fat-free 
mass (FFM) 
52.5 
(31.2) 
67.0 
(23.4) 
61.6 
(29.1) 
54.4 
(29.0) 
2.08 0.56 
TC as percent of 
calculated BMR 
159 
(90) 
243 
(131) 
194 
(120) 
215 
(88) 
2.44 0.49 
TC = total calories. Comparison between groups using the Kruskal-Wallis test. 
 
 
Table 6.10 Median (IQR) macronutrient consumption over three days, as reported in 
the MRC three-day diary 
 HO HWS OC NOC H(3) p-value  
Fat (g) 113.4 
(72.6) 
147.4 
(71.8) 
146.5 
(71.6) 
176.1 
(101.8) 
3.63 0.30 
Fat% of TC 33.2 
(5.5) 
27.0 
(23.0) 
36.9 
(11.3) 
43.5 
(21.9) 
4.42 0.22 
Protein (g) 136.9 
(113.1) 
145.4 
(223.5) 
119.1 
(93.1) 
143.8 
(32.3) 
1.83 0.61 
Protein% of TC 18.4 
(13.8) 
15.7 
(24.9) 
14.4 
(6.6) 
15.4 
(5.7) 
1.76 0.62 
Carbohydrate 
(CHO) (g)  
309.2 
(373.8) 
601.6 
(810.0) 
390.1 
(306.7) 
443.0 
(132.6) 
2.03 0.57 
CHO% of TC 47.6 
(15.0) 
44.2 
(26.8) 
49.1 
(8.5) 
44.0 
(17.9) 
2.58 0.46 
Sugars (g) 44.7 
(115.6) 
106.2 
(99.2) 
87.8 
(64.3) 
66.1 
(78.0) 
4.06 0.26 
Comparison between groups using the Kruskal-Wallis test. 
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Discussion 
 
Hyperphagia  
There was no evidence of hyperphagia in participants with HO compared to 
those who remained HWS, even when intake was adjusted for fat-free mass or 
calculated as a proportion of the estimated BMR of the participants. In fact whilst 
there was no significant difference in intake between obese and non-obese 
participants, there was significantly greater total intake, intake per kg of FFM and 
calories consumed as a proportion of BMR, as well as a longer eating duration in 
controls compared to participants with hypothalamic damage. These results were 
unexpected, as it was hypothesized that those participants with HO would be 
hyperphagic and therefore would consume significantly more than the other groups, 
or at least significantly more than HWS participants [32]. There were no significant 
differences in pleasantness ratings between the groups to suggest that the HO group 
found the meal less pleasant and therefore ate less than they would have with a 
different meal causing an erroneously low intake whilst eating at the UEM. It is 
possible that participants were aware that their intake was being monitored and that 
those with HO altered their intake more than the other groups, however as 
participants were not asked at the end of the session whether they were aware of the 
purpose of the UEM there is no evidence that this is the case and no reason to expect 
that those with HO modified their intake to any greater extent than the other groups. 
One outlier with HO did eat significantly more than all other participants (1169.2g) 
and was excluded from analysis to allow for a more normal distribution. It is possible 
that this excluded individual reflected the upper limit of a range of hyperphagia seen 
in the HO group and was therefore still representative of this group. It is also 
possible that only some of those with HO have hyperphagia. As there was 
significantly higher total intake, calorie intake per kg of FFM and amount of calories 
consumed as a percentage of the estimated BMR in controls than in patients, despite 
no significant difference in BMI or percentage body fat between them, this could 
point toward the possibility of differences in metabolic rate, which in this study were 
calculated (based on age, gender, height and weight) but not measured. It would be 
important to consider measuring basal metabolic rate in future studies. Most 
importantly, due to the difficulties encountered with the UEM, only a small number 
of patients with hypothalamic damage (6 HO, 6 HWS) had data available for 
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analysis. This makes it difficult to conclude that there were no differences between 
the groups and the lack of significant findings may have been due to power. The 
current data could be used to calculate the sample size necessary for future studies, 
including the possibility of assessing for hyperphagia and dividing the groups 
accordingly. 
Monitoring of food intake at the UEM necessitates using a single, 
homogenous food and it is possible that sensory specific satiety [220] was greater in 
the HO group, leading to lower intake than might occur if a more varied meal had 
been offered. It may also be that while intake across a single meal is not increased in 
those with HO, across the course of a day food frequency may be increased (although 
this was not demonstrated in the food diaries undertaken as part of this study). A 
study comparing 15 age-, BMI- and body fat- matched simple-obese controls to 14 
participants with HO found that three hours after eating those with HO reported 
significantly more hunger and desire to eat (VAS ratings, p<0.01) [2], suggesting a 
shorter period of post-prandial fullness. Food intake later in the day following the 
lunch-time UEM meal was not recorded in the study described in this thesis however 
eating patterns and food intake were assessed using three-day food diaries, as 
reported in this chapter.  
Food intake before the lunch-time UEM meal was controlled by asking 
participants to attend fasting and then offering a breakfast meal based on 25% of 
their estimated intake, based on calculated metabolic rate. Basal metabolic rate may 
be altered in those with HO [3, 65], however the results are conflicting. This may 
have affected the calculation of an appropriate breakfast “load”. As participants were 
at home before the breakfast meal, it also is possible that not all may have arrived 
fasting.  
It is also possible that hyperphagia is not a consistent feature of HO in all 
cases, as in some studies obesity has been reported in the absence of increased food 
consumption [42, 43]. 
 
The pattern of eating rate 
Although there were no statistically significant differences between the 
groups in eating rate across the entire meal, or differences for cumulative change in 
eating rate over time, the HO group initially tended towards a higher eating rate than 
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the other groups on visual ascription (Figure 6.2). Their eating rate then reduced, but 
was followed by an increase towards the end of the meal. This finding is unusual, but 
due to low numbers was statistically non-significant. Evidence varies within the 
literature as to whether those with simple obesity have an increased eating rate 
compared to lean individuals and whether they fail to slow their eating rate at the end 
of a meal. In this study, obese controls tended towards an increase in eating rate 
initially (on visual ascription), followed by  a slower reduction compared to the other 
groups; however, most likely due to low participant numbers, this was statistically 
non-significant and does not contribute any further evidence to this literature. 
 
 
Microstructure 
The lack of significant difference between the groups in pleasantness ratings 
throughout the meal suggests that palatability did not influence total intake or eating 
rate. Similarly there were no significant differences in fullness at the start of the 
meal, or through the course of the meal between any of the groups. Baseline hunger 
was significantly lower at the start of the meal in participants with hypothalamic 
damage (HO/HWS) than in controls (OC/NOC) and food intake at the UEM lower 
(even once adjusted for calculated BMR), but there was no significant difference 
between obese (HO/OC) and non-obese (HWS/NOC) participants, or interaction 
between hypothalamic damage vs. controls and obese vs. non-obese. There was no 
evidence of increased hunger in those with HO compared to those HWS and no 
differences in orosensory reward, development of satiation or meal pleasantness to 
suggest that fullness was linked to feelings of a less pleasant meal, or other 
contributory factors.   
The small size of the participant groups may have led to a lack of statistical 
difference between patients with HO and HWS as the study was powered to detect 
differences in brain activation to food stimuli, as discussed in Chapter 5 (the fMRI 
study). Further cross-sectional studies of larger groups of lean and obese participants 
both with and without hypothalamic damage may lead to more significant findings. 
Recruitment of participants with hypothalamic damage who remained weight-stable 
was particularly difficult, but if the study was restricted to investigation with a UEM 
only, this may potentially allow easier recruitment. 
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Self-reported eating behaviour had been assessed using the TFEQ, with the 
intention of considering this as a factor which might influence food consumption (as 
in other studies). The groups, however, were too small to be likely to yield 
significant differences if further separated according to self-assessed eating 
behaviour and this analysis was therefore not undertaken.  
 
 
Biochemistry 
Pre-lunch leptin was significantly higher in obese compared to non-obese 
participants, reflective of leptin resistance in simple obesity and hypothalamic 
obesity [35, 51]. 
There was no difference between the groups in pre-lunch insulin 
concentrations. AUC insulin was higher in obese compared to non-obese 
participants, but there was no significant difference between participants with 
hypothalamic damage and controls, or in the interaction between hypothalamic 
damage vs. controls and obese vs. non-obese. Hyperinsulinaemia after hypothalamic 
damage is a proposed mechanism of HO. Authors have hypothesized that excess 
insulin, secreted due to the effects of vagal nerve disinhibition on the pancreas, 
drives hunger/hyperphagia and accumulation of fat [3, 38, 55]. Results from studies 
measuring insulin concentrations have been conflicting – some have found evidence 
of increased fasting insulin concentrations [3, 4, 9, 29, 29, 39, 51, 52, 54, 57-59], 
others have found no difference in fasting insulin but that differences existed 
following OGTT [55, 56, 312] and others have found no difference in insulin using 
any study methods [51, 52, 57, 58]. As many of these studies were undertaken some 
time after the hypothalamic damage had occurred even in those studies where insulin 
differences were apparent it is not clear whether this was the causal mechanism or 
was secondary to weight gain, as is seen in individuals with simple obesity. There 
was no evidence on either of the study days undertaken for work presented in this 
thesis of greater fasting or pre-lunch insulin concentrations, or higher AUC insulin in 
those with HO compared to the other three groups. However as insulin 
concentrations were only available for six HO and six HWS participants it is very 
difficult to draw any conclusions given the small numbers involved. In fact, this is 
true for all of the reported data and previous studies have contained much larger 
numbers of patients [52, 58, 262]. 
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In terms of the macrostructure of eating behaviour the TFEQ measures 
behavioural traits (restraint, disinhibition, feelings of chronic hunger) which 
influence food choice over time (eating habits) [242] and can outstrip more 
immediate hunger and satiety cues. As such, it was hypothesized that these factors 
may be of greater importance where homeostatic influences on hunger and satiety 
have been disrupted due to hypothalamic damage. In this study, OC had higher 
median scores for disinhibition than the other groups. Increased disinhibition has 
been reported in previous large studies of obese compared to lean individuals [1]. 
Interestingly, the HO group appear to be less disinhibited than OC, with a lower 
median score, although a large range of scores for reported disinhibition, as can be 
seen on the boxplots. Perhaps more pertinent is the lack of evidence of greater 
disinhibition in HO compared to HWS and NOC, in contrast to that seen in OC, 
suggesting that disinhibition is not a driver of obesity as occurs in the simple obese 
population. Once again however the small numbers of participants studied may have 
accounted for lack of difference found. A previous study comparing TFEQ scores in 
HO and OC [2] found significantly lower disinhibition in HO compared to OC, but  
non-obese participants (either with hypothalamic-damage or controls) were not 
studied. That study also found significantly lower hunger reported on TFEQ in HO 
than OC, a feature again not noted in the study presented in this thesis. More 
participants were included in Daousi et al’s study (14 HO, 15 OC) [2] and it is 
possible that significant differences may have been found between the patients 
described in this thesis had the groups been larger. The study was powered to look 
for differences in areas of cerebral activation in response to food stimuli based on 
previous fMRI studies and not powered to detect differences in eating behaviour. 
Disinhibition reflects the likelihood of overeating secondary to external or emotional 
triggers (the theory of externality), for example if offered highly palatable food or 
when upset, as opposed to a homeostatic, physiological drive to eat [313]. There is 
some evidence from the two studies (Daousi et al [2] and the current study) that 
disinhibition is not an important behavioural component in HO, as is seen in simple 
obesity, which would be consistent with a more regulatory rather than externally 
driven theory of intake. Dietary restraint (which assesses behavioural control over 
eating) and hunger were not significantly different across the groups studied here and 
previous studies have shown these factors to be inconsistently and less strongly 
correlated with outcomes, respectively [201].  
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The only other use of the TFEQ in acquired HO in the literature is a case 
report of a 29 year-old male with a BMI of 52 kg/m
2
 and history of 
craniopharyngioma resection aged 8 years, who underwent bariatric surgery [131]. 
TFEQ undertaken before and after surgery found a low level of pre-operative 
restraint (10/21) and disinhibition (8/16) and high hunger ratings (8/14). Hunger and 
disinhibition had reduced by 18 months post-bariatric surgery (2/14 and 4/16, 
respectively). Comparison with an individual case report is difficult and it is also 
unknown as to whether these changes persisted on a more permanent basis. 
Although the TFEQ has been used in large cohorts and has high internal and 
test-retest reliability in both laboratory and non-laboratory settings [191, 201] it 
should be borne in mind that its use has not been validated in patients with structural 
brain lesions and therefore may not be reproducible in this group. It has, however, 
previously been used in studies of HO secondary to a non-structural, non-acquired 
genetic cause, such as melanocortin-4 receptor (MC4R) mutations. A literature 
review describes six studies, four of which use the TFEQ-51 questionnaire to assess 
associations between different MC4R mutations/variants and TFEQ factors, in some 
cases comparing patients with non-carrier overweight/obese individuals [314]. Only 
two of these studies found a significant difference between any TFEQ factors: 
disinhibition was higher in one study of 38 functional MC4R carriers (all obese) 
compared to 33 overweight related non-carriers [315] and hunger scores were higher 
in adults with a particular MC4R variant compared to those without in a study of 
2,438 obese participants [316]. Therefore, despite much larger participant groups 
(71–2,438 individuals, 19-1,880 with MC4R mutations) there were no consistent 
associations between MC4R mutations/variants and TFEQ findings. Whether this 
implies that the TFEQ method is less reliable in patients with any form of HO, or 
whether this simply reflects this particular cohort where the mechanism of HO is 
very different to our cohort is a matter for debate. 
 
The three-day food diaries revealed no significant differences between the 
groups for any of the parameters measured, including the number of eating episodes, 
mean total calories consumed/day or any of the nutritional components of the food 
eaten (CHO, fat, protein). This remained the case even when total calorie 
consumption was calculated against FFM and as a percentage of BMR, with median 
consumption across the four participant groups reported at 159-243% of that needed 
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to match their calculated BMR. Although participants were asked to complete the 
food diaries on a “typical” day, some were undertaken around the Christmas period 
and one participant had eaten out at an event (although this may have represented a 
typical day for that individual). There was a significant amount of variation in both 
the details and the quality of the completed diaries, with some participants (possibly 
those involved in previous weight-/obesity-related research) giving much greater 
detail. This introduces the likelihood of a large amount of error in assessing both the 
types and amounts of food consumed.  
Food diaries, although widely used in research studies [238] can contain 
significant errors, with foods erroneously under-reported (25-37%) or added (10%) 
[240, 317]. The burden of completing food diaries, particularly when dining out, as 
well as the need for literacy and numeracy skills have been described, as well as the 
effects that completing a food diary may have on eating behaviour and reporting, 
particularly in certain groups such as obesity [239]. Under-reporting is more 
prevalent in females, obese participants, those dieting, with higher dietary restraint 
and with various psychosocial factors such as level of education [317, 318], although 
did not appear to be an issue in this study, given that the median total calorie 
consumption reported as a percentage of estimated BMR was greater than 100% in 
all four participant groups. If the food diary aspect of this research project was to be 
repeated with a larger group of participants it would benefit from additional support 
and information being given to participants by a dietician at enrolment of the study to 
enable more accurate completion of the diaries, as well as including eating behaviour 
(as assessed by TFEQ), gender and level of education as covariates in any statistical 
models to help correct for measurement error in reported dietary intakes. 
It is interesting to note the lack of significant difference in calculated BMR 
between the groups, which may reflect the need to use a non-obese, rather than lean 
group of controls and HWS patients. BMR is also affected by age and differences 
between the groups in age may have played a role, although there were no 
statistically significant differences in age between the groups on analysis of the 
three-day food diaries. Finally, power will also have had an effect and due to the 
small amount of participants returning both TFEQs and food diaries it is difficult to 
conclude for certain any lack of difference between the groups. Any future study 
would benefit from a larger number of participants, with a greater difference in BMI 
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between the obese and lean groups. Data from the studies described in this chapter 
could be used to calculate the numbers needed for future studies. 
 
Strengths and limitations of the study 
This study has its limitations: 
- The small size of this study was a significant limitation. This was due in part to the 
rarity of this condition and particularly the difficulty in finding patients with 
hypothalamic damage who remained weight stable. Whilst there were some 
interesting findings, further larger studies may give greater clarification and would 
allow correlation with other clinical and biochemical findings. 
 
- There are variations in the group sizes (due to technical difficulties with some of 
the UEM recordings and inconsistent returns of the TFEQ and three-day food 
diaries) which makes the power of statistical tests weaker than with equal sized 
groups. Therefore even where there are significant p values these should only be 
used as an indication of possible differences and should be further investigated in 
larger studies. 
 
- Weight-stable patients (HWS) were not lean (BMI < 25 kg/m
2
), therefore the BMI-
matched control group were also non-obese but not lean. Although the obese 
participants studied using the UEM had a significantly higher BMI and percentage 
body fat compared to non-obese participants, using the reported Tanita ranges to 
categorise participants into healthy, overfat and obese, a significant proportion of 
participants were either overfat (2/6 NOC) or obese (2/6 NOC and 4/6 HWS), even 
within the HWS and NOC categories. Larger studies, containing patients with 
hypothalamic damage who remained weight-stable with a normal BMI (< 25 kg/m
2
) 
may help to give a clearer picture. 
 
- Ideally the patient groups would have been homogenous, with one underlying 
histological diagnosis causing hypothalamic damage. As noted, it is a relatively rare 
condition and therefore it was accepted at the outset that studying a more 
heterogeneous group would be necessary. 
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 - The basal metabolic rate in this study was calculated based on age, gender, height 
and weight and not measured. It would be important to consider measuring basal 
metabolic rate in future studies, especially as some studies have found lower BMR in 
participants with HO [65]. 
 
- The same homogenous food was used for all participants throughout the UEM 
meal. This may have been liked to a different degree by different study participants, 
although there was no significant difference in rated pleasantness reported on the 
VAS ratings. It is possible however that (given such a small study group) individual 
food preferences affected the findings of this study. As the food used was a savoury 
meal it is possible that the outcomes may have been different if a sweet food was 
used and that sensory specific satiety may have played a part in termination of eating. 
 
The strengths of this study are: 
- This is a unique study as the UEM has never before been used to study the 
microstructure of eating behaviour in patients with hypothalamic damage (either in 
those with or without obesity). 
- This study is also unique in that it considers both the microstructure and 
macrostructure of eating behaviour in patients with hypothalamic damage. 
- A standardised, reasonably physiological overnight fasting period was used. 
- All participants were studied at the same research centre, with the same research 
staff conducting the study days. 
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Conclusions 
There was no evidence of an increase in total food intake, overall increased 
eating rate or a failure to slow eating rate at the end of the meal consumed at the 
UEM in those with HO compared to the other groups. The lack of both greater 
hunger and total food intake in those with HO does not support within-meal 
hyperphagia as a key pathophysiological component of weight-gain in these patients, 
as both of these factors would be expected if patients with HO were hyperphagic. A 
meal eaten at the UEM therefore failed to demonstrate any significant differences 
between the microstructure of eating behaviour in those with HO and those HWS (or 
SO controls); however visual ascription showed some tendencies towards an unusual 
eating pattern in those with HO which might be statistically significant if an 
appropriately powered study was undertaken and this warrants further investigation 
in a larger group of participants. 
 
There were also no significant differences in the macrostructure of eating 
behaviour as measured by TFEQ, or reported differences in dietary intake recorded 
in three-day food diaries between participants with HO and those HWS (or between 
those with HO and controls). The absence of greater disinhibition in those with HO 
may reflect the disruption in internal, homeostatic regulatory mechanisms leading to 
weight-gain, rather than externally-influenced, emotional triggers which can drive 
over-eating and weight-gain in simple obesity. The difficulties with food-diary 
accuracy and under-reporting are well described and participants may have 
benefitted from increased dietetic guidance to enable these to be more accurately 
completed. Finally, a larger cohort, as found in other studies utilising these tools in 
different populations, may have led to more statistically significant differences 
between the groups and the lack of power in the studies may have strongly 
influenced findings. 
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Chapter 7 
 
Final Discussion 
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Hypothalamic obesity (HO) is characterised by an acute increase in body 
weight secondary to a clear hypothalamic insult [7] with weight gain occurring faster 
than any expected age-related increase [9] despite appropriate replacement of 
pituitary hormone deficiencies. Although well-described for over a century [7, 9, 10] 
its exact pathophysiology and optimal treatments remain uncertain. As all patients 
with suprasellar tumours have increased mortality (Standardised Mortality Rate 2.88-
8.75 [19, 71, 72]) and simple, nutritional obesity alone is associated with co-
morbidities such as cardiovascular, renal and liver disease and type 2 diabetes 
mellitus [67, 258], understanding the risk factors and pathophysiology leading to HO 
are vital to try and prevent additional morbidity and mortality in patients with 
hypothalamic damage. This knowledge can aid health-care professionals to better 
direct resources to prevent weight-gain and obesity following hypothalamic damage 
and can potentially open up future avenues for further research into treatments for 
HO. 
 
This thesis describes investigations into the prevalence and underlying 
pathophysiology of HO through several linked clinical research studies.  
The prevalence of HO was explored with a descriptive cohort study, 
undertaken through case-note review. The prevalence of additional risk factors 
contributing to increased morbidity and mortality, known to be present in both adult 
patients with suprasellar tumours and individuals with simple obesity, were also 
investigated. In addition, I was interested in studying these risk factors and metabolic 
outcomes in children and young people with pituitary adenomas (both with and 
without hypothalamic damage) in view of the limited literature available and to 
increase awareness of their prevalence in this patient group. Identification of 
increased cardiovascular risk in this age group would mean these patients would 
benefit from earlier targeted dietary, pharmacological and other interventions.  
Furthermore if this group of patients were shown to develop a higher prevalence of 
obesity even in the absence of hypothalamic damage (as many have microadenomas 
too small to extend into the hypothalamus) it may suggest that additional 
mechanisms contribute to increased obesity risk both in the presence and absence of 
hypothalamic damage. 
 
224 
 
The underlying pathophysiology of HO was investigated using 
complementary approaches to determine whether disturbances in neural pathways 
affect food intake and eating behaviour, leading to weight-gain.  
 
Prevalence of obesity and cardiovascular risk factors in patients with 
sellar/suprasellar tumours 
 Review of a large cohort of 110 adults attending specialist neuroendocrine 
clinics with tumours causing hypothalamic damage (Chapter 3) demonstrated a 
significant increase in median body mass index (BMI) from 28.1 kg/m
2
 at diagnosis 
to 32 kg/m
2 
(p<0.0001) after a median follow-up of 9 years. Additionally, an 
increased prevalence of obesity (63%) and overweight/greater (total 91%) was found 
in patients with hypothalamic damage compared to that found in the general 
population of a similar age [256]. As previously described, weight increase was 
fastest in the first year following tumour diagnosis and treatment (mean BMI 
increased to 30.4 kg/m
2
 at this time, p<0.0001), making this a key period in which to 
address this issue and to target those at increased risk. Disappointingly, in 35 patients 
diagnosed after 2005, despite increased awareness of obesity and strategies in place 
to identify and curtail weight gain, median BMI still increased significantly from 
29.9 kg/m
2
 to 31.7 kg/m
2
 (p<0.001) after a median of 3 years. The need for 
desmopressin (odds ratio [OR] = 3.5, p=0.03), growth hormone [GH] (OR = 2.7, 
p=0.03) and thyroxine (OR = 3.0, p=0.03) were associated with increased risk of HO, 
but there was no correlation between neuroimaging features and weight gain. 
Patients needing supplementation with these pituitary hormones should be 
particularly targeted for weight and lifestyle advice during follow-up. As 
hypertension, type 2 diabetes and cardiovascular disease were also more prevalent in 
the cohort of 110 patients than in the general population of a similar age (55-64 
years) [256], screening for these additional risk-factors should be included in best-
practice guidelines for the follow-up of patients with suprasellar tumours and 
hypothalamic damage. Furthermore, the findings described in this cohort of patients 
provides evidence that multi-disciplinary neurosurgical, endocrine and dietetic 
follow-up is needed, with routine monitoring for obesity and cardiovascular risk 
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factors and a low threshold for treatment in order to prevent further morbidity and 
mortality in this patient group.  
The retrospective review of children and adolescents with pituitary tumours 
(with and without hypothalamic damage) described in Chapter 4 also demonstrated a 
high prevalence of cardiovascular risk factors such as obesity (39%) and 
dyslipidaemia (73%), despite the young age of the participants (mean age at study 
26.9 years). This was the case even in patients with tumours confined to the sella, 
without evidence of hypothalamic involvement. Given the increased prevalence of 
obesity found in this patient cohort (39%) compared to the general female population 
of a similar age (21%), despite the predominance of microadenomas and therefore a 
lack of hypothalamic damage within the cohort, there is some evidence that 
hypothalamic damage is not the only factor contributing to an increased prevalence 
of obesity in children and adolescents with pituitary tumours. This is important to 
bear in mind when considering the underlying pathophysiological mechanisms 
responsible for hypothalamic obesity as it suggests that there may be other 
contributing factors causing weight gain in addition to the hypothalamic damage, at 
least in patients with pituitary adenomas. It also may suggest the need for future 
studies to include cohorts of patients both with and without hypothalamic damage 
when investigating the mechanisms of weight gain in those with acquired 
pituitary/hypothalamic lesions, to allow for potential additional non-hypothalamic 
mechanisms to also be studied. The findings indicate the need to focus on early 
identification and management of risk factors not otherwise commonly found in 
individuals of this age and the necessity for long-term follow-up. The knowledge and 
expertise acquired whilst conducting this research within an adult research and 
clinical neuroendocrine service has enabled me to transfer and apply these skills and 
knowledge within the field of paediatric endocrinology, where I am currently 
practicing as a clinician, and to disseminate and apply these findings into everyday 
clinical practice. 
 Establishment of a UK or European database to allow the study of larger 
numbers of patients with suprasellar tumours would be a valuable resource and 
should be encouraged. Further studies are needed to help determine the optimal 
management of these patients in order to reduce the morbidity and mortality 
226 
 
associated with hypothalamic damage, without compromising long-term disease 
control.  
 
Investigation of the pathophysiology of HO 
 The hypothalamus is the critical homeostatic centre controlling energy 
intake/output. Following damage to this area, the interaction between the remaining 
homeostatic regulators (the nucleus accumbens and brainstem) and the limbic, 
paralimbic and higher cortical regions (which process non-homeostatic factors such 
as emotion, cognition and reward secondary to environmental and hedonic cues and 
food reward) remains poorly understood. At the beginning of this research it was 
hypothesized that in patients with hypothalamic damage who became obese (HO) 
there would be evidence of anomalous neural processing of food stimuli, leading to 
abnormal appetite, excessive food consumption and hyperphagia, which has 
previously been described in HO [11, 23, 40, 41]. This was investigated using four 
tools: i) functional magnetic resonance imaging (fMRI), ii) the Universal Eating 
Monitor (UEM), iii) the Three Factor Eating Questionnaire (TFEQ) and iv) the 3-day 
MRC-Human Nutrition Research diary, each evaluating different aspects of eating 
and appetite. 
 
Chapter 5 describes the use of fMRI to determine whether differential activation of 
various brain regions and neural pathways involved in appetite and eating could be 
responsible for the weight-gain observed in those developing HO. This was a cross-
sectional study of nine patients with HO, seven patients with hypothalamic damage 
remaining weight-stable (HWS), 10 age-matched obese controls (OC) and 10 non-
obese controls (NOC). Although it was hypothesized that in those who had 
developed HO there would be evidence of abnormal neural processing of food 
stimuli, in fact the difference between the groups was found in those who were 
HWS. This group had significantly lower mean BOLD signal (p = 0.001) in brain 
regions associated with food motivation and reward, namely the posterior insula and 
lingual gyrus, when viewing high-calorie food photographs, compared to the other 
three groups. Similar differences have been observed in lean compared to obese 
individuals without hypothalamic damage [164, 300]. Insula activation has also been 
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found to be significantly different in obese individuals who have lost weight (post-
obese) compared to normal-weight/lean controls. Both obese and post-obese 
individuals have demonstrated increased mid-insula activation compared to lean 
individuals [166], however whether this is causal to or a result of weight gain is not 
clear. I therefore postulate that in some patients with hypothalamic damage (those 
who remain HWS) there may be greater preservation of functional and anatomical 
connectivity between the insula, extra-hypothalamic homeostatic areas (such as the 
midbrain VTA and NA) and areas processing food-reward, explaining the pattern of 
reduced insula activation when viewing high-calorie food stimuli and allowing a 
continuation of a more coordinated response between homeostatic and reward-related 
networks regulating appetite/eating and energy balance. 
  
It was then hypothesized that lower insula activation in HWS may protect 
against weight-gain by decreasing hunger and desire to eat, and leading to reduced 
food intake compared to HO. This was not reflected in the UEM findings, food 
diaries, or TFEQ assessment of eating behaviour (Chapter 6). The UEM study 
showed that controls (OC/NOC) ate significantly more and for significantly longer, 
with higher initial ratings of hunger than participants with hypothalamic damage 
(HO/HWS), but there was no difference between obese (HO/OC) and non-obese 
(HWS/NOC) participants, or in the interaction between obese vs. non-obese and 
patients vs. controls. There was therefore no evidence of difference in food 
consumption or hunger between those who developed HO and those remaining 
HWS. Eating rate, change in eating rate, VAS scores of fullness and pleasantness, 
change in fullness and the development of satiation were also no different between 
any of the groups.  This study was not therefore able to replicate evidence of 
hyperphagia in HO which has been reported in other studies [11, 23, 40, 41]. The 
lack of difference, however, is a pertinent finding as it highlights the lack of 
increased hunger in those with HO (although caution must be applied due to the 
small number of participants studied, risking the possibility of a Type II error). The 
evidence from the studies presented in this thesis are in contrast to individuals with 
Prader-Willi syndrome (PWS), where extreme hyperphagia is evident and 
orbitofrontal/pre-frontal cortex differences have been demonstrated on functional 
neuroimaging [171, 189, 195, 319]. While it is possible that sensory specific satiety 
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[220] was greater in the HO group than the other groups and a varied, free-buffet 
lunch may have led to different findings, there was no evidence to suggest this. The 
absence of hyperphagia in HO is in agreement with some other studies [42, 43]. 
The possibility that whilst intake over a single meal is not increased in HO, 
but that food frequency across the course of a day is increased, or that food choices 
are more unhealthy (higher calorie/fat/sugar content) in those with HO were not 
evident either. In the three-day food diaries (Chapter 6) there were no statistically 
significant differences in the number of reported eating episodes, amount of fat, 
protein, carbohydrate or sugar consumed, or the mean total calorie consumption per 
day (even when corrected for fat-free mass and basal metabolic rate). There are, 
however inconsistencies inherent in this method of real-world reporting.  
 Finally, in considering more long-term eating behaviour, the TFEQ showed 
some evidence of increased disinhibition in OC, but no other significant differences 
between the groups in median disinhibition, hunger or restraint scores. Increased 
disinhibition is associated with over-eating and increased BMI and previous studies 
report increased disinhibition in simple nutritional obesity [222]. Again there was a 
notable difference between the obese groups, as those with HO did not have evidence 
of increased disinhibition as was reported by OC, perhaps reflecting a lack of an 
external drive to over-eat, although possibly due to the low numbers of participants 
studied leading to a lack of power to demonstrate any differences. The wide range of 
disinhibition scores in those with HO is noted. Relevant to the three-day food diaries 
undertaken, individuals with high restraint scores have been shown to under-report 
dietary intakes [320], which may have contributed to a lack of difference in reported 
intake between OC and NOC (although there was no significant difference between 
these groups on reported TFEQ restraint scores). There were not enough participants 
in this study to consider eating behaviour as a covariant, however if larger studies 
were undertaken, then scores for eating behaviour (disinhibition, hunger and 
restraint) could be entered as covariates in statistical models to help to correct for 
measurement error in dietary intake reporting. Once again, however, accuracy is 
dependent on individuals not only being aware of their eating behaviour, but also 
being prepared to report it. 
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Hormone analysis from the UEM study day measured leptin concentrations 
and found them to be significantly higher in obese (HO/OC) compared to non-obese 
(HWS/NOC) participants. Leptin resistance has previously been described in both 
simple obesity [35] and HO [51].Both fasting and AUC active ghrelin were lower in 
patients (HO/HWS) compared to controls, but there was no difference between obese 
(HO/OC) and non-obese (HWS/NOC) participants, which might have been expected 
as ghrelin is known to be lower in obesity [36]. This may have been due to the use of 
a “non-obese” group for comparison, rather than a “lean” group, due to the higher 
BMI in those who remained HWS. The use of a lean group (BMI <25 kg/m
2
) in 
future studies would be beneficial, as would study of a larger number of participants, 
as the small number of participants studied may also have led to the lack of evidence 
of difference between the groups. 
 
 
Multiple different mechanisms have been proposed as the cause of weight 
gain and obesity in those with acquired, structural hypothalamic damage. The studies 
undertaken for this thesis found no evidence of several of these proposed 
mechanisms, including hyperphagia and increased energy intake or hyperinsulinism 
due to autonomic nervous system dysregulation. Studies were not undertaken to 
investigate whether reduced physical activity, reduced basal metabolic rate, 
melatonin dysregulation or enhanced 11-β hydroxysteroid dehydrogenase-1 activity 
could be causal contributors [11, 260-262]. It is possible that several mechanisms 
may be responsible and also that this may vary between individual patients or 
underlying pathologies [5, 7, 11]. 
Study of a larger, more homogenous patient group (for example only 
including patients with craniopharyngioma as the cause of hypothalamic damage) 
would have strengthened findings, however due to the rarity of this condition it was 
accepted at the outset that this would not be possible. One of the strengths of the 
functional neuroimaging study however was the use of stringent statistical thresholds 
when analysing the fMRI results. To prevent false-positive findings through the use 
of multiple comparisons, initial whole brain analysis (used to identify areas of BOLD 
signal which differentiated between food images and objects, which were then 
analysed using a region of interest approach) were corrected using a false discovery 
rate (FDR) of p ≤0.05 and a cluster size of k ≥3,000. This high statistical threshold 
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may have reduced the extent of positive findings and rejected additional significant 
voxel clusters where a moderate effect existed but which disappeared after 
correction. The use of a voxel threshold above 3,000 also excluded certain sub-
cortical areas, such as the nucleus accumbens and amygdala, which have been shown 
to differ between lean and simple obese individuals studied. These criteria did 
however reduce the chance of a Type I statistical error. This adds weight to the 
positive findings identified, as the small group sizes (in common with all 
neuroimaging studies) mean the study was only powered to reliably detect larger 
effect sizes.  
Taken in their entirety, these studies do not demonstrate a correlation 
between aberrant neural processing of food intake/eating and clear, appetitive 
behavioural differences in those becoming HO. They do however demonstrate 
differential BOLD signal in food reward-related brain regions in those remaining 
HWS compared to those becoming HO, with lower activation in the lingual gyrus 
and posterior insula. 
 
 
Future directions 
Study of a larger, more homogenous patient group, preferably prospectively 
from the time of diagnosis of hypothalamic damage and repeated after one-, 5- and 
10-year intervals, when obesity has developed or weight-stability has become 
evident, would further enhance and add to the findings in both the neuroimaging and 
eating behaviour aspects of this study. Large studies would necessitate a 
national/international collaborative approach, given the rarity of this condition, with 
consistent approaches to initial surgical management, testing and supplementation of 
pituitary hormone deficiencies, dietetic approaches and treatment of those in whom 
obesity and other cardiovascular risk-factors developed. Multi-centre fMRI studies 
are becoming more widely undertaken and have certain advantages, such as the 
ability to recruit more participants (especially in rare clinical conditions such as 
patients with acquired, structural hypothalamic damage) and to include a more varied 
and therefore representative sample from the general population, but do require 
careful planning in order to ensure consistency of data [321-323]. It is important to 
minimise variability between sites involved in multi-centre fMRI studies as much as 
possible by considering factors such as participant recruitment, cognitive paradigms 
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(including factors such as the presentation of visual cues, resting between scanning 
sessions and administration of questionnaires), participant population (homogeneity 
of the group vs. greater variability to allow the findings to be generalised to the more 
general population with hypothalamic damage and the need for a larger sample size 
where intra-group variability is increased) and scanner software and hardware 
(including scanner manufacturer and strength, type of head coil and the use of 
standard vs. special sequences) [321, 323]. Reassuringly, studies have shown that the 
use of different fMRI scanners in different centres and from different manufacturers 
might cause fewer inconsistencies than was feared [321, 323] although field 
inhomogeneities can exist even when the same make and model of scanner are used 
in different centres, leading to variances in data if not stringently addressed [322]. 
Consistent training of the staff involved in undertaking the study at each site is also 
important [323] as is statistical analysis. The involvement of different sites can be 
included as a covariate in statistical models, but consistent pre-processing and first-
level analysis is also essential [321]. 
Power calculations were undertaken using the online programme 
https://www.stat.ubc.ca/~rollin/stats/ssize/n2.html, based on a primary outcome of 
detecting a decrease in insula activation in the posterior insula of the HWS group 
compared to that of HO, studying only these two groups. Using the measured value 
from the study in this thesis of the mean BOLD signal in the posterior insula of the 
HO group (0.28) and pooled SD of 0.4 whilst viewing high-calorie food photographs 
compared to objects, a further study would require 129 participants per group to 
detect a 50% change in BOLD signal, at α=0.05 with 80% power and 33 participants 
per group to detect a 100% change. Secondary outcomes of lingual gyrus, NA and 
amygdala differences could also be studied, although these would have to be 
considered exploratory outcomes. 
 
Whilst the study characterising the microstructure of eating behaviour 
(Chapter 6) found no differences in cumulative change in eating rate at the UEM in 
those with HO compared to HWS or simple OC using repeated-measures ANOVA, 
visual ascription showed some evidence of an unusual eating pattern in those with 
HO. This may have been statistically significant in an appropriately powered trial 
and therefore use of this technique is warranted in further study of a larger group of 
participants. The same is true for the other tools examining aspects of eating 
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behaviour, as although there was no significant difference between HO and HWS, it 
is possible that this may reflect the size of the study groups (which were powered to 
detect differences in cerebral activation on fMRI) and by studying larger groups 
differences may become evident. Given the temporal pattern of weight gain 
commonly observed in patients with HO (initially rapid, followed by a slower rate of 
weight gain thereafter), changes in eating behaviour may occur over time, therefore 
further studies of food intake and eating behaviour may be better undertaken during 
this critical early phase of rapid weight gain.  
Power calculations were also undertaken for a further UEM study 
(https://www.stat.ubc.ca/~rollin/stats/ssize/n2.html). Using the measured value from 
the study in this thesis of a mean intake of 430g in the HO group and pooled SD of 
177 whilst eating until sated at the UEM, a further study would require 30 
participants per group to detect a 30% difference in food intake between HO and 
HWS, at α=0.05 with 80% power. Using the measured mean overall eating rate in the 
HO group of 62.4g/second and pooled SD of 21.7 whilst eating until sated at the 
UEM, 22 participants would be required per group to detect a 30% difference in 
overall eating rate between HO and HWS, at α=0.05 with 80% power. 
Finally, if further studies were to include the TFEQ, a total of 21 participants 
per group would be required to detect a 50% difference in restraint between HO and 
HWS based on a mean (pooled SD) of 13.0(7.5), 142 per group for a 50% change in 
disinhibition (mean in HO of 4.0, pooled SD 6) and 304 per group for a 50% change 
in hunger (mean in HO of 2.5, pooled SD 5.5) at α=0.05 with 80% power. 
 
 Another interesting avenue would be to study the effects of bariatric surgery 
or GLP-1 receptor agonists in the HO population, with fMRI and UEM studies 
before and after these treatments. A recent study of GLP-1 receptor agonists in 
simple obese individuals with and without type 2 diabetes showed a reduction in both 
their food intake and in previously increased insula and amygdala activation 
compared to lean controls when viewing food photographs [324]. Following bariatric 
surgery, studies of individuals with simple, nutritional obesity found lower 
motivation to eat and increased restraint [325, 326] as well as lower cerebral 
activation to food vs. non-food photographs in regions associated with food 
reward/hedonic responses and motivation to eat, including the insula [325, 327] and 
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lingual gyrus [326]. A difference also existed between types of bariatric procedure 
[327]. It would be particularly interesting to see whether the same insula and/or 
lingual gyrus reductions are seen in participants with HO undergoing bariatric 
procedures and whether this results in comparable insula/lingual gyral activation to 
that seen in HWS. 
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Table 1.2. Prevalence of obesity/weight gain in studies with mixed pathogenesis 
First 
Author 
Age (range) 
at diagnosis 
Number of patients Definition of weight 
gain/obesity 
Follow-up 
(range) 
Initially 
obese (%) 
Obese at latest follow-up (%) 
Daousi [6]  44 (17 – 78) 
years 
52 (42 with follow-
up); 24 PA, 22 CP, 6 
hypothalamic tumour 
BMI ≥ 30 kg/m2 and 
increase ≥ 2 kg/m2 
since diagnosis 
Median 5 
(1 – 19) 
years 
10/42 (24) 
Overweight 
28/42 (67) 
Obese: 22/42 (52) 
Overweight: 37/42 (88) 
BMI ≥ 35 kg/m2: 10/42 (24) 
Adachi [20]  0-15 years 
(at surgery)  
23; 10 CP, 7 
germinoma, 4 optic 
nerve glioma, 2 other 
> 20% overweight  
or body fat > 25% 
(M), > 30% (F < 11 
years), > 35% (F > 11) 
2-13 years - 12/23 (52%) 
Rakhshani 
[81]  
7.6 (2.2–
15.9) years 
39; 33 CP, 3 
germinoma, 1 lipoma, 
1 hamartoma, 1 
glioma 
Report BMI, BMI 
percentile and BMI 
SDS score 
0.3–3.4 
years 
Median BMI 
SDS 1.48 
(−0.6 to 3.6) 
BMI >95th% 27 (69), 85th–
95th% 6 (15), <85th% 6 (15) 
Median BMI SD 2.0 (−0.2 to 2.6) 
Lek [21]  Median 
(IQR) 7.49 
(3.47–11.59) 
years 
46; 11 pilocytic 
astrocytoma, 10 other 
glioma, 13 CP, 4 
prolactinoma, 8 other  
IOTF age- and sex-
adjusted BMI centile 
chart, intersects with 
BMI 30kg⁄m2 at 18 
Median 
3.93 (1.7–
7.3) years 
3/46 (6%) 
Median BMI 
SDS 0.73 
(0.03 to 1.40) 
20/46 (43%) at last follow-up 
 
Median (IQR) BMI SDS 1.85 
(1.11–2.72) 
Crowley 
[19]  
Adult 188 
70 CP, 89 NFPA, 29 
post- TBI 
Obesity: BMI >30 
kg/m
2 
Overweight: 
BMI 25– 29.9 kg/m2 
Median 8 
years (1-
50) for CP 
- CP 66% obese, 26% overweight 
NFPA 47% obese 
Post-TBI 31% obese 
PA = pituitary adenoma, CP = craniopharyngioma, M = male, F = female, NFPA = non-functioning pituitary adenoma
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Table 1.3. Prevalence of obesity/weight gain in craniopharyngioma studies  
First Author Age (range) at 
diagnosis, years 
Number 
patients 
Definition of weight 
gain/obesity 
Follow-up 
(range), yrs 
Initially obese (%) Obese at latest follow-up 
(%) 
Duff [22]  32 ≤ 16 years, 
89 >16 years 
98 Morbid obesity: 
weight ≥ 95th % 
Mean 10 (1-
20) 
10/92 (10.2) 35/92 (35.7) 
Stahnke 
[62]  
Mean±SD  
8.4± 3.3 
28 kg above normal 
weight for height 
- 2.0kg ± SD 3.57 
(12%) 
Grp 1: +3.78 ± SD 1.39kg 
Grp 2: +8.38 ± 2.23kg 
Hoffman  
[328]  
1.8 – 17.6 50  - 1-14, 39% at 
least 5 years 
18 at presentation, 30 
pre-operatively 
52 
 
Pinto 
[29]  
7.7 (2.8–14.5) at 
surgery 
17 Overweight: BMI >2 
SDS 
≤2 Overweight 5/17 (30%) 
 
BMI SD 1.1±0.4 
13/17 overweight (77%). 
BMI SD 4.6±1.5 at 2 years (9 
patients) 
Kalapurakal 
[329]  
Median 6 (1–15) 
 
25 - Median 10 
(3–16) 
- 8/25 (32%) 
Poretti 
[330]  
Mean 9.2 (2.8-
15.9) 
25 Obesity: BMI  > 97th 
centile 
11.3 (SD 7.6) 3/25 (12) 14/23 (61) 
Srinivasan 
[57]  
Mean±SD  
12.2 ±3.7 
15 Overweight: BMI 
85th-95th%,  
obese: BMI > 95th% 
Median 5.1 
(1.8–10.7) 
- Obese 8 (53), overweight 3 
(20) 
Caldarelli 
[331]  
Mean 9 (1.7 - 
15.8)  
52 - Median 9 3/52 (5.8%) 4/10 (40%) 
Kendall-
Taylor [25]  
AO mean 34.3  
(±12.0 SD) 
CO mean 11.8 
(±4.2 SD) 
241 AO; 
152 CO 
Obesity: BMI ≥30.0 
for males and BMI 
≥28.6 for females 
- - CO 39.1%; females 42.9%; 
males 36%.  
AO 51.8%; females 56.9%; 
males 47% 
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First Author Age (range) at 
diagnosis, years 
Number 
patients 
Definition of weight 
gain/obesity 
Follow-up 
(range), yrs 
Initially obese (%) Obese at latest follow-up 
(%) 
Pereira [72]  Median 29. 
 
54 BMI > 30kg⁄m2 49 (6–76)  21 (40%) 
Pierre-Kahn 
[332]  
- 14 BMI > 2 SD - 42.8% obese 
BMI SD 0.2-9.5, mean 
2.0  
85.7% obese  
After 1yr  mean BMI SD 6.3 
 
Tomita 
[333]  
Median 8.2 
(0.92-16) 
54 - 1 - 21 3/54 obese (5.6) Obesity 15/54 (27.8) 
Severe obesity 5/54 
Zuccaro 
[334]  
Mean 10.5 (0.04 
- 21) 
153 - 1-16 22% 35% 
Sainte-Rose 
[32]  
Mean 7.4 
 
66 Hypothalamic 
involvement on MRI 
Mean 7 Mean BMI SD 1.15 Morbid obesity 18% 
BMI correlated with degree 
hypothalamic damage 
Ahmet [33]  Mean age: 8.5 
(2.8-16.1) 
43 BMI ≥ 2 SD 
 
 
4.7 (0.3-10) 8 (19)  
7/8 had hydrocephalus/ 
hypothalamic damage 
25 (58), obesity associated 
with post-op hypothalamic 
damage (MRI) 
Balde [335]  44.7 (21-74) 35 - 7.4 (0.1-19.1) - 63% weight-increase, average 
17.5 ± 14.7 kg 
Vinchon 
[34]  
2.2 – 16.2 45 BMI > 2SD with 
hypothalamic 
involvement 
Mean 11 7 (15.6) 31 obese (70.5), 11 morbidly 
obese (25) 
Mean BMI 30.3 
Hamilton 
[121]  
<19 
 
 
46 BMI ≥ 95th% - - 50 
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First Author Age (range) at 
diagnosis, years 
Number 
patients 
Definition of weight 
gain/obesity 
Follow-up 
(range), yrs 
Initially obese (%) Obese at latest follow-up 
(%) 
Muller [117]  Median 10 (1.2 
– 18) 
120 Measuring change in 
BMI SDS (Δ) 
3 years - No lesion: BMI SDS Δ+0.45 
Anterior only: BMI SDS 
Δ+0.74. Anterior and 
posterior: BMI SDS Δ+3.22 
Gautier 
[24]  
Median (IQR) 
<10: 5.5 (4-6) 
10-18: 12.5 (11-
15) 
AO: 38 (28-52) 
171; 33 
< 10 yrs, 
32 10-18 
yrs, 106 
AO 
- - - BMI> 30 (%) 
<10 years: 19 (67.9) 
10-18 years: 8 (24.2) 
>18 years: 39 (41.5) 
Cohen [118]  Mean 10.7 (2–
17.2) 
33 Obesity: BMI 
SD >2. Severe 
obesity: BMI SD>4 
Mean FU 4.0 
(0.7–9.3) 
18-21%  52-65% (last decade 52%) 
Roth [336]  <21 10 BMI z -score >2 Minimum 2 - 5 (50) 
% = percentile, CO = childhood-onset, AO = adult-onset,  
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Table 1.5. Studies of ghrelin, PYY and HO. 
Number  Age at study  BMI/BMI SDS Fasting ghrelin  Fasting glucose  Fasting insulin  HOMA-IR  Fasting PYY 
Kanumakala 
[47]  
Median 
(years) 
Median (IQR) Median (IQR) 
pg/mL 
Median   
mmol/L 
Median 
pmol/L 
Median  
16 HO 
16 SO 
16NWCo 
p-value 
11.9 
13.8 
13.9 
   - 
5.86 (2.28) 6.59 
(3.63) 
0.63 (0.85) 
- 
1345 (437) 
1399 (354) 
1759 (602) 
0.01
a
, 0.88
b
 
4.35  
4.70 
4.70 
0.01
a
, 0.005
c 
89.7  
114.8 
32.8 
<0.001
a
, 0.78
b 
2.65 
3.41 
0.95 
<0.001
a
, 0.96
b
 
- 
- 
- 
Goldstone 
[39]  
Mean ± SEM 
(years) 
Mean ± SEM Mean ± SEM 
pmol/L 
Mean ± SEM  
mmol/L 
Mean ± SEM  
pmol/L 
Mean ± SEM   Mean ± SEM  
pmol/L 
9 HO 
15 NOC 
26 PWS 
16 SO 
48 ± 5
d,e 
31 ± 2
f 
28 ± 1
f 
38 ± 3 
33.1±1.6 
23.5±0.8
e,g 
32.0±2.0
d 
38.9±1.9
d 
471 ± 76
e
  
807 ± 82
g 
1009 ± 104
f,g 
462 ± 55
d,e 
4.9 ±0.1  
4.8 ±0.1 
4.8 ± 0.1 
5.1 ± 0.1 
111.2 ± 16.8
d,e 
46.8 ± 6.9
f,g 
46.4 ± 7.5
f,g 
105.2 ± 13.1
d,e 
3.21 ± 0.51
d,e 
1.35 ± 0.21
f,g 
1.41 ± 0.22
f,g 
3.26 ± 0.49
 d,e 
22.5±1.9 
20.6±1.6 
23.0±1.7 
23.8±1.8 
Part 2        
10 PWS 
8 NOC 
9 SO 
6 HO 
28 ± 2
f 
28 ±1
f 
34 ± 3 
43 ± 5
d,e 
31.7 ± 1.6
d 
22.0 ± 1.0
e,f,g 
37.3 ± 2.4
d 
34.1 ± 2.3
d 
979 ± 173 
742 ± 62
f,g 
414 ± 38
e 
430 ± 71
e 
4.4 ± 0.1 
4.7 ± 0.1 
4.8 ± 0.2 
4.8 ± 0.2 
38 ± 5
f,g 
46 ± 9
f,g 
97 ± 13
d,e 
138 ± 15
d,e 
1.02 ± 0.14
g 
1.27 ± 0.25 
2.79 ± 0.37
e 
3.94 ± 0.46
d,e 
- 
- 
- 
- 
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Number 
studied 
Age at study 
(years) 
BMI/BMI 
SDS 
Fasting ghrelin  Fasting glucose  Fasting insulin 
per kg fat mass  
HOMA-IR  Fasting PYY 
Daousi [2]  
Median 
(range) 
Mean ± SEM 
(kg/m
2
) 
Median (IQR) 
pmol/L 
Median (IQR) 
mmol/L 
 Median 
(IQR) 
Median (IQR) 
pmol/L 
14 HO 
15 SO 
p-value 
48.4 (29-75) 
48.7 (23-64) 
0.9
h 
37.8 ± 1.5 
37.5 ± 1.7 
0.9
h 
432.8 (306-569) 
564.7 (383-825) 
0.03
i 
5.6 (4.8–6.2) 
5.3 (5.1–5.8) 
 
- 
- 
1.6 (1.3-3.7) 
1.4 (0.9-2.0) 
0.1
h 
29.7 (22.4-36.4) 
23.7 (16.9-28.1 ) 
0.06
j 
Holmer [3]  
Median 
(range) 
Median 
(kg/m
2
) 
Median (range) 
pg/mL 
Median (range) 
mmol/L 
Median (range) 
mIU/L/kg 
  
42 CP 
 
42 controls 
p-value 
F 28 (18–57) 
M 29 (17–57) 
- 
- 
30 (19-41) 
 
23 (18-36) 
<0.001
k 
1013 (628-2532)  
 
1344 (341-3455) 
0.008
l 
- 
 
- 
- 
0.19 (0.05-0.59)  
 
0.21 (0.05-0.33) 
>0.5
m 
- 
- 
- 
- 
- 
- 
- 
- 
With TVE 
Without TVE 
p-value 
- 
- 
- 
32 (21–41) 
25 (19–35) 
0.001
n 
970 (328-1785) 
1197 (764-2532) 
0.008
o 
- 
- 
- 
0.21 (0.05-0.59) 
0.15 (0.06-0.35) 
0.05
p 
- 
- 
- 
- 
- 
- 
 
SO – simple obese; NWCo – normal-weight controls; HO – hypothalamic obese; NOC – non-obese controls; PWS – Prader-Willi syndrome; CP 
– craniopharyngioma. IQR – interquartile range; SDS – standard deviation score; SEM – standard error of the mean; AUC – area under the 
curve; HOMA-IR - homeostatic model assessment-insulin resistance. a: significant differences between the groups, b: no significant difference 
between HO and SO, c: statistically significantly lower fasting glucose in HO than in SO, d: p<0.001 vs. NOC, e: p<0.001 vs. PWS, f: p<0.001 
vs. HO, g: p<0.001 vs. SO, h: no significant difference between HO and SO, i: significantly lower in HO vs. SO, j: significantly lower in SO vs.  
(Continues over) 
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HO, k: significantly higher BMI in CP vs. controls, l: significantly lower ghrelin in CP vs. controls, m: no significant difference between CP and 
controls, n: significantly higher BMI in those with TVE than those without, o: significantly lower ghrelin in those with TVE than those without, 
p: borderline significantly higher fasting insulin per kg fat mass in those with TVE than those without.
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Table 1.6. Studies of leptin and HO. 
Number  Age at study, years BMI SDS/ BMI Leptin:BMI ratio Free leptin index  Leptin Leptin/kg fat mass 
Holmer [3]  
Median Median BMI (IQR) 
kg/m
2
 
  Median (range) 
ng/mL 
Median (range) 
ng/mL·kg 
42 CP 
42 controls 
p-value 
F 28, M 29 
- 
30 (19-41) 
23 (18-36) 
<0.001
a 
- - 
25 (3-215) 
8 (2-37) 
<0.001
b 
0.8 (0.2 - 4.5) 
0.4 (0.1-1.4) 
<0.001
c 
With TVE 
Without TVE 
p-value 
- 
- 
32 (21–41) 
25 (19–35) 
0.001
d 
- - 
28 (4-215) 
16 (3-67) 
0.07
e 
0.7 (0.3-4.5) 
1.0 (0.2-1.6) 0.05
f 
Guran [51]  
Median (IQR) Median BMI SDS 
(IQR) 
Median (IQR) Median (IQR) Median (IQR) 
ng/mL 
 
23 HO 
16 HNO 
22 SO 
p-value 
10.3 (8–14.6) 
11.4 (8.9–14.1) 
10.8 (8.9–12.8) 
NS
g 
2.0 (1.5-2.1) 
0.18 (-0.5-0.56) 
2.1 (1.8-2.3) 
<0.001
h 
4.0 (1.6-5.2) 
1.5 (0.8-3.1) 
2.5 (1.8-3.5) 
<0.05
i 
2.0 (0.8-3.5) 
0.6 (0.3-1.2) 
1.5 (1-2.3) 
<0.05
i
 
89.2 (41–144) 
25.3 (13–53) 
66 (48–90) 
<0.05
i
 
- 
Patel [53]   Mean (SD) BMI 
SDS 
  Median (IQR) 
ng/mL 
Median leptin/BMI 
(IQR) mcg/L:kg/m
2
 
BMI < 2 SDS: 
17 patients  
57 controls 
p-value 
 
14.6 (10.9-17.2) 
13.4 (11.6-15.3) 
0.3
j 
 
0.9 (0.9) 
0.4 (0.7) 
0.02
k 
   
9.2 (4.4-17.6) 
4.5 (2.3-9.4) 
- 
 
0.42 (0.27-0.72) 
0.23 (0.13-0.45) 
0.02
k 
BMI ≥ 2 SDS: 
17 patients 
28 controls 
p-value 
 
13.8 (9.2-15.6) 
12.6 (9.6-13.7) 
0.1
j 
 
2.6 (0.6) 
3.1 (0.7) 
0.03
l 
   
26.9 (18.4-47.6) 
26.8 (16-53.4) 
- 
 
1.08 (0.72-1.57) 
0.95 (0.63-1.35) 
0.6
j 
HNO – hypothalamic non-obese; TVE – third ventricular extension. IQR – interquartile range; SDS – standard deviation score. (Continues over) 
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a: significantly higher BMI in CP vs. controls, b: significantly higher leptin in CP vs. controls, c: significantly higher leptin/kg fat mass in CP vs. 
controls, d: significantly higher BMI in those with TVE than without, e: significantly higher leptin in those with TVE than without, f: 
significantly lower leptin/kg fat mass in those with TVE than without, g: no significant differences between the groups, h: significantly lower 
leptin in HNO vs. HO and SO, i: significantly higher in HO and SO vs. HNO, j: no significant difference between patients and controls, k: 
significantly greater in patients than controls, l: significantly lower in patients than controls.  
 
 
 
 
Table 1.7. Fasting leptin, adiponectin and resistin concentrations (adjusted for fat mass) in patients with HO, CH and SO controls [52]  
 Mean leptin 
concentration (pg/mL) 
Mean adiponectin 
concentration (ng/mL) 
Mean resistin 
concentration 
(pg/mL)  
Number (%) with 
fasting insulin >132 
pmol/L 
Number (%)  with 
HOMA-IR > 2.5  
HO 3420 277 7560 7/28 (26) 6/28 (22) 
CH 2795 219 4590 5/18 (28) 5/18 (27) 
SO 2240 225 4260 8/23 (35) 8/23 (34) 
p < 0.01
a 
< 0.05
b 
<0.01
a,c
, < 0.05
a,d
 = 0.680
e 
 
HOMA-IR > 2.5 (adult cut-off for insulin resistance). All biochemical parameters were adjusted for fat-mass; adiponectin and resistin also 
adjusted for gender and age; fasting insulin and HOMA-IR also adjusted for gender, age and pubertal status.  a: significant difference between all 
three groups, b: significant difference between HO and both CH and SO, c: significant difference between HO and CH, d: significant difference 
between HO and SO, e: no significant difference between the groups 
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Table 1.8. Studies of insulin and HO. 
Number BMI (kg/m
2
) BMI SDS Fasting insulin Peak insulin AUC insulin HOMA-IR Insulin sensitivity 
Simoneau-
Roy [54]  
Mean ± SD Mean ± SD Mean ± SD  
pmol/L 
Mean ± SD  
pmol/L 
Mean ± SD  
pmol/L 
- WBISI 
Mean 
IS  
Mean  
15 CP 
15 SO 
p-value 
35.2 ±8.0 
33.5 ± 4.9 
0.49
a 
2.2 ±14.6 
2.1 ± 0.3 
0.53
a 
242.2 ± 160 
161.3 ±84.3 
0.11
a 
4456 ± 2084 
3028 ± 1335 
0.03
a 
4443 ±2750 
2534 ± 1113 
0.03
a 
- 
- 
5 ± 5 
7 ± 6 
0.11
a 
0.96± 0.3 
1.7±0.7 
0.01
a 
Roth [4]  Median (IQR) Mean ± SEM Median (IQR) 
mU/L 
- - Median (IQR) QUICKI 
15 CrO 
12 CrNW 
15 SO 
12 NOC 
32.9 (30.2 - 36.8)
b 
22.8 (20.1 - 26.6)
b 
31.8 (29.5 - 35.3)
b 
20.2 (16.8 - 24.2)
b 
2.9 (2.5 to 3.4)
b 
1.3 (0.8 to 
1.8)
b
2.6 (2.4 to 
2.8)
b 
1.0 (−0.1 to1.7)b 
28 (12-58)
c,d 
10.5 (6.7-21.5)
e 
15.2 (7.9-23.3)
d,f 
7.4 (2.5-11.5)
c,e,f 
- - 6.0 (2.9-11.1)
 c,d 
2.4 (1.3 - 6.3)
e,g 
3.6 (1.9 - 5.4)
g 
1.83 (0.6 - 2.4)
e 
0.29 (0.27-0.32)
 c,d 
0.34 (0.30 - 0.36)
e 
0.32 (0.3 - 0.35)
f 
0.35 (0.33 - 0.42)
e 
Goldstone 
[39]  
Mean ± SEM - Mean ± SEM  
pmol/L 
Mean ± SEM 
pmol/L 
Mean ± SEM 
min·nmol/L 
Mean ± SEM 
pmol/L 
- 
10 PWS 
8 NOC 
9 SO 
6 HO 
31.7 ± 1.6
h 
22.0 ± 1.0
h,i,j 
37.3 ± 2.4
i 
34.1 ± 2.3
j 
- 38 ± 5
k,l
 
46 ± 9
i,j 
97 ± 13
j,l 
138 ± 15
j,k
 
498 ± 77 
415 ± 96
j 
583 ± 64 
1016 ± 133
j 
49.3 ± 5.8
k 
37.4 ± 5.7
j 
68.2 ± 8.0 
113.2±13.7
j,k 
306 ± 38
k
 
222± 35
j 
431 ± 53 
733 ± 83
 j,k 
- 
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Number BMI (kg/m
2
) BMI SDS Fasting insulin Peak insulin AUC insulin HOMA-IR Insulin sensitivity 
Lustig 1999 
[56]  
Mean ± SEM - Mean ± SEM 
U/mL 
Mean ± SEM 
U/mL 
- - - 
8 HO 
NOC 
36.0 ± 2.5 
Not stated 
- 23 ± 5 
- 
281 ± 47
m 
92 
- - - 
Lustig 2003 
[55]  
Mean ± SEM - Mean ± SEM 
U/mL 
Mean ± SEM 
U/mL 
- - - 
9 on Octreotide 
9 on placebo 
37.4 ± 2.5
m 
36.8 ± 1.2
m 
- 29.2 ± 4.9
m 
36.9 ± 6.8
m 
205.2 ± 22.2
m 
308.8 ± 49.3
m 
- - - 
Srinivasan 
[57]  
- Mean (± SD) Median (range) 
pmol/L 
- - - Min/mUL/min 
9 patients 
9 controls 
p-value 
- 2.24 ± 1.0 
2.59 ± 1.3 
0.26
n 
91 (30-192) 
82 (51-208) 
0.68
n 
- - - 0.95 (0.43-2.48) 
1.17 (0.39-1.74) 
0.86
n 
CP – craniopharyngioma; SO – simple obese; CrO – craniopharyngioma with obesity; CrNW - craniopharyngioma normal weight; NOC – non-
obese controls; PWS – Prader-Willi syndrome; HO – hypothalamic obese; CH – congenital hypopituitarism; HNO – hypothalamic non-obese. 
IQR – interquartile range; SD – standard deviation; SEM – standard error of the mean; AUC – area under the curve; HOMA-IR - homeostatic 
model assessment-insulin resistance; QUICKI -  quantitative insulin sensitivity check index. a: difference between patients with CP and SO, b: 
no significant difference between NOC and CrNW or SO and  CrO, but significant difference between lean and obese groups, c: p<0.01 in CrO 
vs. NOC, d: p<0.05 in CrO vs. SO, e: no significant difference between CrNW and NOC, f: p<0.05 in SO vs. NOC, g: p<0.05 in SO vs. CrNW, 
h: p<0.001 in PWS vs. NOC, i: p<0.001 in NOC vs. SO, j: p<0.001 in NOC vs. HO, k: p<0.001 in PWS vs. HO, l; p<0.001 in PWS vs. SO, m: 
no statistical comparison undertaken, n: no significant difference between patients and controls
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Table 1.9. Holmer et al [3] Insulin Table 
 
TVE = third ventricular extension. a: significantly greater in patients vs. controls, b: no significant difference between patients and controls, c: 
significantly greater in patients with TVE than those without, d: no significant difference between patients with TVE than those without 
  
 Number 
studied 
BMI (kg/m
2
) 
Median (range)  
Fasting insulin  
Median (range) 
mIU/L 
Insulin/kg fat 
mass  
Median (range)  
Fat mass 
Median (range) 
Fat-free mass  
Median (range) 
Patients 
Controls 
p value 
42 
42 
- 
30 (19-41) 
23 (18-36) 
<0.001
a 
6 (1-38) 
3 (1-13) 
<0.001
a 
0.19 (0.05-0.59) 
0.21 (0.05-0.33) 
>0.5
b 
32 (9-64) 
16 (8-46) 
<0.001
a 
55 (40-86) 
55 (37-73) 
0.01
a 
Patients with TVE 
Patients without TVE 
p value 
25 
17 
- 
32 (21-41) 
25 (19-35) 
0.001
c 
7 (2-38) 
4 (1-8) 
<0.001
c 
0.21 (0.05-0.59) 
0.15 (0.06-0.35) 
0.05
d 
40 (9-64)  
20 (12-56) 
0.003
c 
57 (41-86) 
51 (40-68) 
0.02
c 
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Table 1.10. Studies of octreotide [56]. 
Study type  Open-label Octreotide (max 15 mcg/kg/day) [56]  Double-blind placebo-controlled (octreotide max 15 
mcg/kg/day) [55]  
Participants  9 pre-pubertal children (4 M, 5 F; aged 10 - 18 years) with 
HO secondary to leukaemia (2 patients) or brain tumours 
where hypothalamic damage expected (7) and weight gain > 
2 SDS. ≥2 years post-tumour diagnosis 
20 children  (11 M, 9 F; age 14.2 ± 0.7 year) with HO (weight 
gain more than + 2 SDS) secondary to intracranial tumour (13 
CP, 4 hypothalamic astrocytoma, one pineal germinoma) or 
cranial irradiation for ALL (2 patients). ≥1 year post-tumour 
diagnosis 
Before 
treatment 
Mean weight gain previous 6 months: 6.0 ± 0.7 kg (range 
4.1-9.2)   Mean increase in BMI +2.1 ± 0.3 kg/m
2
 (range 1.0-
3.2) 
Mean BMI (± SEM) 36.3 ± 1.3 kg/m
2
 
Annualized weight gain 17.1 ± 3.0 kg/year 
Latest BMI  9 octreotide treated:  - 0.2 ± 0.2 (range - 0.7 to + 0.9) kg/m2 
9 placebo treated:  + 2.2 ± 0.5(range + 0.1 to + 4.4) kg/m2 
Follow up 1 patient 5 months, 7 patients 6 months  6 months 
Side effects  7 had self-resolving abdominal symptoms within the first 
month; 4 had gallstones/gallbladder sludging (self-resolved 
by 6 months after discontinuation of octreotide)  
Octreotide-treated: all had self-resolving abdominal symptoms, 
gallstones or biliary sludging (4 participants, treated with 
ursodeoxycholic acid at 6 months) which resolved by 12 months 
despite continuation of octreotide. 1 had poor compliance. 
3 placebo-treated patients suffered diarrhoea 
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Study Open-label Octreotide (max 15 mcg/kg/day) Double-blind placebo-controlled  
Treatment 
prematurely 
stopped  
1 participant discontinued octreotide within first month due 
to severe peripheral oedema, 1 was non-compliant, 1 dropped 
out after 5 months due to failure to lose weight 
2 additional patients were excluded (1 octreotide-treated, 1 
placebo-treated) for craniopharyngioma recurrence and 
hyperosmolar non-ketotic coma respectively 
Biochemical 
assessment 
All had lower IGF-1 concentrations after six months of 
octreotide; five with measureable GH on stimulation testing 
at baseline had lower peak GH 
IGF-1 essentially unchanged.  
Outcomes Mean weight loss 4.8 ± 1.8 kg at study end (range-12.8 to 
+1.8kg, p=0.0003 on paired t test); mean change in BMI -2.0 
± 0.7 (range -4.7 to +0.8, p=0.0004 on paired t test) kg/m
2
 
Ongoing weight gain on placebo (mean weight gain + 9.2 ± 1.7 
kg, range 3.8 to 19.8; mean BMI increase + 2.2 ± 0.5 kg/m
2
, 
range 0.1 to 4.4) compared to weight stability on octreotide 
(mean weight increase 1.6 ± 0.6 kg, range -0.9 to 5.3, p<0.001; 
mean change in BMI -0.2 ± 0.2 kg/m
2
, range -0.7 to 0.9, 
p<0.001). 
Weight loss in months 4-6 of octreotide treatment. 
Parent-reported improvement in QoL in physical functioning in 
those on octreotide therapy compared to controls (p = 0.03), 
however child-reported QoL remained unaltered 
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Table 1.11. Studies of energy expenditure (EE) and energy intake (EI). 
Study and 
number 
BMI SDS  BMR Adjusted 
BMR 
Activity Energy intake 
Harz [43]  Mean SD ±SEM - - Movement (cpm)  
9 CP home 
11 controls home 
p-value 
2.9±3.0 
2.7±2.7 
- 
- - 228 
282 
0.08
a 
 
10 CP hospital 
15 controls hospital 
p-value 
4.2±2.1 
5.2±1.9 
- 
- - 228 
298 
0.01
a 
 
Shaikh [65]  Median SD Mean±SE kcal/day Mean 
kcal/day 
Total active minutes 
Median(range) 
Mean±SE kcal/day 
18 HO 
13 CH 
16 SO 
p-value 
2.74 
2.44 
3.21 
NS
b 
1667 ± 108 
1535 ± 94 
2150 ± 110 
p<0.01
c 
1619 
1789 
2028 
p<0.001
d 
4,607 (863-6,027) 
4,227 (2,594-5,003) 
4,560 (2,887-5,013) 
NS
b
 
1980 ± 204 
1569 ± 103 
1782 ± 141 
NS
b
 
Holmer [3]  BMI (kg/m
2
) Median % of expected    Median (range) 
42 CP 
42 controls 
p-value 
F: 31 (19-41) M: 28 (21-41) 
F: 21 (18-36) M: 24 (20-34) 
- 
85 (38-126) 
90 (78-101) 
0.003 
- 
- 
- 
- 
- 
- 
1778 (970-3230) 
2094 (1128-5449) 
0.003 
CP = craniopharyngioma,  cpm = counts per minute, BMR = basal metabolic rate. a: significantly lower in CP than controls, b: no significant 
differences between the groups, c: significantly lower in HO and CH vs. SO, d: significantly lower in HO vs. SO, e: significantly lower in CP 
than controls.  
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Table 1.12 Mortality rates 
Study Number 
studied 
Lesion Deaths SMR 
(95% CI) 
SMR (95% CI) in 
selected patients 
Median follow-
up (range) 
Cause of death 
Bulow [71]  60 children 
and adults 
CP 27 (45%) 5.55 (3.68-
8.22) 
F 11.4 (4.9-22.5) 
M 4.79 ( 2.9-7.8) 
12.5 years (1 
day to 40 years) 
 
Pereira 
[72]  
54 children 
and adults 
CP 10 
(18.5%), 
7 female. 
2.88 (1.35-
4.99) 
F 3.8 (1.5-7.2) 
M 1.8 (0.3-4.6) 
10 years (0.5-
37) 
3 infection/sepsis, 1 
Addisonian crisis, 2 
carcinoma, 4 CV events 
Crowley 
[19]  
70 children 
and adults 
CP 21 deaths 
(30%) 
 
8.75 (5.4-
13.3) 
 
F 10.5 (5.0-19.3) 
M 7.6 (3.8-13.5) 
8 years (1-50) 3 CP, 4 other tumours, 3 
CV, 2 CVD, 5 respiratory, 4 
other causes 
Tomlinson 
[73]  
1014 NFPA 57% 
CP 12% 
PRLma 9% 
Idiopathic 
HP 9% 
 Operated: 
1.86. 
Non-
operated: 
1.23 
RTx 2.1, without RTx  
1.5 
CP 8.7, other 1.5 
Untreated Gn deficiency 
2.7, treated 1.3 
 CP patients: CVD SMR 
19.4, respiratory SMR 22.1  
Post-RTx: SMR 4.36 vs. 
1.64 without (p=0.001) 
Neilsen 
[74]  
5412 HP  1.21-3.80 
 
F weighted 2.8 (2.6-3.0) 
M weighted 2.1 (1.9-2.2) 
  
Muller [28]  183 
children and 
adults 
CP 10 deaths 
(5.5% ) 
 
 BMI SDS ≥ 7 20 year 
survival 0.76 (± 0.15) 
BMI SDS 2-7 20 year 
survival 0.96 (± 0.03) 
BMI SDS < 2, 20 year 
survival 0.94 (± 0.04) 
10.8 years (2.2-
25.9) 
2 peri-operative 
deaths excluded 
1 MI, 2 ICH, 1 adrenal 
insufficiency. 
3 “hypothalamic 
dysregulation” 
SMR = standardised mortality rate, CP = craniopharyngioma, NFPA = non-functioning pituitary adenoma, PRLma = prolactinoma, HP = 
hypopituitarism, CV = cardiovascular, CVD = cerebrovascular events, RR = relative risk, SAH = subarachnoid haemorrhage, ICH = intracerebral 
haemorrhage, HP = hypopituitarism, RTx = radiotherapy 
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Table 1.13 Cardiovascular mortality rates 
Study Number of 
patients 
Lesion SMR or RR (95% CI) Risks/cause of death 
Bulow 
[77]  
344 CP or PA CVD SMR 3.39 (2.3-4.99) 
F 4.9 (2.6-8.4) 
M 2.6 (1.4-4.4) 
 
CV SMR 1.75 (1.4-2.19) 
Under 55 years: SMR 6.7 (3.4-12.1) 
Over 55 years: SMR 2.5, 95% CI 1.5-4.3 
Brada 
[78]  
334 PA:  
31% hormone 
secreting,  
63% non-
secreting,  
6% unknown 
RR death 1.58 (1.3-1.9) 
 
Surgically debulked: RR 5.19 (3.5-7.4) 
compared to biopsy only/ no surgical 
intervention 
Pituitary or hypothalamic disease RR 600 (120-1080)  
Other brain tumours RR 8.3 (1.0-15.6) 
 
CVD RR 4.11 (2.7-5.5) - 33 deaths compared to 8 
expected, including 3 SAH 
SMR = standardised mortality rate, RR = relative risk, CP = craniopharyngioma, PA = pituitary adenoma, CVD = cerebrovascular events, CV = 
cardiovascular, SAH = subarachnoid haemorrhage
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Table 1.14. Hamilton [121] use of diazoxide and metformin 
Study type  Open-label, pilot study 
Treatment Diazoxide 2mg/kg/day (max 200 mg/day) and metformin 1g bd 
Participants  7 patients (5 M, 2 F; mean age 15.4 years, range 9.2-18.3) with HO 
secondary to CP, ≥ 1year post-resection with panhypopituitarism. All 
had received at least 6 months of diet and exercise advice 
Pituitary 
disease 
Mean time since diagnosis 5.9 (2.8-8.7) years 
BMI before 
treatment 
Mean BMI 35.5 ± 5.6 kg/m
2
, mean BMI SDS +2.3 (1.8-2.96) 
Latest BMI Mean BMI: −0.3 ± 2.3 (prev 6 months +2.2 ± 1.5 kg/m2, p = 0.02) 
Mean BMI SDS: −0.04 ±0.15 (prev 6 months +0.11 ± 0.08, p=0.02) 
Follow up 6 months 
Side effects  Pedal oedema, vomiting, mildly elevated liver enzymes 
Treatment 
prematurely 
stopped  
9 patients originally recruited, 2 withdrew due to side-effects: 1 had 
pedal oedema after 2 months treatment; 1 experienced vomiting with 
mildly elevated liver enzymes 
Biochemical 
assessment 
All patients had normal fasting and stimulated glucose levels on 
OGTT at baseline and latest follow-up. Insulin sensitivity improved 
from mean±SD 2.2±1.1 to 5.7±8.1. AUC insulin dropped from mean 
2078.8 ± 668.8 pmol/L to 1438.3 ±988.5 pmol/L 
Outcomes 3 patients lost weight, all gained less weight than previously. 
Mean BMI± SD changed by -0.6 ± 2.3 kg/m
2
 after treatment 
compared to +2.2 ± 1.5 kg/m
2
 before (p = 0.02) and mean BMI SDS 
by -0.04 ± 0.15 compared to +0.11 ± 0.08 (p = 0.021) the preceding 
six months. 
AUC insulin at baseline was significantly correlated with a decrease 
in BMI (r = 0.096, p = 0.009). There was no correlation for either 
leptin or adiponectin and no difference in baseline and study-end 
WBISI, AUC insulin, adiponectin, leptin, liver enzymes or fasting 
lipids 
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Table 1.15. Studies of Dextroamphetamine 
Study type  Mason [41] Open-label Ismail [122] Retrospective case-note review 
Treatment Dextroamphetamine 12.5-20 mg/day 5 mg dextroamphetamine bd 
Participants  5 children (3 M, 2 F; mean age 8.3 years, range 6-9). HO 
secondary to CP. All had post-operative hypothalamic damage 
with absent 3rd ventricular floor. All served as their own control 
12 patients (7 F, 5 M; median age 15.1 years in F, 19.6 years 
in M). 9/12 CP. All had surgery (6 total resection); 7 received 
> 51 Gy radiotherapy. All had ≥ 1 pituitary hormone deficit 
Pituitary 
disease 
Mean duration 10.4 months  Median 7.3 years (range 3.3 – 20.5) after tumour diagnosis 
BMI before 
treatment 
Mean BMI at study 32 ± 2.8 kg/m
2
, mean weight gain 2 ± 0.3 
kg/m
2
/month 
Not reported 
Latest BMI  Mean BMI 31±3.3  kg/m
2
 Not reported 
Follow up 24-months Median 15 months (6 – 48) in F and 13 months (7 – 63) in M 
Side effects  Headache (1 participant), resolved with dose decrease. Cyst 
enlargement (1 patient) treated with shunt then radiotherapy 
Insomnia (1 patient), resolved when evening dose omitted. 
Treatment discontinued (1 patient) due to tumour recurrence 
Outcomes Weight gain significantly decreased (mean increase 0.4 ± 0.2 
kg/month, p = 0.009). Decreased mean BMI (31 ± 3.3 kg/m
2
) 
No difference in calorie intake (mean daily calories pre- 
treatment 1189 ± 69, post-treatment 1335 ± 137).  
Increase in physical activity from < 1 hour/day to >2 hours. 
Weight stabilisation/loss in 10. Median reduction in SDS: M   
-0.7 after median 13 months; F -0.44 after 15 months. 
Concentration and exercise tolerance were improved, 
with/without improvement in daytime somnolence 
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Table 1.16. Molloy [123]. Effects of phentermine and dl-fenfluramine or fluoxetine 
Study type  Conference abstract 
Treatment Phentermine with either dl-fenfluramine or fluoxetine with behaviour 
modification 
Participants  10 patients. HO (ideal body weight > 130%) secondary to CP, 
hypothalamic glioma or optic chiasm glioma. No details of age, 
gender, or duration of pituitary disease. One had pre-morbid obesity 
BMI  Weight 165-243% of ideal body weight. Latest BMI - not reported 
Follow up 5 treated for > 3 months  
Co-
morbidities 
5 patients had depression/mood disorder, 4 ADHD and 3 general 
anxiety 
Side effects  No “significant toxicity” or echocardiographic changes 
Outcomes Weight loss 2.9-13.2 kg (mean 7.5kg). No further details given  
 
 
Table 1.17 Greenway [124] Effects of caffeine and ephedrine 
Study type  Observational case studies 
Treatment Caffeine and ephedrine 
Participants  3 F (15, 16 and 25 years). HO secondary to CP (2 patients), pituitary 
adenoma (1 patient). Panhypopituitarism All had surgical resection.  
BMI  27.7 – 41.4 kg/m
2
 Latest BMI - not reported 
Follow up 2-6 years 
Co-
morbidities 
Hemiparesis and visual field loss due to intra-operative carotid artery 
tear and optic nerve damage (1 patient). Cholecystectomy (1 patient) 
Side effects  Shaking (1 patient, resolved) 
Outcomes 2 lost weight: 8-9%, sustained for 2 years.  
1 patient initially lost weight (14% in six months) but weight loss 
stabilised and metformin, propantheline bromide, cimetidine, growth 
hormone and Orlistat were added then discontinued (chronologically). 
Bariatric surgery after 5 years as weight returned to baseline 
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Table 1.18. Fernandes [125] Treatment with triiodothyronine (T3) 
Study type  Observational 
Treatment Supraphysiological doses of T3 25 – 60 micrograms/day 
Participants  3 children (2 F, 1 M). HO secondary to pineal germ call tumour and 
anaplastic astrocytoma, optic glioma and suprasellar mixed germ-
cell tumour. All treated with surgery, chemotherapy and 
radiotherapy. Panhypopituitarism including DI  
Pituitary 
disease 
3.5 – 14 years after diagnosis 
BMI  28.1 kg/m
2 
fell to 21.6 kg/m
2
 
25.7 kg/m
2
 (BMI SDS 2.7) fell to 20.64 kg/m
2
 
25.2 kg/m
2
 (BMI SDS 2.1), latest not reported 
Follow up ≤ 27 months 
Initial 
investigations 
All had T4 in normal range, 2 had T3 in normal range.                    
Patient 1 - BMD: lumbar spine T-score of -3.02 and total hip T-
score of -3.4 (right) and -3.1 (left) 
Investigations 
on treatment  
All had raised T3 levels (242-490 ng/dL). Patient 1 - BMD: lumbar 
spine T-score -1.2, total hip T-score -2.5 (right) and -2.0 (left) 27 
months after starting T3 
Side effects  None 
Outcomes Weight loss 4.3-14kg. 
Patient 2: Height velocity  improved to 8.6 cm in the 11 months 
following T3 administration (previously 4.7 cm/year, despite GH 
treatment)  
Patient 3:  Improvement in school performance reported. 
All reported improvement in energy levels and decrease in appetite 
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Table 1.19. Treatment with incretin mimetics. 
Study Simmons [128]. Thondam [127]  Zoicas  [129]  
Treatment Exenatide 5 micrograms twice daily Exenatide then liraglutide 8 exenatide (mean TDD 11.4 g), 1 liraglutide (0.6 mg) 
Participants  M, 17 years, hypothalamic germ cell 
tumour. Received chemotherapy and 
36 Gy craniospinal RTx, with 18 Gy 
cranial boost. Panhypopituitarism 
(replaced except GH) 4 years 
F, 42 years, hypothalamic 
tumour 33 years previously. 
Received cranial RTx and 
intracranial shunt. GHD, 
partially sighted, self-reported 
hyperphagia 
9 patients - 8 M, 1 unknown; mean age 35.1 years 
(range 17 – 49). 6 Cr, 1 pilocytic astrocytoma, 1 
hypothalamic hamartoma (all surgically resected, 1 
RTx), 1 germinoma (RTx alone). One untreated GHD, 5 
required DDAVP and testosterone supplementation. 
Mean duration pituitary disease 9.5 years (range 3 – 36) 
Initial BMI  39.3 kg/m
2 
 65.1 kg/m
2
 Mean BMI 37.6 ± 7.2 kg/m
2
  
Latest BMI  29.1 kg/m
2
 at 32 months. 1 yr after 
discontinuation: BMI 33.7 kg/m
2
 
61.5 kg/m
2 
after 4 years 
follow-up 
Mean BMI 33.4 kg/m
2
 at last follow-up, p<0.01 
Treatment duration 6-51 months (mean 24.3 months) 
Co-
morbidities 
T2DM, NASH, borderline 
hypertension, osteopenia. 
T2DM (poorly controlled), 
OSA, hyperlipidaemia.  
8 had T2DM 
Side-effects  Occasional nausea, improved 
with liraglutide 
Nausea and vomiting (1 discontinued Exenatide after 2 
weeks, 1 after 6 months, 1 continued despite vomiting) 
Outcomes Weight loss 29 kg after 2.5 years. 
BP and LDL cholesterol improved  
Reduced food cravings, 
increased satiety. 
8 treated and followed-up for at least 6 months lost 
weight. 6 improved appetite/satiety. Significant 
improvements in mean HbA1c (p<0.05), HOMA-IR 
(p<0.05) and fasting triglycerides (p<0.05) 
RTx = radiotherapy, GH – growth hormone, T2DM = Type 2 diabetes, NASH = non-alcoholic steatohepatitis, OSA = obstructive sleep apnoea  
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Table 1.20. Bariatric surgery case reports 
Case report Participant Initial 
management 
Pituitary 
disease 
Co-morbidities Surgery Pre-op 
BMI 
Last 
BMI  
Follow 
-up 
Outcomes 
Inge [130]  14 year-old M, 
CP.  
Subtotal 
resection, RTx. 
Post-operative 
hyperphagia 
Diet and 
exercise, 
octreotide - 
ameliorated 
weight gain 
Fully 
replaced 
(inc GH). 
Duration 
4 years 
LVH, OSA. 
Raised insulin 
and triglycerides 
RGB 
with TV 
aged 18 
years 
67  52.7  30 
months 
Co-morbidities 
improved 
Schultes 
[131]  
8 year-old M, 
CP, surgical 
resection. 
Absent 
hypothalamus 
on MRI brain 
Diet and 
exercise, 
Sibutramine 
Fully 
replaced 
(inc GH). 
Duration 
22 years 
T2DM treated 
with metformin 
and nateglinide; 
nasal CPAP for 
OSA; mildly 
deranged lipids 
DGB  48.5 31.9 18 
months 
Metformin and nasal 
CPAP discontinued. 
Reduced hunger and 
disinhibition 
Bender [133]  7 year-old F, 
CP. 
Hyperphagia 
Liraglutide 
and selective 
proximal 
vagotomy  
Replaced 
(not 
specified). 
Duration 
5 years 
Arthralgia 
resulting in an 
inability to 
walk. 
Aggression with 
meal restriction 
LSG 
aged 12 
years 
57.1 48.7 6 
months 
Reduced 
hyperphagia and 
aggression. 
Arthralgia resolved, 
mobility increased, 
school re-attendance 
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Case report Participant Initial 
management 
Pituitary 
disease 
Co-morbidities Surgery Pre-op 
BMI 
Last 
BMI  
Follow 
-up 
Outcomes 
Page-Wilson 
[134]  
16.5 years F, 
CP. 2 
resections. 
Hyperphagia. 
MRI brain: 
hypothalamic 
damage 
Diet and 
exercise 
advice, 
sibutramine, 
strict exercise 
regimen 
Fully 
replaced 
(inc GH). 
4.5 years 
OA knees. 
Required 
cholecystectomy 
RGB 
aged 21 
51.6 39 19 
months 
BMI reduced after 9 
months, remained 
stable.  
Fasting leptin and 
insulin fell, fasting 
ghrelin increased 
Rottembourg 
[132]  
P1: 6 years, F, 
CP. Gross total 
resection. 
  
P2: 4 years, M, 
CP. Gross total 
resection, RTx 
P1: Diet and 
exercise 
advice. 
 
P2: Diet and 
exercise 
advice, 
octreotide 
P1 & P2:  
Fully 
replaced. 
 
P1: 6 
years 
duration 
Both: raised 
lipids, NAFLD 
 
P1: depression, 
respiratory 
complications  
P2: Raised 
insulin, 
abnormal liver 
function 
P1: 
RBG, 
aged 
12.7 
years 
 
P2: BPD, 
aged 15 
years 
P1: 65  
 
P2: 42  
P1: 43  
 
P2: 32  
P1:  6 
years 
 
P2: 2 
years 
Both: Lipids 
improved. 
P1: Diarrhoea, 
dumping , acute 
pancreatitis.  
P2: Intestinal 
stenosis and 
unremitting 
bradycardia required 
further surgery  
 
M = male, F = female, P1 = patient 1, P2 = patient 2, CP = craniopharyngioma, RTx = radiotherapy, LVH = Left ventricular hypertrophy, OSA 
= obstructive sleep apnoea, OA = osteoarthritis, RGB = Roux-en-Y gastric bypass, DGB = Distal gastric bypass, LSG = Laparoscopic sleeve 
gastrectomy, TV = truncal vagotomy, BPD = bilio-pancreatic diversion with duodenal switch, LFTs = liver function tests.  
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Table 1.21. Bariatric surgery case series 
 
Series Participants Tumour 
treatment 
Initial obesity 
management 
Pituitary 
disease 
Obesity 
surgery 
Pre-op 
BMI  
Latest 
BMI  
Follow 
-up 
Outcomes 
Müller 
[135]  
3 F, 1 M 
Diagnosed CP 
aged 2-21 
years 
Relapses 0-2, 
surgical 
resection 1-3 
occasions, RTx 
(1 patient) 
None (2), 
orlistat and 
sibutramine 
(2) 
 LAGB at 14-
24 years 
+7.3 to 
+13.9 
SDS 
+5.9 to 
+9.9 
SDS 
1.5-3.5 
years 
Dislocation of 
LAGB required 
revision (1 
patient) 
Gatta 
[136]  
2F, 2 M 
3 CP, 1 
choristoma 
All surgically 
resected, 1 
RTx (CP)  
Orlistat (1 
patient) 
Duration 
1.5 – 12 
years 
Sleeve 
gastrectomy (2 
M aged 24 and 
43), gastric 
bypass (2 F 
aged 30 and 
51) 
37.6-51 
kg/m
2
 
34-49 
kg/m
2
 
30-64 
months 
Persisting T2DM 
(2 patients). 
P3: resolution of 
T2DM, NAFLD 
improved 
 
 
M = male, F = female, CP = craniopharyngioma, RTx = radiotherapy, T2DM = type 2 diabetes, NAFLD = non-alcoholic fatty liver,  
P3 = patient 3 
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Table 1.22. Weismann [137] case series. 
Participants 9 children/adolescents (7 F, 2 M). HO secondary to CP. Pituitary disease 2-22 years. Bariatric surgery undertaken post-
pubertally (median age 17 years, range 12-30) in all except one case. 
154 individuals with simple obesity (SO)  
Treatment Sleeve gastrectomy, gastric bypass or LAGB 
BMI pre-
treatment 
HO: median 44.7 kg/m
2
 (range 40.2 – 61.6) 
Follow up HO: median 5.5 years, range 1-9. SO: 5 years 
Outcomes  LAGB: 6 HO, 3 had second surgery due to lack of weight loss. Significantly less weight loss in HO than in SO (p <0.01). 
 
Sleeve gastrectomy: 4 HO (2 after LAGB). After mean follow-up of 2 years (range 0.5-4) patients had regained weight 
lost in the first 6 months post-gastrectomy. SO: ongoing weight loss (percentage weight loss significantly lower in HO 
than in SO at 1 and 2 years, p<0.05). 
 
Gastric bypass: 2 HO (one following LAGB). Significant weight loss after mean follow-up of three years (range 2-4); at 
2, 3 and 4 years (1 patient only for last 2 time-points) no significant difference in percentage weight loss between HO 
patients and 54 controls (median follow-up two years, range 0.5-5) 
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Table 1.23. Results of meta-analysis of patients with CP undergoing bariatric surgery [138]. 
 All LAGB SG RYGB BPD 
Number of patients 21 6 8 6 1 
Mean BMI pre- 
surgery (kg/m
2
) 
49.6 45.6 48.9 45.6 45 
 6 months after bariatric surgery 
Mean weight loss (kg) 
(95% CI) 
Net weight loss (%) 
-20.9 (-35.4 to -6.3) 
 
7 
-12.9 (-33.5 to +7.7) 
 
10.5 
-28.3 (-51.3 to -5.3) 
 
20.7 
-31.0 (-77.5 to +15.5) 
 
18.6 
BMI 40.4 kg/m
2
 
 
11.3 
 12 months after bariatric surgery 
Mean weight loss 
(95% CI) 
Net weight loss (%) 
-15.1 (-31.7 to +1.4) 
 
- 
-7.5 (-28.2 to +13.2) 
 
6.1 
-25.9 (-59.7 to + 7.9) 
 
19.6 
-33.7 (-80.7 to + 13.3) 
 
20.2 
BMI 34 kg/m
2
 
 
24.8 
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Table 1.24. Areas of cerebral activation identified in studies comparing fasted and fed states. 
Study Sex Weight Comparison Findings (rCBF/activation) 
Tataranni 
[149]  
M 11, 
normal 
Fasted Increase in hypothalamus, limbic/paralimbic areas (ACC, hippocampus, parahippocampus and 
insula, ant temporal and post OFC), temporal cortex, thalamus, precuneus, caudate, putamen and 
cerebellum (p<0.005, uncorrected for multiple comparisons on 
15
O-PET scanning) 
 
Tataranni 
[149]  
M 11, 
normal 
Fed (liquid 
meal) 
Increase in inferior parietal lobe and vmPFC and dlPFC (p<0.005, uncorrected for multiple 
comparisons on 
15
O-PET scanning)                                                                                                                          
Negative correlation with insulin in insula (left: r= -0.69, p=0.02; right: r= -0.57, p=0.06) and 
OFC (left: r= -0.72, p=0.01; right: r= -0.59, p=0.05) and FFAs in ACC (r= -0.76, p=0.007)                       
Positive correlation with FFAs in dlPFC (left: r=0.62, p=0.04; right: r=0.28, p=0.04) 
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Table 1.26a. Holsen et al [195]. Comparison of brain activation in PWS and lean controls using fMRI scanning. All findings used the contrast 
food > non-food. 
 Meal Area of increased activation 
LCo Pre Right lateral OFC and medial PFC, left posterior OFC, bilateral fusiform gyrus 
 Post Left posterior OFC, bilateral fusiform gyrus 
 Pre > post Right amygdala, bilateral OFC, left frontal operculum and fusiform gyrus 
 Post > pre Medial PFC 
PWS Pre None in a priori regions 
 Post Bilateral medial PFC and insula, left hippocampus and parahippocampal gyrus, right fusiform gyrus 
 Pre > post None 
 Post > pre Bilateral OFC, medial PFC and insula, left fusiform gyrus 
PWS > LCo Pre None 
 Post Right amygdala, OFC and fusiform gyrus, bilateral PFC and insula, left parahippocampus 
LCo > PWS Pre Bilateral OFC, medial PFC, insula and parahippocampal gyrus, right fusiform gyrus 
 Post None 
LCo: lean controls. PWS: Prader-Willi Syndrome. Pre: pre-meal findings. Post: post-prandial. p<0.01, corrected for whole brain analysis. 
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Table 1.26b. Holsen et al [171]. Comparison of brain activation in PWS, SO and lean controls using fMRI scanning. All findings used the 
contrast food > non-food. 
 Meal Area of increased activation 
PWS > SO Pre Right NA
a
 and amygdala
b 
 Post Right hypothalamus
c
 and amygdala
d
, left hippocampus
c 
SO > PWS Pre Left hypothalamus
e
 and hippocampus
f 
 Post Left OFC
g
 and dlPFC
c 
SO > LCo Pre Bilateral hypothalamus
h
, left amygdala
i
 and OFC
g
, right mPFC
j 
 Post Right hypothalamus
k
 and dlPFC
i 
LCo > SO Pre None 
 Post Right OFC
j 
PWS > LCo Pre Left hypothalamus
g
, mPFC
h
 and hippocampus
j
, bilateral amygdala
g 
 Post Right hypothalamus
j
, amygdala
d
 and hippocampus
g 
PWS: Prader-Willi Syndrome. SO: simple obese. LCo: lean controls. Pre: pre-meal findings. Post: post-prandial. 
p-values (all uncorrected for multiple comparisons) – a: p=0.008, b: p=0.014, c: p=0.003, d: p=0.005, e: p=0.016, f: p=0.006, g: p<0.001, h: p≤ 
0.003, i: p=0.007, j: p=0.001, k: p=0.004
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Appendix 2 
 
Visual Analogue Scale (VAS) 
 
OFFICE USE ONLY: 
PARTICIPANT:    DATE: 
 
TEST DAY: BASELINE / DAY 1 / DAY 2 / DAY 3 
 
TIME: 
 
INSTRUCTIONS FOR PARTICIPANTS: 
Please read each question and then put a mark through the line that best 
represents how you are feeling in relation to that particular sensation at this 
moment. 
 
EXAMPLE: 
 
How TIRED do you feel at this moment? 
 
Not at all         Extremely 
tired          tired 
 
 
PLEASE ANSWER THE FOLLOWING QUESTIONS: 
 
How HUNGRY do you feel at this moment? 
 
Not at all         Extremely 
hungry         hungry 
 
 
How FULL do you feel at this moment? 
 
Not at all         Extremely 
full          full 
 
 
How STRONG is your desire to eat at this moment? 
 
Not at all         Extremely 
strong          strong 
 
THANK YOU 
 
 
269 
 
Three Factor Eating Questionnaire (TFEQ) 
 
Patient code:       
Directions: This booklet contains a number of statements. Each statement should be 
answered either TRUE or FALSE. Read each statement and decide how you feel 
about it, in part I.  
If you agree with the statement, or if you feel that it is true about you, circle the T 
next to the statement.  
If you disagree with a statement, or if you feel that it is false as applied to you, circle 
the F next to the statement.  
Please put down the first answer that comes into your head.  
       
Part I. 
1. When I smell some fish & chips or see a juicy piece of meat I find it very difficult 
to keep from eating, even if I have just finished a meal.   T F 
2. I usually eat too much at social occasions, like parties and picnics. T F 
3. I am usually so hungry that I eat more than 3 times a day.  T F 
4. When I have eaten my quota of calories I am usually very good about not eating 
anymore.         T F 
5. Dieting is so hard for me because I just get too hungry.   T F 
6. I deliberately take small helpings as a means of controlling my weight. T F 
7. Sometimes things just taste so good that I keep on eating, even when I am no 
longer hungry.         T F 
8. Since I am often hungry, I sometimes wish that while I am eating an expert would 
tell me    that I have had enough or that I can have something more to eat.   T         F 
9. When I feel anxious I find myself eating.     T F 
10. Life is too short to worry about dieting.     T F 
11. Since my weight goes up and down, I have gone on reducing diets more than 
once.          T F 
12. I often feel so hungry I just have to eat something.   T F 
13. When I am with someone who is overeating, I usually overeat too. T F 
14. I have a pretty good idea of the number of calories in common foods. T F 
15. Sometimes when I start eating, I just can’t seem to stop.   T F 
16. It is not difficult for me to leave something on my plate.  T F 
17. At certain times of the day I get hungry because I have gotten used to eating then.
          T F 
18. While on a diet, if I eat food that is not allowed, I consciously eat less for a 
period of time to make up for it.      T F 
19. Being with someone who is overeating often makes me hungry enough to eat 
also.          T F 
20. When I feel blue I often overeat.      T F 
21. I enjoy eating too much, to spoil it by counting calories or watching my weight.
          T F 
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22. When I see a real delicacy I often get so hungry that I have to eat right away. 
          T F 
 
23. I often stop eating when I am not really full as a conscious means of limiting the 
        amount I eat.        T F 
24. I get so hungry my stomach often feels like a bottomless pit.  T F 
25. My weight has hardly changed at all in the last ten years.  T F 
26. I am always hungry so it is hard for me to stop eating before I finish the food on 
my plate.         T F 
27. When I feel lonely, I console myself by eating.    T F 
28. I consciously hold back at meals in order not to gain weight.  T F 
29. I sometimes get very hungry late in the evening or at night.  T F 
30. I eat anything I want, anytime I want.     T F 
31. Without even thinking about it I take a long time to eat.   T F 
32. I count calories as a conscious means of controlling my weight.  T F 
33. I do not eat some foods because they make me fat.   T F 
34. I am always hungry enough to eat at anytime.    T F 
35. I pay a great deal of attention to changes in my figure.   T F 
36. While on a diet, if I eat food that is not allowed, I often then splurge and eat 
        other high calorie foods.       T F 
 
      
 
Part II. 
 
Please answer the following questions by circling the number above the response that 
is appropriate for you. 
 
37. How often are you dieting in a conscious effort to control your weight? 
  1   2   3   4
  
         rarely                  sometimes                    usually                  always 
 
 
38. Would a weight fluctuation of 5lb affect the way you live your life? 
  1   2   3   4 
   not at all                        slightly                    moderately                  very much   
 
39. How often do you feel hungry? 
  1   2   3   4 
                   only at                        sometimes                often between               almost  
                mealtimes                 between meals                    meals                      always           
 
40. Do your feelings of guilt about overeating help you to control your food intake? 
  1   2   3   4 
                    never                          rarely                             often                        always 
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41. How difficult would it be for you to stop eating half way through dinner and not 
eat for the next four hours? 
1   2   3   4 
          easy                        slightly                          moderately               very 
                                          difficult                           difficult                  difficult         
  
42. How conscious are you of what you are eating? 
  1   2   3   4 
                     not at all                  slightly                        moderately            extremely           
 
 
43. How frequently do you avoid ‘stocking up’ on tempting foods? 
  1   2   3   4 
almost never               seldom                     usually                     almost  
             always   
 
44. How likely are you to shop for low calorie foods? 
  1   2   3   4 
                 unlikely                       slightly                       moderately                   very 
                                                      likely                               likely                      likely 
 
45. Do you eat sensibly in front of others and splurge alone? 
  1   2   3   4 
                  never                              rarely                          often                         always 
 
 
46. How likely are you to consciously eat slowly in order to cut down on how much you eat? 
  1   2   3   4 
                   unlikely                      slightly                        moderately           very likely 
                                                      likely                              likely                             
 
47. How frequently do you skip dessert because you are no longer hungry? 
  1   2   3   4 
                   almost                          seldom                      at least                     everyday 
                   never                                                             once a week                    
 
 
 
48. How likely are you to consciously eat less than you want? 
  1   2   3   4 
                     unlikely                      slightly                       moderately                    very 
                                                        likely                          likely                           likely 
                                          
 
49. Do you go on eating binges even though you are not hungry? 
  1   2   3   4 
                   never                           rarely                            sometimes           once a week  
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50. On a scale of 0 to 10, where 0 means no restraint in eating (eat whatever you 
want, whenever you want it) and 10 means total restraint (constantly limiting food 
intake and never ‘giving in’), what number would you give yourself. (Choose one 
number only). 
          
  eat whatever you want, whenever you want it 
          
  usually eat whatever you want, whenever you want it     
               
  often eat whatever you want, whenever you want it       
           
  often limit food intake, but often ‘give in’        
               
  usually limit food intake, but rarely ‘give in’        
                
            constantly limiting food intake, never ‘giving in’     
 
 
51. To what extent does this statement describe your eating behaviour ? 
 ‘I start dieting in the morning, but because of any number of things that 
happen during the day, by evening I have given up and eat what I want, promising 
myself to start dieting again tomorrow.’ 
  1   2   3   4         
                  not like me                     a little                     pretty good            describes                                                                         
                                                               like me                      description                      me           
 
 
Appendix 2: 
Please answer the following questions as carefully and honestly as possible. Read 
each question and simply fill in the column which best applies to you. 
 
           
Never 
Seldom 
Sometimes 
Often 
Very often 
           
  
 
1. If you have put on weight, do you eat less than you usually do?  
2.  Do you have a desire to eat when you are irritated?     
3.  If food tastes good to you, do you eat more than you usually do?   
4.  Do you try to eat less at meals times than you would like to eat?   
5.  Do you have a desire to eat when you have nothing to do?    
6.  Do you have a desire to eat when you are fed-up?     
7.  If food smells good and looks good, do you eat more than you usually do?  
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8.  How often do you refuse food and drink offered because you are concerned 
about your weight?        
9. Do you have a desire to eat when you are feeling lonely?    
10.  If you see or smell something delicious do you have a desire to eat it?  
11. . Do you watch exactly what you eat?       
12. Do you have a desire to eat when someone disappoints you?   
13. If you have something delicious to eat, do you eat it straight away?   
14. Do you deliberately eat foods that are slimming?     
15. Do you have a desire to eat when you are cross?      
16. . Do you have a desire to eat when you are expecting something to happen?  
17.  If you walk past the baker do you have a desire to buy something delicious?  
18. When you have eaten too much, do you eat less than usual on the following 
days?  
19. Do you get a desire to eat when you are anxious, worried or tense?   
20. If you walk past a snack bar or cafe, do you have a desire to buy something 
delicious?        
21. Do you deliberately eat less in order not to become heavier?    
22. Do you have a desire to eat when things go against you or when things have gone 
wrong?        
23. If you see others eating, do you also have a desire to eat?    
24. How often do you try not to eat between meals because you are watching your 
weight?         
25. Do you have a desire to eat when you are frightened?     
26. Can you resist eating delicious foods?       
27. How often in the evening do you try not to eat because you are watching your 
weight?      
28. Do you have a desire to eat when you are disappointed?     
29. Do you eat more than usual when you see others eating?    
30. Do you think about how much you weigh before deciding how much to eat?  
31. Do you have a desire to eat when you are upset?      
32. When you see someone preparing a meal, does it make you want to eat 
something?   
33. Do you have a desire to eat when you are bored or restless? 
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Three-day MRC food diary – example page 
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Appendix 3  
 
Food photographs   
 
 
Examples of low calorie food photographs   
   
 
 
 
Examples of high calorie food photographs 
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Appendix 4 
Timeline of study days 
 
Study day 1: screening visit 
1. Informed consent undertaken  
2. All participants (patients and controls) medically screened and adequacy of vision 
assessed in the patient group. 
3. Body composition data collected (height and weight; estimation of percentage 
body fat by whole-body bioelectrical impedance analysis [Tanita Systems, Tanita 
Corp, Tokyo, Japan]). 
4. Estimate of BMR using the Harris-Benedict formula - For men: 66.5 + (13.75 x 
weight) + (500.3 x height) - (6.775 x age) and for women: 655.1 + (9.563 x weight) 
+ (185 x height) - (4.676 x age). 
5. Trial session at the UEM with participants given 25% of their calculated daily 
energy requirement as porridge and orange juice to be eaten to assess whether they 
could consume all of the food and drink provided and to enable familiarisation with 
the UEM. 
5. Participants given TFEQ and 3-day food diaries for completion.  
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Study day 2: fMRI study day timeline 
72 hours 
before fMRI 
Participants asked to refrain from alcohol, strenuous physical 
activity, cigarettes and caffeine-containing drinks 
22.00 previous 
day 
Start fasting 
 
  
Study day: Timepoint Task 
Baseline Cannulate. Blood samples 
 Anatomical then functional imaging 
After 1
st
 scan 1
st
 VAS ratings and 1
st
 photo ratings 
 Test meal (porridge and OJ) 
Immediately after test meal 2
nd
 VAS ratings 
15 mins after meal Blood sample 
30 mins after meal Blood sample 
60 mins after meal Blood sample 
 Functional imaging 
After 2
nd
 scan 3
rd
 VAS ratings and 2
nd
 photo ratings 
90 mins after meal Blood sample 
120 mins after meal Blood sample 
 4
th
 VAS ratings 
150 mins after meal Blood sample 
180 mins after meal Blood sample 
 Functional imaging 
 5
th
 VAS ratings and 3
rd
 photo ratings 
End Blood sample 
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Study day 3: UEM study day timeline 
24 hours 
before UEM 
Participants asked to refrain from alcohol, strenuous physical 
activity, cigarettes and caffeine-containing drinks 
22.00 previous 
day 
Start fasting 
Study day: Timepoint Task 
Baseline Breakfast at UEM (porridge and OJ) 
  
3 hours after breakfast Cannulate. Blood samples 
Lunch Lunch meal UEM (pasta) and completion of intra-
meal VAS scores 
15 mins after end of meal Blood sample 
30 mins after end of meal Blood sample 
60 mins after end of meal Blood sample 
90 mins after end of meal Blood sample 
120 mins after end of meal Blood sample 
150 mins after end of meal Blood sample 
180 mins after end of meal Blood sample 
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Appendix 5 
 
 
PARTICIPANTS’ INFORMATION SHEET B 
 
Abnormal Eating Behaviour and Brain Areas Associated with Hunger in Adult 
Patients with Damage to the Hypothalamus (August 2010 - Version 3). 
 
Part 1 
We would like to invite you to take part in a research study. Before you decide if you 
would like to take part you need to understand why the research is being done and 
what it would involve for you. Please take time to read the following information 
carefully and talk to friends, relatives or your GP about the study if you wish. Ask us 
if there is anything that is not clear or if you would like more information and take 
time to decide whether or not you wish to take part.  
 
Part 1 tells you the purpose of this study and what will happen to you if you take 
part.  
Part 2 gives you more detailed information about the conduct of the study.  
 
What is the purpose of the study?  
The hypothalamus is an area of the brain, which is important in controlling energy 
balance. Obesity is a common problem in people who have had disorders affecting 
this area. Obesity is associated with an increased risk of other health problems. The 
purpose of this study is to help us understand what makes some people with damage 
to the hypothalamus more likely to gain weight. If we can identify individuals at risk 
of obesity from hypothalamic damage early, we can try to prevent them from 
becoming obese.  
 
Why have I been asked to take part?  
The study will compare people in 4 categories:- 
1. People who are obese with damage to the hypothalamus 
2. People who are weight stable with damage to the hypothalamus 
3. People who are obese without damage to the hypothalamus  
280 
 
4. People who are weight stable without damage to the hypothalamus.  
 
You have been asked to take part in one of the control groups (i.e./ one of the groups 
without damage to the hypothalamus). We wish to include participants without 
damage to the hypothalamus so that we can assess what (if any) are the differences 
are seen between the groups and therefore determine which areas of the brain help in 
controlling energy balance. 
 
Do I have to take part?  
It is up to you – you do not have to take part.  
We will describe the study to you in this information sheet, which you can keep. If 
you decide to take part, we will ask you to sign a consent form. If you change your 
mind later on, you are free to withdraw from the study at any time without giving a 
reason.  If you decide not to take part, or change your mind, this will not affect any 
medical care that you receive currently or in the future.  
 
What will happen to me if I take part?  
If you decide to take part we will ask you to:- 
1. Fill in a questionnaire about any attempts you have made to diet to control your 
weight, if you feel you have loss of control over food intake and whether you feel 
able to resist hunger. You will be asked to fill out the questionnaire at home and 
return it during the next study visit.  
2. You will also be given a nutrition diary and asked to fill this out over 3 days at 
home.  
You will also be asked to attend for 3 visits, which will be in addition to any normal 
clinic visits. 
1
ST
 VISIT 
We will ask you to attend our investigational unit at the Clinical Sciences Centre, 
University Hospital Aintree on a day suitable for you. We will answer any questions 
or concerns that you have and if you decide to participate in the study we will ask 
you to sign a consent form agreeing to take part. Your height, weight, waist and hip 
circumference will be recorded and an estimation of body fat made by standing on 
scales with special sensors. You will then be given breakfast and asked to complete 
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ratings of hunger and fullness on a computer screen in front of you as you eat. This 
visit will last about 2 hours. 
 
2
ND 
VISIT 
You will be asked to attend the MARIARC (Magnetic Resonance And Image 
Analysis Research Centre) Centre on Pembroke Place in Liverpool at 0800 in the 
morning after fasting from 22:00 the night before. We will also ask you to refrain 
from alcohol, strenuous physical activity, cigarettes and caffeine containing drinks 
for at least 72 hours before the study day. We will insert a cannula to take blood that 
will be left in your vein for 3 hours. You will undergo 4 magnetic resonance imaging 
(MRI) scans in total. You will be asked to wear a gown (changing rooms are 
provided) and remove items that are affected by the magnetic field (e.g./ hearing 
aids, mobile phones, keys, coin, pens, credit cards (secure lockers are provided)). 
While inside the scanner you will be asked to lie as still as possible on your back, 
with your head immobilized with head cushions.  
 
You’ll have the first 2 MRI scans before being given a breakfast meal. During the 2nd 
scan, you’ll be shown 4 sets of 10 photographs in a mirror inside the scanner. Each 
photograph will be shown for 5 seconds with 1 second in between. You’ll be asked 
to try and remember each photograph for a recognition test at the end of each scan 
and to rate your feelings of hunger, fullness, urge to eat, how much food you think 
you will eat, preoccupation with food, and non-food-related feelings of mood on a 
scale of 0 (low) to 100 (high) before the first scan and after the second scan and to 
rate whether you think the food in the photographs is low or high calorie and how 
appealing you find it. 
 
You will then be given an identical breakfast to that eaten in the laboratory at the 
Clinical Sciences Centre, University Hospital Aintree. The 3
rd
 and 4
th
 scans will be 
done one hour and three hours after eating breakfast. You will again be shown the 4 
sets of 10 photographs and asked to remember them. You will be asked to rate your 
feelings (as previous) before and after both scans. The total scanning time will be 
about 1 hour. 
Blood will be taken at the start and end of each of the three scanning sessions and at 
15, 30 and 60 minutes after eating the breakfast meal (9 samples of 10 ml over 3 
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hours = total 90 ml = 18 teaspoons) for glucose, insulin, free fatty acids, incretins and 
gut hormones. This visit will last about 4 hours. 
 
3
RD
 VISIT 
We will ask you to attend our investigational unit at the Clinical Sciences Centre, 
University Hospital Aintree or the Kissileff Laboratory, in the Eleanor Rathbone 
Building at the University of Liverpool, at around 8:30 am on a day suitable for you. 
We will ask you to fast from 22:00 the night before. We will also ask you to refrain 
from alcohol, strenuous physical activity and cigarettes for at least 24 hours and 
caffeine containing drinks for at least 12 hours before the study day. Bloods will be 
taken from a cannula inserted into a hand or arm vein and will be left there for 6 
hours, to allow further blood samples to be taken. You will be given a standard 
breakfast meal and asked to complete ratings of hunger and fullness on a computer 
screen in front of you as you eat. Three hours after breakfast you will be given a 
standard lunch meal and again asked to complete ratings of hunger and fullness as 
you eat.  Blood samples will be taken immediately after the lunch meal and at 15, 30, 
60, 90, 120, 150 and 180 minutes after this (9 samples of 10 ml over 3 hours = total 
of 90 ml = 18 teaspoons) for measurement of glucose and hormones - insulin and C-
peptide, incretins and hormones made in the gut and by fat cells. You will also be 
asked to continue rating how hungry and full you feel, every hour for three hours 
after finishing the lunch meal. This visit will last about 7 hours. 
 
All venues have bathroom facilities and comfortable seating. The Clinical Sciences 
Centre and the Kissileff Laboratory have a television and magazines available. 
 
Expenses  
For all visits, travel expenses and arrangements to help with transport are available. 
Reimbursement will also be offered in recognition of the time involved in taking part 
in the study – up to £40 for visit 2 and up to £60 for visit 3, up to a total of £100. 
 
What will I have to do?  
We will ask you to fill in the food diary and questionnaire at home and return them at 
the 1
st
 study visit. 
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You will be asked to attend for 3 visits, which will be extra to your normal clinic 
visits and to fast from about ten o’clock the night before each visit. We will ask you 
to refrain from alcohol or strenuous physical activity for at least 24 hours and from 
cigarettes and caffeine containing drinks for at least 12 hours before the visit to the 
Clinical Sciences Centre, University Hospital Aintree. We will also ask you to 
refrain from alcohol, strenuous physical activity, cigarettes and caffeine containing 
drinks for at least 72 hours before the visit to the MARIARC centre in Liverpool 
 
What are the possible disadvantages and risks of taking part?  
There will be the inconvenience of the time taken for three visits to the research 
centres.  
Inserting drips (“cannulae”) may cause slight discomfort and occasionally bruising at 
the site of insertion.  
Some people may find the scanner claustrophobic, or uncomfortable and we will 
check this with you. There are no known risks in properly conducted MRI scanning. 
Certain precautions need to be observed as it involves a strong magnet. Most 
importantly, you cannot have an MRI if you are fitted with a heart pacemaker, 
mini-defibrillator or neurostimulator or have an artificial heart valve; if you have 
surgical clips in your head; if you have ever had an injury which may have left 
metal particles in your eye, head, or elsewhere in your body. 
Occasionally research studies using MRI scans reveal unexpected abnormalities, 
which require medical follow-up, either for further investigation or (more rarely) 
treatment. The scans we do are for research purposes, but they are reviewed carefully 
to avoid missing any abnormality. If any significant abnormality is found, we will 
send the report to your GP who will be able to take it further. 
Most of the blood tests that will be undertaken are currently only used in a research 
setting, however, all blood results will be reviewed carefully to avoid missing any 
abnormality. If any significant abnormality is found, we will send the report to your 
GP who will be able to take it further. 
 
There are no interventions involved that should interfere with your usual 
treatment or normal daily activities. 
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What are the possible benefits of taking part? 
You will not directly benefit from participation in this study.  Knowledge gained 
may help to provide important insights into the development of obesity in people 
who have acquired hypothalamic damage.  
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. More detailed information on this 
and contact details are given in Part 2.  
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2.  
 
This completes part I. If the information in Part 1 has interested you and you are 
considering participation, please read the additional information in Part 2 before 
making any decision.  
 
 
Part 2 of the information sheet  
What will happen if I don’t want to carry on with the study?  
Nothing! You are free to withdraw at any time and without giving a reason.  In case 
of withdrawal, you have the right to make a decision about any information, data and 
samples we have collected. All your data and samples will be destroyed if you wish 
so, and no copy of the data will be retained in any database. 
 
What if there is a problem?  
If you have concerns about any aspect of this study, you should ask to speak with the 
researchers who will do their best to answer your questions. 
 
Please contact Dr Caroline Steele on: (0151) 529 6146. 
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If you remain unhappy and wish to complain formally, you can do this through the 
NHS Complaints Procedure (Details can be obtained from the PALS team, Ground 
Floor, University Hospital Aintree, phone: (0151) 5293287) or you can use the 
complaints procedure at the University of Liverpool, addressed to the Research 
Governance Officer in Legal Services (ethics@liv.ac.uk, 0151 794 8920).  
 
The study does not involve any therapeutic interventions or potentially hazardous 
procedures. In the unlikely event that you become ill or suffer any injury as a direct 
result of a procedure of the study, the study doctor will arrange for the correct 
treatment. In the event that something does go wrong and you are harmed during the 
research and this is due to someone’s negligence then you may have grounds for a 
legal action for compensation against (Aintree Hospital NHS Trust) but you may 
have to pay your legal costs. The normal National Health Service complaints 
mechanisms will still be available to you.  
 
Will my taking part in this study be kept confidential?   
All information collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital will be 
coded (have your name and address removed so that you cannot be recognised). 
Data will not be retained for use in future studies and will be disposed of securely 
after completion of the study. 
 
All the test results will be fed into a secure computer kept in the research centre (3
rd
 
Floor of Clinical Sciences Centre, University Hospital Aintree) and all your data will 
be coded and stored anonymously. Complete data will remain known to members of 
the research team (Dr Caroline Steele and Dr Christina Daousi). 
 
Your GP will be informed of your participation in our study. 
You have the right to check the accuracy of data held about you and correct any 
errors.  
 
What will happen to any samples I give?  
The blood samples are taken for research purposes and will be stored securely in 
freezers at the Clinical Sciences Centre, University Hospital Aintree. They will not 
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be retained after completion of the study. The results of the blood samples and the 
MRI scans will be fed into a secure computer kept in the research centre (3
rd
 Floor of 
Clinical Sciences Centre, University Hospital Aintree) and all your data will be 
coded and stored anonymously. Complete data and access to the samples will only be 
available to the research team (Dr Caroline Steele and Dr Christina Daousi). 
 
It is unlikely that the study will produce any individually significant information 
because the factors we propose to study are not currently part of routine clinical care. 
 
What will happen to the results of the study?  
The overall collective results of the study will be presented and published in medical 
journals in the future after analysis of the complete data. We will not identify you in 
any way when the results are presented or published.  
 
It is unlikely that the study will produce any individually significant information 
because the factors we propose to study are not currently part of routine clinical care. 
 
Who is organising and funding the research?  
The principal researcher is employed by the University of Liverpool, with funding 
from Eli Lilly(a pharmaceutical company), but no additional money will be received 
based on your participation. 
 
Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. This 
study has been reviewed and given favourable ethical opinion for conduct in the 
NHS by Sefton Research Ethics Committee. If you decide to take part in the study, 
you will be given a copy of this information leaflet and a copy of your signed 
consent form to keep at home. 
Further information and contact details  
If you have any concerns, or would like to discuss further any aspects of the study, if 
you have any questions and finally if you have any complaints you can contact Dr 
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Caroline Steele, Clinical Research Fellow in Diabetes & Endocrinology on: 0151 
529 6146. 
 
My postal address is: 
Diabetes and Endocrinology Clinical Research Group, 
3
rd
 floor Clinical Sciences Centre, 
University Hospital Aintree, 
Longmoor Lane, 
Liverpool, 
L9 7AL. 
 
You can also contact the PALS team located on the ground floor, University Hospital 
Aintree for further information.  
 
Thank you for taking the time to read this information sheet. If you have any 
comments or queries please contact Dr Caroline Steele by phone (telephone 
number (0151) 529 6146) or by e-mail (e-mail address 
C.A.Steele@liverpool.ac.uk). 
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